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ABSTRACT 
The food industry has shown increased interest for novel natural antimicrobials 
due to consumer demand for foods with fewer synthetic additives, increased safety, 
quality and shelf-life. Concurrently, the emergence of drug resistant bacteria 
substantiates the need for newer antimicrobial agents. Alternative strategies include the 
use of novel antimicrobials, such as fatty acid derivatives, essential oils and bacteriocins, 
with proven antimicrobial properties against a diverse range of bacteria. 
This study investigated novel carbohydrate fatty acid (CF A) derivatives for their 
antibacterial activity against a range of pathogenic and spoilage bacteria. A series of 
mono-substituted CF A derivatives using lauric and caprylic acids were synthesized. 
Chemical routes allowing the attachment of the fatty acid as either an ester or ether to 
the monosaccharide 6-hydroxyl were developed. Structure/activity relationship studies 
of antimicrobial efficacy allowed some insight into the mechanism of action of these 
compounds. In addition, selected essential oil (EO) individual components and nisin, 
both alone and in combination, were also assessed for possible combination strategies 
with CF A derivatives. 
Minimum inhibitory concentration (MIC), ICso values, increase in lag phase and 
decrease in maximum specific growth rate were determined. Leakage of intracellular 
material absorbing at 260nm, Live/Dead BacLight fluorescence and ATP BacTiterGlo 
luminescence assays assessed membrane disrupting effects. Furthermore, a Phenotypic 
MicroArray assay was used to investigate bacterial cell response in the absence and 
presence of CF A derivatives. 
The laurate ether of methyl a-D-glucopyranoside (9a) and laurate ester of methyl 
a-D-mannopyranoside (4c) showed the highest growth-inhibitory effect. CFA 
derivatives were significantly more effective against Gram positive than Gram negative 
bacteria. The analysis of both ester and ether fatty acid derivatives of the same 
carbohydrate, in tandem with alpha and beta configuration of the carbohydrate moiety 
suggest that the carbohydrate moiety is involved in the antimicrobial activity of the fatty 
acid derivatives and that the nature of the bond also has a significant effect on efficacy. 
Membrane damage was observed and may account for at least a component of the mode 
of action of these compounds. The ATP assay and phenotypic responses suggested that 
another mechanism of action might also account for the antimicrobial activity of the beta 
lauric ether derivative (compound 9b). 
Carvacrol and thymol were found to have the highest antimicrobial activity, 
followed by citral. Nisin in combination with carvacrol, thymol and citral showed 
additive effects against Listeria spp. The antimicrobial effect of the combination was 
improved by lowering the pH from neutral to pH6. 
CF A derivatives with different structures have great potential for developing 
antibacterial agents relevant to the food and health care industries. Nisin in combination 
with individual EO components could lead to useful efficacy as an alternative natural 
preservative. 
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Chapter 1. Introduction 
1. INTRODUCTION 
This study concerned the synthesis of carbohydrate fatty acid (CFA) derivatives 
for evaluation as antibacterial agents, with a view to examining the effect of variation of 
the hydrophilic moiety, the glycoconjugate linkage, and the length of fatty acid chain on 
antimicrobial activity. Previous studies in the School suggested that the carbohydrate 
moiety could markedly affect the antimicrobial activity of the fatty acid (Lou, 2005); 
thus, further investigation was merited. Few studies have attempted to investigate the 
mechanism of action of these compounds; this work seeks to further knowledge through 
investigation of structure/activity relationships and mode of action of these compounds. 
Fatty acid derivatives are a type of 'natural' compound regarded as non-toxic, bio-
compatible and bio-degradable. These types of compounds are of great interest because 
of their wide variety of applications in the health care and food industries. They are 
currently used as emulsifiers, non-ionic surfactants, food additives, and even as non-
caloric fat substitutes. Sugar esters and mono glycerides have been previously studied by 
many authors, and antimicrobial activity against a range of bacteria, yeast, fungi and 
viruses has been demonstrated. Sugar esters are used in Japan as antibacterial agents in 
canned drinks (Suwa et ai., 1988, Moriyama et ai., 1996), although in Europe and USA 
their use in the food industry as a preservative is still limited. 
There is potential to modify the carbohydrate fatty acid derivatives' properties by 
controlling the degree of substitution of the fatty acid and by varying the nature of the 
fatty acid or the sugar itself. 
The literature review which follows will introduce the different aspects and 
techniques used in this study. 
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1.1 ANTIMICROBIALS 
1.1.1 Food preservation and safety 
Food is a very complex substance composed mainly of carbohydrates, proteins, 
fats, water, minerals, vitamins, and many other components. Th e combination of these 
components is that which makes one food different from another. Moreover, each of 
these components are susceptible to a different form of deterioration and changes in the 
food cause consequences ranging from severe hazard to relatively trivial loss of quality. 
It is clear that all foods are perishable and some foods become unfit for human 
consumption more quickly than others, depending on the food type, composition, 
formulation, packaging and storage conditions, as well as to the length of the supply 
chain (Gould, 1995). 
The major deteriorative reactions, which are the major targets for preservation, are 
well known (Table 1.1). They include some that are essentially biological, chemical, 
enzymatic and physical in their mode of action; although these causes are not 
isolated in nature. 
Bacteria, insects, and light, for example, can all work simultaneously to deteriorate 
food in the field or in storage. Likewise, causes such as high temperature, moisture and 
air will affect the multiplication and activities of bacteria, as well as the chemical and 
enzymatic activities of the food. The most serious deterioration include those due to 
microorganisms, following the survival and/or growth of infectious pathogenic bacteria or 
the growth of toxinogenic ones (Lund et aI., 2000). Preservation methods ought to work 
through those factors that most effectively influence the growth and survival of 
2 
Chapter 1. Introduction 
microorganisms and can be exploited safely in foods (Gould, 1995). Such factors include 
physical, chemical and microbiological and are summarized in Table 1.2. 
Table 1.1 Principal quality deterioration reactions of foods 
t Biological 
Growth or presence 
of toxinogenic 
microorganisms 
Growth or presence 
of infective 
microorganisms 
Gr{)wth of spoilage 
microorganisms 
Chemical 
Oxidative rancidity 
Oxidative and 
reductive 
discoloration 
Non-enzymic 
browning 
(Maillard reactions) 
Presence of insects Destruction of 
and/or rodents nutrients 
Adapted from Gould (2000). 
iEnzymatic 
Hydrolytic reactions 
catalysed by lipases, 
proteases, etc 
Rancidity catalysed 
by Jipoxygenases 
Enzymic browning 
catalysed by 
polyphenoloxidases 
Physica.l 
Low or high 
temperatures 
Mechanical 
damage 
Excessive 
moisture 
Light 
Dehydration 
Table 1.2 Major factors affecting microbial growth and survival in foods 
Intrinsic factors Chemical and physical factors that are within the food and 
with which a contaminating microorganism is therefore 
inextricably in contact 
Processing factors Processes that are deliberately applied to a food in order to 
improve its preservation 
Extrinsic factors Factors which influence microorganisms in foods, but which 
are applied from outside the food and act during storage 
Implicit factors Factors related to the nature of the microo.rganisms that are 
present, and to their reactions with the food environment 
Net effects Effects due to the interaction of a combination of factors 
Adapted from Gould (1995). 
Preservation methods are of increasing importance as they delay the growth of 
spoilage micro{)rganisms and guarantee the safety of the consumer by preventing or 
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controlling the presence of pathogens. Concerns regarding food quality and safety issues 
have become more important, as more food products are produced on a large industrial 
scale and distributed worldwide (Roller, 2003). Sometimes several months or years may 
elapse between food production and consumption; therefore a long-term shelf life is often 
necessary. Extension of the shelf life can be achieved by the use of different preservation 
methods (Table 1.3). 
Table 1.3 Preservation methods and their antimicrobial effect. 
Method Factor inf)uenQinggrowtb or ~urvival 
• Refrigeration/Freezing Low temperature to retard growth / Reduction of water 
activity to prevent growth 
• Drying, curing and 
conservmg 
• Vacuum and oxygen 
free packaging 
• Modified atmosphere 
packaging (MAP) 
Reduction in water activity to delay or prevent growth 
Low oxygen tension inhibits strict aerobes and delays growth 
of facultative anaerobes 
Specific inhibition of some microorganisms by carbon dioxide 
addition for example 
• Addition of weak acids Reduction of the intracellular pH of microorganisms 
• Fermentation Reduction of pH value in situ by microbial action and 
additional inhibition by formation of acid or alcohol and by 
other microbial products (e.g. bacteriocins) 
• Emulsification Compartmentalisation and nutrient limitation 
• Addition of chemical Inhibition of specific groups of microorganisms 
preservatives 
• Pasteurization and 
appertizati on 
• Irradiation 
• High hydrostatic 
pressure (Pascalization) 
• Pulsed electric field 
processing (PEF) 
Adapted from Gould (1998). 
High temperatures to inactivate target microorganisms 
Delivery of ionising radiation to eliminate pathogens 
Pressure-inactivation of vegetative bacteria, yeasts and 
moulds 
Short bursts of electricity for microbial inactivation 
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The effectiveness of these technologies depends on a number of factors associated 
with the target microorganism, the food product, as well as the storage and handling 
environment. Thus, some technologies have limited applications. Research on food 
preservation technologies and their optimised application is an ongoing process and the 
development and use of safe antimicrobial preservatives in foods is of great interest to 
the industry. 
Food additives are substances added to food to preserve flavour or improve its 
taste and appearance. Many have been in use for up to a century with a focus on food 
shelf life extension. Food additives are defined in European Union (EU) legislation 
(Article 1(2) of Directive 891107/EEC) as "any substance not normally consumed as a 
food in itself and not normally used as a characteristic ingredient of food whether or not 
it has nutritive value, the intentional addition of which to food for a technological 
purpose results in it or its by-products becoming directly or indirectly a component of 
such foods." Additives used to prevent biological deterioration are called 
"antimicrobials". Antimicrobial agents are defined by the US Food and Drug 
Administration (FDA) 21CFR 170.3(0)(2) as "substances used to preserve food by 
preventing growth of microorganisms and subsequent spoilage, including fungistats, 
mould and rope inhibitors the effects listed by the National Academy of 
ScienceslNational Research Council under 'preservatives'" 
The use of antimicrobials can reduce or eliminate target microorganisms but it may 
also produce favourable conditions for other microorganisms (Davidson and Branen, 
2005). It is recognized that this situation is less likely to develop towards substances that 
have more than one mode of action (Ippolito and Nigro, 2003). Hurdle technology 
combines existing and new preservation techniques to establish a series of preservative 
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factors (hurdles) that microorganisms are unable to overcome (Leistner and Gorris, 
1995). These hurdles may be temperature, water activity, acidity, redox potential, 
preservatives, and others (Figure 1.1). 
pH Value I Pre •• Natlv •• 
Low Wat.r H •• t 
Activity T,..Im.nt 
Antlmlcrobi81 
a.1I 
.. . 
Chilled 
Storage 
Packaging 
Conditions 
Taken from: www.habasitlink.comllink.asp?FI=1114.html 
Figure 1.1 Multiple hurdle technology. 
A crucial phenomenon of concern to hurdle technology is known as the 
homeostasis of microorganisms, which is the tendency of microorganisms to maintain a 
stable and balanced internal environment. Preservative factors functioning as hurdles can 
disturb one or more homeostasis mechanisms, thereby preventing microorganisms from 
multiplying and causing them to remain inactive or die. The optimum way to achieve 
this is to deliberately disturb several homeostasis mechanisms simultaneously (Leistner 
2000; Leistner and Gould 2002). This multi-targeted approach is the essence of hurdle 
technology. It is more effective than single targeting and allows hurdles of lower 
intensity, thereby minimising impact on product quality. There is the further possibility 
that different hurdles in a food not only have an added effect on stability, but can act 
synergistically (Leistner, 1995). 
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1.1.2 Chemical preservatives 
A preservative is a natural or synthetic chemical that is added to foods or 
pharmaceuticals to prevent spoilage, whether from microbial growth or undesirable 
chemical changes. FDA has established regulations that set out the rules on declaration 
of flavours, colourings, and preservatives (21 CFR § 101.22). A definition of chemical 
preservative is contained within 21 CFR §101.22(a)(5) as "any chemical that, when 
added to food, tends to prevent or retard deterioration thereof, but does not include 
common salt, sugars, vinegars, spices, or oils extracted from spices, substances added to 
food by direct exposure thereof to wood smoke, or chemicals applied for their 
insecticidal or herbicidal properties." In Europe, the EU Directive No 95/2/EC, defines 
'preservatives' as substances which prolong the shelf life of foodstuffs by protecting 
them against deterioration caused by microorganisms. 
There are over 80 substances which have permitted use as preservatives. Common 
antimicrobial preservatives include calcium propionate, sodium nitrate, sodium nitrite, 
sulfites (sulfur dioxide, sodium bisulfite, potassium hydrogen sulfite, etc.) and disodium 
EDT A. Chemical food preservatives such as benzoates, sorbates, nitrites and sulfites 
have been used effectively for many years, but their safety has been questioned (Knekt 
et al., 1999). Hence restrictions apply on the levels of additives that are allowed to be 
added to the majority of foodstuffs. This applies not only to the levels of a preservative 
permitted for a particular product, but to the overall dietary intake of the preservative. 
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1.1.3 Natural antimicrobials 
Food preservation is becoming more complex in response to changing 
requirements and regulations. In recent years this has included a consumer led demand 
for foods that are nutritionally healthier, more convenient in use (e.g. easier to store and 
prepare), fresher (e.g. chill-stored), more natural and therefore less heavily processed 
(e.g. mildly heated), less heavily preserved (e.g. less acid, salt, sugar) and less reliant on 
additive preservatives (e.g. sulfite, nitrite, benzoate, sorbate) than previously (Gould, 
2001). Consequently, there is pressure on food manufacturers to remove or reduce the 
traditional chemical preservatives in their foods, and to adopt more natural alternatives 
with strategic combinations of technologies for the maintenance of product quality in 
tandem with extension of shelf life and safety. This has fuelled a search for 'bio' or 
naturally derived preservatives that can be safely incorporated into various food 
products. 
A growing number of improved technologies are being researched or are in the 
early stages of application. Alternative strategies for microbial control and shelf life 
extension include the use of novel 'natural' antimicrobials, which are bioactive 
compounds derived from biological sources (animals, plants or microorganisms) such as 
bacteriocins, organic acids, plant essential oils, enzymes, etc (Table 1.4). 
Ideally, these bio-preservatives have been Generally Recognized As Safe (GRAS), 
resulting from a long history of their association with food without associated health 
concerns (McLay et ai., 2002). Many studies have demonstrated antimicrobial activity 
of natural compounds against pathogenic or spoilage organisms in laboratory media. 
However, few of these have been translated into real food applications. Despite the wide 
range of potential antimicrobials, relatively few are suitable for use, in practice, in 
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particular food products (Roller 2003), due to having a limited spectrum of activity. 
They are often effective only at very high concentrations (Branen and Davidson 2004). 
Table 1.4 Sources of natural antimicrobials. 
Animal 
Chitosan 
Lactoferrin 
Lactoperoxidase system 
Lactoglobulin 
Lactolipids 
Lysozyme 
Ovotransferrin 
Ovoglobulin 
Avidin 
1.1.3.1 Fatty acids and derivatives 
1.1.3.1.1 Fatty acids 
Plant 
Essential oils 
Organic acids 
Saponins 
Flavonoids 
Thiosulfinates 
Cathechins 
Glucosinolates 
Microbial 
Natamycin 
Nisin 
Pediocin 
Other bacteriocins 
One group of chemicals found in nature and considered to have little or no toxicity 
is fatty acids and their corresponding esters. Fatty acids are carboxylic acids, regularly 
with a long aliphatic tail that may be either saturated or unsaturated. They are found in 
animal and vegetable fats and oils and have the general formula CnH2n+lCOOH. 
Fatty acids have a long historical record for antimicrobial activity; however 
interest in this class of natural antimicrobials has resumed in recent times. The 
antimicrobial effects of fatty acids have been well documented (Bergsson et al., 2002; 
Dufour et al., 2003; Glass and Johnson 2004; Kitahara et al., 2006). The bactericidal 
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activity of lipids depends on their nature, particularly chain length, and on the bacterial 
strain involved. Generally, Gram-positive bacteria are lipid sensitive whereas Gram-
negative bacteria are more resistant (Kabara et ai., 1972). Recently, however, lipid 
sensitive Gram-negative bacteria have been described (Petschow et al., 1996; Bergsson 
et al., 2002; Sun et aI., 2003). Distinct experimental conditions, such as the test medium 
used, pH, lipid concentrations, and probably also the bacterial strains tested, may be 
responsible for the observed differences in lipid sensitivity of Gram-negative bacteria 
(Sprong et al., 2001). 
The action of fatty acids results from the undissociated molecules rather than their 
conesponding anions. Therefore, the antimicrobial activity of fatty acids is affected by 
pH, since the hydrogen ion concentration determines the degree of dissociation of the 
acid. Antimicrobial activity has been observed at lower pH levels (4.5-5.0), in 
circumstances where pH alone is not lethal (Sun et al., 2003). Furthermore, changes in 
pH affect the minimum inhibitory concentrations (MIC) of fatty acids (Oh and Marshall, 
2003). 
The antimicrobial effect varies with the length of the acid chain and its degree of 
saturation. The chain lengths of fatty acids that were found to be most effective were 
C12 (saturated), C16:1 (unsaturated) and C18:2 (polyunsaturated). In addition, the chain 
length, the degree and type of unsaturation as well as the geometric isomerism are 
important determinants of the biocidal activity of a fatty acid. 
In studies on hydrolysis of bovine milk fat by pregastric lipase, Sun et aI., (2002) 
found that short-chain and medium-chain fatty acids are preferentially released and such 
hydrolysed milk fat products exert antimicrobial effects in vitro. The efficacy of a fatty 
acid as an antimicrobial is dependent on the compound being in solution but also being 
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sufficiently lipophilic to adsorb to the cell surface (Galbraith et al., 1971). As the 
molecular weight of the fatty acid increases, the hydrophilic properties decrease, 
increasing the solubility in oil and decreasing the solubility in water. When the chain 
length is 12 or longer, the antimicrobial activity is greater for unsaturated fatty acids 
than for saturated forms (Ababouch et ai., 1994a; 1994b). 
Fatty acids chosen for this study are described as follows: 
• Lauric acid 
Lauric acid (LA) or dodecanoic acid (C-12) is a medium chain saturated fatty acid 
with structural formula CH3(CH2) lOCOOH (Figure 1.2), that occurs extensively in the 
seed fats of plants from the Lauraceae or Laurel family. It is the dominant fatty acid in 
cinnamon oil (80-90%), coconut oil (41-56%) and palm kernel oil (41-55%). Lauric 
fatty acids provide up to 12% of total fat content in milk contributing as an energy 
source and as a natural antimicrobial. 
o 
HO 
Figure 1.2 Molecular structure of lauric acid 
Lauric acid, although slightly irritating to mucous membranes, has a very low 
toxicity and so is used in many soaps and shampoos. Sodium lauryl sulfate is the most 
common lauric-acid derived compound used for this purpose. Because lauric acid has a 
non-polar hydrocarbon tail and a polar carboxylic acid head, it can interact with polar 
solvents as well as fats, therefore acting as an emulsifier. 
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Recent studies have demonstrated useful activity of lauric acid against a number of 
pathogens, e.g., Listeria monocytogenes, Salmonella enteritidis, Helicobacter pylori, 
Bacillus cereus (Ababouch et ai., 1994a; Ababouch et al., 1994b; Dawson et ai., 2002; 
Sun et ai., 2003; Hoffmann et ai., 2001), viruses (Bartolotta et al., 2001) and spoilage 
microorganisms (Ouattara et al., 1997; Ouattara et al., 2000). 
Lauric acid is relatively inexpensive and therefore potentially very useful and 
available for infection control and medical treatment in hospitals and health care 
environments. Lauric acid might be a potential antimicrobial material in combination 
with other antimicrobial agents, suitable for external application. For example, Kitahara 
et al., (2006) found that a combination of lauric acid and gentamicin showed synergistic 
activity against MRSA. 
• Caprylic acid 
Caprylic acid (CA) or octanoic acid (C-8) is a short chain saturated fatty acid with 
structural formula CH3(CH2)6COOH (Figure 1.3). It occurs naturally in butterfat and 
palm and coconut oils in the form of triacylglycerols and is also found in breast milk. It 
is an oily liquid with a slightly unpleasant rancid taste and is minimally soluble in water. 
It is an intermediate in the manufacture of perfume esters and of dyes. It has also been 
used in organic synthesis, manufacture of medicines, rubber and latex, plastics, greases 
and lubricants, food additives and pharmaceuticals. 
o 
HO~ 
Figure 1.3 Molecular structure of caprylic acid 
12 
Chapter 1. Introduction 
Galbraith et aI., (1971) noted that fatty acids must be in solution and remain 
sufficiently lipophilic to enable adsorption to bacterial cell surfaces for antibacterial 
activity. Caprylic acid as an 8-carbon, short-chain fatty acid, is less hydrophobic and 
potentially more soluble than medium-chain and long-chain fatty acids, therefore it is 
potentially more effective as a bactericide. 
Nair et al., (2005) examined the efficacy of caprylic acid against a number of 
pathogens, and showed that it exerts antimicrobial activity against a wide range of 
microorganisms including Staphylococcus aureus, Streptococcus agalactiae and 
Streptococcus dysgalactiae. Caprylic acid and its mono glyceride, monocaprylin, can 
inactivate infant pathogens such as respiratory synctial virus, Haemophilus influenza, 
and group B streptococci in infant formula at 37°C (Isaacs et al., 1995). Caprylic acid 
has been evaluated as an alternative or adjunct to antibiotics as an intramammary 
infusion to treat bovine mastitis (Nair et al., 2005). 
1.1.3.1.2 Fatty acid esters 
Due to their amphiphilic nature, fatty acid esters possess emulsifying properties 
and exhibit inhibitory effects against some types of microorganisms. This latter property 
makes them promising substances for use in various aspects of the food and other 
industries. 
Fatty acids have been esterified with monohydric alcohols resulting in inactive 
esters (Kabara et al., 1972). Alternatively, the esterification with certain polyhydric 
alcohols such as glycerol or sucrose yielded active derivatives (Conley and Kabara, 
1973). Monolaurin (ML) is the glycerol monoester of lauric acid (Figure 1.4), which 
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proved to be more active than the free acid. Di1aurin and tri1aurin derivatives were less 
active than the monog1yceride (Kabara et aI, 1972). Therefore, the purity of this 
compound is very important, as many mono glyceride preparations have a number of 
impurities, particularly notable quantities of di- and tri-esters. 
o ~ 
o OH 
Figure 1.4 Molecular structure oflauric acid monoester. 
Mono1aurin is approved for use as an emulsifier in foods at levels dictated by good 
manufacturing practices, however, in addition to its emulsification properties; 
mono1aurin also possesses broad spectrum antimicrobial activity against bacteria, yeasts 
and moulds, but generally is more active against Gram positive bacteria. The use of 
mono1aurin in the food industry as a preservative is still limited. Nevertheless it has 
GRAS status by the US FDA and it is commercially available with the trade name 
Lauricidin® (Med-Chem Laboratories, Inc., Galena, Illinois), as a safe dietary 
supplement for suppression of colds and flu, although these have not been evaluated by 
the FDA. 
Monog1ycerides, especially mono1aurin, have received a lot of attention due to 
their antimicrobial properties against a range of infectious agents including bacteria, 
viruses, yeast and fungi (Kabara et al., 1972; Beuchat 1980; Wang and Johnson 1992; 
Bartolotta et al., 2001; Mansour and Milliere 2001; Rihakova et al., 2001; Walters et al., 
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2003). It has been demonstrated that at concentrations between 25 p,g/ml and 250 ""g/ml, 
monolaurin inhibits growth of bacteria (Branen and Davidson, 2004). 
Monolaurin possesses significant antimicrobial activity against Gram-positive 
pathogens including Listeria monocytogenes (Wang and Johnson, 1992; Petrone et ai., 
1998; Branen and Davidson, 2004; Mbandi et al., 2004) and S. aureus (Kabara et ai., 
1972; Schlievert et ai., 1992; Bergsson et al., 2001; McLay et ai., 2002; Kitahara et ai., 
2004; Kitahara et al., 2006). Although, some Gram negative bacteria have also been 
found to be susceptible (Petschow et ai., 1996; Bergsson et ai., 1998; Bergsson et ai., 
1999; Bergsson et ai., 2002; Sun et al., 2003). 
In studies with L. monocytogenes, Wang and Johnson (1992), observed inhibitory 
effects by C12:0, C18:3 and monolaurin in liquid culture media and milk. Monolaurin 
was bactericidal at >200 mg/ml at 4°C but was not inhibitory at 30°C. Moreover, 
monolaurin was less active in skim milk than in brain heart infusion broth, and inactive 
in whole milk. Of the fatty acids tested, lauric acid showed the highest inhibitory 
activity. 
Wang and Johnson (1997) tested the effects of monoglycerides and their 
combinations on L. monocytogenes in foods. They observed inhibitory effects in some 
foods (seafood salad, pH 4.9, and beef rank slurries, pH 5.0 and 5.5), but not in several 
other foods of animal origin. When 200 p,g/L monolaurin was combined with 0.5% 
lactic acid, significant inhibitory effects were observed for Listeria monocytogenes (Oh 
and Marshall, 1995). 
Monolaurin increased the sensitivity of Bacillus cereus spores to thermal inactivation 
(Chaibi et ai., 1998), and when combined with monocaprin inhibited growth of L. 
monocytogenes (Wang and Johnson, 1997). 
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1.1.3.1.3 Fatty acid ether derivatives 
The alkylglycerol ether (dodecylglycerol) (Figure 1.5) has been synthesised by 
Ved et at., (1984) who showed that depending upon the incubation conditions, this 
compound can display more than 2-fold higher antibacterial activity than monolaurin, 
the acylglycerol ester. As with the monoglyceride, alkylglycerol ether was more active 
against Gram positive than Gram negative bacteria and the antibacterial activity was 
higher at a chain length of 12 carbons (Ved et at., 1984). 
~ 
o OH 
Figure 1.5 Dodecylglycerol 
1.1.3.1.4 Carbohydrate fatty acid derivatives 
Carbohydrate fatty acid (CFA) esters are another class of fatty acid derivatives 
which have wide applications in the food and health-care industry (Watanabe, 1999). 
They are used as emulsifiers, non-ionic surfactants, bleaching boosters and food 
additives. Another attractive feature of carbohydrate fatty acid derivatives is the 
potential to modify their properties by controlling the degree of substitution of the 
carbohydrate, by varying the nature of the fatty acid and also the sugar itself. Sugar fatty 
acid esters with degrees of substitution of 1 to 3 are non-ionic, digestible, absorbable and 
biodegradable detergents of low toxicity. Fully esterified carbohydrate fatty acid 
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derivatives are lipophilic, indigestible and unabsorbable molecules and have been used 
as fat substitutes such as Olestra® (Procter & Gamble). 
Sugar esters are used in Japan as antibacterial agents in canned drinks (Suwa et aI., 
1988, Moriyama et aI., 1996, Mitsubishi-Kagaku Foods Corporation, 2009), although in 
Europe and USA their use in the food industry as a preservative is still limited. Sucrose 
esters of fatty acids (E 473) are food additives permitted in the European Union for use 
as emulsifiers and stabilisers for oil/water emulsions in several processed foods by 
Directive 9S/2/EC on food additives other than colours and sweeteners. The most 
common carbohydrate fatty acid ester utilised to date is sucrose ester, which is produced 
at about 4000 ton/year (Ferrer et at., 2005). The use of carbohydrate esters is continually 
increasing as they are completely biodegradable; they are not harmful to the 
environment and they are non-toxic (Janssen et at., 1991). 
Carbohydrate fatty acid esters have been synthesised chemically and enzymatically 
by interesterification, transesterification and direct esterification. Enzymatic methods 
can allow regioselectivity; nevertheless, they do not allow any flexibility in the 
regiomeric outcome. To date, chemical methods have not given rise to regioselectivity, 
and have also produced mixtures of mono, di- and tri-esters. Recent work in the area of 
carbohydrate fatty acid esters has been focused on establishing an effective 
regioselective enzyme catalysed synthesis of sugar derivatives as surfactants for 
industrial applications (Fregapane et al., 1991; Tsuzuki et at., 1999; Ferrer et at., 2000; 
Devulapalle, 2004). 
However, little work has been done on investigating the role of the carbohydrate in 
antimicrobial activity. Conley and Kabara, 1973, examined the antimicrobial activity of 
a range of sucrose esters and concluded that they had greater efficacy than the 
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corresponding free fatty acid. Diesters of sucrose have been found to be more active than 
the mono esters , which is in contrast with data for the glycerides (Kato and Shibasaki, 
1975; Beuchat, 1980). 
1.1.3.2 Essential oils 
Essential oils (EOs) are aromatic oily liquids obtained from plant material 
(flowers, buds, seeds, leaves, twigs, bark, herbs, wood, fruits and roots). Distillation is 
the most popular, and cost effective method in use today for producing essential oils. 
Other processes include expression, solvent extraction, fermentation or enfleurage. An 
estimated 3,000 EOs are known, of which about 300 are commercially important for the 
food (as flavourings), health-care (fragrances) and pharmaceutical (for their functional 
properties) industries (Burt, 2004). 
The antimicrobial activity of EOs have long been recognised and demonstrated 
against a number of microorganisms (Smith-Palmer et ai., 1998; Hammer et al., 1999; 
Dorman and Deans, 2000; Holley and Patel, 2005; Moreira et al., 2005; Oussalah et al., 
2007; Gutierrez et al., 2008). A small number of food preservatives containing EOs are 
already commercially available. "DMC Base Natural" is a food preservative produced 
by DOMCA S.A. (Alhendin, Granada, Spain) and comprises 50% essential oils from 
rosemary, sage and citrus and 50% glycerol (Mendoza-Yepes et al., 1997). "Protecta 
One" and "Protecta Two" are blended herb extracts produced by Bavaria Corp. 
(Apopka, FL, USA), consisting of one or more EOs dispersed in solutions of sodium 
citrate and sodium chloride, respectively (Cutter, 2000). 
EOs can comprise more than sixty individual components. Major components can 
constitute up to 85% of the EO, whereas other components are present only as a trace 
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(Senatore, 1996). The phenolic components are chiefly responsible for the antibacterial 
properties of EOs (Cosentino et al., 1999). The major components of a number of EOs 
with antibacterial properties are presented in (Table 1.5). 
Table 1.5 Major components of selected EOs that exhibit antibacterial properties. 
Common Latin name of plant Major components 
name source (Approx. %composition) 
Cilantro Coriandrum sativum Linalool 26% 
(immature leaves) E-2-decanaI20% 
Coriander Coriandrum sativum Linalool 70% 
(seeds) 
Cinnamon Cinnamomum Trans-cinnamaldehyde 
zeylandicum 65% 
Oregano Origanum vulgare Carvacrol 0-80% 
Thymol 0-64% 
)'-Terpinene 2 -52% 
p-Cymene Trace-52% 
Rosemary Rosmarinus a-pinene 2 -25% 
officina lis Bornyl acetate 0 -17% 
Camphor 2 -14% 
1,8-cineole 3 -89% 
Sage Salvia officinalis L. Camphor 6 -15% 
a-Pinene 4 - 5% 
/3-pinene 2 - 10% 
1,8-cineole 6 -14% 
a-tujone 20--42% 
Clove Syzygium Eugenol 75- 85% (bud) aromaticum Eugenyl acetate 8 -15% 
Thyme Thymus vulgaris Thymol 10-64% 
Carvacrol 2 - 11 % 
)'-T erpinene 2 -31 % 
E-C~ene 10-56% 
Adapted from Burt, 2004. 
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Oregano (Origanum vulgare) and thyme (Thymus vulgaris) are amongst the most 
active EOs. Several essential oil components have been reported as efficient 
antibacterial or antifungal agents, such as linalool (Knobloch et aI., 1989), 1,8-cineole 
(S6kmen et aI., 2004), a-terpineol, terpinen-4-ol, a-pinene, {3-pinene, {3-caryophyllene, 
a-phellandrene, p-cymene (Dorman and Deans, 2000). 
As potential antimicrobial agents, the natural occurrence of EOs as part of the 
human diet and their biodegradability, suggest low toxic residue problems (Nedorostova 
et al., 2009). A number of EO components have been registered by the European 
Commission for use as flavourings in foodstuffs (Commission Decision of 23 January, 
2002). The flavourings registered are considered to present no risk to the health of the 
consumer. The EU registered flavourings also appear on the "Everything Added to Food 
in the US" list, which means that the US FDA has classified the substances as Generally 
Recognised As Safe (GRAS) or as approved food additives. 
1.1.3.3 Bacteriocins 
Bacteriocins produced by lactic acid bacteria (LAB) are ribosomally synthesized, 
extracellularly released bioactive peptides or peptide complexes that have a bactericidal 
or bacteriostatic effect on other species (Nes et al., 1996). Bacteriocins from LAB have 
been largely studied with the perspective of food protection against pathogenic and 
spoilage bacteria (Cleveland et aI., 2001; O'Sullivan et al., 2002). Although bacteriocins 
are produced by many Gram-positive and Gram-negative species, those produced by the 
LAB are of particular interest to the food industry (Nettles and Barefoot, 1993), since 
these bacteria are natural food isolates and have generally been regarded as safe (GRAS 
status) (Deegan et aI., 2006). 
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Bacteriocins are a heterogeneous group of peptides and proteins and as many as 
five main classes of LAB bacteriocins have been mooted (Klaenhammer, 1993; Nes et 
al., 1996; Kemperman et aI., 2003). Cotter et al. (2005) proposed a revised classification 
scheme which divides the bacteriocins into two distinct categories: the lanthionine-
containing Lantibiotics (class J) and the non-Ianthionine-containing bacteriocins (class 
II), while moving the large, heat-labile murein hydrolases (formerly class III 
bacteriocins) to a separate designation called 'bacteriolysins'. 
Nisin is a polycyclic peptide antibacterial with 34 amino acid residues, and a 
member of the group of related polypeptides termed lantibiotics. It is a heatstable 
peptide extensively modified after translation, resulting in the formation of characteristic 
thioether amino acids lanthionine (Lan) and methyllanthionine (MeLan) (Jack and Sahl, 
1995). These are derived from a two-step process: firstly, gene-encoded serine and 
threonine can be subject to enzymatic dehydration to give rise to dehydroalanine (Dha) 
and dehydrobutyrine (Dhb) , respectively. Then, thiol groups from neighbouring 
cysteines attack the double bond of Dha or Dhb yielding either Lan or MeLan, 
respectively (Figure 1.6). This condensation between two neighbouring residues results 
in the formation of covalently closed rings within the formerly linear peptide, conferring 
both structure and functionality. 
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Figure 1.6 Lanthionine synthesis (a) and nisin structure (b). 
Nisin fonns pores that disrupt the proton motive force and the pH equilibrium 
causing leakage of ions and hydrolysis of ATP resulting in cell death (de Arauz et al., 
2009). Lipid II, a docking molecule or target, is involved in several cases in the 
mechanisms of action of nisin (Brotz et al., 1998). The binding of nisin to lipid II 
facilitates a dual mechanism of action involving pore fonnation and preventing 
peptidoglycan synthesis (Breukink et al. 1999; Wiedemann et al., 2001). 
Nisin remains the most commercially important bacteriocin, although other 
bacteriocins have been characterized and developed for possible approval and use 
(Cleveland et al., 2001). Nisin A and pediocin PA-l, which are the only bacteriocins 
approved for utilization as a preservative or ingredient, are produced by Lactococcus 
lactis and Pediococcus acidilactici, respectively. Nisin is commercially available as 
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Nisaplin ™ (Danisco, Copenhagen, Denmark), while pediocin PA-l is marketed as 
ALTATM 2341 (Kerry Bioscience, Carrigaline, Co. Cork, Ireland). 
A major problem with bacteriocins application is related to the in situ antimicrobial 
efficacy, which can be negatively influenced by various factors, such as binding to food 
components, inactivation by proteases, changes in solubility and charge, or changes in 
the cell envelope of the target bacteria (Jung et a!., 1992; Aesen et al., 2003). The 
chemical composition and the physical conditions of food can have a significant 
influence on the activity of the bacteriocin. Nisin, for example, is 228 times more 
soluble at pH 2 than at pH 8 (Liu and Hansen, 1990). Nisin has been shown to be 
effective in a number of food systems, including dairy products, canned foods and 
processed cheese inhibiting the growth of a wide range of bacteria, (Cutter and Siragusa, 
1995; Ferreira and Lund, 1996; Davies et a!., 1999). 
Although some LAB bacteriocins have been found to be active against Gram-
negative bacteria, they are generally effective against closely related Gram-positive 
species. The addition of bacteriocins along with other natural preservatives might 
increase their efficacy within food matrices against some Gram-negative spoilage 
bacteria that are known to show consistently high resistance to antimicrobials, such as 
Pseudomonas spp. (Hammer et al., 1999; Holley and Patel, 2005). 
1.1.4 Antimicrobial agents and resistance 
Antimicrobials are natural or synthetic drugs which inhibit or kill bacteria. This 
capability makes them unique for the control of deadly infectious diseases caused by a 
large variety of pathogenic bacteria. Antibiotics, also referred as chemotherapeutic 
agents or antimicrobial drugs, are used predominantly for the treatment of bacterial 
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infections in humans and animals; whereas biocides are employed for their antiseptic, 
disinfectant andlor preservative properties. 
Today, more than 15 different classes of antimicrobial drugs are known. They 
differ in chemical structure and mechanism of action. Specific antimicrobial drugs can 
be necessary for the treatment of specific pathogens. Following their 20th century 
triumph in human medicine, antimicrobials have also been used increasingly for the 
treatment of bacterial disease in animals, fish and plants. In addition, they became an 
imp0l1ant element of intense animal husbandry because of their observed growth-
enhancing effect, when added in sub-therapeutic doses to animal feed. 
The persistent emergence of antibiotic-resistant strains of pathogens is making 
successful empirical therapy much more difficult to achieve, as antibiotic choices are 
often severely restricted (Gould, 2009). The increasingly rapid pace at which microbes 
are able to develop or acquire new drug resistance profiles outpaces the rate at which the 
pharmaceutical industry develops, screens and distributes new antimicrobial agents 
(Cloutier, 1995). Thus there is a need for alternative approaches, some products used in 
the past seem to be making a return, and other alternatives are being investigated. 
Infections caused by methicillin-resistant Staphylococcus aureus (MRSA) are 
increasing in both hospital and community settings. S. aureus is one of the most 
common causes of bloodstream infection (or bacteremia). MRS A is a global concern, in 
Europe, the highest rates of MRS A bacteraemia in 2007 were observed in Malta 
(52.4%), Portugal (48.4%), Cyprus (48.2%), Greece (48%), Ireland (38.1%), Croatia 
(37.6%) and UK (35 .6%). The lowest rates (all <2%) were observed in Scandinavian 
countries and the Netherlands (EARSS, 2007). In Ireland, the annual trend decreased 
from approximately 42% between 2002 and 2006 to 38.5% in 2007 (HPSC, 2007). 
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Consequently, there has been considerable interest in discovering and developing new 
antistaphylococcal agents for potential therapeutic application. 
Antimicrobial resistance continues to be a growing problem including other 
pathogens such as enterococci and E. coli (Schmidt et at., 1998). Therefore, measures to 
promote prudent antibiotic use in both hospital and community settings are required to 
reduce the burden of antimicrobial resistance. 
Acquisition of antibiotic resistance genes IS the predominant factor in the 
emergence, evolution and spread of antibiotic resistant bacteria (Hall and Collis, 2001). 
Antibiotic-resistant bacteria are increasingly seen to be just as virulent as their sensitive 
counterparts, and their genetic adaptability gives bacteria a huge advantage over 
mankind (Lindsay and Holden, 2006). This situation arises as a result of the excessive 
and often inappropriate use of antibiotics in human and animal health care for the 
treatment and prevention of bacterial infections (Rao, 1998; Lohner and Staudegger, 
2001). 
Development of antimicrobial resistant foodborne bacterial pathogens can 
potentially compromise human drug treatments. It is now collectively acknowledged that 
the use of antimicrobials in both animals and humans can select for resistant bacterial 
populations (Threlfall et aI., 2000; White et al., 2002). There is concern that 
antimicrobial resistant bacteria in animals may transfer to humans through the food 
chain (Khachatourians, 1998; Overarching AMR Report UK, 2004). While the links 
between animal agriculture and human disease are complicated and in need of additional 
study, evidence is strong enough for scientists and public health organizations to call for 
reduced use of antibiotics in agriculture (Goldman, 2004). Intense animal production in 
the agricultural industry sometimes involves giving livestock animals' large quantities of 
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antibiotics to promote growth and prevent infection. These uses promote the selection of 
antibiotic resistance in bacterial populations. 
It is now more than a decade since the European Union started the withdrawal of 
selected growth-promoting antibiotics (Phillips, 2007). By 2006, the use of antimicrobial 
agents for growth promotion was no longer approved in the EU (Regulation 
1831/2003/EC on additives for use in animal nutrition); however, this use of 
antimicrobial agents for food animals continues in North America and Australia. 
1.2 MICROORGANISMS INVESTIGATED 
Despite improved understanding of infection processes, better methods for 
controlling microorganisms and much stricter regulation of food production, foodborne 
diseases are still a major cause of morbidity and mortality worldwide (Roller, 2003). 
Among the aims of this work is to assess the efficacy of novel antimicrobial 
compounds for possible applications in fields ranging from the food industry to the 
healthcare industry. Thus, a number of gram positive and gram negative bacteria of 
concern for these industries were investigated. 
1.2.1 Listeria 
Listeria species are Gram positive non-sporeforrner bacilli which are Ubiquitous in 
the environment and found world-wide. Listeria monocytogenes is the only important 
human pathogen among the six species currently recognized within the genus, although 
other species have occasionally been associated with human illness. They are not highly 
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pathogenic to healthy adults, however, pregnant women, neonates, the elderly and the 
immuno-compromised are at particular risk and disease in these groups can be severe. 
L. monocytogenes causes the disease listeriosis, which has several manifestations 
such as meningitis, septicaemia, encephalitis, and cervical infections in pregnant 
women, which may result in spontaneous abortion (2ndl3rd trimester) or stillbirth. The 
infective dose of L. monocytogenes is unknown but is believed to vary with the strain 
and susceptibility of the victim. From cases contracted through raw or supposedly 
pasteurized milk, it is safe to assume that in susceptible persons, fewer than 1,000 total 
organisms may cause disease (FDA, 2009). Due to the long incubation time, the tracing 
and identification of the pathogen in the contaminated food can be very difficult. 
Listeria monocytogenes is currently a worldwide concern affecting numerous 
countries. In the EU, in addition to the economic consequences and threats associated 
with outbreaks, listeriosis remains of great public health concern, as it has one of the 
highest case fatality rates of all the foodborne infections: 20-30% (De Valk et al., 2005). 
In 2007, 1,554 confirmed cases of human listeriosis were reported in 24 EU Member 
States and was the fifth most common zoonotic infection in Europe, after 
Campylobacter, Salmonella, Yersinia, and VTEC infections (EFSA, 2009). Despite the 
food controls carried out in EU Member States, the incidences of listeriosis, outbreaks 
and contaminated product recalls continue to occur. L. monocytogenes is widely 
distributed in nature, can adapt to survive and grow in a wide range of environmental 
conditions, being frequently found in a large variety of raw and processed foods, as well 
as in processing plants (Rocourt and Cossart, 1997). Foods most likely to be 
contaminated are unpasteurized cheeses, cold cuts of meat, pates and smoked fish, or 
ready meals which have been pre-cooked and then chilled for some time before 
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consumption. L. monocytogenes has emerged as one of the most important food 
pathogens in ready-to-eat processed meals and dairy foods (FSAI, 2005) due to its 
survival and growth at refrigeration temperatures (2-4 DC) making the control of this 
foodbome pathogen difficult, since refrigeration is one of the most common ways to 
increase the shelflife of ready-to-eat and minimally processed foods. 
1.2.2 Staphylococcus au reus 
S. aureus is a Gram-positive coccus. When viewed microscopically, S. aureus 
appears in clusters, like bunches of grapes. S. aureus belongs to the genus 
Staphylococcus, together with other species, such as S. intermedius, S. hyicus and S. 
epidermidis. S. aureus can be distinguished from S. epidermidis by the production of the 
enzymes coagulase and thermonuclease. 
The main reservoirs of S. aureus are humans and animals. Healthy people carry the 
organism in their nose and throat (50 %), on their hands (5-30 %), and in wounds. S. 
aureus can also colonize food contact surfaces, and it can become a persistent organism 
in slaughterhouses. S. aureus can contaminate foods through contact with contaminated 
hands, materials and surfaces, but also via the air (coughing). Growing in food, some 
strains can produce toxins which cause acute gastro-intestinal diseases if ingested. The 
enterotoxin produced by S. aureus is a heat-stable protein, which survives heating at 100 
DC for 30 - 700 minutes. The organism can grow both with and without oxygen 
(facultatively anaerobic). It is characteristic that staphylococci can grow at low water 
activity (approx 0.86), corresponding with a salt content of about 14 %. S. aureus IS 
extremely heat sensitive and is readily inactivated at temperatures> 46°C. 
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Illness is caused by the consumption of a foodstuff contaminated with the toxin 
which S. aureus may have produced. In order to produce detectable levels of toxin, the 
number of organisms must be over 105-6 per gram of product. The time between 
ingestion of the toxin and display of symptoms is only two to five hours and depends on 
the amount and type of food and the state of health of the person. The main symptoms 
are nausea, vomiting, abdominal cramps and exhaustion. Patients usually recover within 
two days. 
Outbreaks and sporadic cases of staphylococcal food poisoning have been linked 
with foods such as cheese, salami, bakery products, pasta, canned meat, canned fish and 
canned vegetable products. What these products have in common is that they require 
frequent manual handling during preparation and that they are often kept at room 
temperature for some time. Most food intoxications caused by S. aureus are the result of 
poor hygiene practices in household and industrial kitchens. Staphylococcal food 
poisoning has been a notifiable disease in Ireland since 1st January 2004 (S.I No.707, 
2003). 
1.2.2.1 Methicillin-resistant Staphylococcus aureus 
Methicillin-resistant S. aureus (MRSA) infection first emerged in early 1961 and 
has become increasingly prevalent, with serious infections becoming more widespread 
during the past 20-25 years (Kitahara et al., 2006). 
S. au reus becomes methicillin resistant by the acquisition of the mecA gene which 
encodes a penicillin binding protein (PBP2a) with a low affinity for {3-lactams, usually 
carried on a larger piece of DNA called a staphylococcal cassette chromosome SCCmec 
(Hartman and Tomasz, 1981; 1984; 1986). Expression of mecA yields PBP2a, a 
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penicillin binding protein with reduced affinity for ,B-Iactam antibiotic binding. Penicillin 
binding proteins are necessary for correct synthesis of the bacterial cell wall, and when 
they are blocked by penicillin, the cell wall is incorrectly formed, and the cell is liable to 
lyse. PBP2a allows the bacterium to synthesise cell wall normally in the presence of 
methicillin (Pinho et at., 2001). 
MRSA has recently become a major cause of hospital-acquired infections and is 
being recognized with increasing frequency in community acquired infections. S. aureus 
is one of the commonest causes of bloodstream infection (or bacteremia). 
MRSA has caused serious problems in the empirical use of all the major classes of 
antibiotics in common use, for example, the cephalosporins, penicillins, carbapenems, 
quinolones and aminoglycosides. Moreover, MRSA has not replaced methicillin-
susceptible S. aureus (MSSA), but is an additional burden of infection, often doubling or 
trebling the number of clinical staphylococcal infections, whether in the hospital or the 
community (Gould, 2005). Outcomes are worse for MRSA infection than for MSSA, for 
complex reasons including inappropriate empirical treatment (Cosgrove et al., 2006). 
Possibly the major cause of this inferior outcome in MRSA infection is the reliance on 
glycopeptides, which have long been known to be suboptimal for MSSA infections 
(Gould, 2007). Indeed vancomycin, launched in 1958 on the evidence of successful 
treatment in just a handful of patients, was soon dropped from routine clinical use when 
the semisynthetic penicillins were introduced in the 1960s. Unfortunately, we still await 
the development of equivalent drugs for the treatment of MRSA. All new agents and 
those likely to be marketed in the foreseeable future, have significant drawbacks. 
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1.2.3 Escherichia coli 
Escherichia coli are Gram negative rod-shaped bacteria that normally inhabit the 
intestines of humans and warm-blooded animals. Most strains are known to be harmless, 
but several of them can cause mild to serious disease. Verotoxigenic E. coli (VTEC), 
and in particular E. coli 0157:H7, can cause severe diarrhoea and in some cases lead to 
serious complications, even death. 
E. coli is transmitted to humans primarily through consumption of contaminated 
foods, such as raw or undercooked ground meat products and raw milk. Meat can 
become contaminated during slaughter, and organisms can be thoroughly mixed into 
beef when it is minced. Eating meat (especially minced beef) that has not been cooked 
sufficiently to kill E. coli 0157:H7 has caused infection (Adams and Moss, 2000). E. 
coli 0157:H7 has also been found in other animals such as sheep, pigs, goats, poultry, 
and deer. Other risk factors include drinking or swimming in contaminated water, 
handling animal faeces, and eating fruit and vegetables fertilized or irrigated with animal 
manure. Poor personal hygiene and unsafe food preparation practices also increase the 
risk of spreading 0157 :H7 infection (HPSC, 2007). 
E. coli 0157:H7 has been detected throughout the world, but most outbreaks have 
been documented in Canada, United Kingdom and USA (Adams and Moss, 2000). The 
reported incidence ofVTEC disease in Ireland has risen from 2.4 per 100,000 in 2003 to 
3.7 per 100,000 in 2006 (Garvey et al., 2008; EFSA, 2009). People from any age group 
are susceptible to infection with E. coli 0157:H7. However, children, the elderly and 
immuno-compromised persons are more likely to become infected and develop 
complications. 
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The symptoms of 0157:H7 infection includes severe diarrhoea and abdominal 
cramps, often developing into bloody diarrhoea. Symptoms usually occur three to four 
days after exposure. Some people infected by E. coli 0157:H7 may have no symptoms 
at all or only mild diarrhoea. Complications include the haemolytic uremic syndrome 
(HUS) which results in destruction of red blood cells and kidney failure. HUS can also 
affect the nervous system causing seizures and eventually coma. Treatment for E. coli 
infection has been increasingly complicated by the emergence of resistance to most first-
line antimicrobial agents, including fluoroquinolones (Sabate et al., 2008). 
1.2.4 Salmonella 
Salmonella is a genus of rod-shaped Gram-negative enterobacteria. Salmonella 
enterica are involved in causing diseases of the intestines. The three main serovars of 
Salmonella enterica are Typhimurium (until recently, the most common cause of food 
poisoning by Salmonella species), Enteritidis (common cause of food poisoning), and 
Typhi (causative agent of typhoid fever). In humans S. Typhimurium does not cause as 
severe disease as S. Typhi, and is not normally fatal. The disease is characterized by 
diarrhoea, abdominal cramps, vomiting and nausea, and generally lasts up to 7 days. 
Salmonella infections can often be fatal for immuno-compromised or elderly people if 
they are not treated with antibiotics. Salmonella occurs in raw poultry, eggs, beef, and 
sometimes on unwashed fruit and vegetables. 
Salmonellosis remained the second most commonly reported zoonotic disease in 
the EU. In 2007,456 cases of salmonellosis were notified in Ireland (HPSC, 2007), with 
a national crude incidence rate for 2007 of 10.7 per 100,000. 
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1.2.5 Pseudomonas 
Pseudomonas is a genus of gram negative, aerobic, non spore forming bacilli, 
motile by means of one or more polar flagella. Pseudomonas species normally inhabit 
soil, water, and vegetation and can be isolated from the skin, throat, and stool of healthy 
persons. As a result of their metabolic diversity, ability to grow at low temperatures and 
ubiquitous nature, many Pseudomonas can cause food spoilage. 
Pseudomonas aeruginosa is increasingly recognized as an emerging opportunistic 
pathogen of humans. They often colonize hospital food, sinks, taps, mops, and 
respiratory equipment causing urinary tract infections, respiratory system infections, 
dermatitis, soft tissue infections, bacteraemia, bone and joint infections, gastrointestinal 
infections and a variety of systemic infections, particularly in patients with severe bums 
and in cancer and AIDS patients who are immuno-suppressed. 
Pseudomonas jluorescens has multiple flagella. The name 'fluorescens' is due to 
the fact that they secrete a soluble fluorescent pigment called pyoverdin (formerly called 
fluorescein), that diffuses into the medium and is fluorescent under ultraviolet light. 
Pyoverdin is a siderophore, a bacterial product synthesised in response to iron limitation 
(Cox and Adams, 1985), functioning as a powerful iron chelator, solubilizing and 
transporting iron through the bacterial membrane via specific receptor proteins at the 
level of the outer membrane (Schons et aI., 2005). 
P. jluorescens has an extremely versatile metabolism, and can be found in the soil 
and in water. It is an obligate aerobe but celiain strains are capable of using nitrate 
instead of oxygen as a final electron acceptor during cellular respiration. Optimal 
temperatures for growth are 25-30 DC. Heat stable lipases and proteases are produced by 
P. jluorescens and other similar pseudomonas. These enzymes cause milk to spoil, by 
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causing bitterness, casein breakdown, and ropmess due to production of slime and 
coagulation of proteins. 
1.2.6 Enterobacter 
Enterobacter bacteria are gram negative, motile, rod shaped bacteria of the family 
Enterobacteriaceae. They are facultative anaerobes and possess peritrichous flagella. 
Enterobacter aerogenes is considered as one of the main species of this genus. E. 
aerogenes is generally found in the human intestinal tract and does not generally cause 
disease in healthy individuals. E. aerogenes has been isolated from soil, water, 
vegetables, meats, plants, dairy products, and cosmetics. Several strains are pathogenic 
and cause opportunistic infections in immuno-compromised people. 
1.2.7 Lactic acid bacteria (LAB) 
Lactic acid bacteria (LAB) are a group of related Gram-positive, non-spore-
forming strictly fermentative bacteria producing lactic acid as the major end product of 
carbohydrate fermentation. The genera that comprise the LAB are at its core 
Lactobacillus, Leuconostoc, Pediococcus, Lactococcus, and Streptococcus. These 
microbes are broadly used in the production of fermented food products, such as yogurt 
(Streptococcus spp. and Lactobacillus spp.), cheeses (Lactococcus spp.), sauerkraut 
(Leuconostoc spp.) and sausage. 
Though lactobacilli do not negatively affect human health, they represent problems 
and losses for food manufacturers, because they alter the sensorial properties of some 
food products. LAB are characterized by an increased tolerance to a lower pH range, 
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therefore during storage favoured by anaerobic conditions, psychrotrophic LAB usually 
become the dominant bacterial group or occur in very high numbers. LAB may spoil a 
product if it is not manufactured and stored correctly. 
Previous studies have shown LAB to be relevant in the spoilage flora of chill 
stored vacuum-packaged cold-smoked fish products (Lyhs et ai., 1999; Gonzalez-
Rodriguez et ai., 2002; Joffraud et ai., 2006) and salted and fermented ready-to-eat fish 
products (Lyhs and Bjorkroth, 2008). Lb. plantarum, Lb. brevis and B. coagulans are 
bacteria of considerable concern during the processing of acidic and acidified foods, as 
they are amongst the most resistant microorganism to the thermal treatments usually 
used by producers of fruit juices (Edwards et aI., 1998). Others lactobacilli such as Lb. 
casei, Lb. plantarum and Lb. brevis can also grow in and cause spoilage of delicacy 
products, especially mayonnaise-based salads (Delaquis et aI., 1997). The important role 
played by LAB in spoilage of packed, cold stored meat products has been widely 
reported (Chenoll et al., 2007) with the species Lb. curvatus, Lb. sakei, Lb. plantarum 
and Leuconostoc spp. being among those most frequently identified. 
1.3 EVALUATION OF ANTIMICROBIAL ACTIVITY 
Currently there is no standard reproducible method for assessing the antimicrobial 
activity of natural antimicrobials, including plant extracts and their active components 
(King et al., 2008). Inhibition of microbial growth can be detected using a variety of 
methods, including direct microscopic counts, absorbance, assays that incorporate a 
colorimetric and fluorometric growth indicator, bioluminescence assays, turbidity, dry 
weight, and zones of inhibition. 
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An alternative measure of susceptibility is to determine the Minimum Inhibitory 
Concentration (MIC) and the Minimum Bactericidal Concentration (MBC) of an 
antimicrobial. A series of broths are mixed with serially diluted antimicrobial solutions 
and a standard inoculum is applied. After an overnight incubation, the MIC is the lowest 
concentration of an antimicrobial that will inhibit the visible growth of a microorganism. 
The more resistant an organism is, then the higher will be the MIC. The MBC is not as 
commonly seen as the Minimum inhibitory concentration (MIC). It can be determined 
from broth dilution MIC tests by subculturing the broths to agar media without 
antimicrobial. The MBC is the first dilution at which no growth is observed. 
Antimicrobials are usually regarded as bactericidal if the MBC is no more than four 
times the MIC. With static agents, the MIC is much lower than the MBC. 
The most commonly used methods to determine the MIC of an antimicrobial agent 
are briefly described below. 
• Disk-diffusion method 
Diffusion methods have been widely used to investigate the antibacterial activity 
of potential antimicrobial compounds. The organism is inoculated evenly onto an agar 
plate to obtain a confluent lawn of growth. Disks impregnated with antimicrobial agents 
are then placed onto the agar. After a suitable incubation period, the plate is examined 
for zones of inhibited growth around the disk. The size of the zone of inhibition is 
inversely proportional to the MIC of the antimicrobial for the organism. This method is 
an indirect measure of the susceptibility based on MIC zone size correlation. Depending 
on the zone's size, the organism is reported to be susceptible, intelmediate, or resistant 
to the antimicrobial agent. 
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The test however, must be performed under controlled and standardized conditions 
to provide accurate results. For example, the appropriate culture media to use, inoculum 
size and concentration, disk potency and its proper storage. These assays are qualitative; 
a disadvantage is that interpretive charts are needed and they vary with the organism 
being tested. The disk diffusion method can lead to problems of interpretation such as 
growth in the inhibition zone and subjectivity associated with visual assessments 
(Deighton and Balkau 1990). Diffusion methods are not the best choice for testing non 
polar or other samples that do not diffuse in the media well (Cos et ai., 2006). The 
hydrophobic nature of most essential oils and phenolic compounds present in plant 
extracts prevents the uniform diffusion of these substances through the agar medium and 
will therefore impact the evaluation of their antibacterial capability. In general, the 
relative antimicrobial potency of different samples may not always be compared, mainly 
because of differences in physical properties, such as solubility, volatility and diffusion 
characteristics in agar (Cos et al., 2006). 
• Agar-well diffusion method 
It is another type of diffusion technique where the antimicrobial agent is placed 
into wells bored into an inoculated agar plate; this diffuses into the agar around the well, 
and is assayed for an ability to produce an inhibition zone. The hole-punch method is the 
only suitable diffusion technique for aqueous extracts, because interference by 
particulate matter is much less than with other types of reservoirs. 
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• Agar dilution method 
This is one of the most commonly employed methods. Different concentrations of 
antimicrobial agents are incorporated onto agar plates. These are spot inoculated with a 
multipoint inoculator on the surface of the agar with an inoculum equivalent to 4 to 5 log 
CFU per spot applied. Plates are incubated at 35°C overnight and read by observing the 
lowest concentration that inhibits visible bacterial growth. This concentration is reported 
as the MIC. This method provides reliable results, but it is very time-consuming and 
uses a great quantity of material. In general, dilution methods are appropriate for 
assaying polar and non-polar extracts or compounds for determination of MIC and 
MBC-values. 
• Macro broth dilution method (Tube dilution test) 
This method uses tubes with broth containing a test level of antimicrobial agent, 
into which an inoculum of microbes is added. The end result of the test is the minimum 
concentration of antimicrobial which gave a clear solution, i.e., no visual growth. 
Although this test is fairly precise, it is laborious as serial dilutions of the antibiotic must 
be made and only one isolate can be tested in each series of dilutions. 
• Micro broth dilution method 
The broth microdilution method IS a fast and low-cost method for MIC 
determination, is a reference method from the National Committee for Clinical 
Laboratory Standards (NCCLS) and is the method chosen for this study. 
Microtiter plate-based assays have been developed for a wide range of applications 
including monitoring ofbioactive compound production in fermentation samples (Casey 
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et ai., 2004), determination of antimicrobial susceptibility patterns of microorganisms 
(Ruzicka et ai., 2003), and to quantify in vitro the synergistic activity of "natural" 
antimicrobials (Dufour et ai., 2003). The broth micro dilution method appears to be an 
easy and reliable method for determination of the MICs of antibiotics for C. jejuni and 
C. coli, and it may offer an interesting alternative to MIC determination by the agar 
dilution technique or the E test (Luber et ai., 2003). Steward et ai., 1999 compared the 
automated susceptibility instruments used by most clinical laboratories, MicroScan and 
Vitek, and found that they did not perform well compared to broth micro dilution 
because of the high level of minor errors, although many of the errors were within one 
dilution of the reference value. 
1.4 ANTIMICROBIAL MODES OF ACTION 
The basic mechanisms of action of antibiotics are generally well understood. Most 
antibiotics in clinical usage are directed against bacterial cell wall synthesis, protein 
synthesis, or nucleic acid synthesis, which are unique in some ways to bacteria. For 
example, antibiotics that inhibit peptidoglycan synthesis in the cell wall do not affect 
mammalian cells as they have neither a cell wall nor peptidoglycan. Other antibiotics 
target bacterial protein synthesis because bacterial ribosomes (termed 70S ribosomes) 
are different from the ribosomes (80S) of humans and other eukaryotic organisms. 
Antibiotics such as the fluoroquinolones inhibit prokaryotic (not eukaryotic) DNA 
replication, and rifamycins inhibit bacterial (not eukaryotic) DNA transcription. In 
addition, some antibiotics, like polymyxins, interfere with membrane integrity. 
However, membrane inhibition or disruption is not always successful due to similarities 
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in phospholipids in eubacterial and eukaryotic membranes, therefore these types of 
compounds are not recommended to be used systemically. 
By contrast, the mechanisms of antibacterial action of biocides, which comprise 
preservatives, antiseptics and disinfectants, are poorly understood (Russell, 2003). 
Biocides are known to interact with bacterial cell walls or envelopes, produce changes in 
cytoplasmic membrane integrity (cationic agents), dissipate the proton-motive force 
(organic acids and esters), inhibit membrane enzymes (thiol interactors), act as 
alkylating agents ( ethylene oxide), cross-linking agents (aldehydes) and intercalating 
agents (acridines), or otherwise interact with identifiable chemical groups in the cell 
(Denyer and Stewart, 1998). 
1.4.1 Antimicrobial modes of action of fatty acids and derivatives 
Fatty acids and their esters have several modes of action that are non-specific. The 
mechanism of monolaurin inhibitory action is not completely known, but it is thought to 
affect the cell membrane. The modes of action relevant to this study are further 
discussed below. 
• Membrane inhibition or disruption 
The integrity of the cytoplasmic and outer membranes is vital to bacteria, and 
compounds that disorganize the membranes rapidly kill the cells. However, due to the 
similarities in phospholipids in eubacterial and eukaryotic membranes, this action is 
rarely specific enough to permit these compounds to be used systemically and is 
therefore usually limited to topical usage. 
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In most cases, antimicrobial agents that work in this manner create pores in the 
membrane that cause the leakage of cytoplasmic contents. In addition, they may also 
interfere with the functions of enzymes in the membrane. 
The inhibitory action of mono laurin, like fatty acids in general, may be partly due 
to an 'uncoupling' effect of the plasma membrane (Stratford and Anslow, 1996). Wang 
and Johnson (1992) observed that in Listeria cells treated with monolaurin, the 
cytoplasmic contents appeared to separate from the cell envelope but the cell surface 
appeared to remain intact. In other cells, however, breakage of the cell envelope and 
leakage of cytoplasmic contents were observed. 
• Inhibition of enzymes 
Galbraith and Miller (1973b, c) proposed that fatty acids may affect the respiratory 
activity of cells by the inhibition of enzymes involved in oxygen uptake and inhibits the 
transport of amino acids into cells. It also has been shown that monolaurin affects 
neither secretion nor intracellular signalling and most likely acts through the inhibition 
of signal transduction (Ruzin and Novick, 1998; 2000). At lower concentrations, which 
do not significantly alter bacterial growth, monolaurin blocks the production of various 
exoenzymes and virulence factors, including protein A, alpha-hemolysin, 13-lactamase, 
and toxic shock syndrome toxin 1 (TSST -1) in Staphylococcus au reus (Ruzin and 
Novick, 2000). The action ofmonolaurin is not restricted to S. aureus; it also blocks the 
induction of vancomycin resistance in another pathogen, Enterococcus faecalis (Ruzin 
and Novick, 1998). 
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1.4.2 Evaluation of the antimicrobial effect on the cell membrane 
A number of assays have been developed to detect and quantify membrane 
damage. 
• Leakage of material absorbing at 260 nm 
Low molecular weight metabolites known to leak from cells include nucleotides 
and their component structures (purines, pyrimidines, pentose and inorganic phosphate), 
amino acids and inorganic ions. The presence of these materials in a suspension 
indicates damage to the cell at the membrane level and can be determined by their 
absorbance at 260 nm. 
Several studies have implemented this method, called the OD260 assay, to evaluate 
the mode of action of antimicrobial compounds against a different range of 
microorganisms (Liu et ai., 2004; Oonmetta-aree et ai., 2006). O'Neill et ai., (2004) 
compared different assays for detection of agents causing membrane damage in 
Staphyiococcus aureus and concluded that the OD260 assay should be sufficient for most 
purposes since it is effective, rapid and cheap to perform. 
• Ions 
Generally, the first sign of an increase in cytoplasmic membrane permeability is 
provided by leakage of the important intracellular solute potassium, and in recent years 
measurement of potassium loss from bacterial cells has successfully been used to detect 
membrane damage caused by phytochemica1s present in tea tree oil (Cox et ai., 2000), 
oregano essential oil (Lambert et ai., 2001) and galangin (Cushnie and Lamb 2005; 
2006). 
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Potassium and hydrogen can leak and be detected by ion electrodes. Ion-selective 
electrodes are used to monitor the formation of ion channels that affect the membrane 
potential in bacteria. Potentiometric measurements have several inherent advantages 
over spectrophotometric methods, i.e., simplified procedures, low costs and ease of 
continuous monitoring in a turbid cell suspension (Johnston et ai., 2003). 
• Measurement of ATP 
The leakage of low molecular weight compounds is frequently followed by leakage 
of larger cellular constituents [ego adenosine triphosphate (ATP)] either as damage to the 
membrane increases or as soluble products are formed from the gradual breakdown of 
proteins and nucleic acids by the autolytic enzymes of the cell (Johnston et ai., 2003). 
Cells can release nucleotides, such as ATP and UTP, in response to mechanical 
stress or biological activation. Leakage of intracellular ATP is the result of increased 
membrane permeability. Commercial kits are available that measure A TP leakage by 
fluorescence or luminescence methods. 
O'Neill et ai., (2004) recommended that studies requiring maximum sensitivity and 
discrimination should employ the ATP assay. 
• Enzymatic assays 
Enzymatic assays are an aid to assess the damage of the cell membrane. Different 
assays are commercially available to determine different enzymes present in the 
cytoplasm of the cells which can be detected when the membrane has been disrupted. 
For example, the cytoplasmic enzyme lactate dehydrogenase is released into the cell 
culture medium if the membrane is damaged. Another assessment of membrane 
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permeabilization is done by measuring the release of cytoplasmic ,6-galactosidase 
activity from E. coli into the culture medium using ONPG (O-nitrophenyl-,6-D-
galactopyranoside) as the substrate. 
• Fluorescent methods (BacLight assay) 
Conventional direct-count assays of bacterial viability are based on metabolic 
characteristics or membrane integrity. Fluorescent probes provide alternative methods 
for assessment of bacterial physiology (Haugland, 1996; Breeuwer and Abee, 2000). 
Recently the Live/Dead® BacLight™ Bacterial Viability Kits sold by the Molecular 
Probes, Inc. have been used for bacterial enumeration and viability testing in various 
ways (Virta et al., 1998; Bunthof et al., 2001; Singh, 2006). 
The Live/Dead® BacLightTM Bacterial Viability Kits utilize mixtures of SYTO® 9 
green fluorescent nucleic acid stain and the red fluorescent nucleic acid stain, propidium 
iodide. These stains differ both in their spectral characteristics and in their ability to 
penetrate healthy bacterial cells. When used alone, the SYTO 9 stain generally labels all 
bacteria in a population - those with intact membranes and those with damaged 
membranes. In contrast, propidium iodide penetrates only bacteria with damaged 
membranes, causing a reduction in the SYTO 9 stain fluorescence when both dyes are 
present. Thus, with an appropriate mixture of SYTO 9 and propidium iodide stains, 
bacteria with intact cell membranes stain fluorescent green, whereas bacteria with 
damaged membranes stain fluorescent red. 
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• Electron microscopy 
Cellular integrity can be evaluated as reflected by transmission electron 
microscopy. Using electron microscopy, any gross morphological changes that take 
place when cells are exposed to a lethal dose of antimicrobial can be observed. For 
example, (Skrivanova et a!., 2005) using electron microscopy photographs observed that 
there was no visible alteration in the cell wall structure and size of cells, but the 
separation of inner and outer membranes and complete cytoplasm disorganization in 
lauric acid-treated cells was apparent. 
1.4.3 Phenotypic MicroArray to identify antimicrobials and their mechanism of 
action 
Technologies that offer a cell-wide perspective are very useful in biology. 
O'Farrell (1975), and Fodor et al. (1993), initiated using two dimensional methods for 
protein analysis (proteomics), and for nucleic acid analysis (genomics), respectively. 
These technologies and subsequent improvements allow for global analysis of the 
important macromolecules of cells that convey the information flow from DNA to RNA 
to protein. However, the information initially encoded in the genome is ultimately 
displayed at the cellular level as cellular traits or phenotypes (Bochner et al., 2001). 
Phenotype is defined as the observable physical or biochemical characteristics of an 
organism, as determined by both genetic makeup and environmental influences. 
Phenotype MicroArrays (PM) is a recent technology that provides an analogous 
two-dimensional array technology for analysis of live cells to screen the response of an 
organism to thousands of chemical treatments simultaneously (Bochner, 1989). 
45 
Chapter 1. Introduction 
Phenotype MicroArray (PM) are sets of phenotypic assays performed in 96-well 
microplates with chemicals included to create unique culture conditions after 
rehydration. Microplates in the PM set are organized into functional groups as labelled 
in Figure 1.7. Biolog, Inc. (Hayward, CA) currently markets 20 phenotype micro arrays 
that fall into different 'modes of action' categories. These categories include different 
sources (carbon, nitrogen, sulfur, phosphorus), nutritional supplements, nitrogen 
utilization, osmotic sensitivity, toxicity, pH, inhibitors, and chemical sensitivity. 
Biosynthetic 
pathways 
Figure 1.7 The phenotypic assays in the PM set for bacteria (Bochner, 2009). 
Assays of carbon, nitrogen, sulphur and phosphorus metabolism provide 
information about which metabolic pathways are present and active in the microbial 
cells. Assays of ion, pH, and chemical sensitivities provide information on stress and 
repair pathways that are present and active in cells (Bochner, 2009). 
For novel antimicrobials, a large effort is often needed to determine their 
mechanism of action (MOA). Genetic and biochemical approaches are labour intensive 
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and may fail to discover an MOA. Phenotype MicroArray (PM) technology can be used 
to screen and identify novel antimicrobials and to further infer a MOA of an inhibitor 
(Wiater et al., 2004; Biolog, 2007). 
Antimicrobials can be added to cells prior to inoculation into PMs. By looking at 
the phenotypes altered by the antimicrobial compound one can determine the 
physiological functions in the cell that are affected. This information will indicate: (1) 
the site and/or mode of action of a drug, (2) whether the antimicrobial compound is 
specifically hitting one target or whether it is interfering also with other cellular 
processes and therefore likely to cause side-effects, (3) potentially beneficial as well as 
detrimental interactions with other antimicrobial compounds (many of the phenotypes in 
the PMs test for increased sensitivity or resistance to existing drugs). 
Assays are initiated by inoculating all wells with cell suspensions, either alone or 
with the test compound. The assays are respiration based and colorimetric based on 
reduction of a tetrazolium dye. The variable level of purple colour indicates that the cells 
are metabolically active and respiring in some wells but not others. A kinetic response 
curve, which parallels microbial growth, is generated so that a growth parameter can be 
extracted (Bochner, 2009). The software can automatically compare two or more cell 
lines over hundreds to thousands of phenotypes. 
The interaction of the microorganisms' biochemical machinery and inhibitory 
chemicals dictates the growth characteristics. The Biolog system uses OmniLog data 
capture software to exploit growth characteristics to generate a high-resolution 
isobologram, which display the interactions that two inhibitors have on microbial 
growth. Typically, isobolograms are generated by mixing two chemical inhibitors in 
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different proportions at fractional minimal inhibitory concentrations (MICs) and then 
determining if those combinations prevent microbial growth (Figure 1.8). 
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Figure 1.8 Isobolograms to determine chemical interactions a) Classical and b) Biolog 
OmniLog (Biolog, 2007) 
The synergy and antagonism magnitudes taken from such isobolograms can be 
used to cluster chemicals with known mechanisms of action (Figure 1.9). Novel 
inhibitors that cluster within a group of inhibitors are inferred to have the same MOA 
(Biolog, 2007). 
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Figure 1.9 Biolog Isobologram data used to group known antibacterials (Biolog, 2007). 
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1.5 SYNTHESIS OF CARBOHYDRATE FATTY ACID DERIVATIVES 
Carbohydrates are the most widely distributed, naturally occurring compounds on 
Earth. Their general formula is Cn(H20)n. Carbohydrates are highly functionalised small 
organic molecules. Synthetically, they can be reduced to give sugar alcohols, oxidized to 
give sugar acids, substituted at one or more of the hydroxyl groups or derivatized at the 
hydroxyl groups. 
Carbohydrates represent an under-utilised source of diversity; this is partly due to 
their multiple hydroxyl groups which make carbohydrate molecules a particularly 
challenging target for regioselective synthetic modifications. Different degrees of 
substitution result III different physicochemical properties, which in tum will 
influence/affect their function in different applications. Control of regioselectivity of 
carbohydrates is very important when developing a route to carbohydrate derivatives. In 
order to develop a chemical synthesis yielding pure, regiodefined carbohydrate fatty acid 
derivatives it is important to first consider carbohydrate structure and, usually, protecting 
group strategies for polyhydroxylated molecules. 
1.5.1 Structure of carbohydrates: focus on glucose and related sugars. 
The most basic carbohydrate units are called monosaccharides. The most common 
types of structures are the aldoses. Glucose is an example, containing six carbons, 
known as hexose. Aldoses consist of a linear carbon chain with an aldehyde group at C-
1, a varying number of carbon atoms which are secondary alcohols (for D-glucose are at 
C-2, 3, and 4) and a primary alcohol at the other end of the chain (for D-glucose is at C-
6). 
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The aldehyde group of glucose can react intramolecularly with a hydroxyl group to 
give a hemiacetal, forming a heterocyclic ring with an oxygen bridge between two 
carbon atoms. The hydroxyl of this hemiacetal is known as the anomeric hydroxyl. 
Rings with five and six atoms are called furanose and pyranose forms, respectively, and 
exist in equilibrium with the straight-chain form (Figure 1.10.). 
H~ CHO HO 0 
/' HO OH OH OH 
HO 
OH 
OH 
CH20H HO 
Figure 1.10: Pyranose and furanose of glucose 
During the conversion from straight-chain form to cyclic form, the carbonyl carbon 
(anomeric carbon), becomes a chiral center with two possible configurations. The 
resulting possible pair of stereoisomers are called anomers. The two possible 
configurations for glucopyranoside are shown (Figure 1.11). The reaction of glucose, at 
the anomeric position, with an alcohol forms a glycoside, for example a methyl 
glucopyranoside or a dissacharide. This glycosylation reaction locks the configuration of 
the anomeric centre and prevents further equilibrium interconversions. 
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HO~ HO 0 +R'OH-
HO 
OH OH 
H~ HO 0 + 
HO 
OHOR 
H~ HO 0 OR 
HO 
OH 
ex 
Figure 1.11: Glycosylation reaction producing ex and (3 anomers of glucose. 
Each of the carbon atoms that bear secondary alcohols have four different groups 
attached and are stereo genic (or chiral) centres. Each asymmetric centre has two possible 
configurations. Because of this asymmetry, a number of isomers may exist for any given 
monosaccharide formula. Glucopyranoside, its C-4 epimer galactopyranoside and its C-2 
epimer mannopyranoside are an example (Figure 1.12). 
HO~O\ HR.--q 
HO~ HO~ 
OH OR HO OR 
HO--X-~Q 
HO~ 
OR 
Figure 1.12: Glucopyranoside, galactopyranoside and mannopyranoside. 
These can be used as scaffolds from which many products can be obtained after the 
reaction of one or more hydroxyl groups. Monosaccharides can be linked together in 
almost limitless ways to form oligo- and polysaccharides. 
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1.5.2 Protecting groups for a synthetic strategy for carbohydrates 
Although it is possible to synthesise pure oligosaccharides in the laboratory, the 
regioselective protection of hydroxyl groups and the stereos elective assembly of 
glycosidic bonds present a number of challenges (Wang et al., 2007). When a chemical 
reaction is to be carried out selectively at one reaction site in a multifunctional 
compound, other reactive sites are often temporarily blocked, so as not to react. In 
carbohydrates such as glucose, the strategic placement of protective groups that mask 
hydroxyl groups are frequently required because of the polyhydroxylated structure. 
The ability to remove one protecting group in the presence of others is a key 
feature, moreover the steric and electronic nature of the protecting groups are also 
important (Bartolozzi and Seeberger, 2001). 
Protecting groups should satisfy several important criteria. They should be cheap 
or readily available, be easily introduced and formed in good yield, be stable to 
subsequent reaction conditions, be selectively removed under appropriate conditions and 
finally, the by-products of the deprotection should be easily separated from the substrate 
(Kocienski, 2000). 
Protecting groups of relevance to this study are: 
• TriisopropylsUyl Ether 
The triisopropylsilyl ether (TIPS) group is a member of the silyl ether protecting 
groups. Due to its bulky nature it is selective for the primary hydroxyl. Although many 
methods are available for forming silyl ethers, there are two common strategies: reaction 
of the alcohol with a silyl chloride with an amine base at room temperature and reaction 
of the alcohol with a silyl triflate with a hindered amine base at low temperature. One 
extremely reliable and rapid procedure is the Corey protocol in which the alcohol is 
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reacted with a silyl chloride and imidazole at high concentration in DMF (Corey and 
Venkateswarlu, 1972). 
TIPS groups (Figure 1.13) are relatively stable towards basic hydrolysis, oxidation, 
reduction and column chromatography (Kocienski, 2000). 
Reactions with acids or fluorides such as tetra-n-butylammonium fluoride remove 
the silyl group when protection is no longer needed. 
Figure 1.13. Triisopropylsilyl ether protected alcohol 
• Benzyl Ethers 
Benzyl ethers (Figure 1.14, abbreviated Bn) are often used for the protection of 
free primary and secondary hydroxyl groups. 
The most common method for preparing benzyl ethers is the Williamson ether 
synthesis where the alcohols react with benzyl bromide and a strong base such as 
sodium hydride. 
Benzyl ethers are stable to a wide range of aqueous acidic and basic conditions, 
and they are not readily attacked by most metal hydride reducing agents or mild 
oxidising agents (Kocienski, 2000). 
They are most readily cleaved under catalytic hydrogenation with a catalyst such 
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as palladium on carbon. Under these conditions most other groups, including esters, are 
stable. 
Figure 1.14. Benzyl ether protected alcohol 
• Para-methoxybenzyl ether 
The para-methoxybenzyl (PMB) ether (Figure 1.15) has found application in 
organic synthesis as a protecting group for primary and secondary alcohols since it may 
be selectively removed in the presence of many other groups, including ethers. 
Sodium alkoxides prepared from primary and secondary alcohols and sodium 
hydride in DMF or DMSO react with PMB chloride at room temperature to give the 
PMB ethers in good yield (Kocienski, 2000). 
PMB groups are less stable to acid than benzyl groups, but they can be removed 
under specific conditions which do not affect benzyl ethers or silyl ethers and therefore 
find use in the synthesis of functionally complex molecules (Kocienski, 2000). 
PMB can be removed by acid, hydrogenolysis, or oxidation. They may be cleaved 
selectively by oxidation with one electron oxidising agents such as ceric ammonium 
nitrate (CAN). 
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Figure 1.15. Para-methoxybenzyl ether protected alcohol 
• Benzylidene group 
Benzylidene acetals (Figure 1.16) are frequently used in carbohydrate chemistry 
for selective 4,6-di-O- protection in hexopyranosides (Lindhorst, 2007), which is 
particularly useful since it allows manipulation of the remaining hydroxyl groups 
(Chambers et aI., 2003). Moreover, 4,6-di-O-benzylidene protection is particularly 
desirable since regioselective reductive cleavage of the benzylidene group (Garreg, 
1997), which may be performed at any later point in a synthetic sequence, allows 
selective access to either the 4- or 6-hydroxyl groups as desired. 
There are only two methods generally used to prepare benzylidene acetals: reaction 
of a diol with benzaldehyde in the presence of a protic acid or Lewis acid (usually 
ZnCh) or reaction of the diol with benzaldehyde dimethyl acetal in the presence of an 
acid catalyst (p-toluenesulfonic acid). They are stable to most strong bases, mild 
oxidants and metal hydrides. Acidic hydrolysis is an efficient means of cleaving them. 
Phl~O o 0 
HO 
HO OMe 
Figure 1.16. Methyl 4,6-di-O-benzylidene-D-glucopyranoside 
56 
Chapter 1. Introduction 
1.5.3 Monitoring reactions with thin layer chromatography (TLC) 
Thin layer chromatography (TLC) is one of the most popular and widely used 
analytical techniques. Because of its simplicity, wide applications to a great number of 
samples, speed and relatively low cost, it is often used for monitoring chemical reactions 
and for the qualitative analysis of reaction products (Higson, 2006). 
Thin layer chromatography is performed on a sheet of glass, plastic, or aluminium 
foil, which is coated with a thin layer of stationary phase, usually silica gel, aluminium 
oxide, or cellulose. After the sample has been applied on the plate, a solvent or solvent 
mixture (called the mobile phase) is drawn up the plate via capillary action. Because 
different analytes ascend the TLC plate at different rates, separation is achieved (Higson, 
2006). Different compounds in the sample mixture travel at different rates due to the 
differences in the partition co-efficient between stationary phase and mobile phase. By 
varying the mobile phase, the separation of components (measured by the Rr value) can 
be adjusted. The Rr value is a convenient way to express the position of a substance on a 
developed plate. It is calculated as the ratio: 
Rf = distance of compound from origin 
distance of solvent front from origin 
As the compounds being separated may be colourless, several methods exist to 
visualize the spots. Often a small amount of a fluorescent compound is added to the 
adsorbent that allows the visualization of spots under a black light (UV254). Several 
colour stains exist into which the TLC plate is dipped or which are sprayed onto the 
plate. These react with the analyte compounds and coloured spots appear on the TLC 
plate. 
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1.5.4 General synthesis of esters ai1d ethers 
Esters are commonly synthesised by reaction of an alcohol with an activated 
carboxylic acid derivative (Figure 1.17). They can also be formed by acid or enzyme 
catalysed reaction between an alcohol and a carboxylic acid. 
+ RIOH 
Figure 1.17. General synthesis of esters using an activated carboxylic acid 
Ethers are common1y formed by the reaction of an alcohol with an alkyl halide. 
(Figure 1 .18) 
R-X + RIQH RI-O-R + HX I 
Figllre 1.18. General synthesis of ethers. 
58 
Chapter 1. Introduction 
1.6 OBJECTIVES 
1.6.1 General objective 
This study was concerned with the synthesis of carbohydrate fatty acid derivatives 
for evaluation as antibacterial agents, with a view to examining the effect of variation of 
the hydrophilic moiety on antimicrobial activity. Studies focused on lauric and caprylic 
acids, and their ester and ether conjugates were synthesised to allow comparative 
studies. 
Additionally, other natural compounds including bacteriocins and essential oil 
components were screened for antimicrobial activity towards possible combination 
strategies and potential further use in synthesis or modification studies. 
1.6.2 Specific objectives 
• To synthesize pure, regiochemically defined monosaccharide mono-fatty acid esters, 
and their corresponding ethers as potential antimicrobial compounds CAMC). 
• To screen carbohydrate based AMC for quantitative assessment of antimicrobial 
activity compared to structurally similar commercial products. 
• Compare the effect of the AMC on Gram positive and Gram negative pathogens, and 
spoilage microorganisms. 
• Build up knowledge allowing investigation of any structure/activity relationship and 
mode of action of these compounds. 
• To investigate other natural compounds towards possible combination strategies. 
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2. MATERIALS AND METHODS 
2.1 BACTERIA AND GROWTH CONDITIONS 
Tests were performed using pathogenic and spoilage microorganisms. Bacterial 
strains used in this study are listed in Table 2.1. 
Stock cultures were maintained in tryptic soy broth (TSB, SharI au Chemie, Spain) 
or De Man, Rogosa and Sharpe (MRS broth, Sharlau Chemie, Spain) broth for 
Lactobacillus, supplemented with 20% glycerol and stored at -70DC. Cultures were 
routinely grown by subculturing a loopful of stock culture into 9 mL TSB and 
incubating at 35DC for 18-24 hours, except for Pseudomonas spp. and Lactobacillus spp. 
which were incubated at 30De. All cultures were then maintained on tryptic soy agar 
(TSA, Sharlau Chemie, Spain) or MRS agar (MRS agar, Sharlau Chemie, Spain) plates 
at 4 DC and were discarded after subculturing for 2 weeks. Working cultures were 
prepared by inoculating a loop of pure culture into TSB and incubating at the optimum 
temperature for each strain for 18 hours. 
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Table 2.1. List of bacterial strains tested 
Strain 
Gram-positive bacteria 
Lactobacillus p lantarum 
Lactobacillus sakei 
Listeria i/lf/oclla 
Listeria monocytogelles 
Listeria mOllocytogenes 
Listeria mOllocYlogel1es 
Staphylococcus allrells 
Staphylococcus aurells 
Staphylococcus llureus 
Staphylococcus aUreus 
Staphylococcus aurells 
Gram-negative bacteria 
Escherichia coli 
Escherichia coli 
Salmollella ellterica 
(serovar Typhirnu rium) 
Elllerohacler aerogenes 
Pseudomonas aerug inosa 
Pseudomonas jhwrescens 
Pseudomonas pulido 
Reference' Source I Comments 
ATCC 8014 Fermented food 
ATCC I552 1 Moto,starter o f sake 
NCTC 11 288 Cow bra in, serotype 6a 
ATCC 7644 1-luOl, n 
NCTC 11 994 Cheese, serotype 4b 
NCTC 7973 Pig mesenteri c lymph node 
ATCC 25923 Clinical iso late 
NCTC 1803 Mammal , ovine gangrenOliS mastiti s 
ATCC 33591 Methicillin resistant 
ATCC 33592 Blood, Gentamicin- and methici llin-
resistant 
ATCC 43300 clinical isolate, F- I 82, Methicillin- and 
oxaci Ilin-res istant 
ATCC 25922 Clinical isolate 
NCTC 12900 Human, serotype 0 157:1-17 nontox igenic 
ATCC 14028 Animal tissue 
ATCC 13048 
ATCC27853 
• 
• 
Sputum 
Blood culture 
Lettuce 
Lettuce 
a Strains indicated with an asterisk were provided by the Department of Life Sciences, 
University of Li merick, Ire land 
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2.2 BACTERIAL CALIBRATION CURVES 
Bacterial calibration curves were constructed to equate absorbance values with cell 
growth and density in Log lO CFU/mL. 
Bacterial strains were grown overnight in TSB at 35°C. A bacterial suspension was 
prepared in an API ampoule with saline solution (NaCI 0.85%, BioM6rieux, France) to 
obtain a concentration equal to a McFarland standard of 0.5, equivalent to lxl08 
CFU/mL using a Densimat photometer (BioM6rieux, SA, France). The bacterial 
suspenSIOn was diluted 1:100 in sterile TSB broth to obtain approximately lxl06 
CFU/mL. This inoculum (l00 ilL) was added to replicate wells of a 96-well plate 
containing 100 ilL of fresh TSB. The plates were incubated at 35°C for 18 hours in a 
mi crotiterpl ate reader (PowerWave microplate Spectrophotometer, BioTek). 
Subsequently, 100 ilL aliquots were taken at regular intervals and serially diluted in 
sterile saline solution (SS) (Sodium chloride, Sigma, USA) and the appropriate dilutions 
were spread plated on TSA. Plates were incubated at 35°C and after 18-24 hours colony 
forming units were counted. Absorbance values were plotted against the Log lO CFU/mL 
to obtain a logarithmic trendline. The equations and the R2 values were determined. 
2.3 TEST COMPOUNDS 
2.3.1 Fatty acid and monoglyceride standards 
The saturated fatty acids lauric acid (LA - C12) and caprylic acid (CA - C8) as 
well as their corresponding monoglycerides; monolaurin (ML) and monocaprylin (MC) 
(Sigma-Aldrich ~99% purity) were investigated and used as standards in this study. 
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Standard stock solutions ( 100 ruM) of the fatty acids and monoglycerides were 
prepared in sterile hydroalcoholic diluent (ethanol·distilled water, 1:1) and stored at· 
20°C. Stock solutions were diluted in TSB to obtain working concentrations. An 
overview of the concentration ranges used for the standards in the antimicrobial assay is 
given in Table 2.2. The highest final concentration of ethanol (5% and 10%), 
corresponding to the highest concentration of compound used ( IOmM for the Gram 
positive and 20mM for the Gram negati ve bacteria) had a negl igible effect on bacterial 
viability. 
Table 2.2. Range of concentrations llsed for the standard compounds (JlglmL). 
Lauric Monolaurin Capryli c Monocaprylin Ethanol final 
mM 
acid (LA) (ML) acid (CA) (MC) concentration 
100 20032 27440 14422 21829 50% 
20 4006.4 5488 2884.4 4365.8 10% 
10 2003.2 2744 1442.2 2182.9 5% 
5 1001.6 1372 72 1.1 1091.5 2.5% 
2.5 500.8 686 360.6 545.7 1.25% 
1.25 250.4 343 180.3 272.9 0.63% 
0.63 125.2 171.5 90.1 136.4 0.3 1 % 
0.3 1 62.6 85.75 45.1 68.2 0.16% 
0. 16 31.3 42.9 22.5 34.1 0.08% 
0.08 15.7 21.4 11.3 17. 1 0.04% 
0.04 7.8 10.7 5.6 8.5 0.02% 
0.02 3.9 5.4 2.8 4.3 0.0 1 % 
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2.3.2 Carbohydrate fatty acid (CF A) derivatives 
Chemical synthesis was perfomled according to Smith et ClI., (2008). More infonnation 
on the synthesis of compounds can be round in Chapter 3, Sect ion 3. 1 and the 
methodology is detailed in Appendix 1.1 (Smi th el al., 2008 Carbohydrate Research 
paper). An overview of the fatty acid derivatives synthesized and used in the 
antimicrobia l assay is given in Figure 2.1. Test stock solutions (100 mM) of the ratty 
acid derivatives were prepared in steril e hydroalcoholic diluent (ethanol·distilled water. 
I: I) and stored at ·20°C. Test stock solutions were diluted in TSB or appropriate media 
to obta in working concentrations. 
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Figure 2.1 Structures of the novel carbohydrate fatty acid derivatives and non-carbohydrate polyhydroxylated esters synthesized and 
investigated. 
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2.4 ANTIMICROBIAL ACTIVITY OF CFA DERIVATIVES 
The minimal inhibitory concentration (MIC) of carbohydrate fatty acid derivatives 
and standards was determined using an absorbance based broth microdilution assay in 
sterile 96-well plates (Sarstedt Ltd., Leicester, UK) in a final volume of 200 JlL as 
follows. 
2.4.1 Inoculum preparation. 
Bacterial strains were grown overnight in TSB at 35°C. A bacterial suspension was 
prepared in an API ampoule with saline solution (NaCl 0.85%, BioMerieux, France) to 
obtain a concentration equal to a McFarland standard of 0.5, equivalent to 1.5x108 
CFU/mL using a Densimat photometer (BioMerieux, SA, France). The suspended 
inoculum was diluted 1:100 in sterile TSB broth to obtain approximately 1x106 
CFU/mL. The diluted inoculum (100 J!L) was added to each appropriate well. 
2.4.2 Test compounds preparation. 
Standards and carbohydrate fatty acid derivatives were prepared as previously 
described in sections 2.3.1 and 2.3.2. Freshly prepared solutions of the test compounds 
were serially diluted twofold in sterile culture media to a final volume of 100 J!L in the 
96-well plate (Table 2.3). The following controls were used in the microplate assay for 
each organism and test compound: 
Blank: uninoculated media without test compound to assess changes in liquid media 
during the experiment. 
Negative control: uninoculated media containing only the tested compound to 
assess background noise. 
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Positive control J: inoculated media without compound to evaluate the microbial 
growth under optimal conditions. 
Pos itive control 2: inoculated media without compound but includ ing the 
corresponding sugar to evaluate any effect of the sugar alone. 
Positive control 3: inocu lated media without compound but containing appropriate 
amount of ethanol to account for a possible antagon ist or synergisti c acti vity of the 
alcohol used to dissolve the test compound. 
Table 2.3 . Carbohydrate fatly acid derivatives concentrations (J.tg/mL) 
(land ~ a.nd~ a caprylic Ethanol final 
ruM 
lauric ester lauric ether ester concentration 
100 37650 36250 32030 50% 
20 7530 7250 6406 10% 
10 3765 3625 3203 5% 
5 1882.5 1812.5 1601.5 2.5 % 
2.5 941.3 906.3 800.8 1.25 % 
1.25 470.6 453.1 400.4 0.63 % 
0.63 235.3 226.6 200.2 0.3 1 % 
OJI 11 7.7 113.3 100.1 0. 16 % 
0. 16 58.8 56.6 50.0 0.08% 
0.08 29.4 28.3 25.0 0.04% 
0.04 14.7 14.2 12.5 0.02% 
0.02 7.4 7. 1 6.3 0.01 % 
The inoculation scheme yielded fina l concen trations o f each microorganism 
estimated to be 5x 1 OS CFU/mL and chemical compounds ranging from a high test 
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dilution of 1:2 (inoculum mixed with 100 ilL of diluted chemical compound) to a low 
test dilution of 1 :256. Each concentration was assayed in duplicate. 
2.4.3 Broth microdilution assay. 
The 96-well plates were incubated for 18 hours in a microtiterplate reader 
(PowerWave microplate Spectrophotometer, BioTek) at 35°C, except for Pseudomonas 
spp. which were incubated at 30°C, and bacterial growth was monitored by measuring 
the optical density (OD) at 600 nm for each well every 20 minutes with 20 seconds 
agitation before each OD measurement. Each experiment was replicated three times. 
2.4.4 Data analysis. 
2.4.4.1 MIC determination 
The MIC was defined as the lowest concentration of compound that showed no 
increase in OD values for all the replicates compared to the negative control after 18 
hours. The absorbance readings obtained from the kinetic data were plotted against time 
to obtain the growth curves of the test organisms. Subtraction of the absorbance of the 
negative control eliminated interferences due to possible changes in the media. 
2.4.4.2 ICso calculation 
The ICso or the half maximal inhibitory concentration represents the concentration 
of an antimicrobial that is required for 50% inhibition of its target microorganism. The 
ICso was calculated for selected compounds. The reduction in optical density was 
determined by subtracting the OD6oo of the culture at 18 hours containing antimicrobial 
compounds at a range of concentrations, from the OD6oo of the negative control. The 
data was converted to log CFU/mL using the calibration curves previously constructed. 
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The percentage inhibition was then calculated against the positive control 1 results. A 
dose-response curve was constructed for the compounds for a concentration range that 
did not show a 100% inhibition. The slope of the linear portion of the line was calculated 
and the ICso was then calculated using the equation obtained. 
2.4.4.3 Increase in Lag time estimate. 
Lag phase was defined as the time required for the culture to reach a change in 
optical density (~OD) of 0.10. This change in OD was calculated using the Gen5™ 
software supplied with the microplate spectrophotometer used for sample assays. The 
increase in lag phase was determined as the time the culture containing antimicrobial 
compound took to record an increase in ~OD of 0.10 minus the time that the positive 
controll took to record the same increase in ~OD of 0.10. 
2.4.4.4 Maximum specific growth rate (Jlmax) 
The maximum growth rate was also calculated using the Gen5 ™ software. The 
Jlmax was determined from the slope of the regression equation from the linear portion of 
the log plot during early exponential phase. 
2.4.4.5 Statistical analysis of results 
The results for MIC determinations were subjected to statistical analysis. Statistical 
differences were analysed using ANOV A followed by LSD testing at p < 0.05 level 
using SPSS software, Version 15 (IBM). 
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2.5 EFFECT OF pH AND TEMPERATURE ON THE FATTY ACIDS AND 
MONOGLYCERIDES ACTIVITY 
Lauric acid and monolaurin standards were used to assess the potential effect of 
temperature and pH on antimicrobial compound potencies. 
2.5.1 Test conditions. 
A total of 24 combinations of temperature and pH were examined. Four 
temperatures were used with different incubation times to simulate different storage 
conditions: 
• 35°C x I8h (Optimal bacterial growth) 
• 22°C x 48h (Ambient) 
• 10°C x 120h (Temperature abuse for refrigeration) 
• 4°C x I20h (Recommended refrigeration) 
The pH values used (4, 4.5, 5, 5.5, 6, and 7) were used to reflect different pH 
values found in a range of common food products. 
2.5.2 Inoculum and test compounds preparation. 
TSB was used as the basal medium for all experiments in broth. The pH levels of 
the media were adjusted to the appropriate values with 1 M HCI and were measured 
before and after autoclaving using a digital pH meter (Orion 420A) with a glass pH 
electrode (Orion). Measurement of the pH was also determined when the fatty acid or 
monoglyceride were added. Bacterial strains were prepared as described previously 
(Section 2.4.1.) Concentrations of lauric acid and monolaurin corresponding to the 0.5 
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MIC, MIC and 2x MIC were prepared in the pH adjusted broths as previously described 
in section 2.3.1. 
2.5.3 Assay. 
The 96-well plates were inoculated and covered with Parafilm to avoid 
dehydration. The plates were stored in controlled temperature incubators for the specific 
incubation times. Growth was monitored periodically by recording the turbidity of the 
medium using an automated microplate reader (PowerWave microplate 
Spectrophotometer, BioTek). 
2.6 DEGRADATION OF CFA DERIVATIVES MONITORED BY THIN LAYER 
CHROMATOGRAPHY (TLC) 
To determine the fate of the CF A derivatives in bacterial cultures, samples of S. 
aureus ATCC 25923 growing in the presence ofCFA derivatives were analyzed by TLC 
according to Ruzin and Novik, 2000. 
CF A derivatives were added to bacterial cultures at their corresponding MIC 
values. Samples were collected at different time points: 0, after 5, 15, 30 60 and 120 
minutes, centrifuged at 10.000 g for 15 minutes and a sample of the supernatant (8 JLL) 
was spotted onto TLC plates (Whatman silica gel 60A TLC plates (20 x 20, with 
preadsorbent area). Emulsions of LA (30 )lg/mL) and CFA derivative (MIC 
concentration) in TSB broth were used as controls. Plates were air dried and developed 
with hexane-diethyl ether-methanol (70:20: 1 0), air dried, baked at 100°C for 10 min, 
and sprayed with a 0.025% (wt/vol) solution of Coomassie R-250 in 20% (vol/vol) 
methanol until fatty acids were visible as white spots on a blue background. 
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Even though the samples were well separated during loading on the plate (1 cm), 
after development of the TLC plate, lateral dragging was observed. No distinct well 
formed spots could be observed by this method. In order to obtain better analytical data, 
a mini workup was performed on the broth sample to extract the analytes from the 
aqueous broth. Also the plates were loaded with 2 cm distance between samples. No 
evidence oflauric acid was found on the plate, possibly due to low concentration. 
After the first attempt of Ruzin and Novick's protocol failed, it was decided to 
develop a new method suitable for the compounds generated in this study. A solvent 
system which gave rise to suitable mobility to all compounds for analytical purposes and 
a staining system to visualize them was required. The strategy first involved the use of 
pure compounds and subsequently after determining a suitable stationary phase, the 
mobile phase and stain, would be applied to the broth samples. 
The different solvent systems and stains tested are listed below: 
Stationary phase 
Mobile phase 
Stains 
• Silica gel TLC plates on aluminum support without 
preadsorbent area (Fluka) 
• Hexane:diethyl ether (80:20) 
• Hexane:diethyl ether: methanol (70:25:5) 
• Petroleum ether:diethyl ether:acetic acid (90: 10:2) 
• Pure hexane 
• Pure ethyl acetate 
• Ethyl acetate:petroleum ether (1: 1) 
• Ethyl acetate:petroleum ether (1:3) 
• Solution of vanillin in pure ethanol with sulfuric acid 3% 
(wt/v) 
• Sulfuric acid and water (50:50) 
• Iodine vapors 
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2.7 EFFECT OF CFADERIVATIVES ON THE CELL MEMBRANE 
The laurate glucopyranoside derivatives (compounds 4a, 4b, 9a and 9b; Figure 2.1) 
were selected for the mode of action studies in order to assess the influence of structural 
differences in closely related compounds. These focussed on the nature of the fatty acid 
carbohydrate bond (ester or ether) as well as the anomeric configuration (alpha or beta) 
of the sugar. 
2.7.1 Leakage of cellular compounds assay 
2.7.1.1 Inoculum preparation 
Bacterial strains were cultured in TSB and incubated at 35°C for 18-24 h. After 
incubation, bacteria were harvested by centrifugation at 10,000 g for 10 min at 4°C, 
supernatant was discarded and the cells were washed twice with PBS; pH 7.4 (Sigma). 
Cell suspensions were adjusted so that the optical density at 620 nm (OD620) of a 1-in-
100 dilution was 0.3, which corresponded to ~3x1010 CFU/mL. Final concentration of 
cells was approximately 109 CFU/mL. 
2.7.1.2 Leakage of cellular compounds assay 
Standards, CFA derivatives and nisin were added to bacterial suspensions at 4x 
MIC. Suspensions were incubated at 35°C in a water bath. Samples of 1.5 ml were 
removed at time 0, and after 15, 30, 45 and 60 minutes; and then centrifuged at 10,000 g 
for 10 minutes at 4°C. Following this, 200 ilL of supernatant from each treatment were 
added in triplicate to wells of a 96-well plate (Costar) and absorbance values at 260 nm 
were recorded using a UV spectrophotometer (Synergy, Bio-Tek). The following 
controls were included: a bacterial suspension in sterile PBS without antimicrobial 
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agents as the negative control; Fatty acid and monoglyceride control: inoculated PBS 
containing LA or ML; Positive control: Nisin. Where applicable, independent readings 
were also taken in the presence of antibacterial agents only to enable corrections for 
background contributions. 
2.7.2 Modified Live/Dead BacLight assay 
2.7.2.1 Inoculum preparation 
A culture of Staphylococcus aureus ATCC 25923 was grown to late log phase in 
30 mL of TSB. 25 mL of the bacterial culture were concentrated by centrifugation at 
10,000 x g for 10-15 minutes. The supernatant was removed and the pellet resuspended 
in 2 mL of 0.85% NaCl. One mL of this suspension was added to each of two 30--40 mL 
centrifuge tubes containing either 20 mL of 0.85% NaCl (for live bacteria) or 20 mL of 
70% isopropyl alcohol (for killed bacteria). Both samples were incubated at room 
temperature for 1 hour, mixing every 15 minutes and then pelleted by centrifugation at 
10,000 x g for 10-15 minutes. The pellets were resuspended in 20 mL of 0.85% NaCl 
and centrifuged again as in the previous step. Both pellets were then resuspended in 
separate tubes with 10 mL of 0.85% NaCl in each. Optical density of the bacterial 
suspensions was adjusted to yield ~0.30 at OD670 • Five different proportions of S. aureus 
ATCC 25923 (Table 2.4) were mixed in glass culture tubes. The total volume of each of 
the five samples was 2 mL. 
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Table 2.4 Preparation of live- and dead-cell suspensions. 
Ratio of mL Live-Cell mL Dead-Cell 
Live:Dead Cells Suspension Suspension 
0:100 02 0 
10:90 0.2 1.8 
50:50 1.0 1.0 
90:10 1.8 0.2 
100:0 2.0 0 
2.7.2.2 Staining 
To assess membrane damage, the Live/Dead® BacLight viability kit from 
Molecular Probes, Inc. (Eugene, Oreg.) was used as described by Hilliard et at., (1999). 
A IX stain solution was prepared mixing component A (3.34 mmol rl SYTO 9 dye) and 
component B (20 mmol r1 propidium iodide) in the same proportions. 100 /!L of each 
of the bacterial cell suspension mixtures were added in triplicate into separate wells of a 
96-well flat-bottom microplate (Nunc, black). 100 /!L of the IX working stain solution 
were pipetted to each well and mixed thoroughly. The microtiter plate was then 
incubated at room temperature in the dark for 15 minutes. 
2.7.2.3 Fluorescence measurements 
With the excitation wavelength centered at about 485 nm, the fluorescence 
intensity was measured at a wavelength centered at about 530 nm (emission 1; green) for 
each well of the entire plate. With the excitation wavelength still centered at about 485 
nm, the fluorescence intensity was measured at a wavelength centered about 630 nm 
(emission 2; red) for each well of the entire plate. The data was analysed by dividing the 
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fluorescence intensity of the stained bacterial suspensions (Fcell) at emission I by the 
fluorescence intensity at emission 2. 
G/R Ratio = F cell, em lIF cell,em2 
The RatioG/R was plotted versus percentage of live cells m the S. aureus 
suspensIOn. 
2.7.3 BacTiter-GloTM assay 
The BacTiter-GloTM Microbial Cell Viability Assay (Promega) is a method for 
determining the number of viable bacterial cells in culture based on quantitation of the 
ATP present, as an indicator of metabolically active cells. The luminescent signal is 
proportional to the amount of ATP present, which is directly proportional to the number 
of cells in culture. 
An overnight culture of S. aureus ATCC 25923 in Mueller Hinton (MH) broth was 
diluted IOO-fold in fresh MH broth and used as inoculum. CFA derivatives were used at 
a concentration of 4x MIC. Each well of a 96-well microtiter plate contained lOOpJ of 
the inoculum and lOOp,} of the CF A derivatives. Control wells containing medium 
without cells were prepared to obtain a value for background luminescence and cells 
without compound were used as ATP positive control. The microtiter plate was 
incubated at 37°C for 5 hours. One hundred microliters of the culture was taken from 
each well, and was mixed with the same volume of the BacTiter-GloTM reagent in a 
white opaque-walled microtiter plate (Nunc). Plates were incubated for five minutes and 
luminescence was recorded in a multi-detection microplate reader (Synergy HT, Bio-
Tek). 
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2.8 PHENOTYPE MICROARRAy ™ 
Phenotype MicroArray technology was used to assess the differences or changes in 
bacterial growth and metabolic activity between untreated control cells and cells treated 
with selected CF A derivatives; as well as their interactions with known antimicrobials, 
to further elucidate possible antimicrobial mechanisms of action. Figure 2.2 shows the 
experimental stages of the Phenotype MicroArray (PM) technique. For this study, L. 
monocytogenes ATCC 7644 was used. The CFA derivatives selected were alpha ester 
(4a), alpha ether (9a) and beta ether (9b). 
Overnighl grown 
1:'4:115 
Standardi7.l11ion of Dilulion in 'F-X plus 
Slillistil;lIl 
anal)'sis 
inoculum Ictfa7-Olium d)·e. 
Inoculation in PM 
plalcs. 
PM kinetic ~U1l5 
Incubation on Omnilog 
incubator/ reader 
. .....•... 
PM panem~ 
Copyright © 2007 American Institute of Chemical Engineers (AlChE) 
Figure 2.2 Experimental stages of the Phenotype MicroArrays technique 
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2.S.1 Inoculum preparation 
A culture of Listeria monocytogenes ATCC 7644, on BUG + B (Biolog Universal 
Growth medium + Blood) agar with 5% sheep blood, was grown overnight at 3rC and 
sub-cultured a second time. Using an sterile cotton swab, cells were removed from the 
plate and transferred into a sterile capped tube containing 20 mL of inoculating fluid (Ix 
IF-Oa GN/GP Base, Biolog) to obtain a uniform suspension. Cell density was adjusted to 
81 % transmittance (T) on a Biolog turbidimeter, equivalent to approx. 1x108 CFU/mL. 
2.S.2 Inoculation fluids preparation 
PM additive solutions were prepared as 12x stock solutions, filter sterilised and 
stored at 4°C. Additive solutions differed in their constituents, depending on the PM 
plate and test assay. Inoculating fluids were prepared at Ix concentration by mixing the 
appropriate PM additive stock solutions, Biolog Redox Dye Mix F (100x), inoculation 
fluid, IF-Oa GN/GP Base (1.2x) for PM 1 - 8 or IF-lOb GN/GP Base (1.2x) for PM 9 -
20, and previously prepared cells. Control plates for all assays were prepared using the 
L. monocytogenes and no test compound. CF A derivatives were added to the inoculation 
fluids to obtain a final concentration of 0.75 MIC. The appropriate PM inoculating fluid 
(100 ilL) was added to each of the wells. A final cell concentration of approx. 7.3x1 06 
CFU/mL in each well was obtained. 
2.S.3 Phenotype MicroArray assay 
The PM plates were incubated at 37°C in the OmniLog PM system (incubator and 
reader) (Biolog, Inc.), and readings were recorded by the charge-coupled device (CCD) 
camera every 15 min for 24-48 h. 
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2.8.4 Phenotype MicroArray analysis 
Data were analyzed with Omnilog-PM software (Biolog, Inc.), which generated a 
time course curve for tetrazolium colour formation providing quantitative and kinetic 
information about the response of cells in the PM plates. The tetrazolium violet used in 
the system is a redox dye and serves to indicate the utilization of a PM source. Positive 
utilization reactions are indicated when a purple colour forms in the wells, if there is no 
reaction, wells stay colourless. Therefore the results were based on the effect in the 
presence or absence of CF A derivatives on the utilizable vs. non-utilizable response of 
cells, to each PM source. 
Unique phenotypic responses expressed by only one of control or treated cells 
were identified by a unique colour assigned to that cell line in the kinetic curve. Where 
there are similar phenotypic responses in both control and treated cell lines, the software 
can combine both results and a different colour on the kinetic curve is generated (See 
Appendix 2.2 for kinetic curves obtained). This allows the rapid review of the graphic 
output and visual identification of changes between control and treated cells. 
Biolog facilitates cut-off thresholds to allow easier determination of 'hits' for each 
plate. The data from the Omnilog-PM software were filtered, using average height as the 
parameter and then transferred to Excel spreadsheets (Microsoft Corporation). Kinetic 
curves per well were constructed to evaluate the response of the control to each PM 
source compared to the treated cells. This allowed identification of trends between CFA 
derivatives related to the glycoconjugate linkage or anomeric configuration. 
Additionally, the PM inhibitors in plates PM11 to 20 were grouped according to 
their mode of action. The response of Listeria cells treated with the CF A derivatives, to 
each of the PM inhibitors, was allocated a score corresponding to the response of the 
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control cells without CFA derivative. This was related to whether there was a change 
(yellow colour in tab le) or not (blank) and ifthal change was positive or negative for the 
sensitivity or resistance of the cell s towards the PM inhibitors. 
2.8.5 Statistical data analys is 
The relationship/association between the CFA derivatives, according to the score 
obtained with the PM inhibitors' modes of action, was statist ica lly analysed with 
crosstabs and Chi·square using SPSS software, Version 15. 
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2.9 ANTIMICROBIAL ACTIVITY OF NATURAL ANTIMICROBIALS 
(ESSENTIAL OIL COMPONENTS AND NISIN) 
2.9.1 Bacterial strains 
The antimicrobial activity of natural compounds was studied against Listeria 
strains and spoilage microorganisms shown in Table 2.5. 
Table 2.5 Bacterial strains tested. 
Bacterial strains 
Gram-positive 
Lactobacillus sakei ATCC15521 
Listeria innocua NCTC 11288 
Listeria monocytogenes ATCC 7644 
Listeria monocytogenes NCTC 11994 
Listeria monocytogenes NCTC 7973 
Gram-negative 
Escherichia coli ATCC 25922 
Pseudomonas jluorescens * 
Pseudomonas putida * 
* Strains provided by the Department of Life Sciences, University of Limerick, Ireland. 
2.9.2 Test compounds 
2.9.2.1 Essential oil components 
The essential oil (EO) individual components selected for this study and their 
chemical properties are indicated in Table 2.6. Their chemical structures are given in 
Figure 2.3. The EO components were obtained from Sigma-Aldrich, ofthe highest grade 
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available. Stock so.lutions (1M) were prepared i-o 95% ethanol and then diluted in TSB 
orMR broth. 
Table 2.6 Essential oil individual components characteristics. 
Molecular Density 
Compound Formula (gfcm3) Purity % in EOs Weight 
4-Allylanisole CIOHI2O 148.21 0.965 95% 26.9% in basil 
Camphor CIsH24 204.36 0.902 95% < 22% in sage 
Carvacrol C 1oH I4O 150.22 0.976 98% > 40% in oregano 
CaryophyUene C 1sH24 204.36 0.902 98.5% 3-13% in sage 
Citral CIOH160 L52.24 0.888 95% 40-90% III lemon balm 
Eucalyptol C1oH,sO 154.25 0.924 96% 40-75% in age 
Linalool CloHlsO 154.25 0.861 95% 42.3% in basil 
Sabinene CIOH,sO 154.2 98% Matjoram 
Terpinen-4-o1 ClOHls 154.25 0.933 99% Matjoram 
Tbymol ClOH14O 150.22 0.965 99.5% >2% in oregano,thyme 
~ 
o 
HO 
~ 
4-A11ylanisole Camphor Carvacrol 
Caryophyllene Citral Eucalyptol Linalool 
0 HO >-b-
-~ 
Sabinene erpinen-4-ol Thymol 
Figure 2.3 Chemical tructures of EO components. 
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2.9.2.2 Bacteriocin 
Nisin, from Lactococcus lactis 2.5% (;:::i.000.000 per IV/g), was purchased from 
Sigma. Its chemical structure is given in Figure 2.4. A stock solution of 2.5mg/mL was 
prepared in 0.02N HCI and then further diluted in the appropriate media. 
~JylNH o:;X~~,f:Q'~ ~;C«VHO NH2 
~nNH HOJ 0 / 0 0 
, I N N 0 NH ~NH 0 ~ 0yNH orr !=?~y~/ I "'N~ IN" ",N~1'.-~Y'I/ 
o ~ 0 J:~i1fN~~ ~ ::5 .~~ N",~o0 
~o HNH~tHK o 0 0 ~ 
www.chemblink.com/products/1414-45-5.htm 
Figure 2.4 Chemical structure of nisin 
2.9.3 Absorbance based Microtiter Plate Assay 
Ninety-six well microtiter plates (Sarstedt Ltd) were used for the broth 
microdilution method. This assay was based on previous work (Schelz et aI., 2006) but 
with the following modifications, where aliquots of nisin or EO components solutions in 
growth media (200 /-ll) were added into the first row of a microtiter plate. The remainder 
of the wells was filled with 100 /-ll of the appropriate medium. The samples were then 
diluted two fold along each column of the microtiter plate. Concentration ranges used 
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for the EO components in the antimicrobial assay are given in Table 2.7. Finall y, 100 III 
of media containing 2x 106 CFU/mL of the indicator strain was added to all well s. 
Positive controls contained only growth media inoculated with the organism under 
investigation. Negative contro ls contained nisin or the EO components and steril e 
growth media only. The plates were then placed in a microplate spectrophotometer 
(Synergy, Biotck) set at the appropriate tcmperature. The absorbance was recorded at 
600 nm every 30 minutes over a 24 hour incubation period. The Minimum Inhibitory 
Concentration (M IC) was considered as the lowest concentration of the test sample 
resulting in a complete inhibition of growth. MIC's of EO individual components were 
expressed in mM and fo r ni sin in IlglmL. Experiments were performed in dupl icate and 
replicated at least three times. 
Table 2.7. Range of concentrations used for the EO components (JA.g/mL). 
Eucalyptol, 
mM 4- Carvacrol, Citral Linalool, Camphor, Allylanisole Thymol Sabinene, Caryophyllene 
Ter~illen-4-ol 
100 14821 15022 15224 15425 20436 
50 74 10.5 75 11 7612 77 12.5 102 18 
25 3705.25 3755.5 3806 3856.25 5109 
20 2964.2 3004.4 3044.8 3085 4087.2 
10 1482.1 1502.2 1522.4 1542.5 2043.6 
5 74 1.05 751. 1 76 1.2 771.25 102 1.8 
2.5 370.53 375.55 380.60 385.63 510.90 
1.25 185.26 187.78 190.30 192.8 1 255.45 
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2.10 EO COMPONENTS AND NISIN SYNERGY STUDIES 
Combinations of selected EO components and nisin were qualitatively assessed. 
The assay was performed as described in section 2.3.1 but instead of 1001l1, 50 III of the 
supernatant were added to the EO component solutions into the wells at ratio of 1: 1. The 
potential synergy of the EO components in combination with nisin was quantified by the 
Fractional Inhibitory Concentration (FIC) indices, which were derived using 96-well 
microtiter plates. The first row of each plate contained 100 III of the supernatant, the EO 
components dilution, or the EO components in combination with nisin (1: 1) diluted in 
TSB or MRS as appropriate. 
The initial concentrations for each of the antimicrobials were the MIC's as 
previously determined. Wells containing the antimicrobials in the first row were then 
diluted two fold along each column until the end row was reached for each column. 
Then, 100 III of media containing 2xl06 CFU/mL of the bacterium were added to all 
wells. At least 2 columns were used for controls. Positive controls contained growth 
media inoculated with the organism under investigation. Negative controls contained EO 
constituents or nisin and sterile growth media only. The plates were then placed in the 
microplate spectrophotometer (Synergy, Biotek) set at the appropriate temperature. 
Absorbance readings were taken at 600 nm every 30 min after 24 hours of incubation. 
All assays were performed in duplicate and then replicated. 
2.10.1 Determination of the mode of interaction 
The MIC data were transformed to fractional inhibitory concentrations (FIC). The 
FIC of an individual antimicrobial compound is the ratio of the concentration of the 
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antimicrobial in an inhibitory combination with a second test compound to the 
concentration of the antimicrobial alone as follows: 
FICA = (MICA combination / MICA alone) 
The FIC indices were calculated as follows with the FICs for the individual 
antimicrobials: 
FIC index = FICA + FICB, where FICA and FICB are the minimum concentrations that 
inhibited the bacterial growth for samples A and B, respectively. The results were 
interpreted as synergy (FIC < 0.5), addition (0.5 SFIC :91-) or antagonism (FIC > 4). 
2.11 INFLUENCE OF pH ON THE EFFECT OF BACTERIOCIN AND EO 
INDIVIDUAL COMPONENTS 
The effect of pH on the inhibiting capacity of nisin and/or the EO components was 
assessed as described above; using the bacterial broths adjusted at pH values 5.5, 6 and 
7. The desired pH values were obtained by the addition of 1 M HCI or 1 M NaOH when 
appropriate. 
86 
Chapter 3. Design, synthesis and antimicrobial efficacy of CF A derivatives 
3. DESIGN, SYNTHESIS AND ANTIMICROBIAL 
EFFICACY OF CFA DERIVATIVES 
This study involved the design, chemical synthesis and antimicrobial evaluation of 
a series of compounds consisting of a fatty acid component conjugated to a hydrophilic 
core. The chemical syntheses were developed as part of an iterative design process in 
response to the antimicrobial activity results, allowing investigation of any 
structure/activity relationship. The series was designed to investigate the effects of 
carbohydrate versus non-carbohydrate hydrophilic cores, the glycoconjugate linkage, the 
length of fatty acid chain, the number of fatty acids attached to the hydrophilic core and 
the monosaccharide core itself (and the anomeric configuration with respect to 
glucopyranoside). Fatty acid derivatives were screened for quantitative assessment of 
antimicrobial activity compared to structurally similar commercial products. 
3.1 RESULTS 
3.1.1 Chemical Synthesis of Carbohydrate Fatty Acid Derivatives 
The general synthetic strategy involved a series of protection steps to permit the 
functionalisation of the primary hydroxyl of the hydrophilic core. Thus, a chemical route 
has been developed to allow the synthesis of a number of pure, regio-defined, 
monosaccharide mono-fatty acid esters (Scheme 3.1) and the corresponding ether 
derivatives (Scheme 3.2). In order to establish whether a second fatty acid conjugated to 
a monosaccharide would improve antimicrobial activity, a route was developed to 
synthesise a di-laurate derivative of glucopyranoside (Scheme 3.3). Furthermore, to 
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investigate whether the structure and, therefore, the synthesis could be simplified and 
retain activity, non-carbohydrate hydroxylated esters based on a pentaerythritol core 
were synthesised by a straightforward esterification (Scheme 3.4). 
3.1.1.1 General synthesis of ester derivatives 
A chemical route designed to obtain mono-ester sugars is shown in Scheme 3.1 
and is based on the following carbohydrate starting materials: methyl a-D-
glucopyranoside (la), methyl ,B-D-glucopyranoside (lb), methyl a-D-mannopyranoside 
(lc) and methyl a-D-galactopyranoside (ld). The synthesis commenced with the 
selective protection of the primary hydroxyl of sugars la-d with a triisopropylsilyl 
(TIPS) group. The silyl derivatives were then fully protected with benzyl groups (Bn) to 
give 2a-d. The removal of the TIPS group by tetrabutylammonium fluoride in THF 
allowed for the esterification of the free 6-0H position with either lauroyl chloride to 
yield 3a-d or octanoyl chloride to yield Sa. Removal of the benzyl groups by catalytic 
hydrogenation led to the unprotected carbohydrate esters 4a-d and 6a respectively. See 
Appendix 1 (Smith et aI., 2008 Carbohydrate Research paper) for the experimental 
section containing further details of the syntheses, including yields and analytical data 
for purity and in support of the assignment of the structures. 
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OH 
HO~ (''') I,ll 
HO ------.. 
HO OMe 
1a-d 
o )( 
OTIPS 0 C7H15 BnO~Q (iii,vi) Bno~~, Bno~ --- Bno~ 
BnO OMe BnO OM 
2a-d 5a e 
(iii,iV)~ (V)~ 
000 )( )( )( 
o Cn H23 0 C11 H23 0 C7H15 HO~Q - (v) BnO~Q' - HO~ 
HO~"-- Bno~ HO 
HO OMe BnO OMe HO OM 
4a-d 3a-d 6a e 
Scheme 3.1. Synthesis of ester derivatives. 
Reagents and Conditions: (i) DMF anhydr., TIPSCl, imidazole, rt. (ii) DMF anhydr., NaH, 
BnBr, rt. (iii) THF anhydr., ODC, TBAF. (iv) Pyr anhydr., DMAP, Lauroyl Cl, rt. (v) EtOH, Pd-
C, H2• (vi) Pyr anhydr., DMAP, Octanoyl Cl, rt 
3.1.1.2 General synthesis of ether derivatives 
Synthesis of the ether derivatives also commenced with the protection of the 
primary hydroxyl with a triisopropylsilyl group (Scheme 3.2). Attempts to use Bn 
protecting groups for the ether derivatives were unsuccessful as the fatty acid ether was 
not stable enough to withstand the hydrogenation process which was required for 
debenzylation. The sugars were instead fully protected using paramethoxybenzyl ethers 
(PMB), to yield 7a-b. Removal of the TIPS group gave the free primary hydroxyl. Next, 
the lauric ether group was attached using dodecanyl chloride to give the fully protected 
ether derivatives Sa-b. Finally, oxidative cleavage of the PMB groups with ceric 
ammonium nitrate (CAN) gave the mono-dodecanyl sugars 9a-b. 
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OH 
HO~--O ~ HO~ HO -OMe 
OTiPS 
~ (iii,iv) PMBO ~PMBO 
PMBO OMe 
/".... o C l1 H23 PMBO~----O' . 
PMBO_
PMBO OMe 
1a-b 7a-b 8a-b 
(v)~ 
/".... o C11 H23 HO~----O' . 
HO~ 
HO OMe 
9a-b 
Scheme 3.2. Synthesis of ether derivatives. 
Reagents and Conditions: (i) DMF anhydr., TIP SCI, imidazole, rt. (ii) DMF anhydr., THF 
anhydr., O°C, NaH, PMBCI, TBAI. (iii) THF anhydr., O°C, TBAF. (iv) DMF anhydr., dodecanyl 
chloride, O°C, NaH. (v) MeCN:H20 3:1, CAN, rt. 
3.1.1.3 Synthesis ofa di-laurate derivative 
The method used to synthesise di-lauroyl derivative 12a is shown in Scheme 3.3. 
The 4 and 6-0H positions of methyl a-D-glucopyranoside la were protected with a 
benzylidene group using benzaldehyde dimethylacetal. The remaining free OH's were 
then converted to benzyl ethers to give lOa. Removal of the benzylidene acetal using 
catalytic TsOH in MeOH then enabled the esterification of the 4 and 6-0H to give lla. 
Finally, removal of the benzyl groups by catalytic hydrogenation gave the diester 
derivative 12a. 
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o 
H23C1{J\o 
H~O O~ HO 0 (i,ii) PhbO~ (iii ,iv) )l 0 
HO -... BnO -... H23C11 0 BnO 
HO OMe BnO OMe BnO OMe 
1a 10a II 11a 
(v)t 
o 
A H23~11~O 
)l 0 H23Cl1 0 HO 
HO OMe 
12a 
Scheme 3.3. Synthesis of a di-lauroyl derivative. 
Reagents and Conditions: (i) TsOR PhCH(OMe)2 MeCN anhydr., rt. (ii) DMF allhydr., NaB, 
BnBr It. (iii) MeOH, TsOH. (iv) Pyr anhydr., DMAP Lauroyt Ct, rt. (v) EtOH, PdI, H2. 
3.1.1.4 Synthesis of non-carbohydrate hydroxylated esters 
Direct esterification of pentaerythritol 13 using lauroyl chloride and DMAP in 
pyridine, yielded the non-sugar derivatives 14 and 15, shown in Scheme 3.4. 
HOX OH 
HO OH 
13 
Scheme 3.4. Synthesis of non-carbohydrate hydroxylated esters. 
Reagents and Conditions: (i) Pyr anhydr., DMAP, Lauroy! Cl, ft. 
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3.1.2 Bacterial growth and calibration curves 
Bacterial growth curves were constructed to determine cell growth and density 
patterns of each bacterial strain at their optimum growth temperature, to establish the 
appropriate incubation time needed for the antimicrobial experiments and to compare the 
effect of the antimicrobial compounds on bacterial growth under optimum conditions. 
Figure 3.1 shows example growth curves of selected bacteria used in this study. 
From the growth curves shown below we can observe that Listeria strains (Figure 3.1 a 
and b), for example, reached lower OD600 values after 18 hours compared to the S. 
aureus strains (Figure 3.1 c and d). The Gram negative strains, E. coli and P. fluorescens 
showed a shorter lag phase compared to the Gram positive strains. 
Bacterial calibration curves were constructed to equate absorbance values with cell 
growth and density measured in LoglO cfu/mL (Figure 3.2). Absorbance values were 
plotted against the Log lO cfu/mL to obtain a logarithmic trend line. The coefficient of 
equations and the R2 values were obtained, which were subsequently used for the 
determination of ICso values. 
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Figure 3.1 Bacterial growth curves in TSB at 35°C. Error bars represent standard 
deviation values of at least 3 replicates. 
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Figure 3.2 Bacterial calibration curves. Trend line in red. 
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3.1.3 Antimicrobial activity of carbohydrate fatty acid derivatives 
Six carbohydrate fatty acid ester derivatives (4a-d, 6a, 12a), two carbohydrate 
medium chain alkyl ether derivatives (9a-b) and two non-carbohydrate 
polyhydroxylated fatty acid ester derivatives (14, 15), together with their corresponding 
polyhydric alcohols (la-d, 13), fatty acids and mono glycerides as controls, were tested 
against a range of Gram positive and Gram negative bacteria to determine their 
antimicrobial activity. The efficacy of the derivatives and controls were compared using 
MIC, ICso values and increase in Lag phase. 
3.1.3.1 Minimum Inhibitory Concentration 
Minimum Inhibitory Concentration values (MIC) were defined as the lowest 
concentration of compound that showed no increase in cell growth for all the replicates 
compared to a negative control after 18 hours. The minimum inhibitory concentration 
results are shown in Table 3.1. In each antimicrobial efficacy assay, the corresponding 
polyhydric alcohols (carbohydrates and pentaerythritol) for the fatty acid derivatives 
were included, and were shown to have no antimicrobial effect on the microorganisms 
under investigation. Moreover, there was no growth promoting effect noted for these 
sugars when assessed in combination with TSB (results not shown). Although the 
concentrations of ethanol corresponding to that within the assay wells with the highest 
concentrations of compound used (10 mM for the Gram positive and 20 mM for the 
Gram negative bacteria) had a minor effect on bacteria viability, there was no 
antimicrobial effect observed at the concentrations used when incorporated with the 
compounds at MIC levels. 
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Table 3.1. Minimum Inhibitory Concentration values of Carbohydrate Fatty Acid derivatives and Controls in TSB at 37°C after 18 h. 
FA MG Carbohydrate fatty acid derivatives 
Microorganism 
LA CA ML MC 4a 9a 4b 9b 6a 4c 
Gram positive bacteria 
Listeria innocua NCTC 11288 0.63 5 0.04 2.5 0.08 0.04 0.08 5 0.63 0.04 
Listeria monocytogenes ATCC 7644 0.63 >5 0.04 5 0.08 0.04 0.08 2.5 2.5 0.04 
Listeria monocytogenes NCTC 11994 1.25 >5 0.04 2.5 0.31 0.04 0.16 > 2.5 1.25 0.04 
Listeria monocytogenes NCTC 7973 1.25 5 0.04 2.5 0.08 0.04 0.16 > 2.5 0.31 0.04 
Staphylococcus aureus A TCC 25923 0.63 10 0.04 5 0.31 0.04 0.04 2.5 2.5 0.04 
Staphylococcus aureus NCTC 1803 0.63 10 0.04 2.5 0.31 0.04 0.04 1.25 1.25 0.04 
Staphylococcus aureus ATCC 33591 (MRSA) 1.25 10 0.04 2.5 1.25 0.04 0.04 2.5 5 0.04 
Staphylococcus aureus ATCC 33592 (MRSA) 1.25 20 0.04 2.5 0.08 0.08 0.04 5 2.5 0.16 
Staphylococcus aureus ATCC 43300 (MRSA) 1.25 10 0.08 2.5 0.08 0.08 0.04 10 2.5 0.08 
Gram negative bacteria 
Escherichia coli ATCC 25922 >20 10 20 5 20 20 20 20 12.5 ;:::20 
Escherichia coli NCTC 12900 12.5 10 12.5 5 12.5 10 12.5 10 12.5 N.D 
Salmonella Typhimurium ATCC 14028 >20 > 20 20 >20 20 > 20 >20 20 >20 N.D 
Enterobacter aerogenes ATCC 13048 >20 20 20 10 20 >20 >20 >20 >20 N.D 
Pseudomonas fluorescens >20 5 20 5 > 20 >20 >20 >20 5 N.D 
For each analysis the MIC was recorded as the concentration (mM) that resulted in total inhibition of all replicates. N.D: Not detennined; 
FA: Fatty acids; LA: Lauric acid; CA: Caprylic acid; MG: Monoglycerides; ML: Monolaurin; Me: Monocaprylin. 
4a. Methyl 6-0-lauroyl-a-D-glucopyranoside; 9a. MethyI6-0-dodecanyl-a-D-glucopyranoside; 4b. Methyl 6-0-lauroyl-{3-D-glucopyranoside; 
9b. MethyI6-0-dodecanyl-{3-D-glucopyranoside; 6a. MethyI6-0-octanoyl-a-D-glucopyranoside; 4c. MethyI6-0-lauroyl-a-D-mannopyranoside 
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Examples of survivor curves for S. aureus ATCC 25923 and E. coli ATCC 25922, 
obtained using kinetic absorbance assays, are also presented in Figure 3.3 and Figure 3.4 
respectively. 
As can be observed in Table 3.1, the mono glycerides (ML, MC) had greater 
activity (p<0.05) against Gram positive microorganisms than the free fatty acids (LA, 
CA), and comparable activity at the concentrations tested against Gram negative 
microorganisms. Of the monoglycerides and free fatty acids tested, ML had the lowest 
MIC values (p<0.05) and was particularly effective for inhibition of Gram positive 
microorganisms with MIC values of 0.04 mM (excluding S. aureus ATCC43300 with an 
MIC of 0.08 mM), by comparison with the range observed for LA which had MIC 
values between 0.63 mM to 1.25 mM. 
A similar trend was observed for MC when compared with the free fatty acid CA. 
Minimum inhibitory concentration values between 2.5 mM and 5 mM were recorded for 
MC against the Gram positive bacteria tested, in contrast to CA, which had MIC value ~ 
5 mM, being the least effective of all compounds tested against Gram positive bacteria 
with MICs 8- to 16-fold lower than those oflauric acid. 
When tested against the Gram negative bacteria, LA and ML had no activity at 
concentrations up to 20 mM (Table 3.1). An exception to this was recorded for E. coli 
NCTC12900 with a MIC value of 12.5 mM for LA and ML. P. jluorescens was 
susceptible to CA and MC at a concentration of 5 mM for both compounds, whereas for 
E. coli strains (ATCC 25922 and NCTC 12900), MIC values were 10 mM and 5 mM 
respectively. Minimum inhibitory concentrations of CA were ~20 mM for the other 
Gram negative bacteria (Table 3.1). 
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All CFA derivatives tested showed greater antimicrobial activity against Gram 
positive microorganisms than Gram negative (p<0.05). For Gram positive bacteria, the 
lauric ether of alpha glucopyranoside (compound 9a) and lauric ester of alpha 
mannopyranoside (compound 4c) were the most active derivatives with a MIC range of 
0.04 mM to 0.08 mM, comparable to ML (Table 3.1). The next compound in order of 
overall efficacy was the beta lauric ester of glucopyranoside (compound 4b), with MIC 
values of 0.04 mM for S. aureus strains and between 0.08 mM and 0.16 mM for Listeria 
strains. This was followed by the lauric ester of alpha glucopyranoside (compound 4a) 
with a greater MIC range of 0.08 mM to 1.25 mM. The antimicrobial activity of lauric 
ether of beta glucopyranoside (compound 9b) with MIC values from 1.25 mM up to 10 
mM was significantly lower (p<0.05) than that observed with the corresponding lauric 
ether of alpha glucopyranoside (9a). 
The caprylic ester of alpha glucopyranoside (compound 6a) had a greater activity 
(p<0.05) compared to MC against Listeria strains, with MIC values between 0.31 mM 
and 2.5 mM. For S. aureus strains, the activity of alpha caprylic ester was comparable to 
that ofMC, with MIC values of 1.25 mM to 5 mM (Table 3.1). Compound 6a was more 
active than the lauric acid derivatives (4a-c, 9a-b) against E. coli ATCC 25922 and P. 
jluorescens, with MIC values of 12.5 mM and 5 mM respectively (Table 3.1). 
Compound 14 (a non-carbohydrate mono-ester) was evaluated, but its 
antimicrobial activity was negligible (results not shown). Compounds 4d, 12a and 15 
could not be accurately tested for antimicrobial efficacy due to poor solubility in water. 
The results presented in Figure 3.3 show the survivor curves of S. aureus ATCC 
25923 as an example of a Gram positive organism, at a range of concentrations (shown 
on left hand column) for the controls and synthesized compounds tested. 
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Figure 3.3: Antimicrobial effect ofCFA derivatives against S. au reus ATCC 25923. 
The vertical axis in all plots represents OD600 while the horizontal axis is time (18 hours). 
4a.) Methy16-0-lauroyl-a-D-glucopyranoside; 9a.) Methy16-0-dodecanyl-a-D-glucopyranoside; 
4b.) Methyl 6-0-lauroyl-,6-D-glucopyranoside; 9b.) Methyl 6-0-dodecanyl-,6-D-glucopyranoside; 
6a.) Methyl 6-0-octanoyl-a-D-gl ucopyranoside. 
It is clear from the comparison of survivor curves within Figure 3.3, that the most 
effective control compound tested was ML (MIC: 0.04 mM); with comparable efficacy 
noted for alpha lauric ether (compound 9a) and beta lauric ester (compound 4b) of the 
CF A derivatives (MIC: 0.04 mM). The antimicrobial efficacy of the compounds was 
found to be concentration dependent. 
Figure 3.4 shows the survivor curves of E. coli ATCC 25922 as an example of 
Gram negative organism at a range of concentrations (shown on the left hand column) 
for the controls and synthesized compounds tested. 
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Figure 3.4: Antimicrobial effect of CF A derivatives against E. coli ATCC 25922. 
The vertical axis in all plots represents OD600 while the horizontal axis is time (18 hours). 
4a.) Methyl 6-0-lauroyl-a-D-glucopyranoside; 9a.) Methyl 6-0-dodecanyl-a-D-glucopyranoside; 
4b.) Methyl 6-0-lauroyl-j3-D-glucopyranoside; 9b.) Methyl 6-0-dodecanyl-j3-D-glucopyranoside; 
6a.) Methyl 6-0-octanoyl-a-D-glucopyranoside. 
As can be seen from Figure 3.4, MC (5 mM) and CA (10 mM) had a greater 
activity against E. coli ATCC 25922 at lower concentrations than either LA or ML 
controls at equivalent concentrations. The efficacy of the control and synthesized 
compounds was concentration dependent. The carbohydrate fatty acid derivatives 
showed minor activity only at the higher concentration tested (20 mM). An exception 
was for the caprylic ester of alpha glucopyranoside (6a) with antimicrobial activity 
observed at 12.5 mM. 
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3.1.3.2 1Cso values 
The MIC values reported above (Table 3.1) were based on growth or non~growth 
data. An example of the dose-response curve for Listeria monocytogenes ATCC 7644 
with different concentrations of lauric acid is shown in Figure 3.5. 
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Figure 3.5: Dose response curve of Listeria monocytogenes ATCC 7644 with different 
concentrations oflauric acid. 
Experiments were performed to evaluate the extent to which sub-MIC 
concentrations influenced bacterial growth. ICso values were determined for the fatty 
acids, lauric and caprylic acid, beta lauric ether (9b) and alpha caprylic ester (6a), and 
are summarized in Table 3.2 
When the 1Cso values were compared, some trends similar to those recorded for the 
MICs were observed. For example, lauric acid was again more effective against all 
bacteria than the caprylic acid. Differences between strains were also observed, for 
example, L. innocua NCTC 11288, a surrogate of L. monocytogenes but non-pathogenic 
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in character, was more resistant for the beta lauric ether (9b) with an ICso value of 0.879 
mM compared to L. monocytogenes ATCC 7644 with an ICso value of 0.384 mM. the 
same profile was observed for the S. aureus strains, with IC50 values of 0.587 mM and 
0.904 mM for S. aureus ATCC 25923 and MRSA ATCC 33591, respectively, with the 
MRSA strain being more resistant. Similar trends were observed for the alpha caprylic 
ester (6a) and S .aureus strains, with ICso values of 0.700 mM and 1.090 mM. On the 
other hand, the MRSA strain was shown to be more susceptible than the S. au reus to 
caprylic acid with 1Cso values of2.749 mM and 5.111 mM correspondingly (Table 3.2). 
Table 3.2: 1Cso values of fatty acids and carbohydrate fatty acid delivatives. 
Lauric Beta lauric Caprylic Alpha caprylic 
Microorganism 
acid ether (9b) acid ester (6a) 
L. innocua NCTC 11288 0.168 0.879 N.D N.D 
L. monocytogenes ATCC 7644 0.164 0.384 4.842 0.441 
S. aureus ATCC 25923 0.288 0.587 5.111 0.700 
MRSA ATCC 33591 0.214 0.904 2.749 1.090 
Values are expressed as concentration (mM). N.D: not determined. 
3.1.3.3 Increase in lag time and decrease in maximum specific growth rate 
Where appropriate, the increase in lag time was calculated. For the concentrations 
at which a compound was less effective, an increase in the lag time could be estimated to 
allow comparison between compounds and strains. 
The increase in lag time (~A.) and decrease in maximum specific growth rate ()lmax) 
were estimated for L. monocytogenes ATCC 7644 (Table 3.3) and S. aureus ATCC 
25923 (Table 3.4) to allow further comparison between compound efficacies. 
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Results were found to be concentration and compound dependent (p < 0.05). 
Generally, the increase in lag time between concentrations of a compound was observed 
to be more marked than the decrease in growth rate which was more gradual. For 
example, for L. monocytogenes ATCC 7644 at sub-MIC concentrations, compound 4b 
(beta lauric ester) had an increase in lag time from 0.5h to 5.3h associated with a small 
increase in concentration from 0.02 mM to 0.04 mM. This trend was also true for LA, 
CA, MC and compound 9b (beta lauric ether) (Table 3.3). With respect to ~-max, 
different patterns were observed, there was a gradual decrease noted with LA, CA, MC 
and compound 9b, associated with the higher MIC values for these compounds. 
Whereas, for ML and compound 4b, there was a non-linear association of ~-max 
reduction with concentration, associated with the very low MIC values determined for 
these compounds. 
For S. aureus ATCC 25923, increase in lag time was found to be concentration and 
compound dependent, with a major effect at concentrations close to the MIC values 
(Table 3.4) (p < 0.05). For example, at 2-fold sub-MIC concentrations, the fatty acids 
(LA, CA) and monoglyceride (ML, MC) standards, as well as compound 4a (alpha 
lauric ester) and compound 6a (alpha caprylic ester), showed a significant increase in lag 
time of approximately two to six hours compared to that of the cultures without 
treatment. At a 4-fold sub-MIC concentration, a relatively small increase was observed. 
For compound 9b (beta lauric ether), a different trend was observed, with a more 
gradual increase in lag time with an effect observed even at 8-fold sub-MIC 
concentrations (from 1.25 to 0.16 mM) (Table 3.4). 
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Table 3.3 Effect of FA, MG and CPA derivatives on the Lag time (A) and Maximum 
specific growth rate (!J.max) of L. monocytogenes ATCC 7644 
ComEound (mM} ll'A !h) St.Dev. lJrnax !h-I ) St.Dev. 
LA 0 0.30 ± 0.034 
0.04 0.0 ± 0.06 0.22 ± 0.049 
0.08 0.2 ± 0.26 0.17 ± 0.041 
0.16 2.0 ± 1.00 0.10 ±0.017 
0.31 4.8 ± 1.73 0.07 ± 0.037 
0.63 no growth 0 
ML 0 0.30 ± 0.034 
0.02 2.3 ± 1.09 0.25 ±0.040 
0.04 no growth 0 
4a 0.08 no growth 0 
9a 0.04 no growth 0 
4b 0 0.30 ± 0.034 
0.02 0.5 ± 0.07 0.31 ± 0.003 
0.04 5.3 ± 0.67 0.27 ± 0.006 
0.08 no growth 0 
9b 0 0.30 ± 0.034 
0.16 0.2 ±0.18 0.30 ± 0.013 
0.31 0.5 ±0.25 0.27 ± 0.009 
0.63 5.0 ±O.55 0.12 ±O.O59 
1.25 no growth 0 
CA 0 0.30 ± 0.034 
0.31 0 0.26 ±0.027 
0.63 0 ±0.04 0.24 ± 0.037 
1.25 0.1 ± 0.17 0.26 ±0.044 
2.5 0.8 ± 0.19 0.21 ± 0.034 
5 3.1 ± 1.62 0.18 ± 0.097 
10 no growth 0 
MC 0 0.30 ± 0.034 
0.31 0.2 ±0.29 0.26 ±0.029 
0.63 0.3 ±0.40 0.25 ± 0.043 
1.25 1.1 ± 0.41 0.19 ± 0.046 
2.5 5.6 ± 1.35 0.01 ± 0.034 
5 no growth 0 
6a 0 0.30 ± 0.034 
0.31 0.4 ± 0.47 0.24 ± 0.035 
0.63 1.6 ±0.94 0.22 ± 0.008 
1.25 1.0 ±0.27 0.12 ± 0.008 
2.5 1.9 ± 0.34 0.08 ±O.OOI 
5 no S!'owth 0 
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Table 3.4 Increase in Lag time (~A) for S. aureus ATCC 25923 in the presence of 
standards and CF A derivatives 
Compound fl.>' Compound fl.>' SD (mM) ~hl SD (mM) !h) 
LA 0 CA 0 
0.04 0.0 ± 0.000 0.63 0.0 ± 0.000 
0.08 0.0 ±o.ooo 1.25 0.2 ± 0.009 
0.16 0.5 ± 0.364 2.5 0.6 ± 0.221 
0.31 4.2 ± 0.898 5 3.0 ± 0.312 
0.63 N.G 10 N.G 
ML 0 MC 0 
0.02 3.9 ± 0.684 1.25 0.0 ± 0.000 
0.04 N.G 2.5 1.8 ± 0.986 
5 N.G 
4a 0 6a 0 
0.04 0.0 ± 0.000 0.63 0.5 ± 0.327 
0.08 0.7 ± 0.167 1.25 1.3 ± 0.376 
0.16 6.1 ± 0.595 2.5 N.G 
0.31 N.G 
9b 0 
0.16 2.7 ± 1.777 
0.31 3.9 ± 2.865 
0.63 4.1 ± 2.021 
1.25 6.4 ± 1.615 
2.5 N.G 
Values are expressed as the difference between the treated culture and culture without 
compound. SD: Standard deviation. N.G.: No growth. LA: Lauric acid; CA: Caprylic acid; ML: 
Monolaurin; MC: Monocaprylin; 4a. MethyI6-0-lauroyl-a-D-glucopyranoside; 9b. Methyl 6-0-
dodecanyl-,6-D-glucopyranoside; 6a. MethyI6-0-octanoyl-a-D-glucopyranoside. 
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3.1.4 Effect of pH and Temperature on the fatty acids and monoglycerides 
activity 
To assess the effect of pH and temperature on the antimicrobial efficacy of the 
fatty acid derivatives, the growth of selected bacterial strains (L. innocua ATCC33090, 
S. aureus ATCC25923, E. coli ATCC 25922 and Pseudomonas fluorescens) was 
recorded at different temperatures (35°C, 22°C, 10°C and 4°C) in combination with a 
range of pHs (4, 4.5, 5, 5.5, 6, 7) in the absence or presence of test compounds (LA or 
ML). 
3.1.4.1 Effect of pH levels on antimicrobial efficacy 
The changes in pH values measured after autoclaving the media with adjusted pH 
levels were minor and deemed to have no major influence on the experiment. Changes in 
pH, after addition of the compounds, were also recorded to assess possible influence of 
the addition of compounds in the media on bacterial growth; and were also found to be 
minor (Table 3.5). 
Table 3.5. Effect of fatty acids and monoglycerides on the pH of the culture media. 
~edia pH 
TSB 7.16 ± 0.007 
TSB (10% EtOH) 7.28 ± 0.012 
TSB + Lauric acid 5 mM (10% EtOH) 7.10 ±0.007 
TSB + Monolaurin 5 mM (10% EtOH) 7.28 ±0.005 
TSB + Caprylic acid 5 mM (10% EtOH) 6.93 ± 0.007 
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Bacterial growth curves were constructed from the OD600 data at an optimum 
temperature of 35°C with the different pH concentrations, in the absence of test 
compounds (Figure 3.6). 
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Figure 3.6 Effect of different pH levels on bacterial growth at 35°C in TSB. 
After the incubation time, no growth was observed for any of the strains tested at 
pH 4 in the absence of test compound; therefore further studies did not include pH 4. L. 
innocua ATCC33090 was very susceptible at pH 4.5 with no increase in OD600 recorded 
after 24 hours of incubation; S. aureus ATCC 25923, E. coli ATCC 25922 and P. 
jluorescens grew at pH 4.5 but had an increased lag time and reduced maximum specific 
growth rate. In general, results show that as pH lowered, a decrease in the optical density 
and an increase in the lag phase were observed for each of the strains. For example, the 
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lag phase of S. aureus ATCC 25923 at pH 7 was approximately 5.8 hours, but at lower 
pH levels the lag phase increased up to 8 hours and 10.5 hours for pH 5 and 4.5, 
respectively (Table 3.6). 
Table 3.6 Effect of pHs on the Lag time (A) 
L. innocua S. aureus E. coli 
pH 
ATCC33090 ATCC 25923 ATCC 25922 
P. fluorescens 
4 N.G N.G N.G N.G 
4.5 N.G N.D 15.5 ± 4.98 17.3 ± 1.35 
5 10.8 ± 0.13 10.5 ± 0.05 6.9 ± 0.10 8.8±0.15 
5.5 7.6 ± 0.54 5.9 ± 1.28 7.4 ± 1.98 7.5 ± 2.16 
6 7.1±0.38 5.7 ± 0.27 5.1 ± 0.42 6.2 ± 0.17 
7 6.7 ± 0.23 5.8 ± 0.56 5.1±O.l5 5.6±0.12 
N.G: No growth. N.D: Not determined. Values are expressed as time in hours. 
Standard deviations next to each value. 
For Listeria innocua ATCC33090, a less pronounced increase in the lag phase 
between pH 7 and 5.5 was observed, but at pH 5 a lag phase of approximately 11 hours 
was recorded, compared with 6.7 hours at pH 7. A similar trend was observed for the 
Gram negative bacteria tested, which could grow slowly at pH 4.5 in the absence of test 
compound: the lag phase increased to 15-17 hours at pH 4.5 compared to 5.6 hours at 
pH 7. 
The effect on the maximum specific growth rate was also affected by pH level. 
Between pH 4 and 5.5 a marked decrease in growth rate was observed with almost half 
of the values found at pH 7 (Table 3.7). 
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Table 3.7 Effect of pH on the maximum specific growth rate (Ilmax) 
L. innocua S. aureus E. coli 
pH 
ATCC33090 ATCC 25923 ATCC 25922 
P. fluorescens 
4 N.G N.G N.G N.G 
4.5 N.G N.D 0.124 ± 0.020 0.140 ± 0.013 
5 0.174 ± 0.046 0.101 ± 0.003 0.115 ± 0.003 0.124 ± 0.005 
5.5 0.325 ± 0.050 0.208 ± 0.013 0.249 ± 0.086 0.186 ± 0.046 
6 0.376 ± 0.031 0.252 ± 0.031 0.280 ± 0.025 0.207 ± 0.051 
7 0.384 ± 0.026 0.253 ± 0.038 0.232 ± 0.026 0.222 ± 0.005 
N.G: No growth. N.D: Not determined. Values expressed as (hoi). 
Standard deviations next to each value. 
With the addition of antimicrobial compounds at 35°C, there were interactions 
observed between pH level and compound concentration. No growth was observed for S. 
aureus ATCC 25923 at the range of LA concentrations tested, but at pH 7 (Figure 3.7.a) 
growth was permitted in the presence of LA at Y2 MIC; whereas at pH 5, the efficacy of 
the compounds was enhanced (Figure 3.7.b), potentially reducing MIC values and 
concentrations required for useful efficacy. 
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Figure 3.7 Effect of pH on the MIC values of lauric acid against S. aureus ATCC 25923 
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As a result, the inhibition of growth by lauric acid is dependent not only on 
concentration but also on pH. Similar findings were obtained by Sun et al. (2003) who 
reported a dramatic effect of pH on the potency of fatty acids. 
By contrast, the antimicrobial efficacy of monolaurin was not influenced by pH. 
Growth at sub-MIC concentrations was observed both at pH 7.0 and pH 5.0 (Figure 3.8). 
a) pH7 
2.0 ..,-------------
e 1.6 ..j~-----­
~ 1.2 4--------, '-----
=> 
\CO 0.8 4--------;11- ----
~ 
o 0.4 +-------I----.....",.~ 
0.0 ~~m_2&_~~~~~ 
00:00 03:00 06:00 09:00 12:00 15:00 18:00 
llme (hours) 
-+- Control ___ 1/2 MIC MIC ~ 2xMIC 
b) 
e 
= 
=> 
=> \CO 
~ 
0 
pHS 
2.0 
1.6 ------------
1.2 
0.8 
0.4 
0.0 
00:00 03:00 06:00 09:00 12:00 15:00 18:00 
Time (hours) 
-'-Control - 1/2 MIC MIC -+-2xMIC 
Figure 3.8 Effect of pH on the efficacy ofmonolaurin against S. aureus ATCC 25923 at 
3.1.4.2 Effect of temperature and pH levels on antimicrobial efficacy 
L. innocua ATCC33090 grew at 22°C at all pH levels tested (Figure 3.9.a). The 
addition of lauric acid at a sub-MIC concentration caused a substantial decrease in 
growth at all pH levels after 24 hours of incubation (Figure 3.9.b) while growth was 
completely arrested at MIC concentrations. Similar trends were observed with 
monolaurin at sub-MIC, however, at 48 hours, higher OD values were achieved by 
comparison with lauric acid (Figure 3.9.c). 
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Figure 3.9 Effect of lauric acid and monolaurin at sub-MIC concentrations on the 
growth of L. innocua ATCC33090 at 22°C fOT different pH levels. 
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At lower temperatures of 10°C and 4°C, no growth was observed for L. innocua 
ATCC33090, S. au reus ATCC 25923 and E. coli ATCC 25922 after 96 hours even in 
the absence of antimicrobial compounds. However, P. fluorescens grew at 10°C after 96 
hours for control samples and those with lauric acid at 112 MIC concentration (Figure 
3.10). 
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Figure 3.10: Effect of lauric acid and monolaurin concentrations on the growth of P. 
fluorescens at 10°C at different pHs. 
As an overall result we observed that pH had an effect on bacterial growth and 
on antimicrobial efficacy of the fatty acid, but did not affect the efficacy of the 
monoglyceride. Temperature had no effect on the antimicrobial efficacy of the 
compounds, but it was observed to be dependent on the nature of the strains. 
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3.2 DISCUSSION 
Sugar esters have shown increased interest due to advantages with regard to 
environmental compatibility compared to petrol-derived standard products, as they are 
biodegradable and formed from renewable sources such as fatty acids and sugars (Ferrer 
et ai., 2005). With respect to their use as emulsifiers, an advantage of carbohydrates as 
the water solubilising hydrophilic component is their ability to offer a full range of HLB 
(hydrophilic lipophilic balance) values. This can be achieved by varying the 
carbohydrate itself (monosaccharide vs disaccharide, glucose vs galactose etc), and by 
controlling the degree of esterification. However, it is the antimicrobial potential of 
carbohydrate fatty acid derivatives, which has received less attention than their 
functional properties as emulsifiers or non-ionic surfactants, which is of interest in this 
study. There is limited information on the antimicrobial properties of CFA derivatives 
for use as food preservatives. This is in contrast to the extensive literature for 
monoglycerides, such as monolaurin, which is one of the most active antimicrobial fatty 
acid derivatives investigated to date (Conley and Kabara 1973; Bell and De Lacy 1987; 
Schlievert et ai., 1992; Ababouch et ai., 1994a; Blaszyk and Holley 1998; Chaibi et ai., 
1998; Bergsson et ai., 2001; Ruzicka et ai., 2003; Sun et ai. , 2003; Devulapalle et ai., 
2004; Peterson and Schlievert 2006). 
Previous studies on antimicrobial properties of sugar esters primarily focused on 
sucrose or other disaccharide ester derivatives (Hathcox and Beuchat, 1996). Some 
workers have pointed out that many of the studies were not carried out usmg 
regiochemically pure compounds (Devulapalle et al., 2004), thus making it difficult to 
definitively ascribe antimicrobial activity to a specific chemical structure. Moreover, 
many studies were semi-quantitative at best and did not include reference or control 
113 
Chapter 3. Design, synthesis and antimicrobial efficacy of CF A derivatives 
compounds that would allow comparison of efficacy with commercially available 
antimicrobial fatty acid derivatives. Thus, it was often difficult to ascertain from the 
literature whether novel antimicrobial fatty acid esters were better than existing 
commercial products for a given application. It was also difficult to compare the efficacy 
of these derivatives as synthesized by different groups. 
The correlation of chemical structure with efficacy andlor mechanism of action has 
been difficult. Rios and Recio (2005) pointed out that many articles on natural products 
claim so-called "exciting" antimicrobial activities, despite major flaws in methodologies 
used. Most frequent amongst them are the lack of sound criteria for activity, the 
omission of appropriate in-test controls, the inclusion of unrealistically high assay 
dosages and the nature of the bioassay itself (selection of target organism, endpoints, 
etc). 
There are several different assays for screenmg antimicrobial activity. Many 
publications report the antimicrobial activity of plants using general in vitro screening 
assays for microbial growth inhibition. The standard general screening assays include 
diffusion assays, dilution assays and bioautographic assays. Paper disc diffusion assays 
are generally used for screening of antibacterial and antifungal activities from natural 
extracts and compounds. However, the diffusion method is not appropriate for testing 
nonpolar samples or samples that do not easily diffuse into agar where a zone of 
inhibition diameter has to be measured (Cos et ai., 2006). For that reason, in the present 
study, a broth microdilution method was chosen. 
Frequently, natural products are tested only against a single species or class of 
microorganisms. When the product exhibits high antimicrobial activity, it is then 
identified as a potential 'hit'. However, this 'narrow focus' strategy overlooks the 
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incidence of false-positives, which can easily be solved by inclusion of other microbial 
screens of bacteria, fungi, parasites and/or viruses (Cos et al., 2006). Hence, in the 
present study a range of Gram positive and Gram negative bacteria from food or clinical 
isolates were included, focusing on Listeria monocytogenes and Staphylococcus aureus. 
This study was primarily concerned with the synthesis of carbohydrate fatty acid 
derivatives for evaluation as antibacterial agents, with a view to discerning the impact of 
the following structural variations on antimicrobial efficacy: 
(i) variation of the length of fatty acid chain (lauric and caprylic), 
(ii) the type of fatty acid carbohydrate linkage (ester and ether), 
(iii) the monosaccharide core (glucopyranoside, mannopyranoside or 
galactopyranoside ), 
(iv) the anomeric configuration of the sugar moiety (a or (3 glucopyranoside), 
(v) the role of carbohydrate versus non-carbohydrate hydrophilic cores 
(carbohydrate and pentaerythritollaurates) 
(vi) the degree of substitution (monoester or diester) of the carbohydrate. 
In general, the CFA derivatives synthesized in this study were shown to be more 
effective against Gram positive than Gram negative bacteria (p<0.05). This trend was 
also observed for the fatty acid and mono glyceride controls, in accordance with previous 
studies (Conley and Kabara 1973; Bergsson et al., 2002; Ruzicka et al., 2003). We 
obtained similar MIC values of 10 p,g/mL (0.04 mM) for monolaurin against L. 
monocytogenes as those reported by Wang and Johnson (1992), and Oh and Marshall 
(1993). We reported MIC values for lauric acid between 125 p,g/mL (0.63 mM) and 250 
p,glmL (1.25 mM), lower than those reported by Kitahara et al. (2004), of 400 p,g/mL 
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against methicillin-susceptible Staphylococcus aureus (MSSA) and MRSA, probably 
due to strain differences. 
The MIC values (0.04 mM) of lauric derivatives 9a (alpha lauric ether) and 4c 
(lauric ester of mannopyranoside) against Listeria strains were found to be equivalent to 
that of monolaurin and in excess of that reported by Monk et al., (1996), for a lauroyl-
sucrose ester. 
The importance of the chain length of the fatty acid ester was investigated using 
both lauric and caprylic derivatives. With respect to the effect of chain length on 
antimicrobial activity of the CF A derivatives, there was a difference in efficacy between 
Gram positive and Gram negative bacteria. Lauric acid and derivatives had higher 
activity against Gram positive bacteria, whereas caprylic acid and its ester derivative 
(compound 6a) were more active than lauric acid derivatives against E. coli ATCC 
25922 and P. fluorescens. This trend was also observed for the monoglyceride controls 
and is in accordance with general trends observed for medium and short chain fatty acids 
(Conley and Kabara, 1973). 
The data obtained in this study is also comparable to that of Nair et al. (2004a), 
where populations of L. monocytogenes and E. coli 0157:H7 were shown to decline 
below detection levels using 50 mM of MC or CA in bovine milk. The same authors, 
Nair et al. (2005b), described antimicrobial activity for both CA and MC and found that 
Streptococcus spp. were the most sensitive, and E. coli the most tolerant. Whilst both 
lauric and caprylic fatty acid derivatives retained good activity against Gram positive 
bacteria, only the caprylic acid derivative displayed useful efficacy against Gram 
negative bacteria. 
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The enhanced efficacy of the shorter chain fatty acid over the medium chain fatty 
acid could be attributed to differences in the outer membrane structure and permeability 
between Gram negative and Gram positive bacteria. The outer membrane of Gram-
negative bacteria behaves as a entry barrier against fatty acids, but the cell wall of Gram-
positive bacteria may adsorb and transport fatty acids into the inner membrane 
(Galbraith and Miller, 1973b; Kitahara et al., 2004). 
A detailed study by Ruzin and Novick (2000) showed the rapid hydrolysis of ML 
with liberation of lauric acid (t1/2 of ~5 min) in S. aureus cultures. The Geh lipase 
(glycerol ester hydrolase) was found to be responsible for approximately 80% of the 
monolaurin hydrolysing activity in the supernatant, but the same authors also reported 
cell-associated lipolytic activity. This activity might be explained by the action of either 
intracellular or membrane-bound lipases. However, intracellular lipases, in S. aureus, are 
not expected to play any significant role in ML degradation, since, ML is a surfactant 
and is considered unlikely to reach the cytoplasm, therefore they suggested that S. 
aureus had one or more membrane bound esterases that participated in the hydrolysis of 
monolaurin and release of lauric acid. They were not, however, able to rule out the 
possibility that ML itself might have some inhibitory action prior to its hydrolysis. 
These findings raise important questions for fatty acid derivatives of 
carbohydrates. It is not clear, for example, whether fatty acid esters of carbohydrates are 
similarly hydrolysed by extracellular or membrane-bound enzymes or whether their 
mode of action might depend on such hydrolysis. The clarification of the role of the free 
fatty acid in antimicrobial efficacy was related to the design of compounds with an ester 
or an ether glycoconjugate linkage. 
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Reporting on the antimicrobial efficacy of ether and ester glyceride compounds, 
Isaacs et ai., (1995), suggested that ether lipids should remain antimicrobial for a longer 
period of time than monoglycerides with ester linkages, due to their greater stability in 
biological systems. The current work suggests that while membrane bound or free 
esterases may cleave ester bonds of a glycerol or a carbohydrate fatty acid derivative, the 
ether carbohydrate fatty acid derivatives retained higher activity than the ester 
derivatives, as the ether linkage is not readily hydrolysed by esterases in biological 
systems (Ved et ai., 1984), and that the release of a free fatty acid may not be required 
for antimicrobial activity. This is in agreement with Isaacs and Lamp (2000), who 
suggested that changing the linkage in a monoglyceride between the fatty acid and the 
glycerol backbone from an ester bond to an ether linkage, could increase the 
antimicrobial activity of some medium-chain mono glycerides. 
However, an alternative explanation whereby the antimicrobial activity of the fatty 
acid ether derivative is due to binding at a site different to that of the ester derivative 
cannot be discounted. This explanation would, however, have to postulate two sites of 
action for these compounds, both equally bactericidal, which seems unlikely. 
In an effort to probe the role of the carbohydrate moiety in antimicrobial efficacy, 
ester and ether fatty acid derivatives of the following carbohydrates were synthesized 
and tested: a-glucose, ,a-glucose, a-mannose and a-galactose. Of these, differences in 
efficacy were measured for compounds with the same glycoconjugate bond and alkyl 
chain length (compounds 4a, 4b, 4c and 4d). The results showed that the lauric ester 
derivative of methyl ,a-D-glucopyranoside (4b) and methyl a-D-mannopyranoside (4c), 
showed higher activity than any other ester derivatives against Listeria spp. and S. 
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aureus strains, indicating that the nature of the carbohydrate moiety plays a role in the 
antimicrobial efficacy of CF A derivatives. 
From these studies we conclude that the sugar itself may be a factor in determining 
efficacy. This is consistent with the findings of Watanabe et ai., (2000) who also 
concluded that the configuration of the hydroxyl group in a carbohydrate moiety 
markedly affected antibacterial activity. In these studies, we also found that a minor 
structural change in the carbohydrate may have a major influence on the solubility of a 
compound in water. For example, compounds 4a, 4b, and 4c (a-glucose, ,a-glucose, a-
mannose) were soluble, whereas the structurally similar compound 4d (a-galactose) was 
practically insoluble. This further highlights the importance of the choice of 
carbohydrate moiety for antimicrobial efficacy of CFAs. 
The differences observed in this study between compounds with ester or ether 
bonds of the same carbohydrate fatty acid (compounds 4a and 9a; and compounds 4b 
and 9b) show that the nature of the bond between the fatty acid and the sugar also has an 
influence on antimicrobial activity. Compound 9b (13 lauric ether) was less inhibitory 
than the free fatty acid (LA) and monoglyceride (ML) against Listeria spp. and S. aureus 
strains. In some cases, compound 9a (a lauric ether) had an enhanced activity by 
comparison with compound 4a (a lauric ester) and 4b (13 lauric ester), particularly for 
Listeria spp. However, the same compounds had comparable levels of efficacy against 
Gram negative bacteria. 
Further evidence of a role for the carbohydrate moiety in CF As efficacy came from 
data for the lauric ester anomers of methyl glucopyranoside 4a and 4b. When these 
compounds were tested against S. aureus, the beta configuration showed higher activity, 
whereas against Listeria strains similar activity for both derivatives was observed. The 
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lauric ether anomers of methyl glucopyranoside 9a and 9b also showed a marked 
difference in activity when tested against S. aureus and Listeria spp., with the alpha 
configuration showing higher activity for both strains (MICs 0.04 mM to 0.08 mM) 
compared to the beta configuration (MICs 1.25 mM to 10 mM), p<0.05. 
In general, the alpha configuration of the carbohydrate moiety of the compounds 
synthesized was more effective than the beta, for both ester and ether derivatives of the 
same carbohydrate. This further indicates that the carbohydrate can have a role in the 
antimicrobial efficacy of the carbohydrate fatty acid derivative. 
What is surprising is that antimicrobial activity is not sensitive to the presence or 
absence of the bulky carbohydrate group but is sensitive to the configuration of the 
anomeric carbon of the carbohydrate moiety. Despite their similarity in structure, 
compound 9a (a-glucose lauric ether), was far more active against most S. aureus and 
Listeria strains than compound 9b G3-glucose lauric ether). The reasons for this 
discrepancy were not clear from these studies and required further investigation of the 
mechanism of action of these compounds. 
The non-carbohydrate pentaerythritol monoester 14, which has the same number of 
free hydroxyl groups as the carbohydrate monoester derivatives (4a-d), showed 
negligible activity against both microorganisms tested (s. aureus ATCC 25923 and E. 
coli ATCC 25922), indicating that the carbohydrate structure might play an important 
role in the antimicrobial activity of these compounds. 
We found that not only were free single or multiple hydrophilic groups necessary 
for biological activity, as observed by Conley and Kabara (1973), but that the overall 
structure of the hydrophilic moiety conjugated to the fatty acid is important for 
antibacterial activity. For example, the antimicrobial activity associated with the lauroyl 
120 
Chapter 3. Design, synthesis and antimicrobial efficacy of CFA derivatives 
pentaerythritol monoester 14 with three free hydroxyl groups was negligible compared 
to compounds 4a, 4b and 4c which also had the same number of free hydroxyl groups. 
This could be related to the more highly constrained nature of the ring structure of the 
carbohydrates and the associated entropic benefit upon binding to a biological receptor, 
compared to the more flexible pentaerythritol structure. It could also be related to the 
fixed orientation of the hydroxyl groups of the carbohydrate, and the increased 
likelihood of recognition of a carbohydrate derivative by a biological receptor compared 
to a pentaerythritol derivative. However, this remains speculative until further evidence 
for the mechanism of action of these compounds is realised. 
The degree of substitution of these derivatives was also shown to be crucial as both 
the non-sugar pentaerythritol diester 15 and the carbohydrate methyl CX-D-
glucopyranoside diester 12a were much less soluble in water than the corresponding 
monoesters. As a consequence, no antimicrobial activity data for these compounds could 
be obtained. Results for diester 12a demonstrate that more than one fatty acid esterified 
to a monosaccharide render the compound insufficiently soluble for antimicrobial 
activity evaluation by the methodology chosen for this study. While this is a limiting 
factor for more general applications of these compounds, such low solubility as found 
for compounds 4d, 12a and 15 would limit their potential for application in food systems 
as antimicrobials in any case. 
Combinations of sub-MIC preservatives with other minimal 'hurdles' may 
contribute to the control of microbiological issues in food systems while minimizing 
sensory and quality impacts on a food (Gutierrez et al., 2008). Thus, in this study we 
evaluated the extent to which sub-MIC concentrations influenced bacterial growth. 
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The half maximum inhibitory concentration (ICso) was defined as the 
concentration required for 50% inhibition of growth. For some compounds, like 
monolaurin and the lauric esters, the inhibition of growth was very effective at almost all 
concentrations tested, making it difficult to calculate an ICso due to the insufficiency of 
data points. For that reason, future studies should encompass a wider range of low 
concentrations for both control and novel compounds. 
ICso values obtained, showed similar trends for lauric and caprylic acid efficacy to 
those recorded for MICs. Although, differences in the degree of sensitivity between 
strains were observed for L. innocua NCTC 11288 and L. monocytogenes ATCC 7644; 
and for S. aureus ATCC 25923 and MRSA ATCC 33591. This observation reinforces the 
importance of including a range of bacteria species to avoid the incidence of false-
positives as potential 'hits'. 
The data obtained from the increase in lag phase and decrease in maximum 
specific growth studies showed that sub-MIC concentrations can also modify bacterial 
growth significantly. Antimicrobial efficacy of compound 9b (beta lauric ether) was 
considerably lower than that of the other derivatives, but these results show that 
nevertheless, there is a significant effect of this compound on bacterial growth, even at 
sub-MIC concentrations. Nair et ai., (2004b) also observed this behaviour using 
monocaprylin (50 mM) which reduced Enterobacter sakazakii growth in reconstituted 
infant formula by >5 log CFU/ml at 37°C, whereas approximately 1.5 log CFU/ml of the 
pathogen survived after 24 h of incubation using half the concentration of antimicrobial. 
The reduction in population density and the increase in the lag phase observed 
when strains were incubated at different pH levels, indicates that pH had an effect on 
bacterial growth and on antimicrobial efficacy of the fatty acid, but did not affect the 
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efficacy of the monoglyceride. No growth was observed at any concentration of lauric 
acid tested at pH 4, whereas, growth was observed at the Y2 MIC of monolaurin at all pH 
levels tested after 48 hours. This is in accordance with the study reported by Sun et al., 
(2003), who observed that bactericidal potency of monoglycerides, unlike that of free 
fatty acids, does not show any variation over a broad pH range, as these molecules 
remain un-ionised. However, Oh and Marshall (1993a) demonstrated that at 35°C, L. 
monocytogenes grew well in the presence of 18 J..lM monolaurin in a medium adjusted 
(with HCI) to pH 5.5. However, when the pH was further reduced to pH 5.0, the 
bacterium did not grow. 
The enhanced efficacy of lauric acid against S. aureus ATCC 25923 at pH 5 could 
be explained as follows; at low pH bacterial cells take up fatty acids and monoglycerides 
at a higher rate which reduces the bacterial membrane-medium interfacial tension, 
thereby resulting in an enhanced inhibitory effect on the target bacterium (Galbraith and 
Miller, 1973a; Oh and Marshall. 1992). 
In this study, temperature seemed to have no effect on the antimicrobial efficacy of 
the fatty acid and its derivatives, but it was observed to be more dependent on the nature 
of the microorganisms, as the sensitivity of the bacteria could differ depending on the 
storage temperature. The antimicrobial effect was more marked at higher temperatures 
(35°C and 20°C) than at lower temperatures (lO°C and 4°C). This was expected because 
the microorganisms were mesophilic in nature, whereas at refrigeration temperatures, 
the metabolism of the microorganisms becomes slower; therefore, growth and death 
rates are lower. Nair et al. (2005a), observed that monocaprylin had a markedly 
increased antibacterial effect at room temperature, which again could be attributed to the 
mesophilic nature of E. coli 0157: H7. 
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The significantly reduced antibacterial effect of fatty acid and derivatives at 4°C 
can also be attributed to the decreased solubility of lipids at lower temperatures (Nair et 
al., 2004b). The reduced antibacterial effect of fatty acid and monoglyceride at lower 
temperatures could also be due to the changes in the fatty acid profile and fluidity of the 
bacterial cell membrane at refrigeration temperatures. Electron microscopic examination 
of bacterial cells exposed to mono glycerides has revealed plasma membrane 
disintegration, leaving the peptidoglycan cell wall intact (Bergsson et aI., 1998). 
Changes in cell membrane lipid composition, including alterations in the relative 
proportions of different fatty acid classes, and increased lipid unsaturation and fluidity 
upon exposure to refrigeration temperatures have been reported (McElhaney, 1976; 
Russel, 1984). These changes in the bacterial cell membrane may interfere with the 
action of fatty acid and monoglycerides, resulting in a reduced antibacterial effect. 
The results obtained for Pseudomonas show that even at low temperatures lauric 
acid could be active against spoilage microorganisms, at MIC values, after 4 days. This 
is of interest for potential application studies with respect to control of spoilage of 
refrigerated fresh food products, many of which can be associated with Pseudomonas 
spp. 
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4. MECHANISM OF ACTION STUDIES 
Following the antimicrobial activity studies, in which the CFA derivatives 
synthesised demonstrated interesting antimicrobial activity against certain bacteria, and 
where the efficacy was to a certain extent related to compound structural differences, 
this study seeks to further our knowledge through extending the investigation of the 
structure/activity relationships and mode of action of CFA derivatives. 
It has been proposed that the cell membrane is the principal site of action of fatty 
acids and their esters. A detailed study by Ruzin and Novick (2000) showed that 
monolaurin inhibited the production of exoenzymes and virulence factors in S. aureus at 
sub-MIC concentrations. Moreover, they were able to show rapid hydrolysis of 
monolaurin with liberation of lauric acid (tll2 of ~5 min) in the presence of S. aureus 
cells, suggesting that the prolonged inhibitory effects associated with monolaurin might 
be due to liberation of lauric acid by hydro lases present in the cell preparation. However, 
they were not able to rule out the possibility that monolaurin itself might have some 
inhibitory action prior to its hydrolysis. 
These findings raised important questions for CF A derivatives. It is not clear, for 
example, whether fatty acid esters of carbohydrates are similarly hydrolysed or whether 
their mode of action might depend on such hydrolysis. Results in chapter 3 showed that 
an ether analog of a CFA (compound 9a) retained higher or similar antimicrobial 
activity to the ester derivative, thus indicating that the release of a free fatty acid was not 
an absolute requirement for antimicrobial activity since ethers will not be hydrolysed by 
enzymes present in cell preparations. 
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4.1 RESULTS 
4.1.1 Degradation of CFA derivatives monitored by thin layer chromatography 
(TLC) 
Following a report by Ruzin and Novik (2000), which described a TLC method to 
determine the fate of monolaurin in bacterial cultures, a modified method was developed 
using S. au reus ATCC 25923 grown in the presence ofthe CFA derivatives. 
Section 2.6 described in detail the development of this method. Optimum results 
were obtained using pure ethyl acetate as the mobile phase and a vanillin solution as the 
staining agent. Figure 4.1 shows a chromatogram of pure compounds analysed by this 
TLCmethod. 
Figure 4.1. TLC plate developed with pure ethyl acetate and stained with a vanillin 
solution. 1. Lauric acid (LA); 2. a ester: Methyl 6-0-lauroyl-a-D-glucopyranoside (compound 
4a); 3. a ether: Methyl 6-0-dodecanyl-a-D-glucopyranoside (compound 9a) and 4. glue: 
Methyl-a-D-glucopyranoside (1a). 
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It appeared that the TLC was suitable as a method to distinguish free fatty acids 
from their ester and ether derivatives. However, when attempts were made to use this 
assay to monitor the degradation of CF As in cell suspensions it was not successful. This 
was possibly due to the low concentration of compounds in the broth. It was concluded 
that the method was not sufficiently sensitive for use. 
Due to time limitations, these experiments were not pursued further. An alternative 
approach, using more advanced analytical techniques is required to monitor the 
degradation of CFAs in cell suspensions. Techniques such as LC-NMR (Liquid 
Chromatography - Nuclear Magnetic Resonance) and LC-MS (Liquid Chromatography-
Mass Spectrometry) may be more useful. Following appropriate sample preparation, 
these techniques could separate the desired analytes by HPLC (High-Performance 
Liquid Chromatography), and when coupled with a Mass Spectrometer or a Nuclear 
Magnetic Spectrometer, could unambiguously identify the analyte. In addition, these 
techniques have limits of detection considerably lower than the TLC method employed. 
4.1.2 Mode of action studies 
4.1.2.1 Leakage of material absorbing at 260nm 
Nucleic acid and its related compounds, such as pyrimidines and purines, are 
known to absorb UV light at a wavelength of 260 nm. The presence of these materials in 
a suspension can be used as an indicator of damage to the cell membrane. 
Leakage was determined using nisin as a control compound known to cause 
membrane damage. Table 4.1 shows the changes in OD26o readings for all strains and 
compounds tested for up to 120 min of exposure. The five bacterial strains showed 
similar patterns in their release of material absorbing at 260 nm. When S. aureus 
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suspensions were treated with Nisin, LA, ML and CF A derivatives using concentrations 
of four times their respective MICs it was observed that the amount of UV absorbing 
substances released increased as the time of exposure increased. OD260 increased rapidly 
at first, becoming more gradual after 60 minutes (Figure 4.2). An exception was 
observed for compound 9b, the ,a-glucose lauric ether, which even after 120 min of 
exposure did not show any significant increase in material absorbing at 260 nm (Figure 
4.2), indicating a lack of effect on the cell membrane. 
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Figure 4.2 Effect of test compounds on release of UV absorbing substances from: a) S. 
aureus ATCC25923, b) S. aureus ATCC43300 (MRSA). 
These results were not conclusive in establishing a unique or distinctive mode of 
action for the CF A derivatives with structural differences. All of the derivatives gave 
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broadly similar profiles fo r release of 00260 absorbing substances with the exception of 
the beta ether derivative whieh was similar to the negative control. The beta ether 
(compound 9b) data was consistent with its antimicrobial efficacy. Thus, we can 
conclude that membrane damage is clearl y an aspect of the mode of action of CFAs. 
Consequentl y further and more specific mode of action studies were considered. 
Moreover, it is advisable to use multiple methods to delelTIline diverse mechanisms of 
act ion of these derivatives and to establish trends. 
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Table 4.1 Effects ofCFAs on membrane integrity of S. aureus strains measured by release ofUV absorbing corneonents at 260 nm. 
. Time Negative Positive control Fatty acid Monoglyceride Carboh~drate fatt~ acid derivatives Orgamsm ( . ) 
mms control (Nisin) (LA) (ML) 4a 9a 4b 9b 
S. aureus 0 0 0 0 0 0 0 0 0 
ATCC 15 0.019 ±0.006 0.169 ±0.054 0.120 ±0.005 0.180 ±0.088 0.107 ±0.021 0.lO6 ±O.029 0.149 ±O.046 0.037 ±0.033 
25923 30 0.033 ±O.019 0.257 ±0.055 0.214 ±0.078 0.201 ±0.042 0.155 ±0.021 0.155 ±0.020 0.220 ±0.082 0.045 ±0.027 
45 0.050 ±0.031 0.321 ±0.061 0.264 ±0.038 0.226 ±0.043 0.208 ±0.039 0.189 ±0.013 0.299 ±0.036 0.056 ±O.037 
60 0.098 ±0.062 0.410 ±0.080 0.255 ±O.024 0.272 ±0.078 0.240 ±0.037 0.234 ±0.033 0.315 ±O.074 0.062 ±0.040 
120 0.073 ±O.004 0.396 ±O.012 0.334 ±0.040 0.291 ±0.003 0.415 ±O.OlO 0.355 ±0.015 0.408 ±O.031 0.088 ±O.007 
S. aureus 0 0 0 0 0 0 0 0 0 
NCTC 15 0.008 ±0.009 0.023 ±O.OlO 0.138 ±0.005 0.144 ±0.006 0.087 ±0.009 0.058 ±0.020 0.156 ±O.005 0.001 ±O.OOO 
1803 30 0.029 ±0.012 0.077 ±0.006 0.176 ±0.009 0.172 ±0.009 0.164 ±0.082 0.141 ±0.029 0.204 ±0.008 0.004 ±0.005 
45 0.048 ±0.001 0.166 ±0.023 0.308 ±0.001 0.344 ±0.004 0.267 ±0.016 0.2lO ±0.021 0.289 ±O.021 0.018 ±0.004 
60 0.049 ±0.002 0.190 ±0.013 0.239 ±0.020 0.267 ±0.005 0.277 ±0.009 0.254 ±0.001 0.274 ±O.002 0.003 ±0.004 
120 0.084 ±0.009 0.256 ±0.011 0.288 ±0.068 0.309 ±0.008 0.323 ±0.012 0.316 ±0.019 0.305 ±0.006 0.001 ±O.OOO 
S. aureus 0 0 0 0 0 0 0 0 0 
ATCC 15 0.007 ±0.004 0.127 ±0.006 0.073 ±O.012 0.125 ±0.039 0.083 ±O.046 0.065 ±0.005 0.110 ±O.012 0.006 ±0.006 
33591 30 0.016 ±0.014 0.152 ±O.036 0.066 ±O.OlO 0.162 ±0.033 0.138 ±O.069 0.127 ±O.020 0.155 ±O.050 0.013 ±0.013 
45 0.040 ±0.007 0.198 ±0.050 0.149 ±O.016 0.204 ±O.060 0.163 ±0.072 0.191 ±O.027 0.287 ±0.110 0.043 ±O.034 
60 0.047 ±0.046 0.239 ±0.100 0.095 ±0.045 0.311 ±0.114 0.219 ±0.102 0.233 ±O.076 0.315 ±O.131 0.036 ±0.040 
120 0.033 ±0.003 0.244 ±0.019 0.073 ±0.005 0.439 ±0.007 0.248 ±0.004 0.206 ±0.013 0.270 ±O.OlO 0.015 ±0.003 
S. aureus 0 0 0 0 0 0 0 0 0 
ATCC 15 0.011 ±0.009 0.101 ±0.013 0.137 ±0.017 0.178 ±0.055 0.187 ±0.074 0.162 ±0.042 0.266 ±0.071 0.019 ±0.023 
33592 30 0.032 ±0.032 0.164 ±0.006 0.180 ±0.051 0.264 ±0.021 0.278 ±0.081 0.228 ±0.050 0.315 ±0.037 0.049 ±0.034 
45 0.043 ±0.043 0.206 ±0.011 0.134 ±0.014 0.275 ±O.OOI 0.342 ±0.013 0.266 ±0.004 0.372 ±O.008 0.002 ±0.012 
60 0.043 ±O.043 0.249 ±0.006 0.201 ±O.028 0.290 ±O.017 0.344 ±O.078 0.303 ±0.044 0.419 ±O.015 0.015 ±0.038 
120 0.096 ±O.096 0.352 ±O.l27 0.237 ±0.008 0.314 ±0.038 0.399 ±0.070 0.352 ±0.053 0.473 ±O.069 0.013 ±O.022 
S. aureus 0 0 0 0 0 0 0 0 0 
ATCC 15 0.010 ±0.007 0.109 ±0.005 0.135 ±0.002 0.352 ±0.006 0.180 ±0.083 0.138 ±0.068 0.160 ±0.057 0.056 ±O.048 
43300 30 0.031 ±0.019 0.180 ±0.011 0.167 ±0.003 0.488 ±0.009 0.323 ±O.114 0.265 ±0.092 0.314 ±0.085 0.047 ±0.037 
45 0.030 ±0.003 0.242 ±0.020 0.225 ±0.012 N.D 0.336 ±0.004 0.255 ±0.009 0.336 ±0.002 0.020 ±0.006 
60 0.029 ±0.006 0.248 ±0.043 0.236 ±0.006 0.528 ±O.002 0.422 ±0.096 0.343 ±0.045 0.411 ±O.068 0.042 ±0.035 
120 0.050 ±0.031 0.289 ±0.130 0.416 ±0.044 0.542 ±0.009 0.507 ±0.036 0.415 ±0.027 0.494 ±O.036 0.039 ±0.040 
4a. Methyl 6-0-lauroyl-a-D-glucopyranoside; 9a. Methyl 6-0-dodecanyl-a-D-glucopyranoside; 4b. Methyl 6-0-lauroyl-,6-D-glucopyranoside; 9b. Methyl 6-0-
dodecany1-,6-D-g1ucopyranoside. ± figures next to each result indicate standard deviation values. 
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4.1.2.2 Modified Live/Dead BacLight assay 
Bacterial membrane damage was further assessed using the Live/Dead® BacLight™ 
viability assay. The fluorescence intensities of the stained bacterial suspension at 535nm 
(G, green) and 615nm (R, red) represent live and dead cells, respectively. A standard 
curve was constructed by plotting the fluorescence G/R ratios obtained from 
preparations of known live:dead cell ratios, which were calculated by dividing the green 
and red intensities (Figure 4.3). The results from control staphylococcal cells and cells 
treated with the CF A derivatives or standards are shown in Figure 4.4 and are expressed 
as the percentage of results obtained with control cultures not exposed to the 
antimicrobial compounds using the standard curve. 
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Figure 4.3. Standard curve for the live and dead cells fluorescence G/R ratio 
Exposure of staphylococcal cells to CF A derivatives showed altered cytoplasmic 
membrane permeability for lauric acid and the alpha compounds. Both alpha lauric ester 
(compound 4a) and the alpha lauric ether (compound 9a), had a low fluorescence ratio, 
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corresponding to 10-20% viability by comparison with the untreated control (Figure 
4.4). 
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Figure 4.4. Effect of CFA derivatives on S. aureus ATCC 25923 membrane integrity 
measured using the BacLight assay. Error bars represent standard deviation. 
On the other hand, the beta lauric ester (compound 4b) derivative showed a higher 
fluorescence ratio, corresponding to retention of approximately 75% viability. The beta 
ether derivative (compound 9b) did not significantly affect the fluorescence ratio, 
suggesting that this compound did not cause membrane damage, which was m 
agreement with the observation for the leakage studies at 260nm for this compound. 
4.1.2.3 BacTiter Glo assay 
The BacTiter-Glo TM Microbial Cell Viability assay was used to determine the 
number of viable bacterial cells in a culture based on quantitation of the ATP present. 
The luminescence signal is proportional to the amount of A TP present, which is directly 
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proportional to the number of metabolically active cells in the culture. The results are 
shown in Figure 4.5. Monolaurin and the alpha lauric derivatives (compounds 4a and 
9a) resulted in a significant decrease in ATP levels, of around 99%, and were 
comparable to the results achieved with nisin as the positive control for membrane 
disruption. For lauric acid and both beta derivatives (compounds 4b and 9b), there was 
also a significant decline in ATP detected, with a decrease around 70-80%, but to a 
lesser extent than that observed with the alpha lauric derivatives. Again, this reinforces 
the importance of the anomeric configuration of the sugar moiety in antimicrobial 
efficacy. 
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Figure 4.5. Antimicrobial activity of CF A derivatives using the BacTiter-Glo ™ assay. 
Values are expressed as a percentage of those obtained with control cultures not exposed to the 
antimicrobial compounds. Error bars represent standard deviation. 
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4.1.2.4 Phenotype MicroArray 
Phenotype MicroArray (PM) analyses were used to assess differences in bacterial 
metabolic activity and phenotypic response between untreated control cells and cells 
treated with selected CFA derivatives (PM 1-10); as well as their interactions with 
known antimicrobials (PM inhibitors, PM 11-20). This allowed us to further differentiate 
structure-related responses for different CFAs. This technology couples electron 
transport to the reduction of a tetrazolium dye and thereby provides a direct 
colourimetric measurement of respiration or growth on a variety of substrates. Note that 
respiration may be a direct reflection of growth. 
Data presented here were based on utilization vs. non-utilization of PM sources by 
L. monocytogenes ATCC 7644 cells with or without CFA derivatives. Kinetic curves for 
each test well were constructed to evaluate the response of the control cells to each PM 
source and compared with the response of cells treated with CFA derivatives. The full 
range of kinetic curves constructed can be found in Appendix 2.3 and 2.4. 
The data analysis focussed on key activity trends between compounds, possibly 
related to the glycoconjugate linkage or anomeric configuration, and possible 
antimicrobial mechanisms of action. 
The following figures represent significant results from PM plates where a notable 
difference between control andlor treated cells was observed. The Omnilog units 
represent values based on the height of the curve and may be interpreted as cell growth. 
An example featuring the utilization of particular carbon sources (positive response) is 
shown in Figure 4.6. 
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Figure 4.6 Utilization of PM carbon sources by L. monocytogenes ATCC 7644. 
The above figure (Figure 4.6) shows a positive response of L. monocytogenes 
ATCC 7644 for the two PM carbon sources, a) a-D-glucose and b) J3-Methyl-D-
glucoside, which were also constituents of the CFA derivatives synthesised. No growth 
promoting effect was observed in the presence of the CF A derivatives. Moreover, the 
alpha ester derivative (compound 4a) increased the lag phase associated with PM source 
utilisation and the beta ether derivative (compound 9b) had a negative effect on the PM 
source utilisation which is similar to a reduction in growth. 
In Figure 4.7.a it was observed that Listeria utilized the PM source thymidine, but 
to a lesser extent by comparison with a-D-glucose, PMI-C9 (Figure 4.6.a). The addition 
of the ether derivatives (compounds 9a and 9b) did not significantly change the growth 
(PM source utilisation) compared to the control. However, the addition of the ester 
derivative (compound 4a), increased the lag time up to 24 hours. A similar trend was 
observed for D-tagatose and 2,3-butanone (Figure 4.8.e-f), but here, additionally, the 
alpha ether (compound 9a) enhanced the growth of the microorganism and a difference 
between the ether derivatives was observed, suggesting an anomeric configuration 
effect. 
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Figure 4.7 L. monocytogenes ATCC 7644 cells with and without CFA derivatives 
grown in PM 1 Carbon sources 
Figure 4.7 .b-d show that the microorganism did not use these PM sources 
particularly well up to 24 hours. For comparison where PM sources were well utilised 
refer to PMI-C9 (Figure 4.6.a), which is evidenced by the utilisation growth curve for 
this well. The addition of the alpha ester (compound 4a), did not indicate any significant 
change by comparison with control. However, with the addition of the ether derivatives 
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(compounds 9a and 9b), the utilisation of these PM sources increased, primarily after 24 
hours, by comparison with the inhibition of the utilisation of this PM source in the 
presence-ofthe-aIpha-ester-{compounci-4aj;-'Fhus,-the-tr-enci-o-f-a-lpha ester having greater 
antimicrobial efficacy against this microorganism was retained. A similar trend was 
observed for adenosine as a PM source (Figure 4.7.e), but in this case, only the beta 
ether (compound 9b) seemed to promote the utilisation of the PM source after 24 hours. 
A different trend was observed for glucuronamide (Figure 4.7.f), where the 
microorganisms' response was greater from the beginning in the presence of this PM 
source, and was also enhanced in the presence of both ether derivatives (compounds 9a 
and 9b). It may be that glucuronamide in the presence of the CFA derivative becomes 
more utili sable itself. The opposite case where in the presence of the PM source, the 
CFA derivative became metabolisable is unlikely. In the case of the ester compounds, it 
would be likely due to the release of the carbohydrate moiety through hydrolysis, 
however this would render the fatty acid free, which would lead to antimicrobial 
activity. No such hydrolysis is possible with the ether derivatives. 
The carbon PM sources, ,B-D-allose, 3-0- ,B-D-galactopyranosyl-D-arabinose and 3-
methyl-glucose, in Figure 4.8.a, c, d, had a similar trend to that observed for a-keto-
butyric acid, a-D-lactose and 2-deoxy adenosine (Figure 4.7.b-d), where an effect of 
glycoconjugate linkage was noted. The alpha ester (compound 4a) retained greater 
antimicrobial efficacy where the utilisation of the PM sources was inhibited; but at the 
same time, there was a difference for the response in the presence of the ethers for these 
PM sources, thus indicating that anomeric configuration is also important. 
137 
a) Beta-D-allose (PM2-B3) 
200 ~---------------------------
~ 150 ~---------------------­
"= c 
:::I 
bIl 100 
..s 
'c 
e 50 o 
8 16 24 32 40 
c) 3-0-beta-D-galactopyran osyl-D-arabi nose 
(PM2-B12) 
e) D-Tagatose (PM2-D6) 
200 
48 
II ISO -1--------------------------
'= :::I 
~ 100 ~----------- -- -
'= e 50 t--~ ...... ~~~~~~ o 
8 16 
_ control 
alpha ether (9a) 
24 32 40 48 
nme (h) 
--- alpha ester (4a) 
__ beta ether (9b) 
Chapter 4. Mechanism of action studies 
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Figure 4.8 L. monocytogenes ATCC 7644 cells with and without CFA derivatives 
grown in PM2 Carbon sources 
The utilisation of arbutin PM source (Figure 4,8,b) was minimal, even for control 
wells, After 16 hours it seemed that a shift in metabolism occurred and thereafter 
utilisation was strong, This trend was also evident in the presence of the alpha ether 
(compound 9a). However, when the alpha ester (compound 4a) and beta ether 
(compound 9b) were present, the utilisation was inhibited for up to 32 hours, 
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Figure 4.9 L. monocytogenes ATCC 7644 cells with and without CFA derivatives 
grown in PM3 Nitrogen sources 
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For nitrogen PM plate 3 (Figure 4.9.a-h), a general trend was obvious, where the 
alpha ether (compound 9a) promoted the growth or utilisation of the PM sources. Again 
the alpha ester (compound 4a) retained the greatest antimicrobial efficacy in the 
presence of nitrite, L-asparagine, L-glutamine, L-Ieucine, L-valine and glucuronamide as 
PM sources (Figure 4.9.(a-f). For complete nitrogen PM sources utilisation wells refer to 
Appendix 2.3, where the same trends were recorded for PM3-wells A2, A3, A7, A9, BI, 
B4, BS, Bll, C2, C9, Cll, E6, G7 and H6. 
Furthermore, the beta ether (compound 9b) was more inhibitory to PM source 
utilisation by comparison with control in the presence of L-valine, glucuronamide and 
N-acetyl-D-glucosamine (Figure 4.9.e-g). 
However, in the antimicrobial efficacy studies (Chapter 3), the beta ether 
(compound 9b) was not a promising candidate. This may perhaps support the hypothesis 
of an alternative site of action, as proposed in conjunction with the trends observed in 
lag phase and OD260nm studies. Additionally, this was one of the few instances where 
the alpha ester (compound 4a) did not inhibit the utilisation ofa PM source (N-acetyl-D-
glucosamine and allantoin) by the Listeria (Figure 4.9.g-h). 
For phosphorus and sulphur sources, PM plate 4 (Figure 4.10.a-h), similar trends 
were observed as noted for the nitrogen sources, in which alpha ether (compound 9a) 
promoted growth or the use of the PM source and, the alpha ester (compound 4a) again 
retained the greatest antimicrobial efficacy in the presence of these PM sources, 
phosphate, D,L-a-glycerol phosphate, phosphocreatine, tetratione and dithiophosphate 
(Figure 4.1O.a, c, e, f, g). For complete nitrogen PM sources utilisation wells refer to 
Appendix 2.3, where the same trends were recorded for PM plate 4 in wells A4, BS, B6, 
D4, DS, E1, F3, F9, GI, G2, G8, H2 and H4. 
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Figure 4.10 L. monocytogenes ATCC 7644 cells with and without CFA derivatives 
grown in PM4 Phosphorus and Sulphur sources 
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The presence of the beta ether (compound 9b), which is normally a poor inhibitor 
of growth, here again prevented growth or utilisation of the PM sources by Listeria. 
Hence, confirming that anomeric configuration played a distinct role as alpha ether and 
beta ether derivatives show different trends for the same PM source. 
It was also observed that growth in the control well, in the absence of CFA 
derivatives, was not particularly good up to 24 hours in the presence of nucleotides as 
PM sources, whereas in the presence of alpha ether (compound 9a), the utilisation of the 
PM sources was enhanced, as previously seen for other PM wells. However, in this 
instance, the alpha ester (compound 4a) was also associated with a strong utilisation of 
the PM source after 16 hours (Figure 4.10.b,d). 
For peptide nitrogen sources, PM plate 6 (Figure 4.11.a-f), different trends within 
the plate were observed. For example, the growth in the control well containing Alanine-
Asparagine (Figure 4.11.a) was strong up to 24 hours. In the presence of the ether 
derivatives, these PM sources were utilised but to a lesser extent, and as observed 
previously, in the presence of alpha ester (compound 4a), an increased lag phase was 
recorded. Similar trends were observed for Alanine-Threonine and Arginine-Glutamic 
acid (Figure 4.11.b, c), where the alpha ester (compound 4a) was completely inhibitory 
with no utilisation of the PM source evident up to 48 hours. 
142 
Chapter 4. Mechanism of action studies 
a) Ala-Asn (PM6-AS) b) Ala-Thr (PM6-B2) 
200 200 
'" 150 
'" 150 
.-= 
.-= 
= 
= 
= = 
.r 100 =n 100 .,g 
'= '= E 50 E 50 0 0 
..... ,r/ 
0 0 
0 8 16 24 32 40 48 0 8 16 24 32 40 48 
c) Arg-Glu (PM6-B9) d) Arg-Val (PM6-C6) 
200 200 
'" 150 !l 150 . 
.-= 
= 'c 
= = 
=n 100 ; 100 Q 
'a 'c 
E 50 = 50 0 
."'- " 0 ~[ ,., Pf< , .&., !I!l. , .- ~.-'~ 0 0 
0 8 16 24 32 40 48 0 g 16 24 32 40 48 
e) Asn-Glu (PM6-C7) t) Gly-Cis (PM6-E4) 
200 200 
!l 150 !l 150 
'= '= = = 
; 100 .r 100 
'c 'c 
= 50 = 
50 
.r:- 0 0 
0 0 
0 8 16 24 32 40 48 0 8 16 24 32 40 48 
TIme (h) TIme (h) 
_ Control -- alpha ester (4a) _ Control --alpha ester (4a) 
alpha ether (9a) __ beta ether (9b) alpha ether (9a) ___ beta ether (9b) 
Figure 4.11 L. monocytogenes ATCC 7644 cells with and without CFA derivatives (4a, 
9a, 9b) grown in PM 6 Peptide nitrogen sources 
For other PM sources including Arginine-Valine and Asparagine-Glutamic acid, 
the alpha ester (compound 4a) and beta ether (compound 9b) inhibited utilisation 
strongly by comparison with the control (Figure 4.11,d, e). 
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In PM plate 7 (Figure 4.12.a-f), further peptide nitrogen sources were evaluated. 
The alpha ester (compound 4a) again retained the greatest antimicrobial efficacy in 
presence of these PM sources. The ether derivatives (compound 9a and 9b) again 
seemed to promote utilisation of the PM sources. 
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Figure 4.12. L. monocytogenes ATCC 7644 cells with and without CFA derivatives 
grown in PM7 Peptide nitrogen sources 
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From PM plates 1 to 8, we found the following key trends: 
• In general, the alpha ester (compound 4a) had a greater inhibitory effect on 
PM sources utilisation by comparison with the ethers. An exception was in 
the presence of a nucleoside or nucleotides, where utilisation of the PM 
sources was promoted in the presence of the alpha ester. 
• The alpha ether (compound 9a) generally promoted the utilisation of the 
PM sources above that observed for the control. Thus, the glycoconjugate 
bond to either an ester or an ether seems to play a role in phenotypic 
response to different PM sources. 
• The role of anomeric configuration was again observed where the 
utilisation of PM sources by the beta ether (compound 9b) was different to 
that of the alpha ether (compound 9a). Generally, the beta ether (compound 
9b) promoted PM source utilisation but to a lesser extent than the alpha 
ether. However, the beta ether was occasionally inhibitory for up to 24 
hours and most notably was particularly inhibitory in the presence of 
nucleotides, contrary to the trend observed for the other two CF A 
derivatives. 
For PM plates 9 and 10, which record effects on osmolarity and pH, no particular 
differences or trends related to glycoconjugate linkage or anomeric configuration were 
observed. 
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Plates PMll-PM20 yielded information about how resistant/sensitive L. 
monocytogenes ATCC 7644 cells, both with and without CFA derivatives were to a 
variety of known inhibitors, including toxic agents and antibiotics (See Appendix 2.1 for 
full PM plates information). 
L. monocytogenes ATCC 7644 cells treated with CFA derivatives showed different 
sensitivities to certain PM inhibitors compared to the control cells. For example, cells 
treated with alpha lauric ester (compound 4a) became more susceptible to ,B-lactam 
antibiotics (e.g. cloxacillin, nafcillin, oxacillin, penicillin G) present in the PM plates, by 
comparison with the control cells (Figure 4.13). Beta lactam antibiotics act by inhibiting 
the synthesis of the peptidoglycan layer of bacterial cell walls. In contrast, cells treated 
with the CF A ether derivatives (compound 9a and 9b) behaved similarly to the control 
cells with no CFA derivatives included. Again, this is important for observing the 
structure/activity relationship, as it would indicate that the glycoconjugate bond might 
influence the mode and/or site of action of the CFA derivatives. 
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Figure 4.13 L. monocytogenes ATCC 7644 cells with and without alpha ester derivative 
(compound 4a) grown in PM plate containing cloxacillin (,B-lactam antibiotic). 
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Listeria control cells were susceptible to chlortetracycline at the highest 
concentrations tested and resistant to the two lowest concentrations (PMll, wells AS-
A8). When alpha ester (compound 4a) and alpha ether (compound 9a) derivatives were 
present, Listeria cells displayed an increase in lag time or a decrease in growth, 
respectively, at the lowest concentrations tested. This suggests an additive or synergistic 
effect between the inhibitors, where the sensitivity to either the antibiotic at the lower 
concentration or the CF A derivative was increased (Figure 4.14). 
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Figure 4.14 L. monocytogenes ATCC 7644 cells with and without a) alpha ester (4a) 
and b) alpha ether (9a) derivatives, grown in PM plate containing chlortetracycline. 
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Listeria control cells were resistant to the aminoglycosides, tobramycin, paromycin 
and sisomycin, at the concentrations tested, which work by binding to a site on the 
bacterial 30S and 50S ribosome subunits, preventing formation of the 70S complex. 
When the alpha ester (compound 4a) was present, an increase in sensitivity to this class 
of antibiotics was observed for the two highest concentrations tested (Figure 4.15). 
Paromomycin 
300 
250 
'" ;<: 200 c 
= b1I 150 
.9 
'c 100 6 
50 
0 
0 4 8 12 16 20 24 
~o 13 (alpha ester) ----039 (alpha ester) 117 (alpha ester) ~3 SI(alpha ester) 
~O.13 (control) ~039 (control) --+-- 1 17 (contro) ~-3 .51 (control) 
300 250 -1---__ _ 
., 
'§ 
0/) 150 -1---" 
.9 
Sisomicin 
~ 100 +-~jl~~~~;;~~::::~~~~~~~~~ 50 !8 
O +------r----~------,_----~------r_----~ 
o 4 8 12 16 20 24 
____ 00] (alpha ester) ____ 004 (alpha ester) 012 (alpha ester) ~o 37 (alpha ester) 
__ 0 01 (comroI) ~O.04(control) --+-- 0 I2(control) --0 37 (control) 
Tobramycin 
300 
250 
'" ;<: 200 c 
= 
b1I 150 
.9 
'c: 100 E 
0 50 
0 
0 4 8 12 16 20 24 
Time 
--+-- 0 ,05 (alpha esler) ----O.16 (alpha ester) 047 (alpha ester) ~ 141 (alpha ester) 
__.__ 0 ,05 (control) ~o 16 (control) --+-- 0 47 (control) -- I.4 I(control) 
Figure 4.15 L. monocytogenes ATCC 7644 cells with or without alpha ester derivative 
(compound 4a) grown in PM plates containing aminoglycosides. 
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An interesting trend was observed, where the control cells had resistance to lauryl 
sulfobetaine, a zwitterionic surfactant, especially at lower concentrations. In the 
presence of all CF A derivatives tested, Listeria became more susceptible to the lower 
concentrations (Figure 4.16) suggesting a synergy or additive effect. 
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Figure 4.16 L. monocytogenes ATCC 7644 cells, with or without a) alpha ester (4a); b) 
alpha ether (9a) and c) beta ether (9b), grown in PM plates containing lauryl 
sulfobetaine. 
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The PM inhibitors in plates PMl1 to 20 were grouped according to their mode of 
action. The response of Listeria cells treated with the CFA derivatives, to each of the 
PM inhibitors, was allocated a score corresponding to the response of the control cells 
without CFA derivative. This was related to whether there was a change (yellow colour) 
or not (blank) and if that change was positive or negative for the sensitivity or resistance 
of the cells towards the PM inhibitors. Table 4.2 summarises the key trends for the CFA 
derivatives tested, according to the interaction observed with the PM inhibitors and their 
mode of action. Statistical analysis showed a relationship/association (p ~0.05) between 
alpha ester (compound 4a) and alpha ether (compound 9a) when analysing the 
phenotypic responses against the antimicrobial compounds in the PMI0-20. No 
association between alpha ester (compound 4a) and beta ether (compound 9b) was 
found. However, there was a high correlation (p ~0.05) between alpha ether (compound 
9a) and beta ether (compound 9b). Other types of toxic compounds were not associated 
with any key discernible effects in conjunction with the CFA derivatives. 
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T bi 42 PM 'nh'b' a e . 1 1 Itors an dCFAd ' envatlves rno d f eo 1 ' h' actIOn re atIOns . IPS, 
PM inhibitors Mode of action (l ester (l ether ~ ether (4a) (9a) (9b) 
Atropine acetylcholine receptor, antagonist + + + 
Thiosalicylate anti-capsule + 
Ketoprofen anti-capsule 
- -
Sodium salicylate anti-capsule + 
Sanguinarine ATPase, Na+lK+ and Mg++ + 
Propanolol beta-adrenergic blocker + + + 
cell cycle modulation, Calmodulin 
inhibitor (gn) phospholipase C, ADP 
Compound48/80 ribosylation + 
cell cycle modulation, DNA 
synthesis, Ca(2+)/calmodulin 
dependent protein phosphorylation 
Trifluoperazine and lipids and phospholipids (yst, m) + 
Cephalothin cell wall + 
Amoxicillin cell wall + 
Cloxacillin cell wall + 
Nafcillin cell wall + 
Penicillin G cell wall + 
Carbenicillin cell wall + 
Oxacillin cell wall + 
Azocillin cell wall + 
Carbenicillin cell wall + 
Phenethicillin cell wall + + 
4-Aminopyridine channel blocker. K + + 
5-Chloro-7-iodo-8-
hydroxyquinoline chelator, lipophilic -
8-Hydroxyquinoline chelator, lipophilic + + + 
Orphenadrine cholinergic antagonist + + + 
Pridinol cholinergic antagonist + -
Promethazine cyclic nucleotide phosphodiesterase + 
DNA unwinding, gyrase (GN), 
Novobiocin topoisomerase (GP), quinolone + 
Sulfamonomethoxine folate antagonist + 
folate synthesis, dihyldrofolate 
Trimethoprim reductase inhibitor -
Chloroxylenol fungicide + + 
Tolylfluanid fungicide + + + 
Captan fungicide - -
inhibits 3PGA dehydrogenase (L-
D-Serine serine and pantothenate synthesis) + 
Dodine membrane + 
Niaproof membrane - -
Benzethonium 
chloride membrane + 
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Table 4.2 continued. 
PM inhibitors Mode of action a ester a ether ~ ether (4 a) (9 a) (9 b) 
Dodecyltrimethyl 
ammonium bromide membrane + 
Cetylpyridinium 
chloride membrane + + 
Poly-L-lysine membrane 
-
Lauryl sulfobetaine membrane + + + 
Amitriptyline membrane + + + 
l-Chloro-2,4-
dinitrobenzene oxidation 
- + + 
Iodoacetate oxidation 
-
Paromomycin protein synthesis + 
Sisomicin protein synthesis + + 
Tobramycin protein synthesis + + + 
Chlortetracycline protein synthesis + + 
Tetracycline protein synthesis + 
Penimepicycline protein synthesis + + 
Thiamphenicol protein synthesis 
-
Oleandomycin protein synthesis 
- -
Lincomycin protein synthesis 
-
Puromycin protein synthesis + + 
Iodonitro tetrazolium 
chloride respiration + + + 
Pentachlorophenol respiration, ionophore, H+ 
-
3,5-Dinitrobenzene respiration, ionophore, H+ + -
Sodium azide respiration, uncoupler + 
Tetrazolium violet respiration, un coupler + + 
Crystal violet respiration, uncoupler 
-
+ 
respiratory enzymes,carboxamide, 
Oxycarboxin fungicide + 
Diamide thiol crosslinking agent - + 
Potassium chromate toxic anion + + 
Boric acid toxic anion -
Sodium cyanate toxic anion + 
Sodium m-arsenite toxic anion + + 
Sodium metasilicate toxic anion + 
Sodium periodate toxic anion 
-
Sodium orthovanadate toxic anion - - -
Sodium dichromate toxic anion + 
Cadmium chloride toxic cation - -
Lithium chloride toxic cation + + 
Antimony III chloride toxic cation + 
Phenylarsine oxide tyrosine phosphatase inhibitor -
voltage-gated Na+ channels 
Lidocaine antagonist + + 
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4.2 DISCUSSION 
Various hypotheses have been proposed to explain the general mechanism of 
action of free fatty acids and their monoglycerides on bacteria. It was speculated that the 
biophysical and biochemical effects of fatty acids on the molecular structure of the 
cytoplasmic membrane are associated with the hydrocarbon chain of added fatty acids 
on insertion into the phospholipid bilayer of the membrane, thus destabilizing the 
membrane (Kitahara et at., 2004). Based on results of electron microscopic studies, 
monoglycerides were proposed to act as non-ionic surfactants that penetrate and become 
incorporated into the bacterial plasma membrane, thereby altering membrane 
permeability (Bergsson et ai., 1998, 2001). Wang and Johnson (1992) found that 
monolaurin, a compound closely related to CFA esters, produced marked morphological 
changes in L. monocytogenes cells. 
Other authors hypothesised that short and medium chain fatty acids diffuse into 
bacterial cells in their undissociated form and dissociate in the protoplasm, leading to 
intracellular acidification with resultant inactivation of intracellular enzymes and 
inhibition of amino acid transport (Freese et ai., 1973; Viegas and Sa-Correia, 1991). 
For the compounds in this study, this particular explanation would stand only if we 
consider the liberation of lauric acid from the ester derivative by hydrolases as the sole 
mechanism of action, however, this then does not explain ( or involve) the mode of 
action of the ether derivatives. 
The mechanism of the induction of autolysis by these types of compounds, 
including sucrose esters of fatty acids, remains to be elucidated, although it is suggested 
that they may disorganize the membrane structure and trigger an as yet unidentified 
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autolysin control system, possibly located in and/or on the cell membrane (Tsuchido, et 
aI., 1993). 
All of the CF A derivatives studied here, except for the beta ether (compound 9b), 
had the ability to affect the cytoplasmic membrane of S. aureus as judged by the leakage 
of 260-nm-absorbing material assay and the BacLight Live/Dead fluorescence assay; 
however, derivatives with different structures had different concentration-activity 
profiles. 
In contrast to the leakage at 260nm and the BacLight data, which indicated no 
membrane damage, the beta ether (compound 9b) had a significant effect on bacterial 
growth as seen by the increase in lag time and decrease of A TP levels, suggesting that 
this compound could have a different mechanism of action other than membrane 
damage. The BacLight Live/Dead fluorescence and the A TP luminescence assays focus 
on the viability of microorganisms, but from different perspectives. The first assesses the 
permeability of the cell membrane and the second involves the metabolic state of the 
cell. For example, the beta lauric ester (compound 4b), which had a high antimicrobial 
activity, showed poor ability to permeabilize the membrane as measured by the 
Live/Dead fluorescence assay, but showed a decrease in the metabolic activity using the 
ATP luminescence assay. These results also suggest that the CFA derivatives have 
mechanisms of action not solely related to membrane damage. 
It must also be noted, however, that the use of methods involving uptake of 
fluorescent probes for investigation of membrane integrity can give rise to misleading 
results, due to the ability of cells to extrude the probes or to uptake stain while retaining 
viability (Ueckert et al., 1995; Breeuwer and Abee, 2000). The use of multiple methods 
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to determine diverse mechanisms of action of these derivatives is advisable, therefore 
further assays, such as the Phenotype MicroArray assay were considered. 
All CFA derivatives had an effect on methicillin-resistant S. aureus to an extent 
similar to that of the non-resistant strains, suggesting that the mechanisms of methicillin 
resistance did not affect the derivatives efficacy. Although lauric acid and CF A 
derivatives might not be as effective compared with other antimicrobial agents 
(antibiotics), it may be a potential antimicrobial material and ointment base for infection 
control. Combinations of lauric acid or its derivatives with other antimicrobials have 
also shown additive or synergistic effects against pathogenic or spoilage bacteria in 
several food matrices (Bell and De Lacy, 1987, Wang and Johnson, 1997; Blaszyck and 
Holley, 1998; Yamazaki et ai., 2004). 
Other researchers have reported that monolaurin at sub-MIC concentrations 
inhibited production of f3-lactamases, toxic shock syndrome toxin 1 and other 
exoproteins in S. aureus at the level of transcription by interfering with signal 
transduction (Schlievert et ai.,1992; Projan et ai., 1994). Moreover, interference with 
signal transduction has been shown in other genera, for example, monolaurin suppressed 
growth of vancomycin- resistant Enterococcus faecalis in the presence of vancomycin 
and blocked the induction of vancomycin resistance (Ruzin and Novick, 1998). 
Generally, isolates of L. monocytogenes are susceptible to a large range of 
antibiotics (Hof et aI., 1997; White et al., 2002), however Listeria spp. are regarded as 
tolerant to all f3-lactam antibiotics (Hof, 2003). The CesRK two-component system 
contributes to the intrinsic resistance of L. monocytogenes L028 to antibiotics of the f3-
lactam family (Kallipolitis et al., 2003; Gottschalk et aI., 2008). The PM results 
confirmed that L. monocytogenes ATCC 7644 had resistance against j3-lactam 
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antibiotics, but on exposure to the alpha ester (compound 4a) became more susceptible 
to the antibiotics. This suggests that similar to mono laurin, the alpha ester derivative 
(compound 4a), at sub-MIC concentrations, could also inhibit production of 13-
lactamases in L. monocytogenes at the level of transcription by interfering with signal 
transduction, as proposed by Schlievert et al. (1992); Projan et al. (1994) and Ruzin and 
Novick (1998). 
It is also possible that fatty acid derivatives might work synergistically with certain 
antibiotics as has been previously reported by Ved et al., (1990), who showed that 
dodecylglycerol and penicillin G acted synergistically to decrease the MIC of both 
compounds against Gram positive bacteria. Haynes et al. (1994) observed that the alkyl 
glycerol ether, rac-1-0-dodecylglycerol, inhibited the growth of members of two genera 
of yeasts, Candida and Cryptococcus, and was strongly synergistic with amphotericin B. 
Similarly, Rouse et al., (2005) demonstrated that mupirocin and monolaurin 
formulations were active in vitro against S. aureus. 
The phenotypic responses of Listeria cells with and without CF A derivatives 
provided very useful information confirming that glycoconjugate bond and anomeric 
configuration had an effect on the antimicrobial efficacy and mode or site of action of 
the CFA derivatives. When considering the role of the glycoconjugate bond, the alpha 
ester (compound 4a) proved to be the most inhibitory compound, by comparison with 
the ether (compound 9a). Additionally, the alpha configuration was the most inhibitory 
when assessing the anomeric configuration. Statistical analysis showed an association (p 
~ 0.05) between alpha ester (compound 4a) and alpha ether (compound 9a) when 
analysing the phenotypic responses against the antimicrobial compounds in the PM! 0-
20, as well as between alpha ether (compound 9a) and beta ether (compound 9b). No 
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association between alpha ester (compound 4a) and beta ether (compound 9b) was 
found. 
Nucleotides play central roles in metabolism. In that capacity, they serve as 
sources of chemical energy (adenosine triphosphate and guanosme triphosphate), 
participate in cellular signaling (cyclic guanosine monophosphate and cyclic adenosine 
monophosphate), and are incorporated into important cofactors of enzymatic reactions 
(coenzyme A, flavin adenine dinucleotide, flavin mononucleotide, and nicotinamide 
adenine dinucleotide phosphate). Cyclic adenosine monophosphate (cAMP, cyclic AMP 
or 3'-5'-cyclic adenosine monophosphate) is a secondary messenger that is important in 
many biological processes. cAMP is derived from adenosine triphosphate (ATP) and 
used for intracellular signal transduction in many different organisms, conveying the 
cAMP dependent pathway. The increased response of Listeria treated with alpha ether 
(compound 9a) and alpha ester (compound 4a) in the presence of nucleotides as PM 
sources, suggests that these compounds could have an effect on signal transduction. 
The beta ether derivative (compound 9b) inhibited the utilisation of N-acetyl-D-
glucosamine (NAG) as a PM source in contrast to the utilisation observed in the control 
assay, as well as that in the presence of the alpha ester (compound 4a) and alpha ether 
(compound 9a). NAG is a key component of peptidoglycan, which is an essential 
component of the bacterial cell's wall. The bacterial growth inhibition could be attributed 
to the depletion of peptidoglycan content. Our findings are concurrent with the studies 
by Ved et al. (1984c), who reported that dodecylglycerol, the 12-carbon alkyl ether of 
glycerol, inhibited the synthesis of the peptidoglycan of Streptococcus faecium ATCC 
9790 and Streptococcus mutans BHT. That metabolic regulation represents the second 
known mode by which dodecylglycerol expresses antibacterial activity. The first one 
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was reported by the same authors, Ved et al., (1984a,b), who found that dodecylgJycerol 
stimulated autolys in activity, which degraded ce l1 ~wal1 peptidoglycan. However, they 
did not conclude that those were the onl y modes of action of dodecylglyccrol, as other 
mechanisms could be also possible. 
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5. SCREENING OF OTHER NATURAL ANTIMICROBIAL 
COMPOUNDS (ESSENTIAL OIL COMPONENTS AND NISIN) 
The present study was designed to establish the MICs of selected plant essential oil 
(EO) individual components against food-borne pathogens, focusing on Listeria 
monocytogenes and a range of spoilage bacteria. Additionally, the MIC of nisin was 
determined to investigate potential synergistic activity with the optimum EO 
components. This screening of natural compounds like nisin and essential oil 
components for antimicrobial activity was performed to evaluate the potential for 
combination strategies with the CFA derivatives. Generally, nisin is more active at lower 
pH values; therefore the combined effect between nisin and the EO components at 
neutral pH and lower pH levels was investigated. Furthermore, the efficacy of the 
combinations (additive, synergistic, or antagonistic) on the inhibition of the pathogens 
was evaluated. 
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5.1 RESULTS 
5.1.1 Antimicrobial activity of EO components and nisin 
The antimicrobial activity of 10 plant essential oil individual components 
(allylanisole, camphor, carvacrol, caryophyllene, citral, eucalyptol, linalool, sabinene, 
terpinenol and thymol) and nisin was evaluated against a range of foodbome pathogens 
and spoilage bacteria. The MICs of all the antimicrobials were calculated and are 
presented in Table 5.1. 
Nisin and EO components showed varying degrees of individual activity against 
the microorganisms tested. Nisin displayed a very low antibacterial activity against the 
Gram-negative bacteria, although this was expected. Among the EO components, 
carvacrol and thymol displayed the highest antimicrobial activity against the full range 
of bacteria with MICs ranging from 1.25 to 2.5 mM. The MIC for carvacrol against 
Pseudomonas spp. was 5 mM. Citral had a high antimicrobial activity against Listeria 
spp. with MIC values between 2.5 and 5 mM. Citral, sabinene and terpinenol showed 
moderate activity against E. coli ATCC 25922 with MIC values of 12.5 mM. In general, 
Gram-positive bacteria were more sensitive to all the EO components than Gram-
negative bacteria. L. monocytogenes was one of the most sensitive organisms, whereas 
Pseudomonas spp. were the most resistant microorganisms. 
Some of the EO components tested, like camphor and sabinene, had a negligible 
antimicrobial activity possibly due to poor solubility in water. 
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Table 5.1 Minimum Inhibitory Concentration (MIC) values of nisin (jlglruL) and EO individual components (mM) at pH7. 
Nisin or EO ~ 
-'0 -components I- - Q Q 
'" 
Q .. ~ 
= Q I- ~ 
-
.~
..c: ~ I = 
C. Q 
= 
~ 
-~ Q ~ 
= 
Q 
CI:I ~ CI:I e.~ - - = ... E: = t: CI:I --;.. CI:I CI:I ... C. ... I- ~ '" CI:I ~ .. = ,.Q I-Microorganis~ ... == CI:I U-a . .. = . .. CI:I ~ Z < U U U r"l ~ ~ ~ ~ 
Lb. sakei 9.77 >25 >25 2.5 3.13 10 >20 20 ~5 >10 2.5 ATCC15521 
L. innocua 320.0 >25 12.5 1.25 25 5 >10 >10 >25 >5 1.25 NCTC11288 
L. monocytogenes 249.2 25 12.5 1.25 >25 2.5 >10 25 >25 12.5 1.25 ATCC7644 
L. monocytogenes 225.0 25 >25 2.5 25 2.5 >10 25 ~5 12.5 1.25 NCTCl1994 
L. monocytogenes 266.7 25 12.5 1.25 >25 2.5 >10 ~5 >25 >10 1.25 NCTC7973 
E. coli ND >50 25 2.5 >50 12.5 >25 25 12.5 12.5 1.25 ATCC25922 
P. jluorescens ND >50 50 5 >50 25 >25 >50 50 50 2.5 
P.putida ND >50 50 5 >50 >25 >25 >50 50 50 1.25 
For each analysis the MIC was recorded as the concentration that resulted in total inhibition of all 
replicates after 24 hours. ND: Not determined. 
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5.1.2 Influence of pH on antimicrobial activity. 
In order to investigate the influence of pH on the antimicrobial activity of Nisin 
and EO components on Listeria strains, experiments were performed in media adjusted 
to pH 7, 6 and 5.5. Bacterial growth was supported at all pH levels tested. A decrease in 
the pH from neutral to pH 6 or pH 5.5 resulted in enhanced activity for nisin, with an 
approximate 2-fold decrease in MIC values recorded (Figure 5.1). 
A lack of useful interactive effect with pH was observed for the EO components, 
carvacrol, citral and thymol, with no considerable reduction in MIC values. 
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. pH7 ~ 300.0 
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u 
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Figure 5.1 Influence of pH on MICNisin (JLg/mL) values 
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5.1.3 Synergy studies between EO components and nisin 
The quantitative effects of selected EO components (carvacrol, citral and thymol) 
in combination with nisin against Listeria strains were described in terms of FIC indices 
(Table 5.2). At pH 7 none of the combinations tested displayed synergistic activity 
against the bacteria strains used in this study, however, combinations of EO components 
with nisin showed additive effects, and at pH 6 an enhanced additive effect was 
generally observed with Carvacrol or Citral in combination with nisin. At pH 6, citral 
combined with nisin had synergistic effects against L. monocytogenes ATCC7644. No 
antagonism was observed for any of the combinations evaluated. 
Table 5.2 FIC indices for combinations of nisin and selected EO components against 
Listeria species at different pHs. 
L. innocua L. monocytogenes L. monocytogenes L. monocytogenes 
Combination pH 
NCTC11288 ATCC7644 NCTCl1994 NCTC7973 
Nisin + 7 1.16 ± 0.28 (A) 1.14 ± 0.45 (A) 1.23 ± 0.40 (A) 0.72 ± 0.21 (A) 
Carvacrol 6 1.19 ± 0.31 (A) 0.95 ± 0.29 (A) 1.08 ± 0.33 (A) 1.08 ± 0.38 (A) 
Nisin + 7 1.09 ± 0.31 (A) 0.91 ± 0.40 (A) 0.77 ± 0.49 (A) 1.17 ± 0.29 (A) 
Thymol 6 1.02 ± 0.35 (A) 0.94 ± 0.35 (A) 1.06 ± 0.35 (A) 1.25 ± 0.25 (A) 
Nisin + 7 1.00 ± 0.20 (A) 0.92 ± 0.14 (A) 1.31 ± 0.38 (A) 1.25 ± 0.35 (A) 
Citral 6 1.00 ± 0.25 (A) 0.5 ± 0.00 (S) 0.63 ± 0.18 (A) 0.75 ± 0.00 (A) 
(S): Synergy (FIC < 0.5), (A): Addition (0.5 ::;FIC ~) or (An): Antagonism (FIC > 4). Standard 
deviations are indicated beside each value. 
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5.2 DISCUSSION 
Listeria monocytogenes IS currently a worldwide concern affecting numerous 
countries. In the European Union (EU), in addition to the economic consequences and 
threats associated with outbreaks, listeriosis remains of great public health concern, as it 
has one of the highest case fatality rates of all the foodborne infections: 20-30% (De 
Valk et al., 2005). International guidelines for microbiological criteria in respect of 
many foodstuffs have not yet been established. In USA there is a 'zero tolerance' (no 
detectable level permitted) for L. monocytogenes, whereas current ED legislation states 
products must either comply with a limit of 100 colony forming units per gram (cfu/g) 
throughout their shelf-life or have an absence of L. monocytogenes in 25g for ready-to-
eat (R TE) foods intended for infants and for special medical purposes (Regulation (EC) 
No 207312005). This study aimed to investigate the antimicrobial activity of the 
combination of nisin, a bacteriocin, with selected EO components focusing on Listeria 
monocytogenes. Investigating combination strategies can lead to a reduction in the 
concentrations required for pathogen or spoilage microorganism control, which can be 
particularly important in the case of antimicrobial or preservative properties for 
foodstuffs due to the potentially high sensory impact. 
Essential oils or their individual components, e.g., carvacrol, thymol, eugenol and 
citral, have been shown to exhibit antimicrobial activity against foodborne pathogenic 
bacteria (Escherichia coli 0157:H7, Salmonella spp. Listeria spp., Bacillus cereus and 
B. subtilis), and food spoilage bacteria (Helander et al., 1998; Dorman and Deans, 2000; 
Olasupo et al., 2004; Friedman et at., 2004), therefore they have potential for application 
as novel food preservatives. 
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The observation in this study of the potential of EO components, singly and in 
combination with bacteriocins, to inhibit foodbome and spoilage bacteria, is a further 
indication of the antimicrobial activity of these compounds. 
Synergistic effects are important in the light of the potential for combination 
strategies between bacteriocins and EO components as well as CF A derivatives with 
other antimicrobials for practical application to microbiological issues within the food 
and other industries. Preuss et al.(2005), found that Origanum oil, carvacrol, and other 
essential oils, combined with monolaurin killed S. aureus in vitro, and proposed that 
Origanum and/or monolaurin, alone or combined with antibiotics, might prove useful in 
the prevention and treatment of severe bacterial infections. 
Previous studies have concentrated more on the antimicrobial activity of different 
plant EO's and some of their individual components, but a limited number of studies 
have focused on the potential combination of these compounds with other 
antimicrobials. Most of the synergistic studies were tested using Bacillus spp. Pol and 
Smid (1999) have reported a synergistic effect between nisin and carvacrol against B. 
cereus and L. monocytogenes. Additionally, Ettayebi et al. (2000) observed that the 
concentration of nisin required for antimicrobial activity against L. monocytogenes and 
B. subtilis could be lowered by combination with thymol. In the current work, 
combining thymol with nisin did not yield synergistic activity, however the combination 
was additive but somewhat influenced by pH, with enhanced additive activity at pH 7 
instead of pH 6. Periago and Moezelaar (2001) also reported synergistic action between 
carvacrol and nisin against B. cereus. All the mentioned studies have reported 
synergistic effects on viable counts, although true synergistic effect can be best 
confirmed by the use ofFIC indices as suggested by Olasupo et al. (2004). 
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The combination of bacteriocins along with other natural preservatives might 
increase their efficacy within food matrices against some Gram-negative spoilage 
bacteria known to show resistance to antimicrobials, such as Pseudomonas spp. 
(Hammer et a!., 1999; Holley and Patel, 2005). Also, the use of high concentrations of 
nisin may encourage the selective growth of nisin-resistant bacterial sub-populations 
(Crandall and Montville, 1998). Thus, the combination of EO components with 
bacteriocins could lead to useful efficacy against both spoilage and pathogenic target 
organisms and reduce the concentration of bacteriocin required reducing the risk of 
resistance. 
In general, the Gram-positive bacteria were more sensitive to nisin than the Gram-
negative, and in particular, the Listeria spp. were the most susceptible organisms. Plant 
EO components and nisin are generally more active against gram-positive bacteria than 
gram-negative bacteria (Cleveland et al., 2001; Burt 2004). Davidson and Branen (2005) 
suggested that the outer membrane surrounding the cell wall of Gram-negative bacteria 
might restrict diffusion of hydrophobic compounds through its lipopolysaccharide 
covering. 
When EO components are used in combination with other antimicrobials, such as 
bacteriocins, the dose of added phenolic compounds could be lowered thereby 
decreasing their impact on the food flavour and taste (Galvez et aI., 2007). 
The effectiveness of nisin increases when pH decreases due to the higher solubility 
and stability of nisin at lower pH (Lui and Hansen, 1990). 
According to Juven et al. (1994), the increased antibacterial activity of an essential 
oil at low pH can be related to the fact that the essential oil constituents become more 
hydrophobic at low pH and dissolve better in the lipid phase of the bacterial membrane. 
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In the present study no significant effect was observed in the efficacy of the EO 
components tested at lower pI-I levels. However, in the case of nisin combined with 
citral, a synergistic effect was observed when pH was lowered from neutral to pH 6. 
Future direction for this work could include synergy studies between EO 
components and CFA derivatives. As well as the use of EO components as scaffolds for 
further derivatisation or synthetic elaboration including analogue synthes is. The 
potential advantages of EO component derivatisation could include improved 
acceptabili ty of the organoleptic profile and/or enhanced antimicrobial efficacy resulting 
from a stmcturel activity relationship studies of closely related synthetic analogues. 
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Chapter 6 OVERALL DISCUSSION 
Despite several decades of improved antimicrobial therapy, infectious diseases caused 
by bacteria, fungi, viruses and parasites are still a major cause of morbidity and mortality in 
humans (Cos et al., 2006). The emergence of drug resistance in bacteria, e.g. methicillin-
resistant S. aureus (MRSA), vancomycin-resistant enterococci (VRE) , extended spectrum 
~-lactamase-producing Enterobacteriaceae and multi-drug resistant Mycobacterium 
tuberculosis (MDRTB), continues to evolve and spread globally. This is posing a threat to 
human health, since the number of empirical agents suitable for selected indications is 
reduced and the pace at which new antibiotics are being produced is slowing (Russell, 
2002; Isturiz, 2008). 
Simultaneously, the epidemiology offoodborne diseases is rapidly changing as newly 
recognized pathogens emerge and well recognized pathogens increase in prevalence or 
virulence and become associated with new food vehicles. 
Consumer awareness and demand for fresh, minimally processed and "natural" foods, 
along with the requirement for maintenance and enhancement of safety, quality and shelf-
life characteristics, has fuelled research for alternative antimicrobials for use in foods. 
Due to their chemical diversity, natural products, either as pure compounds, their 
derivatives or as extracts, may provide opportunities for new drug leads or nature-derived 
preservatives that can be safely incorporated into food products (Cos et ai., 2006). 
In this present study, the effect ofpolyhydroxylated fatty acid derivatives as inhibitors 
of a range of Gram positive and Gram negative microorganisms of concern to the food and 
healthcare industries has been examined. 
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Carbohydrate fatty acid derivatives are an interesting class of compounds with 
appealing characteristics and many and diverse applications. The effects of the fatty acid 
chain length, the hydrophilic core, as well as the degree of substitution on the carbohydrate 
are all factors that will affect the properties of these compounds and, as a result, their 
applications. 
The literature has many reports of novel antimicrobial CF As but it is difficult to 
compare them. Deductions from the literature are difficult for a number of reasons: the lack 
of studies using pure compounds, lack of comparative studies, use of different test 
organisms, use of different test conditions, etc. In the present study, using an iterative 
design approach to generate a novel set of pure compounds, in tandem with carefully 
designed evaluations, we have been able to eliminate as much of the uncertainty with 
respect to the issues outlined above as possible. Thus, allowing antimicrobial efficacy 
structure/activity relationship comparisons. 
Ester and ether derivatives of the same carbohydrate fatty acid have been found to be 
more effective than the free fatty acid, but differences between antimicrobial efficacy have 
been observed which suggested that the nature of the bond conjugating the fatty acid to the 
carbohydrate and the carbohydrate in itself might playa role in antimicrobial activity. 
Although the antimicrobial effects of fatty acid derivatives are well established, the 
mechanism of action of such compounds is poorly understood. Furthermore, in contrast to 
the extended investigation on mode of action of monoglycerides, there are few studies that 
attempt such an insight for other fatty acid derivatives. Research on the antimicrobial action 
of fatty acid derivatives has focused on their effects on cellular membranes (Kabara and 
Marshall, 2005). However, the proof that this is the sole mechanism is not extensive. 
Moreover, this explanation does not account for structural differences between compounds. 
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Based on leakage of components at 260nm, it was clearly demonstrated that 
carbohydrate fatty acid derivatives 4a-b and 9a (alpha ester, alpha ether and beta ester), 
disrupted the cell membrane, causing an increase in substances absorbing at 260nm. In 
accordance, permeabilization by the fluorescent nucleic acid stains, SYT09 (stains all cells 
green) and propidium iodide (stains cells with damaged membrane red) using the BacLight 
assay with the same compounds, was also found to disrupt the outer membrane of S. aureus 
at MIC levels. Nevertheless, compound 9b (13 ether) notably had a significant effect on 
bacterial growth as seen by the increase in lag time and decrease of ATP levels, suggesting 
that this compound could have a mechanism/site of action other than membrane damage. 
The different phenotypical responses of Listeria monocytogenes to the CF A derivatives 
also support the proposed alternative mechanism/site of action of ester and ether 
derivatives. 
Potential combination strategies of naturally derived compounds are of great interest 
to both food and health-care industries, because of their broad spectral range, lower toxicity 
and cost (Lambert and Lambert, 2003). Therefore other natural antimicrobials namely 
essential oil individual components and nisin were also included in this study to assess 
other structures and combination potential. Conditions of the media, such as lowering the 
pH, was shown to enhance the efficacy of some compounds, hence this should be taken into 
account in addition to other extrinsic factors for their application in food. 
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7. CONCLUSIONS 
This study has developed and used a regio-selective synthesis for carbohydrate fatty 
acid derivatives, which yielded pure compounds for evaluation as antimicrobials as a key 
objective of our work. The emphasis on compound purity and defined structures was 
critical to discern the impact of structural variations on antimicrobial efficacy, and that 
activity could be related to the structural changes with confidence. 
In summary, this study draws the following conclusions: 
(i) When assessing the variation of fatty acid chain length, laUl1c acid derivatives 
were found to be more active against Gram positive bacteria by comparison to 
caprylic acid derivatives. 
(ii) In general, the CFA derivatives were found to be significantly more active 
against the Gram positive bacteria than the Gram negative bacteria tested. 
(iii) Lauric esters of a- and f3-Methyl glucopyranoside and a-Methyl 
mannopyranoside as well as the lauric ether of a-Methyl glucopyranoside 
were the most active compounds, comparable to monolaurin for antimicrobial 
efficacy. 
(iv) The analysis of both ester and ether fatty acid derivatives of the same 
carbohydrate, in tandem with alpha and beta configuration of the carbohydrate 
moiety suggest that the carbohydrate moiety and the anomeric position of the 
carbohydrate are involved in the antimicrobial activity of the fatty acid 
derivatives and that the nature of the glycoside bond also has a significant 
effect on efficacy. 
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(v) When assessing the role of carbohydrate versus non-carbohydrate hydrophilic 
cores (carbohydrate and pentaerythritollaurates), it was found that the nature 
of the carbohydrate core plays a role in the efficacy of carbohydrate fatty acid 
derivatives as antimicrobials, and therefore further optimisation may be 
possible. 
(vi) Monoester derivatives were more effective than di-ester derivatives, due to 
poor solubility of the di-ester compounds. 
(vii) Membrane damage was found to be one of the mechanisms/site of action for 
these types of compounds. 
(viii) The results for the beta ether derivative 9b indicate an alternative mechanism 
or site of action. 
(ix) Carbohydrate fatty acid derivatives have potential as effective antimicrobial 
compounds for use as preservatives to address a range of microbiological 
stability and safety issues. 
(x) Useful combination with other antimicrobials (antibiotic or natural inhibitors) 
may provide opportunities for new drug leads suitable against drug resistant 
bacteria. 
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8. FUTURE RECOMMENDATIONS 
The use of a synthetic route to control production of regio-chemically defined 
compounds allowed the optimization of the carbohydrate moiety configuration and 
glycoconjugate linkage with regard to antimicrobial efficacy. 
The quantity yield of the test compounds was at the expense of purity where the yield 
was relatively low, minimising the number of bacteria that could be studied. However, to 
confirm the trends outlined with respect to the importance of the carbohydrate moiety and 
the role of the nature of the glycoconjugate bond, further studies are warranted using a 
wider range of bacterial species and strains, in particular Gram-positive microorganisms. 
This would allow for evaluation of potential species and strain effects and an expanded trial 
incorporating a wide range of S. aureus strains is warranted. This study should also 
incorporate the potential for stress response effects or potential for bacterial resistance or 
adaptation to the novel compounds. 
This study has indicated that a-monosaccharide mono-fatty acid esters and their 
corresponding ethers have most potential and future studies are proposed to develop an 
alternative enzymatic synthesis protocol to yield greater quantities of selected compounds 
thereby allowing full screening studies using a more limited number of test compounds but 
with a full array of bacteria. 
An alternative approach, using more advanced analytical techniques is proposed to 
monitor the degradation of CFA derivatives in cell suspensions. Techniques such as LC-
NMR (Liquid Chromatography - Nuclear Magnetic Resonance) and LC-MS (Liquid 
Chromatography - Mass Spectrometry) are recommended. 
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Carbohydrate fatty acid derivatives have potential as effective antimicrobial 
compounds for use as preservatives to address a range of microbiological stability and 
safety issues, therefore, studies incorporating the CFA derivatives to different food systems 
are advisable to assess the effect of food components on the CFA derivatives efficacy. 
Combining CFA derivatives with EO's or their individual components may be useful, 
as CFA derivatives could help the use and incorporation of EO's in different systems 
overcoming solubility issues and decreasing the organoleptical effect of EO's in certain 
food products. 
More studies are advisable to assess the combination effects of the CFA derivatives 
with other antimicrobials, like antibiotics, which may provide opportunities for new drug 
leads suitable against drug resistant strains. 
Further studies on the mode of action of the ether derivatives are required. Electron 
microscopy assays might be valuable to assess the effect of the ether derivatives on the 
bacterial cell envelope. Studies assessing the possibility of the ether derivatives to bind to 
cell surface receptors and interfere with signal transduction are also required. 
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Introduction 
Abstract 
Aims: This study investigates the antimicrobial activity and mode of action of 
novel carbohydrate fatty acid (CFA) derivatives against Staphylococcus aureus 
and methicillin-resistant Staph. aureus (MRSA). 
Methods and Results: Minimum inhibitory concentrations (MICs) and the 
effect of CFA derivatives on lag phase were determined using a broth micro-
dilution method. Lauric acid carbohydrate esters and corresponding ether 
analogues showed the greatest antimicrobial activity with MIC values between 
0'04 and 0'16 mmoll- I . Leakage studies at 260 nm following exposure to CFA 
derivatives at 4x MIC showed a significant increase in membrane permeability 
for all compounds, after c. 15 min exposure except for the lauric beta ether 
CFA derivative. Further assessment using both BacLight and luminescence ATP 
assays confirmed that an increase in membrane permeability and reduced met-
abolic activity was associated with CFA treatment. 
Conclusions: All strains were significantly inhibited by the novel compounds 
studied, and efficacy was related to specific structural features. Cell-membrane 
permeabilization was associated with CFA treatment and may account for at 
least a component of the mode of action of these compounds. 
Significance and Impact of the Study: This study reports the antimicrobial 
action of CFA compounds against a range of Staph. aureus and MRSA strains, 
and provides insights into their mode of action. 
Staphylococcus aureus is an important human pathogen 
that can grow in inappropriately stored food causing a 
wide variety of diseases in humans either through toxin 
production or invasion. Staphylococcus aureus may occur 
as a commensal on human skin; it can also be present in 
the anterior nares, with a mean carriage rate of 37'2% in 
the general population (Kluytmans et al. 1997). Staphylo-
coccus aureus is also one of the most common causes of 
bloodstream infection (or bacteremia) (Petti and Fowler 
2003). 
(PBP2a) with a low affinity for fJ-lactams, usually carried 
on a larger piece of DNA called a staphylococcal cassette 
chromosome SCCmec (Hartman and Tomasz 1986). 
Infections caused by MRSA are increasing in both hospi-
tal and community settings (Chopra 2003). In Ireland, 
there were 1394 reports of Staph. aureus bacteraemia in 
2007, of which 537 (38'5%) were MRSA (HPSC 2007). 
Consequently, there has been considerable interest in dis-
covering and developing new antistaphylococcal agents 
for potential therapeutic application (Chopra 2003). 
Carbohydrate fatty acid (CFA) esters are biodegradable, 
nontoxic compounds currently being used as nonionic 
surfactants in the food and health care industries. The 
antibacterial activity of fatty acid carbohydrate derivatives 
is increasingly of interest. Many authors have shown that 
these compounds are active against a range of pathogens 
Methicillin-resistant Staph. aureus (MRSA) and antibi-
otic resistance is a global concern. Staphylococcus aureus 
becomes methicillin resistant by the acquisition of the 
mecA gene that encodes a penicillin binding protein 
@ 2009 The Authors 
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(Monk et al. 1996j Yang et al. 2003j Devulapalle et al. 
2004j Ferrer et al. 2005j Habulin et al. 2008). 
Unlike antibiotics, fatty acids and their derivatives have 
diverse modes of action that appear to be nonspecific and 
development of resistance to these compounds has not 
been reported (Kabara and Marshall 2005). Kitahara et al. 
(2006) proposed lauric acid (LA) as a potential anti-
microbial material, suitable for external application, 
which could be combined with other antimicrobial 
agents. For example, Ved et al. (1990) demonstrated that 
monolaurin (ML), the glycerol monoester of LA, acted 
synergistically with penicillin G at concentrations below 
its minimum micelle concentration. Kitahara et al. 2006 
found that a LA and gentamicin combination showed 
synergistic activity against MRSA. 
The exact mode of action of CFAs on bacteria is 
unknown. However, it has been proposed, and is widely 
believed, that the cell membrane is the principal site of 
action of fatty acids and their esters (Kabara 1993). Wang 
and Johnson (1992) found that ML, a compound closely 
related to CFA esters, produced marked morphological 
changes in Listeria monocytogenes cells, while Bergsson et al. 
(2001) demonstrated that Staph. aureus was killed by fatty 
acids and derivatives, especially monocaprin, through disin-
tegration of the cell membrane. The mechanism of the 
induction of autolysis by these types of compounds, remains 
to be elucidated, although it is suggested that they may dis-
organize the membrane structure and trigger an, as of yet 
unidentified, autolysin control system, possibly located in 
andlor on the cell membrane (Tsuchido et al. 1993). 
It has also been suggested that ML may affect the respi-
ratory activity of cells by the inhibition of enzymes 
involved in oxygen uptake andlor inhibit the transport of 
amino acids into cells (Galbraith and Miller 1973). Other 
researchers have reported that ML at subminimum inhib-
itory concentrations (MIC) concentrations inhibited pro-
duction of p-Iactamases, toxic shock syndrome toxin 1 
and other exoproteins in Staph. aureus at the level of 
transcription by interfering with signal transduction 
(Schlievert et al.1992j Projan et al. 1994). Interference 
with signal transduction has been shown in other genera, 
for example, ML suppressed growth of vancomycin-resis-
tant Enterococcus faecalis in the presence of vancomycin 
and blocked the induction of vancomycin resistance 
(Ruzin and Novick 1998). 
A detailed study by Ruzin and Novick (2000) showed 
that ML inhibited the production of exoenzymes and vir-
ulence factors in Staph. aureus at concentrations that did 
not inhibit bacterial growth. Moreover, they were able to 
show rapid hydrolysis of ML with liberation of LA (t1l2 
of c. 5 min) in the presence of Staph. aureus cells. These 
findings led them to suggest that the prolonged inhibitory 
effects associated with ML might be because of liberation 
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of LA by hydrolases present in the cell preparation. They 
were not, however, able to rule out the possibility that 
ML itself might have some inhibitory action prior to its 
hydrolysis. These findings raise important questions for 
fatty acid derivatives of carbohydrates. It is not clear, for 
example, whether fatty acid esters of carbohydrates are 
similarly hydrolysed or whether their mode of action 
might depend on such hydrolysis. 
Previous studies in this laboratory, using Listeria 
strains, showed that an ether analogue of a CFA retained 
higher or similar antimicrobial activity to the ester deriva-
tive, indicating that the release of a free fatty acid was 
not an absolute requirement for antimicrobial activity 
(Nobmann et al. 2009). The analysis of both ester and 
ether fatty acid derivatives of the same carbohydrate, as 
well as both alpha and beta configurations of the carbo-
hydrate moiety, suggested that the carbohydrate moiety 
might also be involved in the antimicrobial activity of 
fatty acid derivatives (Nobmann et al. 2009). 
The current study assessed the antimicrobial efficacy of 
these novel CFA derivatives against a range of Staph. 
aureus strains, as well as further investigating the mecha-
nisms of action of the range of compounds to assess rela-
tionships between the defined structural differences and 
the mode of action. Antimicrobial efficacy was evaluated 
by comparison of MIC and effects on cell lag time, while 
more detailed studies on how the compounds might work 
included membrane permeability studies monitoring 
absorbance at 260 nm, BacLight LivelDead assay and cell 
viability using BacTiter Glo assay. 
Materials and methods 
Bacteria and culture conditions 
Bacterial strains used in this study are listed in Table 1. 
Stock cultures were maintained in tryptic soy broth (TSBj 
Scharlau Chemie, Barcelona, Spain) supplemented with 
20% glycerol at -70°e. For use in experiments, working 
cultures were grown routinely by subculturing a loop full 
of stock culture into TSB tubes and incubating at 35°C 
for 18 h. 
Table 1 Staphylococcus aureus strains used in this study 
Strain Reference Source/comments 
Staph. aureus ATCC 25923 Clinical isolate 
Staph. aureus NCTC 1803 Mammal, ovine gangrenous mastitis 
Staph. aureus ATCC 33591 Methici llin resistant 
Staph. aureus ATCC 33592 Blood, Gentamicin- and 
methicillin-resistant 
Staph. aureus ATCC 43300 Cl inica l isolate, F-182, methicillin- and 
oxacillin-resistant 
2 
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Test compounds 
LA, caprylic acid (CA), and their corresponding mono-
glycerides, ML and monocaprylin (MC) (Sigma-Aldrich; 
c. 99% purity), were used as standards for comparison 
against the CFA derivatives. Nisin, from Lactacoccus lactis 
2'5% (~1000 000 IV-I g-l), was purchased from Sigma, 
and was used as a positive control compound for mem-
brane disruption studies. CFA derivatives used in this 
study (Fig. 1) were synthesized according to Smith et al. 
2008. Stock solutions (100 mmoll- 1) of test compounds 
(CFA derivatives and standards) were prepared in sterile 
hydro alcoholic diluent (ethanol-distilled water, 1 : 1) and 
stored at -20°C. Stock solutions were diluted in TSB or 
phosphate-buffered saline solution (PBS, pH 7'4; Sigma) 
to obtain working concentrations. 
Minimal inhibitory concentration 
MICs were determined using a broth micro dilution 
assay as previously described (Nobmann et al. 2009). 
Briefly, serial dilutions of each compound were prepared 
in sterile TSB to a final volume of 100 III in 96-well 
microtiter plates (Sarstedt Ltd, Drinagh, Co. Wexford, 
Ireland). Each well was inoculated with 100 III of the 
test organism in TSB to a final concentration of 
c. 1 x 106 CFU ml- 1. The MIC was taken as the lowest 
concentration of test compound at which growth was 
inhibited after 24 h of incubation at 35°C. Controls 
included: (i) uninoculated media without test compound 
to assess changes in the media; (ii) uninoculated media 
containing the test compound to assess background 
noise; (iii) inoculated media without test compound to 
evaluate the microbial growth under optimal conditions; 
(iv) inoculated media without test compound but con-
taining corresponding amount of ethanol to account for 
Compound 1 
o 
~ 
H
2
,c11 . ~o 
HO 0 
HO 
HO Me 
a possible antagonist or synergistic activity of the alco-
hol used in the preparation of the test compound. 
Increase in lag time (Al) 
The increase in lag time was calculated using data from 
absorbance-based broth microdilution assays using 
GEN5™ software (BioTek, Bedfordshire, UK). The A2 
was defined as the time required for the culture with test 
compound to record an increase in OD600 of O· 10 minus 
the time that the culture without compound, took to 
reach the same increase in OD600 . 
Effect of antimicrobial compounds on the cell membrane 
For the mode of action studies, the laurate glucopyrano-
side derivatives (compounds 1-4) were selected. These are 
a closely related group of compounds that differ by a 
single structural variable and were evaluated in order to 
asses relationships between structural differences e.g. 
glycoconjugate linkage and anomeric configuration and 
antimicrobial efficacy. 
Leakage of 260-nm-absorbing material 
Bacterial strains were cultured in TSB and incubated at 
35°C for 18 h. After incubation, bacteria were harvested 
by centrifugation at 10 000 g for 10 min at 4°C, the 
supernatant was discarded and the cells were washed 
twice with PBS; pH 7'4. Suspensions were adjusted to 
achieve a bacterial concentration of c. 109 CFU ml- 1. The 
CFA derivatives were added to bacterial suspensions at 4x 
MIC. Suspensions were incubated in a water bath at 
35°C. Samples of 1,5 ml were removed at time 0, and 
after 15, 30, 45, 60 and 120 min; centrifuged at 10 000 g 
for 10 min at 4°C. Two hundred microlitres of superna-
tant for each treatment was added to the wells of a 
Compound 2 
H23CI1------~ 
HO 0 
HO 
Compound 3 
o 
H~C1~~0 
HO 0 OMe HO 
HO 
MethyI6·0-lauroyl-a-o-
glucopyranoside 
HO OMe 
Methyl 6-0-dodecanyl-a-
o-glucopyranoside 
Methyl 6-0-lauroyl-j}o-
glucopyranoside 
Figure 1 Structures of the novel carbohy-
drate fatty acid derivatives investigated 
for antimicrobial activity. 
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96-well plate (UV-transparent flat-bottom microplates, 
Corning-Costar Cat. No. 3635; Fisher Scientific, Ireland), 
and absorbance values at 260 nm were recorded using a 
UV spectrophotometer (Synergy HT; Bio-Tek). The fol-
lowing controls were included: a bacterial suspension in 
sterile PBS without antimicrobial agents as the negative 
control; a fatty acid control (inoculated PBS containing 
LA); a positive control: nisin and finally a mono glyceride 
control: ML. Where applicable, independent readings 
were also taken, in the presence of antibacterial agents 
only, to enable corrections for background contributions. 
Modified Live/Dead BacLight assay 
The LivelDead® BacLight viability kit from Molecular 
Probes, Inc. (Eugene, OR, USA) was used as described by 
Hilliard et al. (1999). In this assay, the SYTO-9 and pro-
pidium iodide stains compete for binding to the bacterial 
nucleic acid. SYTO-9 labels cells with both damaged and 
intact membranes, whereas propidium iodide penetrates 
only cells with damaged membranes. 
A culture of Staph. aureus ATCC 25923 as a model 
organism was grown to late log phase in 30 rn1 of TSB. 
Twenty-five millilitres of the bacterial culture was concen-
trated by centrifugation at 10 000 g for 10 min. The 
supernatant was removed and the pellet was washed once 
in filter-sterilized distilled water and resuspended to 
1I1Oth of the original volume and then diluted 1: 20 
into either sterile de-ionized water (for live bacteria esti-
mation), 70% isopropyl alcohol (for dead bacteria estima-
tion) or sterile de-ionized water containing test 
compounds at 4x MIC. 
Different proportions of the live and dead cells were 
mixed to obtain cell suspensions containing five different 
ratios, i.e. 100: 0, 75 : 25, 50: 50, 25 : 75 and 0 : 100 
(in %), of live and dead cells for a data set to provide a 
standard curve. 
Bacterial and treatment suspensions were incubated at 
room temperature for 1 h. At the end of the incubation 
period, the suspensions were centrifuged at 10 000 g for 
10 min, washed once in sterile de-ionized water, and 
resuspended to achieve 2 x 107 bacteria per m!. 
A volume of 100 III of each bacterial or treatment sus-
pension was added in triplicate into separate wells of a 
96-well microplate (black; Nunc). A Ix stain solution was 
prepared by mixing component A (3'34 mmol rl SYTO 
9 dye) and component B (20 mmoll-1 propidium 
iodide) in equal proportion. To each well, 100 III of Ix 
stain solution was then added, and the plate was incu-
bated in the dark for 15 min at room temperature. At the 
end of the incubation period, with the excitation wave-
length at 485 nm, the fluorescence intensity of SYTO-9 
was measured at 530 nm (emission 1; Green) for each 
well. With the excitation wavelength still centred at 
P. Nobmann et al. 
485 nm, the fluorescence intensity of propidium iodide 
was measured at 630 nm (emission 2; Red) for each well 
of the entire plate. The GreenlRed (GIR) ratio was 
obtained by dividing the fluorescence intensity of the 
stained bacterial suspensions (F cell) at emission 1 by the 
fluorescence intensity at emission 2. 
G/R ratio = F cell, emissionliF cell, emission 2 
The Ratio G/R was plotted vs percentage of live cells in 
the Staph. aureus suspension. 
BacTiter-Glo™ assay 
The BacTiter-Glo ™ Microbial Cell Viability assay is a 
method for determining the number of viable bacterial 
cells in a culture based on quantifying the ATP present, 
as an indicator of metabolic activity. The luminescent sig-
nal is proportional to the amount of ATP present, which 
is directly proportional to the number of cells in culture. 
An overnight culture of Staph. aureus ATCC 25923 in 
Mueller Hinton (MH) broth was diluted 100-fold in fresh 
MH broth and used as inoculum. CFA derivatives were 
used at a concentration of 4x MIC. Each well of a 96-well 
microtiter plate contained 100 /11 of the inoculum and 
100 III of the CFA derivatives. Control wells containing 
medium without cells were prepared to obtain a value for 
background luminescence. Cells without compound were 
used as an ATP positive contro!' The microtiter plate was 
incubated at 35°C for 5 h. One hundred microlitres of 
the culture was taken from each well, and mixed with the 
same volume of the BacTiter-Glo ™ reagent in a white 
opaque-walled microtiter plate (Nunc). Plates were incu-
bated for 5 min, and luminescence was recorded in a 
multi-detection microplate reader (Synergy HT). 
Statistical analysis 
All experiments were performed in duplicate and replicated 
at least three times. Statistical differences between com-
pound efficacies were determined using ANOV A followed by 
LSD (least square differences) testing at P < 0'05 level 
using spss software, ver. 15 (SPSS Inc., Rochester, NY). 
Results 
Minimum inhibitory concentration 
The MICs of the CFA derivatives for the five Staph. 
aureus strains tested are shown in Table 2. The concentra-
tion of ethanol in the control wells corresponding to the 
concentration of ethanol in the test wells had no indepen-
dent inhibitory effect on bacterial growth. CA was the 
least effective of all compounds tested (P < 0'05), with 
MICs of 10 mmol r 1 or greater for all bacteria. In con-
trast, LA had MICs 8-16-fold lower than those of CA. 
4 
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Table 2 Minimum inhibitory concentration (MIC) values of carbohydrate fatty acid (CFA) derivatives and standards 
Fatty acid Monoglyceride CFA derivatives 
Micro-organism LA CA ML MC 2 3 4 5 6 
Staphylococcus aureus AlCC 25923 0·63 10 0·04 5 0·31 0·04 0·04 2·5 2·5 0·04 
Staph. aureus NCTC 1803 0·63 10 0·04 2·5 0·31 0·04 0'08 1·25 1·25 0·04 
Staph. aureus AlCC 33591 1·25 10 0·04 2-5 1-25 0-04 0·04 2-5 5 0·04 
Staph. aureus AlCC 33592 1·25 20 0·04 2·5 0·08 0-08 0·04 5 2-5 0·16 
Staph. aureus AlCC 43300 1-25 10 0·08 2·5 0·08 0·08 0-04 10 2-5 0·08 
MIC was recorded as the concentration (mmol I-I) that resulted in total inhibition of all replicates after 24 h at 35°(, 
LA, lauric acid; CA, caprylic acid; ML, monolaurin; MC, monocaprylin; 1, Methyl 6-0-lauroyl-cx-D-glucopyranoside; 2, Methyl 6-0-dodecanyl-IX-D-
glucopyranoside; 3, Methyl 6-0-lauroyl-{l-D-glucopyranoside; 4, Methyl 6-0-dodecanyl-{l-D-glucopyranoside; 5, Methyl 6-0-octanoyl-cx-D-glucopyr-
anoside; 6, Methyl 6-0-lauroyl-a-D-mannopyranoside. 
ML and MC showed greater activity (P < 0'05), with val-
ues between 0'04-0'08 and 2-5-5 mmoll- l respectively, 
than their corresponding free fatty acids (LA, CAl with 
values between 0-63-1-25 and 10-20 mmol I-I. Com-
pounds 2 (IX-glucose lauric ether), 3 (f3-glucose lauric 
ester) and 6 (IX-mannose lauric ester) were the most 
active CFA derivatives with MIC values between 0'04 and 
0'16 mmoll- l, comparable to ML (Table 2). The next in 
order of overall efficacy was compound 1 (IX-glucose lau-
ric ester), with MICs between 0'08 and 1'25 mmoll- I 
with a difference between strains observed. The antimi-
crobial activity of compound 4 (f3-g1ucose lauric ether) 
was significantly lower than that observed with the corre-
sponding IX-glucose lauric ether (compound 2, P < 0-05), 
but additionally for compound (4) in particular, strain 
differences were observed (Table 2). Compound 5 had an 
activity comparable to Me. 
Increase in lag time for Staphylococcus aureus 
Where appropriate, the increase in lag time was estimated 
for Staph_ aureus ATCC 25923 in the presence of a range 
of CFA derivatives. For the concentrations at which the 
compounds were less effective (sub-MIC concentrations), 
an increase in the lag time could be calculated to allow 
comparison between compounds and concentrations. The 
effect was found to be concentration and compound 
dependent, with a major effect at concentrations close to 
the MIC values (Table 3) (P < 0-05). For example, at 
twofold sub-MIC concentrations, the fatty acids (LA, CAl 
and monoglycerides (ML, MC) standards, as well as com-
pound 1 and compound 5, showed a significant increase 
in lag time of c. 2-6 h compared to that of the cultures 
without treatment. At a fourfold sub-MIC concentration, 
a relatively small increase was observed. 
For compound 4, a different trend was detected, with a 
more gradual increase in lag time with an effect observed 
even at eightfold sub-MIC concentrations (from 1'25 to 
0-16 mmol rl). 
© 2009 The Authors 
Table 3 Increase in lag time (6.)_) for Staphylococcus aureus Alee 
25923 in the presence of standards and carbohydrate fatty acid 
derivatives 
Staph. aureus Alee 25923 
Compound M Compound M 
(mmoll- I ) (h) SD (mmoll- I ) (h) SD 
LA 0·04 0·0 ± 0-000 CA 0·63 0-0 ± 0-000 
0'08 0·0 ± 0·000 1·25 0·2 ± 0-009 
0-16 0-5 ± 0·364 2·5 0·6 ± 0·221 
0·31 4-2 ± 0·898 5 3-0 ± 0·312 
0·63 NG 10 NG 
ML 0·02 3·9 ± 0·684 Me 1·2 5 0·0 ± 0-000 
0·04 NG 2·5 1-8 ± 0·986 
5 NG 
0-04 0·0 ± 0-000 5 0·63 0·5 ± 0-327 
0·08 0·7 ± 0·167 1·25 1·3 ± 0·376 
0'16 6-1 ± 0·595 2·5 NG 
0·31 NG 
4 0'16 2-7 ± 1·777 
0-31 3·9 ± 2-865 
0-63 4·1 ± 2·021 
1·25 6-4 ± 1-615 
2·5 NG 
Values are expressed as the difference between the treated culture 
and culture without compound. 
SD, standard deviation; NG, no growth; LA, lauric aCid; CA, caprylic 
acid; ML, monolaurin; MC, monocaprylin; 1, Methyl 6-0-lauroyl-cx-D-
glucopyranoside; 4, Methyl 6-0-dodecanyl-{l-D-glucopyranoside; 5, 
Methyl 6-0-octanoyl-a-D-glucopyranoside. 
Leakage of material absorbing at 260 nm 
Nucleic acid and its related compounds, such as pynml-
dines and purines, absorb UV light at a wavelength of 
260 nm. The presence of these materials in a suspension 
may be used as an indicator of damage to the cell mem-
brane. Leakage was determined using nisin as a control, a 
compound that is known to cause membrane damage. 
Table 4 shows the increase of OD260 for all the strains 
and compounds tested after 120 min of exposure. The 
Journal compilation © 2009 The Society for Applied Microbiology, Journal of Applied Microbiology 5 
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Table 4 Effects of carbohydrate fatty acids (CFAs) at 4x minimum inhibitory concentration on membrane integrity in Staphylococcus aureus strains measured by release of UV absorbing 
components at 260 nm 
Organism 
Staph. aureus 
ATCC 25923 
Staph. aureus 
NCTC 1803 
Staph. aureus 
ATCC 33591 
Staph. aureus 
ATCC 33592 
Staph. aureus 
ATCC 43300 
Time 
(mins) 
o 
15 
30 
45 
60 
120 
o 
15 
30 
45 
60 
120 
o 
15 
30 
45 
60 
120 
o 
15 
30 
45 
60 
120 
o 
15 
30 
45 
60 
120 
Negative control 
Positive control 
(nisin) 
Free fatty acid 
(lauric acid) 
o 
0-019 
0·033 
0-050 
0·098 
0-073 
o 
0·008 
0-029 
0-048 
0-049 
0-084 
o 
0-007 
0-016 
0·040 
0-047 
0-033 
o 
0·011 
0·032 
0·043 
0·043 
0·096 
o 
SD 
±0'006 
±0·019 
±0·031 
±0·062 
±0'004 
±0-009 
±0·012 
±0-001 
±0-002 
±0·009 
±0-004 
±0-014 
±0-OD7 
±0·046 
±0'003 
±0-009 
±0-032 
±0-043 
±0'043 
±0-096 
0-010 ±0-007 
0·031 ±0-019 
o 
0·169 
0·257 
0-321 
0-410 
0·396 
o 
0-023 
0·077 
0·166 
0-190 
0-256 
o 
0-127 
0-152 
0-198 
0-239 
0-244 
o 
0·101 
0·164 
0·206 
0·249 
0·352 
o 
0·109 
0-180 
0-030 ±0-003 0·242 
0·029 ±0-006 0-248 
0·050 ±0-031 0-289 
SD 0 
±0-054 0-120 
±0'055 0·214 
±0·061 0·264 
±0-080 0-255 
±0'012 0-334 
o 
±0-01O 0·138 
±0-OD6 0·176 
±0'023 0·308 
±0·013 0-239 
±0'011 0-288 
o 
±0-D06 0-073 
±0'D36 0·066 
±0-05D 0-149 
±0'100 0-095 
±0·019 0·073 
o 
±O'D13 0·137 
±0'OD6 
±D·Dll 
±0'006 
±0'127 
±0-005 
±0-011 
0·180 
0·134 
0-201 
0-237 
o 
0-135 
0·167 
±0-02D 0-225 
±0-043 0-236 
±0'130 0-416 
SD 
±0'D05 
±0·078 
±0·038 
±0{)24 
±0'040 
±0'005 
±0'OD9 
±O'ODl 
±0-020 
±D'068 
±0-D12 
±0-01O 
±0'D16 
±0-045 
±0·005 
±0'017 
±0'051 
±0·014 
±0·028 
±0-008 
±0·002 
±0-003 
±0'012 
±0·006 
±0'044 
Monoglyceride 
(monolaurin) 
o 
0·180 
0·201 
0·226 
0-272 
0-291 
o 
0·144 
0-172 
0·344 
0-267 
0-309 
o 
0-125 
0·162 
0-204 
0-311 
0·439 
o 
0·178 
0·264 
0-275 
0-290 
0·314 
o 
0-352 
0-488 
ND 
0-528 
0-542 
SD 
±O'088 
±O'042 
±0'043 
±0'078 
±0-003 
±0-006 
±0-OD9 
±0·004 
±0'005 
±0'008 
±0-D39 
±0'D33 
±0'D60 
±0-114 
±0'007 
±0·055 
±0·021 
±O-ODl 
±0·017 
±0'038 
±0·006 
±D-009 
±0-002 
±0-009 
(FA derivatives 
o 
0·107 
0·155 
0-208 
0·240 
0-415 
o 
0·087 
0-164 
0-267 
0-277 
0·323 
o 
0-083 
0·138 
0·163 
0-219 
0·248 
o 
0-187 
0·278 
0-342 
0·344 
0-399 
o 
0-180 
0·323 
0-336 
0-422 
0·507 
SD 
±0-021 
±0'021 
±0·039 
±0·037 
±0·01O 
±0-009 
±D-082 
±0·016 
±0·009 
±0'012 
±0-046 
±0·069 
±0'072 
±0-102 
±0'004 
±0-074 
±0-081 
±0·013 
±0'078 
±0'070 
±0-083 
±0'114 
2 
o 
0·106 
0·155 
0-189 
0-234 
0'355 
o 
0·058 
0-141 
0-210 
0-254 
0-316 
o 
0-065 
0' 127 
0-191 
0-233 
0·206 
o 
0·162 
0·228 
0-266 
0·303 
0·352 
o 
0-138 
0-265 
±0-004 0-255 
±0-096 0-343 
±0·036 0-415 
SD 
±0'029 
±0-020 
±0'013 
±0·033 
±0·015 
±0·020 
±0-029 
±0·021 
±0'001 
±0-019 
±O-OOS 
±0-020 
±D'027 
±0-076 
±0·013 
±0·042 
±0-050 
±0·004 
±0·044 
±0-053 
±0-068 
±0·092 
3 
o 
0-149 
0·220 
0·299 
0-315 
0-408 
o 
0-156 
0-204 
0-289 
0-274 
0·305 
o 
0·110 
0·155 
0-287 
0-315 
0·270 
o 
0266 
0-315 
0·372 
0·419 
0·473 
o 
SD 
±0-046 
±0-082 
±0·036 
±0'074 
±0·031 
±0·005 
±0-008 
±0·021 
±0'002 
±0'OD6 
±D·D12 
±0'D5D 
±D·l10 
±0-131 
±0·01O 
±D-D71 
±0'D37 
±0·008 
±0·015 
±0·069 
0-160 ±D·D57 
0·314 ±0-D85 
±D·D09 0-336 ±D-OD2 
±0·045 0-411 ±0-068 
±D'027 0·494 ±0-036 
4 
o 
0·037 
0·045 
0·056 
0·062 
0-088 
o 
0-001 
0-004 
0·018 
0-003 
0·001 
o 
0·006 
0·013 
0-043 
0·036 
0-015 
o 
0-019 
0-049 
0·002 
0·015 
0-013 
o 
0·056 
0-047 
0·020 
0·042 
0·039 
SD 
±0-033 
±0'027 
±0·037 
±0'040 
±0'007 
±O'OOO 
±0-005 
±0-004 
±0'004 
±O-OOO 
±0-006 
±0-013 
±D-034 
±0-040 
±0·003 
±0·023 
±0-034 
±0-012 
±0'038 
±0-022 
±0-048 
±0'037 
±0-006 
±0-035 
±0-040 
1, Methyl 6-0-lauroyl-cx-D-glucopyranoside; 2, Methyl 6-0-dodecanyl-cx-D-glucopyranoside; 3, Methyl 6-0-lauroyl-p-D-glucopyranoside; 4, Methyl 6-0-dodecanyl-p-D-glucopyranoside; 6, Methyl 6-
O-Iauroyl-cx-o-mannopyranoside; ND, not determined; SD, standard deviation_ 
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P. Nobmann et al. 
five bacterial strains showed similar patterns in their 
release of material absorbing at 260 nm. The amount of 
UV absorbing substances released increased as the time of 
exposure increased, when Staph. aureus suspensions were 
treated with nisin, LA, ML and CFA derivatives at 4x 
MIC. The OD26o increased rapidly at first, and the absor-
bance values continued to increase, but more gradually 
after 60 min. An exception was observed for compound 
4, ,B-glucose lauric ether, which even after 120 min of 
exposure did not display a significant increase in 
OD26o nm' 
Live/Dead BacLight assay 
Bacterial membrane damage was further assessed by using 
the Live/Dead® BacLight viability assay. The fluorescence 
intensities of the stained bacterial suspension at 535 nm 
(G, green) and 615 nm (R, red) represent live and dead 
cells, respectively. The fluorescence G/R ratio, obtained 
by dividing the green and red intensities, were plotted 
against the live : dead cells ratio used for the standard 
curve. Results are shown in Table 5. 
Exposure of staphylococcal cells to CFA derivatives (at 
4x MIC for 1 h) showed altered cytoplasmic membrane 
permeability for LA and the alpha compounds. Both 
alpha lauric ester (compound 1) and the alpha lauric 
ether (compound 2), had a low fluorescence ratio, corre-
sponding to 10-20% viability compared to the untreated 
control. 
On the other hand, the beta lauric ester (compound 3) 
derivative showed a higher fluorescence ratio, correspond-
ing to retention of c. 75% viability. The beta ether deriva-
tive (compound 4) did not significantly affect the 
fluorescence ratio, which was in agreement with the 
observation for the leakage studies at 260 nm for this 
compound. 
Table 5 Effect of carbohydrate fatty acid derivatives at 4x minimum 
inhibitory concentration on membrane integrity in Staphylococcus 
aureus ATCC 25923 measured by the BacLight assay 
Antimicrobial compounds Live % SD 
None (nontreated culture) 100 
Nisin (positive control) 8·36 ± 3·00 
Lauric acid 8·39 ± 1-66 
Alpha lauric ester (1) 17·38 ± 5·41 
Alpha lauric ether (2) 16·34 ± 3·13 
Beta lauric ester (3) 76·05 ± 13·62 
Beta lauric ether (4) 147·85 ± 48·93 
Values are expressed as percentage of those obtained with control 
cultures not exposed to the antimicrobial compounds. 
SD, standard deviation; 1, Methyl 6-0-lauroyl-il:-D-glucopyranoside; 2, 
Methyl 6-0-dodecanyl-Cl-D-glucopyranoside; 3, Methyl 6-0-lauroyl-f3-D-
glucopyranoside; 4, Methyl 6-0-dodecanyl-f3-D-glucopyranoside. 
© 2009 The Authors 
Mechanism of action of novel carbohydrate fatty acid derivatives 
BacTiter Glo assay 
The luminescence signal is proportional to the amount 
of ATP present, which is directly proportional to the 
number of metabolically active cells in the culture. The 
results are shown in Fig, 2. The alpha lauric derivatives 
(compounds 1 and 2) resulted in a noticeable decrease 
in ATP levels. For the LA and the beta derivatives (com-
pounds 3 and 4), there was also a decline in ATP 
detected, but to a lesser extent than that observed with 
the alpha lauric derivatives. Again, this reinforces the 
importance of the anomeric configuration in antimicro-
bial efficacy. 
Discussion 
The emergence of MRSA, vancomycin-resistant entero-
cocci, and extended spectrum ,B-lactamase-producing 
Enterobacteriaceae has seriously reduced the number of 
empirical agents suitable for selected indications (Isturiz 
2008). Natural products, either as pure compounds or as 
standardized extracts, may provide opportunities for new 
drug leads because of the unmatched availability of chem-
ical diversity (Cos et al. 2006). 
Previous work in this laboratory showed that novel 
CFA derivatives were active against Gram-positive bacte-
ria, especially the foodborne pathogen L. monocytogenes 
(Nobmann et al. 2009). Thus, the present study evaluated 
the antimicrobial properties of pure novel CFA esters and 
100 
75 
::> 
...J 
a: 50 
eft 
25 
a ~i} 
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Figure 2 Relative luminescence activity of Staphylococcus aureus 
ATCC25923 cells in response to carbohydrate fatty acid derivatives 
using the BacTiter-Glo™ assay. Values are expressed as percentage of 
those obtained with control cultures not exposed to the antimicrobial 
compounds. 1, Methyl 6-0-lauroyl-Cl-D-glucopyranoside; 2, Methyl 
6-0-dodecanyl-<X-D-glucopyranoside; 3, Methyl 6-0-lauroyl-f3-D-gluco-
pyranoside; 4, Methyl 6-0-dodecanyl-f3-D-glucopyranoside. Error bars 
represent standard deviation values of replicate experiments. 
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their corresponding ether analogues, against five 
Staph. aureus strains including MRSA strains. 
Ruzin and Novick (2000) showed that ML was rapidly 
hydrolysed (t1/2 of c. 5 min) by esterases in Staph. aureus 
cultures suggesting that inhibitory activity could be 
because of free fatty acid liberated from ML by hydrolysis. 
Isaacs and Lamp (2000) suggested that changing the link-
age in a mono glyceride between the fatty acid and the 
glycerol backbone from an ester bond to an ether linkage 
could increase the antimicrobial activity of some 
medium-chain monogIycerides. Here, we have examined 
antimicrobial activity using pure CFA derivatives whose 
carbohydrate moieties were effectively 'locked' in either 
the alpha or beta configuration. These compounds also 
differed in the type of fatty acid carbohydrate linkage 
(ester and ether conjugates) and the length of fatty acid 
chain (LA and CAl. 
The CFA derivatives showed various antimicrobial 
activities against a panel of Gram-positive bacteria. In the 
data presented here, we show that there is little difference 
in antibacterial activity between a fatty acid derivative of 
alpha methyl glucoside whether the linkage is via an ester 
or an ether bond (compound 1 and 2). This finding sug-
gests that the hydrolysis of the bond between the fatty 
acid and the carbohydrate is not required for antimicro-
bial activity, as the ether linkage is not readily hydrolysed 
by esterases. However, an alternative explanation whereby 
the antimicrobial activity of the fatty acid ether derivative 
is because of binding at a site different to that of the 
ester derivative cannot be discounted. This explanation 
would, however, have to postulate two sites of action for 
these compounds, both equally bactericidal, which seems 
unlikely. 
What is surprising is that antimicrobial activity is not 
sensitive to the presence or absence of the bulky carbohy-
drate group but is sensitive to the configuration of the 
anomeric carbon of the carbohydrate moiety. Despite 
their similarity in structure, compound 2 (er:-glucose 
lauric ether) was far more active against most Staph. aur-
eus strains than compound 4 (P-glucose lauric ether). 
This observation is in agreement with Watanabe et al. 
(2000) who found that configuration of the hydroxyl 
group in the carbohydrate moiety markedly affected the 
antibacterial activity. 
The study of lag time increase showed that sub-MIC 
concentrations of CFAs can modify bacterial growth 
significantly. Antimicrobial efficacy of compound 4 was 
considerably lower than that of the other derivatives; nev-
ertheless, these results show that there is a significant 
effect of this compound on bacterial growth, even at sub-
MIC concentrations. This is important in light of its 
potential combination with other antimicrobials for opti-
mization of application of CFA derivatives. It is also pos-
P. Nobmann et al. 
sible that these antimicrobial agents might also work 
synergistically with certain antibiotics as has been previ-
ously reported by Ved et al. (1990), who showed that 
dodecylglycerol and penicillin G acted synergistically to 
decrease the MIC of both compounds towards Gram-
positive bacteria. Haynes et al. (1994) observed that the 
alkyl glycerol, ether rac-I-O-dodecylglycerol, inhibited the 
growth of members of two genera of yeasts, Candida and 
Cryptococcus, and was strongly synergistic with amphoter-
icin B. Similarly, Rouse et al. (2005) demonstrated that 
mupirocin and ML formulations were active in vitro 
against Staph. aureus. Preuss et al. (2005) found that 
Origanum oil, carvacrol, and other essential oils, com-
bined with ML killed Staph. aureus in vitro, and proposed 
that origanum and/or ML, alone or combined with anti-
biotics, might prove useful in the prevention and treat-
ment of severe bacterial infections. 
All of the CFA derivatives studied here, except for 
compound 4, had the ability to affect the cytoplasmic 
membrane of Staph. aureus as judged by the leakage of 
260-nm-absorbing material assay and the BacLight Live/ 
Dead fluorescence assay; however, derivatives with differ-
ent structures had different concentration-activity profiles. 
In contrast to the leakage at 260 nm and the BacLight 
data, which indicated no membrane damage, compound 
4 appreciably had an effect on bacterial growth as seen by 
the increase in lag time and decrease of ATP levels, sug-
gesting that this compound could have a different mecha-
nism of action than membrane damage. The BacLight 
Live/Dead fluorescence and the ATP luminescence assays 
focus on the viability of the micro-organism, but from 
different perspectives, the first one assesses the permeabi-
lity of the cell membrane and the second one involves the 
metabolic state of the cell. For example, compound 3, 
which had a high antimicrobial activity, showed low abil-
ity to permeabilize the membrane according to the Live! 
Dead fluorescence assay, but showed a decrease in the 
metabolic activity according to the ATP luminescence 
assay. These results suggest that the CFA derivatives 
might have different mechanisms or sites of action that 
do not only involve membrane damage. 
All CFA derivatives had an effect on MRSA to an 
extent similar to that of the nonresistant strains, suggest-
ing that the mechanisms of methicillin resistance did not 
affect the CFA derivatives efficacy. 
Conclusions 
A range of CFA derivatives were shown to have useful 
antimicrobial activity against Staph. aureus strains, with 
compound efficacy related to structural differences. Car-
bohydrate anomeric configuration and fatty acid chain 
length have significant effects on anti-microbial efficacy. 
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CFA derivatives had the ability to affect the cytoplasmic 
membrane of Staph. aureus and MRSA strains and may 
account for at least a component of the mode of action 
of these compounds. Further insight into the mechanism 
of action will aid in the production of CFA derivatives as 
possible future therapeutic antimicrobial compounds. 
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Novel mono-substituted carbohydrate fatty acid (CFA) esters and ethers were investigated for their 
antibacterial activity against a range of pathogenic and spOilage bacteria focussing on Listeria monocytogenes. 
Carbohydrate derivatives with structural differences enable comparative studies on the structure/activity 
relationship for antimicrobial efficacy and mechanism of action. The antimicrobial efficacy of the synthesized 
compounds was compared with commercially available compounds such as monolaurin and monocaprylin. 
as well as the pure free fatty acids. lauric acid and caprylic acid. which have proven antimicrobial activity. 
Compound efficacy was compared using an absorbance based broth microdilution assay to determine the 
minimum inhibitory concentration (MIC). increase in lag phase and decrease in maximum growth rate. 
Among the carbohydrate derivatives synthesized. lauric ether of methyl IX-D-glucopyranoside and lauric ester 
of methyl IX-D-mannopyranoside showed the highest growth-inhibitory effect with MIC values of 0.04 mM. 
comparable to monolaurin. CFA derivatives were generally more active against Gram positive bacteria than 
Gram negative bacteria. The analysis of both ester and ether fatty acid derivatives of the same carbohydrate, 
in tandem with alpha and beta configuration of the carbohydrate moiety suggest that the carbohydrate 
moiety is involved in the antimicrobial activity of the fatty acid derivatives and that the nature of the bond 
also has a significant effect on efficacy, which requires further investigation. This cIass of CFA derivatives has 
great potential for developing antibacterial agents relevant to the food industry, particularly for control of 
Listeria or other Gram-positive pathogens. 
1. Introduction 
Consumer demand for fresh, minimally processed and "natural" 
foods, along with the requirement for maintenance and enhancement of 
safety, quality and shelf-life characteristics has fuelled research for 
alternative antimicrobials. Listeria monocytogenes has emerged as one of 
the most important food pathogens in ready-to-eat processed meals and 
dairy foods (EFSA, 2007), given that it can adapt to a wide range of food 
processes and storage conditions including refrigeration temperatures, 
and acidic or high salt foods. Moreover, Listeria has one of the highest 
case fatality rates of all the foodborne infections: 20-30% (De Valk et aI., 
2005). Therefore, there is a need for investigation of new approaches for 
the control or elimination of this pathogen in foods whilst also 
addressing food spoilage concerns. 
Fatty acids (FA) and their corresponding esters are one group of 
chemicals found in nature considered to have little or no toxicity, with 
proven antimicrobial activity. K.1bara et al. (1972) showed that whHe 
fatty acids esterified with monohydriC aJcohol.s were inactive againsr 
microorganisms, those esterified with certain polyhydric alcohols 
yielded antimicrobial derivatives (Conley and Kabara, 1973). Mono-
• Corresponding author. Tel.: +353 14027594; fax: +353 14024495. 
E-mail address: paula.bourke@dit.ie (P. Bourke). 
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glycerides (MG) are commonly employed in the food industry as 
flavoring and emulsifYing agents and Monolaurin (ML), a food-grade 
glycerol monoester of lauric acid, is approved in the US as a food 
emulsifier (21 CFR GRAS 182.4505). The anti-listeria] activity of fatty 
acids and monoglycerides has been previously documented (Oh and 
Marshall, 1993; Wang and Johnson, 1997; Sprong et al" 2001 ). Their 
antimicrobial activity against spoilage microorganisms has also been 
reported (Ouattara et a!., 1997; Blaszyk and Holley, 1998). 
Sugar esters are biodegradable. nontoxic and non ionic surfactants, 
currently employed in the food, pharmaceutical, cosmetics and 
detergent industries (Hill and Rhode, 1999; Piccicuto et al., 2001 ). 
Furthermore, their antimicrobial activities have been reported (Monk 
et aI., 1996; Devulapalle et aI., 2004; Ferrer et aI., 2005). 
Carbohydrate fatty acid (CFA) esters have been synthesized chemi-
cally and enzymatically by interesterification, transesterification and 
direct esterification. An issue regarding the synthesis of commercial 
sucrose esters is related to the high functionality of the carbohydrate 
molecule with many hydroxyl groups, which compete during the 
derivatization step, leading to product mixtures of mono-, di- and 
polyesters (Hill and Rhode, 1999). Enzymatic synthesis of novel sugar 
fatty acid esters has been widely employed and can be highly 
regioselective, although for some carbohydrates minor regiomeric 
isomers may be obtained. 
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The exact mode of action of fatty acid esters has not yet been 
elucidated, but the cytoplasmic membrane is thought to be the primary 
site of action for fatty acid esters, affecting respiratory activity through 
inhibition of enzymes involved in oxygen uptake (Kabara, 1993). Ruzin 
and Novick (2000) reported a monolaurin esterase activity in association 
with the S. au reus cell membrane and cytoplasm. It was shown that the 
half life of monolaurin in cultures of S. aureus was ca. 5 min due to its 
cleavage by cellular esterases. These studies raise the question as to 
whether the ester, or free fatty acid derived from hydrolysis of the ester, 
was responsible for antimicrobial activity. 
Recently, a number of novel fatty acid derivatives of carbohydrates 
have been synthesized and their antimicrobial activity assessed 
(Devulapalle et aI., 2004; Ferrer et aI., 2005 ). These workers have 
pointed out that a complication of some earlier studies was that they 
were carried out using commercial preparations that contained a 
mixture of compounds. Thus, it was difficult to correlate antimicrobial 
activity with chemical structure. It is clear that future studies in this area 
will require the use of pure compounds. Moreover, there is a need to 
standardize antimicrobial activity of novel compounds by the use of 
reference compounds. Finally, quantification of antimicrobial activity is 
desirable to allow comparison between different studies. 
The objectives of this study were to compare the in vitro antimicrobial 
activity of a range of pure, novel, fatty acid esters with the corresponding 
fatty acid ethers and commercial fatty acids and monoglycerides to 
ascertain the role of the free fatty add in the antimicrobial efficacy. These 
compounds were compared quantitatively to allow an estimation ofthe 
enhancement of the efficacy over the free fatty acids. This work has used 
a synthesis designed to allow the production of pure, novel regiochemi-
cally defined monosaccharide mono-fatty acid esters, and their 
corresponding ethers. The effect of different carbohydrate scaffolds as 
well as a non-carbohydrate (pentaerythritol) on antimicrobial efficacy 
was also examined. The effect of fatty acid chain length and anomeric 
configuration of the carbohydrate was also explored. 
The activity of eight CFA derivatives and three non-carbohydrate 
polyhydroxylated ester derivatives, together with their corresponding 
monosaccharide, fatty acids and monoglycerides as controls, were 
assessed against a range of Gram-positive and negative bacteria of 
interest to the food industry. Efficacy and structure-activity relation-
ships were assessed by comparing MIC values, the increase in lag phase 
and maximum specific growth rate. 
2. Materials and methods 
2.1. Bacteria and growth conditions 
Bacterial strains used in this study are listed in Table 1. Stock cultures 
were maintained in tryptic soy broth (ISB, Sharlau Chemie, Spain) 
supplemented with 20% glycerol at -70 '(' Cultures were routinely 
grown by subculturing 100 ~ of stock culture into 9 mL TSB and 
Table 1 
Microorganisms used in this study 
Strain Reference' Source 
Gram-positive bacteria 
Listeria innocua NCTC 11288 Cow brain, serotype 6.a 
Listeria monocytogenes ATCC 7644 Human 
Listeria monocytogenes NCTC 11994 Cheese. serotype 4b 
Listeria monocytogenes NCTC7973 Pig mesenteric lymph node 
Gram-negative bacteria 
Escherichia coli ATCC 25922 Clinical isolate 
Escherichia coli NCTC 12900 Human, serotype 0157:H7 non toxigenic 
Salmonella enterica ATCC 14028 Animal tissue 
(serovar Typhimurium) 
Enterobacter aerogenes ATCC 13048 Sputum 
Pseudomonas fluorescens • Lettuce 
• Strains indicated with an asterisk were provided by the Department of Life Sciences, 
University of Limerick. Ireland. 
incubating at 35 'c for 18 h, except for Pseudomonas spp. which were 
incubated at 30'(. All cultures were then maintained on tryptic soy agar 
(TSA, Sharlau Chemie, Spain) plates at 4 '(' Working cultures were 
prepared by inoculating a loop of pure culture into TSB and incubating at 
the optimum temperature for each strain for 18 h. A bacterial suspension 
was prepared in saline solution (NaCl 0.85%, BioMerieux, France) 
equivalent to a McFarland standard of 0.5. using the Oensimat 
photometer (BioMerieux, SA, France), to obtain a concentration of 
1 x lOs cfulmL. This suspension was then serially diluted in TSB to obtain 
a working concentration of 1 x lOG cfu/mL 
2.2. Chemical synthesis 
Chemical synthesis was performed according to Smith et al. (in 
press). An overview of the test compounds synthesized and used in 
the antimicrobial assay is given in Fig. 1. 
2.3. Test compounds preparation 
The saturated free fatty acids, lauric acid (LA-Cd and caprylic acid 
(CA-Cs), as well as their corresponding monoglycerides, monolaurin 
(ML) and monocaprylin (MC) (Sigma-Aldrich -99% purity), were used as 
standards in this study. 
Stock solutions (100 mM) of test compounds and standards were 
prepared in sterile hydroalcoholic diluent (ethanol-distilled water, 1: 1) 
and stored at - 20'(' Stock solutions were diluted in TSB to obtain initial 
working concentrations (10 or 20 mM). 
2.4. Antimicrobial activity assay 
Solutions of the working test compounds and standards were serially 
diluted in sterile TSB to a final volume of 100 ~L within the 96-well 
microtiter plate. 100 ~L of freshly prepared inoculum of the organism 
under study was added to each appropriate well. The final concentration 
of each microorganism in each well was approximately 5 x 105 cfu/mL 
and the concentration of chemical compounds ranged from 1:2 to 1 :256. 
Each concentration was assayed in duplicate. The following controls 
were used in the microplate assay for each organism and test compound; 
blank: uninoculated media without test compound to account for 
changes in the media during the experiment; negative control: 
uninoculated media containing only the test compound; positive control 
1: inoculated media without compound; positive control 2: inoculated 
media without compound but including the corresponding sugar to 
evaluate any effect of the sugar alone; and positive control 3: inoculated 
media without compound but with the equivalent concentration of 
ethanol used to dissolve the test compound thereby assessing any 
activity of the alcohol. The 96-well plates were incubated for 18 h in a 
microtiterplate reader (PowerWave microplate Spectrophotometer, 
BioTek) at 35 'C, except for Pseudomonas spp. which were incubated at 
30°C, and effects were monitored by measuring the optical density (00) 
at 600 nm for each well every 20 min with 20 s agitation before each 00 
measurement. Each experiment was replicated three times. 
2.5. Data analysis 
2.5.1. Minimum inhibitory concentration (MIC) 
The MIC was defined as the lowest concentration of compound that 
showed no increase in 00 values for all the replicates compared to the 
negative control after 18 h. The absorbance readings obtained from the 
kinetic data were plotted against time to obtain the growth curves of the 
test organisms. Subtraction of the absorbance of the negative control 
eliminated interferences due to possible variations in the media. 
2.5.2. Lag time increase (A) 
The increase in lag time was calculated using the Gen5™ software . 
The increase in lag time was defined as the time required for the culture 
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Fig. 1. Structures of the novel carbohydrate fatty acid derivatives and non-carbohydrate polyhydroxylated esters synthesized and investigated. 
with test compound to record an increase in 00600 of 0.10 minus the 
time that the positive control 1 without test compound required to 
record the same increase in 00600• 
were determined using ANOVA followed by LSD testing at p <O.OS 
level using SPSS software, Version 15. 
2.5.3. Maximum specific growth rate (/1,no,) 
The maximum growth rate was also calculated using the GenS™ 
software. The 11m.x was determined from the slope of the regression 
equation from the linear portion of the log plot during early exponential 
phase. 
2.5.4. Statistical analysis 
All experiments were performed in duplicate and replicated at 
least three times. Statistical differences between compound efficacies 
Table 2 
3. Results 
3.1. Antimicrobial activity of carbohydrate fatty acid derivatives 
3.1.1. Minimum inhibitory concentrations 
The MlC results are summarized in Table 2. The monoglycerides, ML 
and MC, had greater activity (p<O.OS) against the Gram positive Listeria 
spp. compared to their corresponding free fatty acids (lA, CA), and 
comparable activity at the concentrations tested against the Gram 
negative microorganisms. Of the monoglycerides and free fatty acids 
Minimum Inhibitory Concentration (MIC: mM) values of carbohydrate fatty acid derivatives and standards in tryptic soy broth at 37 ·C after 18 h 
Microorganism FA MG Carbohydrate fatty acid derivatives 
IA CA ML MC I 2 3 4 5 6 
Listeria innocua NCTC 11288 0.63 5 0.04 2.5 0.08 0.04 0.08 5 0.63 0.04 
Listeria monocytogenes ATCC 7644 0.63 >5 0.04 5 0.08 0.04 0.08 2.5 2.5 0.04 
Listeria monocytogenes NCTC 11994 1.25 >5 0.04 2.5 0.31 0.04 0.16 >2.5 1.25 0.04 
Listeria monocytogenes NCTC 7973 1.25 5 0.04 2.5 0.08 0.04 0.16 >2.5 0.31 0.04 
Escherichia coli ATCC 25922 >20 10 20 5 20 20 20 20 12.5 ~20 
Escherichia coli NCTC 12900 12.5 10 12.5 5 12.5 10 12.5 10 12.5 N.D 
Salmonella Typhimurium ATCC 14028 >20 >20 20 >20 20 >20 >20 20 >20 N.D 
Enterobacter aerogenes ATCC 13048 >20 20 20 10 20 >20 >20 >20 >20 N.D 
Pseudomonas j/uorescens >20 5 20 5 >20 >20 >20 >20 5 N.D 
For each analysis the MIC was recorded as the concentration (mM) that resulted in total inhibition of all replicates. N.D: Not determined. 
1. Methyl 6-0-lauroyl-<Y-D-glucopyranoside: 2. Methyl 6-0-dodecanyl-<Y-D-glucopyranDside: 3. Methyl 6-0-lauroyl-~-D-glucopyranoside:4. Methyl 6-0-dodecanyl-~-D-
glucopyranoside: 5. Methyl 6-0-octanoyl-<Y-D-gluCDpyranoside: 6. MethyI6-0-1auroyl-<Y-D-mannopyranoside. 
P. Nobmann et al. / IntemationalJoumal of Food Microbiology 128 (2009) 440-445 443 
tested, ML had the lowest MIC values (p<0.05) and was particularly 
effective for inhibition of Listeria strains with MIC values of 0.04 mM, by 
comparison with the range observed for LA with MIC values between 
0.63 mM to 1.25 mM. A similar trend was observed for MC 
(MIC=2.5 mM, 5.0 mM) compared to the free fatty acid CA (MIC~5 mM). 
When tested against the Gram negative bacteria, LA and ML had no 
activity at concentrations up to 20 mM (Table 2). An exception to this 
was recorded for E. coli NCTC12900 with a MIC value of 12.5 mM for LA 
and ML P.fluorescens was susceptible to CA and MC at a concentration of 
5 mM for both compounds, whereas for E. coli strains, MIC values were 
10 mM and 5 mM respectively. Minimum inhibitory concentrations of 
CA were ~20 mM for the other Gram negative bacteria (Table 2). 
All CFA derivatives showed greater antimicrobial activity against 
Gram positive microorganisms than Gram negative (p <0.05). For Lis-
teria spp., compounds 2 and 6 were the most active derivatives with MIC 
values of 0.04 mM, comparable to ML (Table 2). The next in order of 
overall efficacy was compound 3 with MIC values between 0.08 mM and 
0.16 mM for Listeria spp. Compound 1 recorded an MIC range of 0.08 mM 
to 0.31 mM. The antimicrobial activity of compound 4 was significantly 
lower than that observed with the corresponding a-ether (Table 2). 
Compound 9 (a non-carbohydrate mono-ester) was evaluated, but its 
antimicrobial activity was negligible (results not shown). Compounds 7, 
8,10 and 11 could not be accurately tested for antimicrobial efficacy due 
to poor solubility in water. Compound 5 had a greater activity (p <0.05) 
compared with MC against all Listeria strains (Table 2). Compound 5 was 
more active than the lauric acid derivatives against E. coli ATCC 25922 
and P. fluorescens, with MIC values of 12.5 mM and 5 mM respectively 
(Table 2). 
Table 3 
Effect of FA. MG and CfA derivatives on the Lag time (l\.) and Maximum specific growth 
rate (Pm,,) of L. monocytogenes ATCC 7644 
Compound 
Ml 
1 
2 
3 
4 
CA 
MC 
5 
(mM) 
0 
0.04 
0.08 
0.16 
0.31 
0.63 
0 
0.02 
0.04 
0.08 
0.04 
0 
0.02 
0.04 
0.08 
0 
0.16 
031 
0.63 
1.25 
0 
0.31 
0.63 
1.25 
2.5 
5 
10 
0 
0.31 
0.63 
1.25 
2.5 
5 
0 
0.31 
0.63 
1.25 
2.5 
5 
)l.(h) 
0.0 
0.2 
2.0 
4.8 
No growth 
2.3 
No growth 
No growth 
No growth 
0.5 
53 
No growth 
0.2 
0.5 
5.0 
No growth 
0 
0 
0.1 
0.8 
3.1 
No growth 
0.2 
03 
1.1 
5.6 
No growth 
0.4 
1.6 
1.0 
1.9 
No growth 
Sl Dev. 
±0.06 
±0.26 
t1.00 
H73 
H09 
±0.07 
to.67 
±0.18 
±0.25 
±0.55 
to.04 
to.17 
±0.19 
t1.62 
±0.29 
±0.4O 
±0.41 
:1:1.35 
to.47 
±0.94 
±0.27 
±0.34 
1'",.. (h-') 
0.30 
0.22 
0.17 
0.10 
0.07 
0 
0.30 
0.25 
0 
0 
0 
0.30 
031 
0.27 
0 
0.30 
0.31 
0.27 
0.12 
0 
0.30 
0.26 
0.24 
0.26 
0.21 
0.18 
0 
0.30 
0.26 
0.25 
0.19 
0.01 
0 
0.30 
0.24 
0.22 
0.12 
0.08 
0 
St. Dev. 
:1:0.034 
:1:0.049 
±0.041 
±0.017 
:1:0.037 
±0.034 
:1:0.040 
:1:0.034 
±0.003 
±0.006 
±0.034 
:1:0.013 
±0.009 
:1:0.059 
±0.034 
:1:0.027 
±0.037 
±0.044 
±0.034 
:1:0.097 
±0.034 
±0.029 
±0.043 
±0.046 
:1:0.034 
±0.034 
±0.035 
±0.008 
:1:0.008 
±0.001 
In each antimicrobial efficacy assay, the corresponding carbohy-
drates for the fatty acid derivatives were included as a control. but had 
no antimicrobial or growth promoting effect on the microorganisms 
under investigation. Although the concentrations of ethanol corre-
sponding to that within the wells with the highest concentrations of 
compound used (10 mM for the Gram positive and 20 mM for the Gram 
negative bacteria) had a minor effect on bacteria viability, there was no 
anti-microbial effect observed at the concentrations used when 
incorporated with the compounds at MIC levels. 
3.J.2.1ncrease in Lag time and decrease of maximum specific growth rate 
The increase in lag time and decrease in maximum specific growth 
rate was estimated for L. monocytogenes ATCC 7644 to allow further 
comparison between compound efficacies. Results were found to be 
concentration and compound dependent (Table 3) (p <0.05). Generally, 
the increase in lag time between concentrations of a compound was 
observed to be more marked than the decrease in growth rate which was 
more gradual. For example. at sub-MIC concentrations. compound 3 had 
an increase in lag time from 0.5 h to 5.3 h associated with a small 
increase in concentration from 0.02 mM to 0.04 mM. This trend was also 
true for LA, CA, MC and compound 4 (Table 3). With respect to j1-max. 
different patterns were observed, there was a gradual decrease noted 
with LA, CA, MC and compound 4, associated with the higher MICvalues 
for these compounds. Whereas. for ML and compound 3, there was a 
non-linear association of Il-max reduction with concentration, asso-
ciated with the very low MIC values determined for these compounds. 
4. Discussion 
The antimicrobial potential of carbohydrate fatty acid derivatives has 
received less attention than their other functional properties as 
emulsifiers or non-ionic surfactants. In contrast to the extensive 
literature for the antimicrobial properties of monoglycerides, there is 
limited information about the use of CFA derivatives as food preserva-
tives. Previous studies on antimicrobial properties of sugar esters mainly 
involved sucrose or other disaccharides esters (Hathcox and Beuchat, 
1996; Oevulapalle et al.. 2004). Many of the studies were not carried out 
using regiochemically pure compounds, were not quantitative and did 
not include controls to compare activity offree fatty acids with fatty acid 
derivatives. As a result correlation of chemical structure with efficacy 
and/or mechanism of action has been difficult. 
The current study evaluated the antimicrobial properties of pure 
fatty acid esters and their corresponding ethers to provide insights into 
structure/activity relationships for these compounds. The CFA deriva-
tives synthesized in this study were shown to be more effective against 
Gram positive than Gram negative bacteria (p < 0.05). This trend was also 
observed for the fatty acid and monoglyceride controls, in accordance 
with previous studies (Conley and Kabara, 1973; Ruzickaet aI., 2003). We 
obtained similar MIC values of 10 ~/ml for monolaurin against L. 
monocytogenes as those reported by Wang and Johnson (1992), and Oh 
and Marshall (1993). The activity oflauric derivatives 2 and 6 against L. 
monocytogenes was found to be equivalent to that of monolaurin and in 
excess of that reported by Monk et al. (1996), for a lauroyl-sucrose ester. 
With respect to the effect of chain length on antimicrobial efficacy of 
the CFA's. there was a difference in efficacy between Gram positive and 
Gram negative bacteria. Lauric acid and derivatives had higher activity 
against Gram positive bacteria, whereas caprylic acid and its derivative 5 
were more active than lauric acid derivatives against E. coli ATCC 25922 
and P. fluorescens. Our data are similar to that of Nair et al. (2004a). 
where populations of L. monocytogenes and E. coli 0157: H7 were shown 
to decrease below detection levels using 50 mM of MC or CA in bovine 
milk. The same authors, Nair et al. (2005), described antimicrobial 
activity for both CA and MC and found that Streptococcus spp. were the 
most sensitive, and E. coli the most tolerant. Whilst both lauric and 
caprylic fatty acid derivatives retained good activity against Gram 
positive bacteria, only the caprylic acid derivative displayed useful 
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efficacy against Gram negative bacteria. These trends were also observed 
with the free FAs and MGs. The enhanced efficacy of the shorter chain 
fatty acid over the medium chain fatty acid could be attributed to the 
differences in the outer membrane structure and permeability between 
Gram-negative and Gram-positive bacteria. 
This study also looked at fatty acids conjugated to sugars by ether 
bonds. Such bonds are not as readily hydrolyzed in biological systems as 
their ester equivalents. It was interesting to note that these compounds 
still retained antimicrobial activity indicating that hydrolysis ofthe ester 
bond is not necessary for antimicrobial activity. Compound 4 (R> ether) 
was less inhibitory than the free fatty acid (IA) and monoglyceride (ML) 
against Listeria spp. In some cases, compound 2 (a ether) had an 
enhanced activity by comparison with compound 1 (a ester) and 3 (R> 
ester), particularly for the Listeria spp. This may be due to the greater 
stability of ether bonds over esters (Ved et aI., 1984), since ether bonds 
are not subject to cleavage by cellular esterases. Reporting on the 
antimicrobial efficacy of ether and ester glyceride compounds, Isaacs 
et al. (1995), suggested that ether lipids should remain antimicrobial for 
a longer period of time than monoglycerides with ester linkages, which 
assumes that the fatty acid component does not require release, for 
example, by esterases for activity. Ruzin and Novick (2000) showed that 
monolaurin was rapidly hydrolyzed (t1/2 of -5 min) by esterases in S. 
aureus suggesting that inhibitory activity could be due to free fatty acid 
liberated from monolaurin by hydrolysis. The differences observed in 
this study between the ester and ether bonds of the same carbohydrate 
fatty acid (compounds 1 and 2 and compounds 3 and 4) show that the 
nature of the bond between the fatty acid and the sugar has an influence 
on antimicrobial activity. 
The focus of many studies on the mechanism of action of monoglyc-
erides is on cellular membranes. Ruzin and Novick (2000) reported a 
monolaurin esterase activity in association with the cell membrane and 
also in the cytoplasm and the Geh lipase was responsible for 
approximately 80% of the monolaurin hydrolysing activity. The same 
authors reported increased lipolytic activity in membrane fractions of S. 
aureus and concluded that S. aureus had a membrane bound esterase 
that participated in the hydrolysis of monolaurin and release of lauric 
acid. However, the current work suggests that while membrane bound 
or free esterases may cleave ester bonds of a glycerol or a carbohydrate 
fatty acid derivative, the ether carbohydrate fatty acid derivatives 
retained higher activity than the ester derivatives and that the release of 
a free fatty acid may not be required for potent antimicrobial activity. 
In an effort to probe the importance ofthe carbohydrate moiety, ester 
and ether fatty acid derivatives based on the following carbohydrates 
were synthesized and tested: a-glucose, R>-glucose, a-mannose and a-
galactose. Of these, differences in efficacy were measured for 
compounds which have the same glycoconjugate bond and alkyl chain 
length (see entries in Table 2 for compounds 1, 3, 6, 7). Therefore we 
conclude that the sugar itself can be a determining factor on efficacy. 
This is in accordance with the findings of Watanabe et al. (2000) who 
also concluded that the configuration of the carbohydrate moiety in 
similar compounds markedly affected antibacterial activity. In addition, 
we found that a minor structural change in the carbohydrate can have a 
major influence on the solubility of the compound. For example, 
compounds 1, 3, and 6 are soluble, whereas the structurally similar 
compound 7 is insoluble. This further highlights the importance of the 
choice of carbohydrate. 
We found that not only were free single or multiple hydrophilic 
groups necessary for biological activity, as observed by Conley and 
Kabara (1973), but that the nature of the hydrophllicgroup per se is also 
important for the antibacterial activity, as antimicrobial activity 
associated with the lauroyl penta erythritol monoester 9 with three 
free hydroxyl groups was negligible compared to compounds 1, 3 and 6 
which also had the same number offree hydroxyl groups. 
Results for compound 8 demonstrates that there is a limit to the 
number of fatty acids which can be esterified to a monosaccharide and 
this appears to be one, whereas for the sucrose it has been demonstrated 
that it is two (Kato and Shibasaki, 1975). Due to the poor solubility in 
water of compounds 7, 8, 10 and 11, their potential for application in food 
systems is limited. 
The data obtained from the increase in }.. and decrease in Il-max 
studies showed that sub-MIC concentrations can modify bacterial 
growth significantly. Nair et al. (2004b) also observed this behaviour 
using MC (50 mM) which reduced Enterobacter sakazakii in recon-
stituted infant formula by >5 log CRJ/ml at 37 DC, whereas approxi-
mately 1.5 log CFU/ml of the pathogen survived after 24 h of incubation 
using half the concentration of antimicrobial. This is important towards 
possible combinations with other antimicrobials or alternative pre-
servation strategies for optimization of practical application of CFA 
derivatives to microbiological issues within the food and other 
industries. Combinations of sub-MIC preservatives with other minimal 
'hurdles' may contribute to the control of microbiological issues in food 
systems while minimizing sensory and quality impacts on a food. 
Combinations ofIA or a derivative and other antimicrobials have shown 
additive or synergistic effects against pathogenic or spoilage bacteria in 
several matrices (Bell and De Lacy, 1987, Wang and Johnson, 1997; 
Blaszyk and Holley, 1998; Yamazaki et aI., 2004). 
Lauric esters of methyl glucopyranoside (1 and 3) had comparable 
activity (p > 0.05) against all Gram positive bacteria tested, regardless of 
the anomeric configuration of the sugar. With regard to the lauric ethers, 
compound 2 showed lower MIC values (0.04 mM) against the Gram 
positive microorganisms compared to compound 4 (2.5 mM to 5 mM, 
p<0.05). This suggests that the alpha or beta configuration of the ether 
derivative has a considerable effect on the anti-microbial efficacy. In 
general, the alpha configuration of the carbohydrate moiety of the 
synthesized compounds was more effective than the beta, for both ester 
and ether derivatives of the same carbohydrate. This further supports 
the observation that the carbohydrate moiety has a role in the 
antimicrobial efficacy of the carbohydrate fatty acid derivative. This 
finding suggests that there is potential to develop carbohydrate fatty 
acid derivatives with an efficacy comparable to that of glycerol fatty acid 
derivatives such as monolaurin. 
5. Conclusions 
A series of pure, regiochemically defined monosaccharide mono-
fatty acid esters and their corresponding ethers were evaluated for 
antimicrobial activity. The (fA derivatives were found to be Significantly 
more active against Gram positive bacteria than Gram negative bacteria, 
and lauric esters of methyl glucopyranoside and mannopyranoside as 
well as the lauric ether of methyl glucopyranoside were comparable to 
Monolaurin for antimicrobial efficacy. The analysis of both ester and 
ether fatty acid derivatives of the same carbohydrate, in tandem with 
alpha and beta configuration of the carbohydrate moiety suggest that 
the carbohydrate moiety is involved in the antimicrobial activity of the 
fatty acid derivatives and that the nature of the bond also has a 
significant effect on efficacy, which requires further investigation. No 
significant variability in the efficacy of the compounds was observed 
between Listeria strains. The use of a synthetic route to control 
production ofregiochemically defined compounds allows the optimiza-
tion of the carbohydrate moiety configuration and bond with regard 
to anti-microbial efficacy, highlighting compounds suitable for regiose-
lective enzymatic synthesis. Carbohydrate fatty acid derivatives 
have potential as effective antimicrobial compounds for use as 
preservatives to address a range of microbiological stability and safety 
issues. Additional knowledge on the mode of action of such compounds 
in combination with data on their MICs would allow for effective 
applications. 
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A series of fatty acid ester and ether derivatives have been chemically synthesised based on carbohydrate 
and non-carbohydrate polyhydroxylated scaffolds. The synthesised compounds, along with their corre-
sponding fatty acid monoglyceride antimicrobials, were evaluated for antimicrobial activity against 
Staphylococcus aureus and Escherichia coli. Of the derivatives synthesised, several of the carbohydrate-
based compounds have antimicrobial efficacy comparable with commercially available antimicrobials. 
The results suggest that the nature of the carbohydrate core plays a role in the efficacy of carbohydrate 
fatty acid derivatives as antimicrobials. 
1. Introduction 
The antimicrobial effects of fatty acids have been well docu-
mented.1 Generally, long-chain fatty acids have activity against 
Gram-positive bacteria, while short-chain fatty acids are more ac-
tive against Gram-negative bacteria, Lauric acid (a medium-chain 
fatty acid) is regarded as the most active, with reported activity 
against both Gram-positive and Gram-negative bacteria.2 Lauric 
acid and gentamicin combined have been reported to show activity 
against MRSA.3 Lauric acid is inexpensive and, therefore, may be 
very useful for infection control in hospitals. 
Esterification of fatty acids with monohydric alcohols such as 
methanol or ethanol has been shown to reduce their antimicrobial 
activity.4 In contrast, esterification of fatty acids to the polyhydric 
alcohol glycerol increased their effectiveness.5 One of the most ac-
tive of these antimicrobial derivatives is monolaurin (Lauricidin®), 
the glycerol monoester of lauric acid, which is used as a key ingre-
dient of antimicrobial food additives to inhibit the growth of unde-
sirable microorganisms.6,7 
More recently, a study has shown that the corresponding ether 
of monolaurin, dodecylglycerol, had greater potency against Strep-
tococcus faecium than monolaurin itself, albeit depending on the 
incubation conditions.s The greater potency of dodecylglycerol 
was ascribed to its greater retention by the cell and its action on 
specific receptors or enzymes, 
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Another class of fatty acid derivatives that has broad applica-
tions in the food industry is that of the carbohydrate fatty acid es-
ters.9,IO While they are most commonly employed as surfactants, 
their antimicrobial properties have been documented.11 The use 
of carbohydrate esters is increasingly favoured since they are bio-
degradable, are not harmful to the environment and are non-
toxic.12 
The most common carbohydrate fatty acid esters utilised to 
date are sucrose esters. They are commercially available and 
used for a variety of food applications, Kato and Shibasaki 
showed that the sucrose ester of lauric acid had potent antimi-
crobial activity against certain Gram-positive bacteria and fungi. 
They further showed that, in contrast to findings with glycerides, 
the diester of sucrose was more active than the monoester. Of 
the diesters tested, sucrose dicaprylate showed the highest 
activity.13 
Other oligosaccharide fatty acid esters, including maltose and 
maltotriose, have been synthesised. These sugar esters were shown 
to inhibit the growth of Streptococcus sobrinus and are therefore 
potentially of significant value in the development of oral-hygiene 
products.14 One study investigating the effect of carbohydrate 
mono esters reported that among those synthesised, galactose 
laurate, fructose laurate and the redUcing 6-0-lauroylmannose 
showed the highest inhibitory effect against Streptococcus mutans, 
while other analogues of hexose laurates showed no activity, lS This 
finding strongly suggests that the carbohydrate moiety can mark-
edly affect the antimicrobial activity of the fatty acid, and, there-
fore, further investigation is merited. 
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Scheme 1. Reagents and conditions: (i) DMF anhyd. TIPSCI. imidazole, rt; (ii ) anhyd 
DMF. NaH. BnBr. rt; (iii) THF anhyd, 0 °C. TBAF, rt; (iv) anhyd Pyr, DMAP, Lauroyl CI, 
rt; (v) EtOH, Pd/C, Hz; (vi) Pyr anhyd, DMAP. oetanoyl CI. rt. 
Recent work in the area of carbohydrate Fatty acid esters has 
focused on establishing an effective regioselective, enzyme-cataly-
sed synthesis of sugar derivatives for use as surfactants for indus-
trial applications; 1&-20 however, relatively few studies have 
examined role of the carbohydrate in antimicrobial activity.14.21.22 
This study is concerned with the synthesis of carbohydrate and 
polyhydroxylated non-carbohydrate fatty acid derivatives for eval-
uation as antibacterial agents, with a view to examining the effect 
of variation of the hydrophilic moiety on antimicrobial activity. 
Therefore, we designed chemical syntheses to investigate the 
effects of carbohydrate versus non-carbohydrate hydrophilic cores, 
the number of fatty acids attached to the hydrophilic core, the 
monosaccharide core itself (and the anomeric configuration with 
respect to glucopyranoside), the glycoconjugate linkage and the 
length of fatty acid chain on antimicrobial activity. 
A quantitative assay for antimicrobial activity was used to allow 
comparisons between compounds, and all were measured relative 
to the free fatty acids and monolaurin as reference compounds. 
Enzymatic synthesis of novel sugar fatty acid esters has been 
widely employed and can be highly regioselective, although for 
some carbohydrates minor regiomeric isomers may be obtained. 
For this study, we have developed a chemical route to allow the 
synthesis of a number of pure, regio-defined, monosaccharide 
mono fatty acid esters (Scheme 1). We have also developed a route 
to the corresponding ether derivatives (Scheme 2). In order to 
establish whether a second Fatty acid conjugated to a monosaccha-
ride would improve antimicrobial activity, a route was developed 
to synthesise a di-Iaurate derivative (Scheme 3). Furthermore, to 
investigate whether the structure and, therefore, the synthesis 
could be simplified and retain activity, non-carbohydrate hydrox-
ylated esters based on a pentaerythritol core were synthesised by 
a straightforward esterification (Scheme 4). 
HO .?H 0 J!:!!l H~HO OMe ~IPS PMBO 0 ~ PMBO PMBO OMe 
la·b 7a·b 
Scheme 2. Reagents and conditions: (i) DMF anhyd, TlPSCI, imidazole, rt; (i i) anhyd 
DMF, THF anhyd, O°C, NaH. PMBCI, TBAI. rt; (iii) anhyd THF, 0 °C, TBAF, rt; (iv) 
anhyd DMF, dodecanyl chloride. O°C. NaH, rt; (v) 3 :1 MeCN-H20 , CAN, rt. 
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Scheme 3. Reagents and conditions: (i) pTSA. PhCH(OMeh. anhyd MeCN. rt; (ii) 
anhyd DMF. NaH, BnBr. rt (95% yield over 2 steps); (iii) MeOH, TsOH; (iv) anhyd Pyr, 
DMAP. Iauroyl CI, rt (38% yield over 2 steps); (v) EtOH, Pd /C. Hz (75% yield). 
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Scheme4. Reagents and conditions: (i ) Pyr anhyd. DMAP. lauroyI CI. rt (14. 14%: 15. 
29%). 
2. Results and discussion 
2.t. Synthesis 
A chemical route designed to obtain monoester sugars is shown 
in Scheme 1 and is based on the following carbohydrate starting 
materials: methyl <X-D-glucopyranoside (ta), methyl p-o-gluco-
pyranoside (tb), methyl Ot-D-mannopyranoside (te) and methyl 
<x-o-galactopyranoside (td). The synthesis commenced with the 
selective protection of the primary hydroxyl group of sugars ta-
d with a triisopropylsilyl (TIPS) group. The silyl derivatives were 
then fully protected with benzyl .groups to give 2a-d. The removal 
of the TIPS group by tetrabutylammonium fluoride in THF allowed 
for the esterification of the free 6-0H position with either lauroyl 
chloride to yield 3a-d or octanoyl chloride to yield Sa. Removal 
of the benzyl groups by catalytic hydrogenation led to the unpro-
tected carbohydrate esters 4a-d and 6a, respectively (Table t). 
Synthesis of the ether derivatives also commenced with the 
protection of the primary hydroxyl group with a triisopropylsilyl 
group (Scheme 2). The sugars were then fully protected using p-
methoxybenzyl chloride (PMB), to yield 7a-b. Removal of the TIPS 
group gave the free primary hydroxyl. Next, the Iauryl ether group 
was attached using dodecanyl chloride to give the fully protected 
ether derivatives Sa-b. Finally, oxidative cleavage of the PMB 
groups with ceric ammonium nitrate (CAN) gave the mono-
dodecanyl sugars 9a-b (Table 2). 
The method used to synthesise di-O-lauroyl derivative t2a 1s 
shown in Scheme 3. The 4 and 6-0H positions of methyl <x-o-gluco-
pyranoside (ta) were protected with a benzylidene group using 
benzaldehyde dimethylacetal. The remaining free OHs were then 
converted to benzyl ethers to give tOa. Removal ofthe benzylidene 
acetal using a catalytic amount ofTsOH in MeOH then enabled the 
esterification oFthe 4- and 6-0H to give lla. Finally, removal of the 
benzyl groups by catalytic hydrogenation gave the diester deriva-
tive 12a. 
Direct esterification of pentaerythritol13, using lauroyl chloride 
and DMAP in pyridine, yielded the non-sugar derivatives t4 and t5 
as shown in Scheme 4. 
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Table 1 
Percentage yields of compounds 2a-d, 3a- d, 4a- d, Sa and 6a 
Carbohydrate 
(1) 
2,3,4-Tri-O-Bn-6-0-TIPS 
(2) 
2,3,4-Trl-O-Bn-6-O-lauroyl 
(3) 
6-().L.luroyl 
(4) 
2,3.4-Trf-O-Bn-6-0-ocfa nayl 
(5) 
6-0-0ctanoyl 
(6) 
Ho~l - 0 HO~ 
HO OMs 
(la) 
JH '" 
H~~OMe 
HO 
(lb) 
I1\OH HO -HO 
OMe 
(lc) 
HttH - 0 
HO~ 
HO OMe 
(Id) 
Table 2 
2a 
85% 
2b 
80% 
2c 
51% 
2d 
50% 
Percentage yields of compounds 7a-b, 8a- b and 9a- b 
Carbohydrate 2,3,4-Trl-O-PMB- 2,3,4-Tri-O-PMB-
6-O-TIPS 6-O-dodecanyl 
(1) (7) (8) 
HO~OMe 7a Sa 59% 50% 
HO 
HO 
(lb) 
H~ 7b 8b 
HO OMe 61% 85% 
(la) 
3a 
72% 
3b 
70% 
3c 
64% 
3d 
60% 
6-0-0odecanyl 
(9) 
9a 
73% 
9b 
76% 
2.2. Antimicrobial activity of the fatty acid derivatives 
Two non-carbohydrate polyhydroxylated fatty acid ester deriv-
atives. six carbohydrate fatty acid ester derivatives and two carbo-
hydrate long-chain alkyl ether derivatives, together with their 
corresponding poly hydric alcohols, fatty acids and monoglycerides 
as controls, were tested against a Gram-positive bacterium, Staph-
ylococcus aureus, and a Gram-negative bacterium, Escherichia coli, 
to assess their antimicrobial activity. The efficacy of the derivatives 
and controls was compared using minimum inhibitory concentra-
tion values (MIC), which is defined as the lowest concentration of 
compound that shows no increase in cell growth for all the repli-
cates compared to a negative control after 18 h. 
The polyhydric alcohols (carbohydrates and pentaerythritol) 
showed no antimicrobial activity or growth-promoting effects for 
the microorganisms under the conditions used (results not shown), 
The data in Table 3 show that the monoglycerides, monolaurin 
and monocaprylin, had greater activity compared to the free fatty 
acids, lauric acid and caprylic acid, against S. aureus. Of the mono-
glycerides and free fatty acids tested, monolaurin had the lowest 
MIC values for S. aureus, with a value of 0.04 mM compared to a 
Table 3 
4a 
86% 
4b 
75% 
4c 
75% 
4d 
86% 
5a 
63% 
MIC values of fatty acid derivatives and controls 
Compound 
Lauric acid 
Monolaurin 
Caprylic acid 
Monocaprylin 
Methyl 6-O-lauroyl-oc-D-glucopyranoside (4a) 
Methyl 6-O-lauroyl-jl-o-glucopyranoside (4b) 
Methyl 6-0-octanoyl-oc-o-glucopyranoside (Sa) 
Methyl 6-O-dodecanyl-oc-o-glucopyranoside (9a) 
Methyl 6-O-dodecanyl-p-o-glucopyranoside (9b) 
MethyI4,6-di-0-Iauroyl-oc-o-glucopyranoside (12a) 
Methyl 6-O-Iauroyl-<X-D-mannopyranoside (4c) 
Methyl 6-O-lauroyl-<x-o-galactopyranoside (4d) 
Monolauroyl pentaerythritol (14) 
Dilauroyl pentaerythritol (15) 
a Not determined due to insolubility. 
S. au reus ATCC 
25923 (mM) 
0.63 
0.04 
5 
2.5 
0.31 
0.04 
2.5 
0.04 
2.5 
N~ 
0.04 
>10 
>10 
NO 
Sa 
73% 
E. coli ATCC 
25922 (mM) 
10 
20 
12.5 
6.25 
20 
20 
12.5 
20 
20 
NO 
20 
>20 
>20 
NO 
value of 0.63 mM for lauric acid. Furthermore, monocaprylin 
showed MIC values of 2.5 mM against S. aureus compared to the 
value of 5.0 mM for caprylic acid. With respect to E. coli, monolau-
rin showed less inhibitory effect than lauric acid with values of 
20 mM and 10 mM, respectively. In contrast, monocaprylin 
showed activity against E. coli at concentrations of 6.25 mM com-
pared with caprylic acid value of 12.5 mM. 
All fatty acid derivatives showed greater antimicrobial activity 
against S. aureus than E. coli. 
Among the sugar fatty acid esters and the sugar alkyl 
ethers prepared, methyl 6-0-dodecanyl-cx-D-glucopyranoside (ga), 
methyl 6-0-lauroyl-cx-o-mannopyranoside (4c) and methyl 6-0-
lauroyl-~-o-glucopyranoside (4b) showed the best inhibitory 
effects for S. aureus, with MIC values of 0.04 mM. The next deriva-
tive in order of efficacy was methyl 6-0-lauroyl-cx-o-glucopyrano-
side (4a), with a value of 0.31 mM. Methyl 6-0-octanoyl-cx-o-
glucopyranoside 6a was comparable to monocaprylin against S. 
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aureus with values of 2.5 mM. This compound was also more active 
than any of the lauric acid derivatives against E. coli. Methyl 6-0-
dodecanyl-p-D-glucopyranoside (9b) gave similar results as those 
for 6a for S. aureus with values of 2.5 mM. The galactopyranoside 
ester derivative 4d and the mono-O-lauroyl pentaerythritol 14 
were the least active compounds tested, both with comparatively 
negligible MIC values of >10 mM for S. aureus and >20 mM for 
E. coli. 
The di-substituted methyl 4,6-di-0-Iauroyl-<X-D-glucopyran-
oside (12a) did not show any activity comparable with either the 
monoglycerides or indeed the monosubstituted sugar derivatives. 
This was attributed to poor solubility in water, as was the case 
for the di-substituted non-sugar compound di-lauroyl pentaeryth-
ritol15. 
2.3. Discussion 
In this present study, we have evaluated the effect of polyhydr-
oxylated fatty acid derivatives as inhibitors of a Gram-positive 
(S. aureus) and a Gram-negative (E. coli) microorganism of concern 
to the food and healthcare industries. Several of the synthesised 
compounds have antimicrobial efficacies comparable with com-
mercially available antimicrobials against S. aureus. 
We studied the effect of carbohydrate versus non-carbohydrate 
hydrophilic cores (carbohydrate and pentaerythritollaurates), the 
degree of substitution (monoester and diester), the monosaccha-
ride core (glucopyranoside, mannopyranoside and galactopyrano-
side), the anomeric configuration (<X and p glucopyranoside), the 
type of fatty acid carbohydrate linkage (ester and ether) and the 
length of fatty acid chain (lauric and caprylic) on antimicrobial 
activity. 
As with the monoglycerides and free fatty acids, all of the fatty 
acid derivatives that were found to be active showed greater anti-
microbial activity against S. aureus than E. coli. 
The non-carbohydrate pentaerythritol monoester 14, which has 
the same number of free hydroxyl groups as the carbohydrate 
monoester derivatives, showed negligible activity against both 
microorganisms tested, indicating that the carbohydrate itself 
could play an important role in the antimicrobial activity of these 
compounds. 
The degree of substitution of these derivatives was also shown 
to be crucial as both the non-sugar penta erythritol diester 15 and 
the carbohydrate methyl <x-o-glucopyranoside diester (12a) were 
much less soluble in water than the monoesters. As a consequence, 
no antimicrobial activity results for these compounds could be 
obtained. 
With regard to the influence of different sugar cores, the 
results showed that the lauric ester derivative of methyl 
O!-D-mannopyranoside (4c) and methyl p-o-glucopyranoside (4b) 
showed higher activity than any other ester derivatives against 
S. aureus, supporting the observation that the nature of the carbo-
hydrate is involved in the antimicrobial efficacy of the derivatives. 
This conclusion is consistent with results of an earlier study by 
Watanabe et al.15 
Further evidence for this is noted in the results for the lauric 
ester anomers of methyl glucopyranosides 4a and 4b. A difference 
was noted when these compounds were tested against S. aureus, 
with the beta configuration showing higher activity. The lauric 
ether anomers of methyl glucopyranosides 9a and 9b also 
showed a marked difference in activity when tested against 
S. aureus. with the alpha configuration showing a much higher 
activity. 
In addition, the difference in activity between the ester and 
ether conjugates of the same carbohydrate showed that for the 
methyl O!-D-glucopyranoside derivatives, the ether derivative 9a 
was more active than the ester 4a; however. for methyl P-D-gluco-
pyranoside, the ester 4b was more active than the ether 9b. These 
results indicate that, in combination with other factors, the nature 
of the bond conjugating the fatty acid to the carbohydrate could 
play some role in antimicrobial activity. 
The importance of the chain length of the fatty acid ester was 
investigated using both lauric and caprylic derivatives. The lauric 
ester derivative 4a showed much higher activity against S. aureus 
compared to the corresponding caprylic ester derivative Ga. Con-
versely, the caprylic ester derivative 6a showed higher activity 
against E. coli compared with the lauric derivative 4a. This trend 
was also observed for the mono glyceride controls and is in accor-
dance with general trends observed for medium- and short-chain 
fatty acids.2 
In conclusion. these results suggest that the nature of the carbo-
hydrate core plays a role in the efficacy of carbohydrate fatty acid 
derivatives such as antimicrobials, and therefore further optimisa-
tion may be possible. However. to confirm the trends outlined with 
respect to the importance of the carbohydrate moiety and the role 
of the nature of the glycoconjugate bond, further studies are war-
ranted using a wider range of Gram-positive and Gram-negative 
microorganisms. which would allow for evaluation of potential 
species and strain effects. 
3. Experimental 
3.1. Synthesis 
3.1.1. General methods 
All air- and moisture-sensitive reactions were performed under 
an inert nitrogen atmosphere. All reactions performed under a 
hydrogen atmosphere were performed in a Parr hydrogenator. 
Anhydrous DMF, THF, pyridine and MeCN were purchased from 
Sigma-Aldrich. TLC was performed on aluminium sheets precoated 
with Silica Gel 60 (HF254• Fluka). and spots were visualised by UV 
and charring with 1 :20 H2S04-EtOH. Flash column chromatogra-
phy was carried out with Silica Gel 60 (0.040-0.630 mm, E. Merck) 
using a stepwise solvent polarity gradient correlated with TLC 
mobility. Chromatography solvents used were EtOAc (Riedel-de-
Haen), MeOH (Riedel-deHaen) and petroleum ether (bp 40-60 °C, 
Fluka). Optical rotations were determined with an M-% Series 
Optical Activity Ltd polarimeter. NMR spectra were recorded with 
Varian Inova 300 and Varian AS 400 spectrometers. Chemical shifts 
are reported relative to internal Me4Si in CDCl3 (c'i 0.0) for lH and 
CDCl3 (" 77.0) for 13e. Coupling constants are reported in hertz 
(Hz). FTlR spectra were recorded with a Nicolet FT-IR 5DXB infra-
red spectrometer, samples were prepared in a KBr matrix. Low-
resolution electrospray-ionisation mass spectra (LRESIMS) were 
measured in the positive-ion mode on a Micromass Quattro 
tandem quadropole mass spectrometer. Methyl O!-o-glucopyrano-
side. methyl P-D-glucopyranoside, methyl O!-o-mannopyranoside, 
methyl O!-o-galactopyranoside, pentaerythritol, 1-chlorododecane, 
lauroyl chloride and octanoyl chloride were purchased from 
Sigma-Aldrich. 
3.1.2. Methyl 2,3,4-tri-O-benzyl-6-0-triisopropylsilyl-ot-n-
glucopyranoside (2a) 
A solution of 1a (5 g. 25 mmol) in anhyd DMF (120 mL) was 
treated with chlorotriisopropylsilane (TIPSC!, 15 mL, 75 mmol) 
and imidazole (5 g, 75 mmol) and allowed to stir at room temper-
ature for 24 h. The crude TIPS-protected intermediate was then 
concentrated in vacuo and dissolved in EtOAc. The organic extract 
was washed with 10% HC! and water, followed by satd aq NaHC03 
and finally satd aq NaC!. It was then dried over anhyd MgS04 and 
concentrated under reduced pressure.23 The crude product was 
dissolved in anhyd DMF (50 mL) and cooled to O°e. NaH (5 g, 
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125 mmol) was added portionwise, BnBr (9 ml, 75 mmol) was 
added, and the mixture was allowed to warm to room temperature 
and stirred for 24 h. MeOH (50 ml) was added to quench the reac-
tion, and the mixture was stirred for 1 h. The solution of the fully 
protected sugar was then concentrated in vacuo, and the residue 
was dissolved in EtOAc. The solution was washed with water, dried 
over anhyd MgS04 and concentrated under diminished pressure,24 
The resulting crude product was purified by chromatography 
(petroleum ether-EtOAc) to give 2a (13.2 g, 85%); [IXjo 10.7 (c 
0.07, CHCl3); FfIR (KBr): 2923, 1733, 1498, 1455, 909, 884, 791, 
695 cm-1; lH NMR (400 MHz, CDCI3): 0 7.36-7.27 (ms, 15H, aro-
matic H), 4.91, (AB d, 2H, J 11.0, OCH2Ph), 4.78, (AB d, 2H, J 11.0, 
OCH2Ph), 4.74 (AB d, 2H, J 12.0, OCH2Ph), 4.61 (d, 1 H, J1.2 3.5, H-
1), 3.99 (apt t, 1H,12.3 9.5, h4 9.5, H-3), 3.84 (d, 2H, JS.6 4.5, 
H-6a,6b), 3.64 (m, IH, H-5), 3.55-3.49 (overlapping signals, 2H, 
H-2,4), 3.37 (s, 3H, OCH3), 1.10-1.02 (ms, 18H, each TIPS CH3), 
0.88 (m, 3H, each TIPS CH); 13C NMR (CDCh): 0 139.1, 138.7, 
138.5 (each s, each aromatic C), 128.65, 128.63, 128.3, 128.2, 
128.1, 128.0, 127.9, 127.8 (each d, each aromatic CH), 98.0 (d, C-
1), 82.5, 80.5, 78.1, 76.1 (each d), 76.1, 75.3, 73.6 (each t, each 
CH2Ph), 62.9 (t, C-6), 55.0 (q, OCH3). 18.3, 18.2 (each q, each TIPS 
CH3), 12.2 (each d, each TIPS CH); lRESIMS: Found, mlz 643.3; re-
quired, 643.9 [M+Nar. 
3.1.3. Methyl 2.3.4-tri-O-benzyl-6-0-triisopropylsilyl-p-o-g1uco-
pyranoside (2b) 
Treatment of 1b (4.5 g, 23.17 mmol) as described for 1a gave 
2b (8.7 g, 80%); [IXjo 23 (c 0.01, CHCh); FTIR (KBr): 2863, 1730, 
1497, 1454, 1399, 1277, 882, 802, 751, 697 cm-'; 'H NMR 
(400 MHz, CDCl3): 0 7.37-7.28 (ms. 15H, aromatic H), 4.90, 4.88, 
4.83 (each AB d, 6H,J 11.0, OCH2Ph), 4.30 (d, lH,J'.2 7.5, H-I), 
4.00-3.90 (overlapping signals, 3H, H-5,6), 3.66 (m, IH, H-3), 
3.53 (s, 3H, OCH3), 3.41 (m, IH, H-2), 3.34 (m, 1H, H-4), 1.26-
1.05 (ms, 21H, TIPS); 13C NMR (COCh): 0 138.98, 138.92, 138.7 
(each s, each aromatic C), 128.69, 128.65, 128.62, 128.5, 128.3, 
128.2, 128.0, 127.9, 127.8 (each d, each aromatic CH), 104.7 (d, 
C-1), 84.9, 82.9, 77.8, 76.2 (each d), 76.0. 75.3, 75.0 (each t, each 
CH2Ph), 62.7 (t, C-6), 56.9 (q, OCH3), 18.3, 18.2 (each q, each TIPS 
CH3), 12.3 (d, TIPS CH); lRESIMS: Found, mlz 643.3; required, 
643.9 [M+Nar. 
3.1.4. Methyl 2.3,4-tri-O-benzyl-6-0-triisopropylsilyl-0!-o-man-
nopyranoside (2c) 
Treatment of 1c (4 g, 20 mmol) as described for 1a gave 2c 
(6.5 g, 51%); [IXjo 25.5 (c 0.05, CHCh); FTIR (KBr): 3056, 2864, 
1496, 1363, 1324, 970, 882, 790, 734, 696 cm-I; 'H NMR 
(400 MHz, CDCh): 0 7.38-7.24 (multiple signals, 15H, each aro-
matic H), 4.79 (AB d, 2H, J 11.0, OCH2Ph), 4.72 (AB d, 2H, J 12.0, 
OCH2Ph), 4.71-4.64 (overlapping signals, 3H, OCH2Ph, H-l), 3.95 
(dd, IH,12.3 2.0, h4 11.0, H-3), 3.93-3.87 (overlapping signals, 
3H, H-4,6a,6b), 3.76 (dd, IH,],,2 2.5, H-2), 3.59 (dd, IH, J 5.5, J 
7.0, H-5), 3.31 (s, 3H, OMe), 1.12-1.04 (multiple signals, 21H, TIPS); 
13C NMR (COCh): 0138.68,138.61,138.4 (each s, each aromatic C), 
128.3,128.2,127.9,127.67,128.63,127.5,127.4 (each d, each aro-
matic CH), 98.5 (d, C-l), 80.3,76.7,74.9,73.3 (each d), 75.1, 72.5, 
72.1 (each t, each CH2Ph), 63.2 (t, C-6), 54.4 (q, OMe), 18.0, 17.9 
(each q, each TIPS CH3), 12.3 (each d, each TIPS CH2); lRESIMS: 
Found, mlz 638.5; required, 638.9 [M+H20r· 
3.1.5. Methyl 2.3.4-tri-O-benzyl-6-0-triisopropylsilyl-0!-o-galac-
topyranoside (2d) 
Treatment of 1d (4.0 g, 20.0 mmol) as described for 1a gave 2d 
(6.4 g, 50%); [IXjo 20.6 (c 0.07, CHCI3); FfIR (KBr): 3030,2865,1496, 
1454, 1350, 1194, 1054, 882, 793, 734, 696 cm-'; 'H NMR 
(400 MHz, CDCI3): c5 7.41-7.22 (multiple signals, 15H, each aro-
matic H), 4.82 (AB d, 2H, J 12.0, OCH2Ph), 4.71 (AB d, 2H, J 11.5, 
OCH2Ph), 4.77 (AB d, 2H, J 12.0, OCH2Ph), 4.68 (d, lH, J'.2 3.5, 
H-l), 4.04 (dd, 1H, 12.3 10.0, H-2), 3.95-3.92 (overlapping 
signals, 2H, H-3,5), 3.74-3.64 (overlapping signals, 3H, H-4,6), 
3.36 (s, 3H, OMe), 1.12-0.86 (mUltiple signals, 21H, TIPS); 13C 
NMR (CDCh): c5 137.9, 137.7, 137.5 (each s, each aromatic C), 
127.33, 127.28, 127.22, 127.15, 127.06, 126.62, 126.48, 
126.45 (each d, each aromatic CH), 97.6 (d, C-l), 78.1, 75.4, 74.0, 
70.1 (each d), 73.7, 72.5, 72.2 (each t, each CH2Ph), 61.4 (t, C-6), 
54.1 (q, OMe), 16.94, 16.93 (each q, each TIPS CH3), 10.8 (each d, 
each TIPS CH2 ); lRESIMS: Found, mlz 638.5; required, 638.9 
[M+H20r. 
3.1.6. Methyl 2.3.4-tri-O-benzyl-6-0-lauroyl-0!-o-glucopyrano-
side (3a) 
Compound 2a (3.0 g, 4.8 mmol) was dissolved in anhyd THF 
(80 ml), and the solution was cooled to 0 0c. Tetrabutylammonium 
fluoride (1 g, 4 mmol) was added, and the solution was allowed to 
warm to room temperature and stirred for 1 h.25 It was then con-
centrated in vacuo, and approximately 1 mmol of the resulting 
6-0H residue was dissolved in anhyd pyridine (25 ml). 4-Dimeth-
ylaminopyridine (DMAP, catalytic amt) and lauroyl chloride 
(0.29 ml, 1.22 mmol) were added, and the solution was allowed 
to stir at room temperature for 24 h.26 It was then concentrated 
under reduced pressure, and the resulting benzylated ester deriva-
tive was purified by chromatography (petroleum ether-EtOAc) to 
give 3a (0.47 g, 72%); [IXjo 7.5 (c 0.02, CHCI3); FfIR (KBr): 2924, 
2853, 1738, 1603, 1502, 1454, 1249, 1072 cm-'; 'H NMR 
(400 MHz, CDCI3 ): c5 7.35-7.26 (ms, 15H, aromatic H), 4.92, (AB d, 
2H,J 10.5, OCH2Ph), 4.72, (AB d, 2H,J 10.5, OCH2Ph), 4.64 (AB d, 
2H,J 12.0, OCH2Ph), 4.59 (d, lH,J1.2 3.5, H-l), 4.27 (d, 2H,J5.6 3.5, 
H-6a,6b), 4.01 (apt t, IH,12.3 9.5,h4 9.0, H-3), 3.82 (d apt t, lH, 
J4.5 10.0, H-5), 3.53 (dd, lH, H-2), 3.48 (apt t, IH, H-4) 3.37 (s, 
3H, OCH3 ), 2.35 (m, 2H, aliphatic OCOCH2ClOH21 ), 1.61 (m, 2H, 
aliphatic OCOCH2CH2CgH,g), 1.28-1.24 (ms, 16H, aliphatic 
OCOC2H4CgH,6CH3), 0.87 (m, 3H, aliphatic OCOC lOH20CH3); 13C 
NMR (COCh): c5 171.1 (s, C=O), 138.6, 138.1, 137.9 (each s, each 
aromatic C), 128.5, 128.48, 128.46, 128.1, 128.03, 127.98, 127.90, 
127.7 (each d, each aromatic CH), 98.0 (d, C-1). 88.0, 79.9, 77.6, 
68.6 (each d), 75.8, 75.1, 73.4 (each t, each CH2Ph), 60.4 (t, C-6), 
55.2 (q, OCH3), 34.2, 31.9, 29.8, 29.6, 29.5, 29.3, 29.2, 24.9, 22.7, 
21.1 (each t, each aliphatic CHz), 14.2 (q, aliphatic CH3); lRESIMS: 
Found, mlz 669.39; required, 669.85 [M+Nar. Anal. Calcd for 
C4oHs407: C, 74.27; H, 8.41. Found: C, 73.98; H, 8.30. 
3.1.7. Methyl 2.3.4-tri-O-benzyl-6-0-lauroyl-p-o-glucopyrano-
side (3b) 
Treatment of 2b (3.0 g, 4.8 mmol) as described for 2a gave 3b 
(2.2 g, 70%); [IXjo 8.3 (c 0.03, CHCI3); FTIR (KBr): 2924, 2853, 
1739, 1497, 1454, 1356, 1151, 1070, 735 cm-I; 'H NMR 
(400 MHz, CDCb): c5 7.36-7.24 (ms, 15H, aromatic H), 4.87, 4.84, 
4.72 (each AB d, 6H, J 10.5, OCH2Ph), 4.37 (d, 2H, J5.6 11.5, 
H-6a,6b), 4.31 (d, lH,J,.z 8.0, H-l), 4.25 (m, IH, H-5), 3.67 (apt t, 
IH, J2.3 8.5, h4 8.5, H-3), 3.56 (s, 3H, OCH3), 3.54 (m, IH, H-4), 
3.43 (dd, 1 H, H-2), 2.32 (m, 2H, aliphatic OCOCH2ClOH2,), 1.62 
(m, 2H, aliphatic OCOCH2CHzCgH,g), 1.26-1.24 (ms, 16H, each ali-
phatic OCOC2H4CBH,6CH3), 0.88 (t, 3H, J 6.0, J 7.0, aliphatic 
OCOCl1 H23CH3); 13C NMR (CDCl3): c5 173.6 (5, C=O), 138.43, 
138.42, 137.8 (each s, each aromatic C), 128.8, 128.5, 128.4, 
128.38, 128.34, 128.26, 128.11, 128.07, 127.97, 127.92, 127.8, 
127.7,127.69,127.64,127.5 (each d, each aromatic CH), 104.7 (d, 
C-1). 84.6, 82.3, 77.6, 72.9 (each d), 75.7, 75.1, 74.8 (each t, each 
OCHzPh), 62.9 (t, C-6), 57.1 (q, OCH3), 34.2, 31.9, 29.6, 29.5, 29.3, 
29.2, 29.1, 24.9, 24.7, 22.6 (each t, each aliphatic CH2), 14.1 
(q, aliphatic CH3); lRESIMS: Found, mlz 669.2; required, 669.9 
[M+Nar. Anal. Calcd for C4oHs407: C, 74.27; H, 8.41. Found: C, 
73.91; H, 8.79. 
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3.1.S. Methyl 2,3,4-tri-O-benzyl-6-Olauroyl-a-o-mannopyrano-
side (3c) 
Treatment of 2c (6.2 g, 10.0 mmol) as described for 2a gave 3c 
(4.1 g, 64%): [IX)D 23.3 (c 0.04, CHCh): FTIR (KBr): 3031, 2924, 
2853, 1737, 1496, 1454, 1362, 1066, 1027, 970, 909, 735, 697 
cm-': 'H NMR (400 MHz, CDCh): {, 7.38-7.25 (multiple signals, 
15H, each aromatic H), 4.77 (AB d, 2H,1 10.5, OCH2Ph), 4.74 (d, 
IH, 1'.2 2.0, H-l}, 4.72 (AB d, 2H,1 12.5, OCH2Ph), 4.61 (s, 2H, 
OCH2 Ph), 4.38 (dd, IH,1s.6. 2.5,16 •. 6b 12.0, H-6a), 4.33 (dd, IH, 
1S.6b 5.0, H-6b), 3.94-3.88 (overlapping signals, 2H, H-3,4), 3.78 
(dd, IH,12.3 2.5, H-2), 3.76 (m, IH, H-5), 3.31 (s, 3H, OMe), 2.32 
(t, 2H,1 7.5,17.5, aliphatic OCOCH2ClOH2,), 1.61 (m, 2H, aliphatic 
OCOCH2CH2CgH,g), 1.31-1.54 (ms, 16H, aliphatic OCOC2H4-
CSH16CH3), 0.91-0.86 (m, 3H, aliphatic OCOC,oH20CH3): 13C NMR 
(CDCh): c5 173.7, (s, C=O), 138.32, 138.21, 138.17 (each s, each aro-
matic C), 128.4, 128.38, 128.33, 128.05. 127.90, 127.76, 127.63, 
127.23 (each d, each aromatic CH), 98.9 (d, C-l}, 75.2, 74.6, 74.4, 
69.9 (each d), 80.1, 72.6, 72.1 (each t, each CH2Ph), 63.3 (t, C-6), 
54.8 (q, OCHJ ), 34.2, 33.9, 31.9, 29.61, 29.48, 29.44, 29.33, 29.27, 
29.17, 29.07, 24.9, 24.7, 23 .8, 22.7, 21.1 (each t, each aliphatic 
CH2), 14.1 (q, aliphatic CH3): lRESIMS: Found, mlz 664.6: required, 
664.9 [M+H20r. Anal. Calcd for 40HS407: C, 74.27: H, 8.41. Found: 
C, 74.35: H, 8.25. 
3.1.9. Methyl 2,3,4-tri-O-benzyl-6-0Iauroyl-a-o-galactopyrano-
side (3d) 
Treatment of 2d (5.7 g, 9.2 mmol) as described for 2a gave 3d 
(3.6 g, 60%): [IX)D 27.8 (c 0.09, CHCh): FTIR (KBr): 3030, 2924, 
2853, 1738, 1496, 1454, 1350, 1099, 1049, 735, 696 cm-': 'H 
NMR (400 MHz, COelJ ): {, 7.41-7.23 (multiple signals, 15H, each 
aromatic H), 4.83 (AB d, 2H,1 12.0, OCH2Ph), 4.81 (AB d, 2H,1 
11.5, OCHzPh), 4.77 (AB d, 2H,1 12.0, OCH2Ph), 4.68 (d, IH, 11.2 
3.5, H-l), 4.16 (dd, lH,l 7.5,1 11.5, H-4), 4.07-4.03 (overlapping 
signals, 2H, H-2,5), 3.94 (dd, 1H,1 3.0,110.0 H-6a), 3.86-3.84 (over-
lapping signals, 2H, H-3,6b), 3.35 (s, 3H, OMe), 2.23 (m, 2H, ali-
phatic OCOCH2ClOH2 ,), 1.57 (m, 2H, aliphatic OCOCH2CH2CgH,g), 
1.31-1.18 (ms, 16H, aliphatic OCOC2H4CsH,6CH3), 0.88 (t, 3H, 1 
6.5,1 7.0, aliphatic OCOClOH20CH3): 13C NMR (CDCI3): {, 173.4 (s, 
C=O), 138.7, 138.4, 138.2 (each s, each aromatic C), 128.42, 
128.36, 128.32, 128.11, 127.90, 127.75, 127.59, 127.51, 127.21 
(each d, each aromatic CH), 98.7 (d, C-l), 78.9, 76.3, 74.9, 68.4 
(each d), 74.6, 73.63, 73.54 (each t, each CH2Ph), 63.3 (t, C-6), 
55.3 (q, OCHJ), 34.1, 33.8, 31.9, 29.359, 29.45, 29.32, 29.26, 
29.12,24.9,24.8,22.7 (each t, each aliphatic CH2), 14.1 (q, aliphatic 
CHJ): lRESlMS: Found, mlz 664.6: required, 664.9 [M+H20r. Anal. 
Calcd for C4oHs407: C, 74.27: H, 8.41. Found: C, 74.67: H, 8.68. 
3.1.10. Methyl 6-0-lauroyl-ot-o-g1ucopyranoside (4a) 
Compound 3a (0.34 g, 0.2 mmol) was dissolved in EtOH (1 ml), 
and Pd/C (0.1 g) was added. The mixture was allowed to shake un-
der hydrogen atmosphere of 2 psi until all protecting groups had 
been removed, as shown by TlC, to yield 4a. The suspension was 
filtered and concentrated in vacuo27 to give 4a (0.17 g, 86%): [IX)D 
19 (c 0.02, CHCI3): FTIR (KBr): 3734, 3445, 2955, 2924, 2850, 
2359,2341. 1728 cm-' : 'H NMR (400 MHz, CDCh): {, 4.75 (d, IH, 
1'.2 3.5, H-l), 4.33 (m, 2H, H-6), 3.75-3.73 (overlapping signals, 
2H, H-3,5), 3.35 (apt t, IH,h4 9.5,hs 9.5, H-4), 3.54 (dd, IH,12.J 
9.5, H-2), 3.41 (s, 3H, OMe), 2.35 (t, 2H, 1 7.5, aliphatic 
OCOCH2ClQH2,), 1.63 (m, 2H, aliphatic OCOCH2CH2CgH,g), 1.38-
1.23 (ms, 16H, aliphatic OCOC2H4CsH,6CH3), 0.88 (t, 3H,1 7.0, ali-
phatic OCOC lOH20CHJ ): BC NMR (COCh): {, 174.2 (s, C=O), 99.4 
(d, C-l). 74.1 , 71.9, 70.4, 69.8 (each d), 63.5 (t, C-6), 55.2 (q, 
OCH3), 34.2, 31.9, 29.66, 29.64, 29.5, 29.4, 29.3, 29.2, 24.9, 22.7 
(each t, each aliphatic CHz), 14.1 (q, aliphatic CH3): lRESIMS: 
Found, mlz 399.3: required, 399.5 [M+Nar. Anal. Calcd for 
C'9H360 7: C, 60.61: H, 9.64. Found: C, 60.69: H, 9.83. 
3.1.11. Methyl 6-0-lauroyl-p-o-g1ucopyranoside (4b) 
Treatment of 3b (2.0 g, 3.0 mmol) as described for 3a gave 4b 
(0.86g, 75%): [aID -25.5 (c 0.05, CHCh): FTIR (KBr): 3421, 2921, 
1744,1703, 1016cm- ':'H NMR (400 MHz, CDel3): {, 4.40 (d, lH, 
1'.2 11.5, H-1), 4.28 (dd, 1H,12.3 6.0, H-2), 4.21 (d, 2H,15.6 7.5, 
H-6), 3.54 (s, 3H, OCH3), 3.49 (m, lH, H-3), 3.39-3.31 (overlapping 
signals, 2H, H-4,5), 2.34 (m, 2H, aliphatic OCOCH2ClQH2,), 2.02 (s, 
3H, OH), 1.62 (m, 2H, aliphatic OCOCH2CH2CgH,9), 1.28-1.26 (ms, 
16H, aliphatic OCOCZH4CsH'6CH3), 0.88 (t, 3H, 1 6.5, aliphatic 
OCOClOH20CH3): BC NMR (CDCI3): Ii 174.2 (s, C=O), 103.6 (d, 
C-l), 76.5, 73.9, 73.4, 70.3 (each d), 63.6 (t, C-6), 57.0 (q, OCH3), 
34.2, 31.9, 29.61,29.60,29.5,29.3,29.2, 29.1. 24.9, 22.7 (each t, 
each aliphatic CH2), 14.1 (q, aliphatic CH3): lRESIMS: Found, mlz 
399.1: required, 399.5 [M+Nar. Anal. Calcd for C'9H360 7: C, 
60.61: H, 9.64. Found: C, 60.25: H, 9.91. 
3.1.12. MethyI6-0-lauroyl-ot-o-mannopyranoside (4c) 
Treatment of 3c (3.3 g, 5.0 mmol) as described for 3a gave 4c 
(l.4g, 75%): [aID 33.3 (c 0,01 , CHCh): FTIR (KBr): 3421, 2923, 
1736, 1466, 1197, 1057 cm- I : 'H NMR (400 MHz, CDCI3): Ii 4.70 
(s, IH, H-l), 4.45 (br s, IH, OH), 4.36 (d, 2H,1 4.0, H-6), 3.96-3.92 
(overlapping signals, 2H, OH, H-2), 3.78 (dd, IH,12.3 2.5,h4 9.0, 
H-3), 3.71 (m, 1H, H-5), 3.62 (apt t, IH, 14.5 9.5, H-4) 3.36 (s, 3H, 
OMe), 2.35 (t, 2H,l 7.5,17.5, aliphatic OCOCH2CIOH2,), 1.61 (m, 
2H, aliphatic OCOCH2CH2CgH,9), 1.29-1.25 (ms, 16H, aliphatic 
OCOC2H4CsH,6CH3), 0.88 (t, 3H, 1 6.5, 1 7.0, aliphatic 
OCOClQH20CH3): BC NMR (CDel3): Ii 174.7 (5, C=O), 100.9 (d, 
C-l}, 71.5, 70.5, 70.4, 67.7 (each d), 63.9 (t, C-6), 54.9 (q, OCH3), 
34.2, 31.9, 29.7, 29.6, 29.5, 29.4, 29.36, 29.34, 29.19, 24.9, 22.7 
(each t, each aliphatic CH2), 14.1 (q, aliphatic CH3): lRESIMS: 
Found, mlz 377.3 : required, 377.5 [M+Hr. Anal. Calcd for 
C'9H3607: C, 60.61: H, 9.64. Found: C, 60.71: H, 9.53. 
3.1.13. Methyl 6-0-lauroyl-ot-o-galactopyranoside (4d) 
Treatment of 3d (2.8 g, 4.4 mmol) as described for 3a gave 4d 
(1.43 g, 86%): [aID 56.25 (c 0.01, CHCl3): FTIR (KBr): 3250, 2918, 
1741, 1467, 1194, 1025 cm- ': 'H NMR (400 MHz, CDCI3): {, 4.63 
(apt t, IH,1 6.5,1 5.0, OH-3), 4.57 (d, 1H,1 6.5, OH-2), 4.55 (d, 1H, 
]"23.5, H-1), 4.13 (dd, lH,15.Ga 8.0,16 •. Gb 11.5, H-6a), 4.07 (dd, IH, 
1S.6b 4.0, H-6b), 3.75 (dd, IH, H-5), 3.68 (apt t, IH,13,4 3.5,14.5 3.0, 
H-4), 3.58 (ddd, IH,12.3 10.0,lz,oH 16.5, H-2), 3.52 (m, 1H, H-3), 
3.24 (s, 3H, OMe), 2.28 (t, 2H,1 7.5, aliphatic OCOCH2ClOH2 ,), 
1.63 (t, 2H, 1 7.0, aliphatic OCOCHzCH2CgH,g), 1.28-1.23 (ms, 
16H, aliphatic OCOC2H4CaH16CH3), 0.85 (t, 3H, 1 7.0, aliphatic 
OCOCIOH20CH3): 13C NMR (CDCI3): Ii 178.2 (s, C=O), 104.8 (d, 
C-l}, 74.9, 74.1, 73.7, 73.1 (each d), 68.8 (t, C-6), 59.8 (q, OCH3), 
38.9,36.5,34.24,34.10,33.97,33.93,33.75,29.5,27.3, (each t, each 
aliphatic CHz), 18.9 (q, aliphatic CH3): lRESIMS: Found, mlz 399.3: 
required, 399.5 [M+Nat. Anal. Calcd for C19H3607: C, 60.61: H, 
9.64. Found: C, 60.60: H, 9.88. 
3.1.14. Methyl 2,3,4-tri-O-benZYI-6-0ortanoyl-ot-o-g1ucopyrano-
side (Sa) 
Compound 2a (5.0 g, 8.5 mmol) was dissolved in anhyd THF 
(150 ml), and the solution was cooled to 0 °(, Tetrabutylammo-
nium fluoride (2.2 g, 8.5 mmol) was added, and the solution was 
warmed to room temperature and stirred for 1 h.2s The mixture 
was then concentrated in vacuo, and the resulting 6-0H residue 
was dissolved in anhyd pyridine (100 ml). 4-Dimethylaminopyr-
idine (DMAP, catalytic amt) and octanoyl chloride (2.9 ml, 
17 mmol) were added, and the mixture was stirred at room tem-
perature for 24 h.26 The solution was then concentrated under 
reduced pressure and purified by chromatography (petroleum ether-
EtOAc) to give Sa (3.9 g, 63%): [aID 20.8 (c 0.07, CHCI3): FTlR (KBr): 
2927,1738,1497,1454,1360,1163,1093,738,697 cm- I;'H NMR 
(400 MHz, CDCh): c5 7.37-7.26 (ms, 15H, aromatic H), 4.93, (AB d, 
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2H,1 10.5, OCH2Ph), 4.74, (AB d, 2H,1 12.0, OCH2Ph), 4.73 (AB d, 2H, 
}l0.5, OCH2Ph), 4.60 (d, IH,11.2 3.5, H-1), 4.28 (d, 2H,1s.s 3.0, H-6), 
4.01 (apt t, lH,h,3 9.5,h4 9.5, H-3), 3.81 (m, IH, H-5), 3.54 (dd, IH, 
H-2), 3.48 (dd, IH,14.s 10.5, H-4), 3.37 (5, 3H, OCH3), 2.31 (m, 2H, 
aliphatic OCOCH2CsH13 ), 1.62 (m, 2H, aliphatic OCH2CH2CsHl1 ), 
1.30-1.05 (ms, 8H, aliphatic OC2H4C4HsCH3), 0.87 (m, 3H, aliphatic 
OCSH12CH3); 13C NMR (CDCI3): i5 173.8 (5, C=O), 138.8, 138.3, 138.1 
(each 5, each aromatic C), 128.7, 128.6, 128.3, 128.29, 128.27, 
128.3. 128.25, 128.20, 128.1 127.9 (each d, each aromatic CH), 
98.3 (d, C-l), 82.2, 80.2. 77.8, 68.9 (each d), 76.1. 75.3, 73.6 (each 
t, each OCH2Ph), 63.1 (t, C-6). 55.4 (q, OCH3), 34.4, 31.9, 29.2, 
25.0, 22.8, 17.9 (each t, each aliphatic CH2). 14.3 (q, aliphatic 
CH3); lRESIMS: Found, mlz 613.4; required, 613.7 [M+Nat. Anal. 
Calcd for C3sH4S07: C, 73.19; H, 7.85. Found: C. 73.25; H, 7.61. 
3.1.15. Methyl 6-0-octanoyl-Of-D-glucopyranoside (6a) 
Treatment of Sa (3.6 g, 6.2 mmol) as described for 3a gave 6a 
(1.44 g, 73%); [ala 27.9 (c 0.4, CHCI3); FTIR (KBr): 3388, 2922, 
1712,1465,1193,1106, 724cm-1; lH NMR (400 MHz, CDCh): /j 
5.82 (s, 3H, each OH), 4.76 (d, IH, J,.2 3.5, H-l), 4.35 (d, 2H.1s.s 
4.0, H-6), 3.78-3.72 (overlapping signals, 2H, H-3,5), 3.54 (dd, 
IH, h3 9.5. H-2), 3.41 (5. 3H, OCH3), 3.36 (dd, IH, h4 9.5,hs 
10.0, H-4), 2.35 (m, 2H. aliphatic COCH2CsH13) 1.64 (t. 2H, 1 7.0, 
aliphatic COCH2CH2CsHll ) , 1.31-1 .05 (ms, 8H, aliphatic 
COC2H4C4HsCH3), 0.88 (t, 3H, 1 5.5,1 7.0, aliphatic COCSH12CH3); 
13C NMR (CDCI3): i5 179.5 (s, C=O), 99.4 (d, C-1). 74.1, 72.0, 69.7, 
70.3 (each d), 63.4 (t, C-6). 55.3 (q, OCH3), 34.1, 31.7, 31.6. 29.9, 
28.9,24.8 (each t, each aliphatic CH2). 14.1 (q, aliphatic CH3); LRE-
SIMS: Found, mlz 343.1; required, 343.4 [M+Nat. Anal. Calcd for 
ClsH2S07: C, 56.23; H, 8.81. Found: C, 56.47; H, 8.73. 
3.1.16. Methyl 2,3,4-tri-O-p-methoxybenzyl-6-0-triisopropyls-
i1yl-Of-D-g]ucopyranoside (7a) 
A solution of 1a (5.0 g, 25.0 mmo!) in anhyd DMF (120 mL) was 
treated with chlorotriisopropylsilane (TiPSCI, 15 ml, 75 mmol) and 
imidazole (5 g. 75 mmol). and allowed to stir at room temperature 
for 24 h. The crude TIPS-protected intermediate was then concen-
trated in vacuo, and the resulting residue was dissolved in EtOAc. 
The organic extract was then washed with 10% HCI and water, fol-
lowed by satd aq NaHC03 and finally satd aq NaCl. It was then 
dried over anhyd MgS04 and concentrated under reduced pres-
sure.23 The TIPS-protected crude product was then split into two 
parts, and half was dissolved in a mixture of anhyd DMF (30 ml) 
and anhyd THF (20 mL). This solution was then added dropwise 
at O°C to a suspension of NaH (2.5 g, 62.5 mmo!) in anhyd 
DMF (10 mL) and anhyd THF (7 ml), p-methoxybenzyl chloride 
(17 ml, 125 mmol) and tetrabutylammonium iodide (18.5 g, 
50 mmol). The mixture was stirred at ~ 10 °C for 30 min and then 
allowed to warm to room temperature and stirred for 24 h. MeOH 
(50 ml) was added to quench the reaction, and the mixture was 
stirred for 1 h. The solution was then concentrated under dimin-
ished pressure and dissolved in EtOAc. The organic extract was 
washed with water, dried over anhyd MgS04 and concentrated in 
vacuo.2S The resulting residue was purified by chromatography 
(petroleum ether-EtOAc) to give 7a (5.15 g, 59%); [c.:]o 11.6 (c 
0.05, CHCI3); FTIR (KBr): 3479, 2936, 2864, 1464, 1421, 1360, 
1302, 883, 820 cm-1; IH NMR (400 MHz, CDCh): /j 7.34-6.73 
(ms, 12H, aromatic H), 4.88 (AB d, 2H,1 10.5 OCH2Ph), 4.78 (d, 
IH, 11 .2 5.0, H-l), 4.75, 4.71 (each AB d. 2H.1 12.0 OCH2Ph), 4.63 
(m. IH, H-2), 3.99 (apt t, IH, h 4 9.0.14.s 9.0, H-4). 3.89 (m. 2H, 
H6). 3.77 (m, 9H, each PhOCH3), 3.57-3.49 (overlapping signals, 
2H. H-3,5). 3.39 (s, 3H, OCH3), 1.28 (m. 3H, each TIPS CH), 1.16-
1.06 (ms. 18H, each TIPS CH3); 13C NMR (CDCI3): /j 159.6, 159.5, 
159.4. 131.6, 131.4, 131.0 (each 5, each aromatic C). 129.99, 
129.93, 129.8. 114.13, 114.08, 113.6 (each d, each aromatic CH), 
98.1 (d, C-l), 82.2. 80.2, 77.8, 72.1 (each d), 75.8, 74.9, 73.2 (each 
t, each OCHzPh), 63.1 (t, C-6), 55.47, 55.40, 55.36 (each q, each 
PhOCH3), 55.0 (q. OCH3), 18.27, 18.25 (each q, each TIPS CH3), 
12.3 (d, each TIPS CH); lRESIMS: Found, mlz 733.3; required, 
733.9 [M+Nat. 
3.1.17. Methyl 2,3,4-tri-O-p-methoxybenzyl-6-0-triisopropyl-
silyl-P-D-g]ucopyranoside (7b) 
Treatment of1b (4.5 g, 23.17 mmol) as described for 1a gave 7b 
(10.1 g, 61 %); [ala 4.8 (c 0.05, CHCh): FTIR (KBr): 2939. 1586, 1464, 
883,821,760,683 cm- I; lH NMR (400 MHz, CDCl3): i5 7.30-6.84 
(ms, 12H, aromatic H). 4,85, 4.80, 4.73 (each AB d, 2H,1 10.5, 
OCH2Ph), 4.27 (d, lH,11.2 7.5, H-l), 3.95 (m. IH, H-6a), 3.87 (dd. 
IH,14.s 11.0, 1s.s 4.5. H-5), 3.78 (m, 9H, PhOCH3), 3.59 (m, IH, 
H-3), 3.53 (5, 3H, OCH3) 3.36 (apt t, IH, h.3 9.0, H-2), 3.29-3.24 
(overlapping signals, 2H, H-4,6b), 1.10-1.04 (ms, 21H, TIPS); 13C 
NMR (CDCI3): /j 159.5, 159.4, 131.2, 131.1, 130.9, (each 5, each aro-
matic C), 129.9, 129.8, 128.7, 114.1, 114.04, 114.01 (each d, each 
aromatic CH), 104.7 (d, C-l), 84.7, 82.6, 77.5, 76.2 (each d), 75.7, 
74.9. 74.7 (each t, each OCHzPH), 62.7 (t, C-6), 56.8 (q, OCH3), 
55.5 (each q, each PhOCH3), 18.3, 18.2 (each q, each TIPS CH3), 
12.2 (d, each TIPS CH); lRESIMS: Found, mlz 733.3 ; required, 
733.9 [M+Nar. 
3.1.1S. Methyl 2,3,4-tri-O-p-methoxybenzyl-6-0-dodecanyl-Of-
D-glucopyranoside (Sa) 
Compound 7a (4.0 g, 5.5 mmol) was dissolved in anhyd THF 
(100 mL). and the solution was cooled to O°c. Tetrabutylammo-
nium fluoride (1.4 g, 5.5 mmol) was added, and the solution was 
allowed to warm to room temperature and stirred for 1 h.25 The 
mixture was then concentrated in vacuo, and the resulting 6-0H 
residue was dissolved in anhyd DMF (100 mL). l-Chlorododecane 
(1.8 mL, 11 mmol) was added, and the solution was cooled to 
o °C before NaH (0.11 g, 2.75 mmol) was added portionwise. The 
mixture was then allowed to warm to room temperature and 
was stirred for 24 h. MeOH (50 ml) was added to quench the reac-
tion, and the mixture was stirred for 1 h.z9 The crude PMB-pro-
tected ether was then concentrated under diminished pressure 
and purified by chromatography (petroleum ether-EtOAc) to give 
Sa (1.89 g, 50%); [c.:]o -8.6 (c 0.06. CHCI3); FTIR (KBr): 2924, 
2854,1613,1586,1464,1359,1301,1248,1172,1037,820cm- l ; 
IH NMR (400 MHz, CDCI3): /j 6.85-7.30 (ms, 12H, aromatic H), 
4.92 (d, IH,11.Z 10.5, H-l), 4.85 (AB d, 2H,1 10.5, OCHzPhOCH3). 
4.74 (dd, lH, h 3 9.5, H-2), 4.69, (AB d, 2H,1 10.5, OCHzPhOCH3), 
4.60 (AB d, 2H,1 11.5 OCHzPhOCH3 ), 4.55 (apt t, IH, h,4 9.5, H-3), 
3.95 (m, IH, H-5), 3.80 (5, 9H, each PhOCH3), 3.53-3.37 (overlap-
ping signals, 3H, H-4.6a.6b), 3.36 (5, 3H, OCH3). 1.60 (m, 2H, ali-
phatic CH2ClIHz3). 1.30-1.25 (ms, 20H, aliphatic CH2CloHzoCH3), 
0.89 (t. 3H,1 7.0, aliphatic Cll H20CH3 ); 13C NMR (CDCl3): (j 159.6. 
159.5, 159.4, 131.3, 131.0, 130.6 (each s, each aromatic C), 130.0, 
129.8, 129.6, 114.07, 114.05, 114.03 (each d, each aromatic CH), 
98.5 (d, C-1). 82.1, 79.8, 77.7, 70.2 (each d), 75.7. 74.9, 73.3 (each 
t, each OCHzPh), 72.0 (t, aliphatic OCH2Cll HZ3 ), 69.5 (t, C-6), 55.5 
(q, PhOCH3), 55.3 (s, OCH3), 32.2, 29.94. 29.91, 29.89, 29.87, 
29.84,29.7,29.5,28.4 (each t, each aliphatic CH2), 14.4 (q, aliphatic 
CH3); LRESIMS: Found, mlz 745.5; required, 745.9 [M+Nat. Anal. 
Calcd for C43Hs209: C, 71.44; H, 8.64. Found: C, 71.09; H, 8.73. 
3.1.19. Methyl 2,3,4-tri-O-paramethoxybenzyl-6-0-dodecanyl-
p-o-glucopyranoside (Sb) 
Treatment of 7b (3.2 g, 4.5 mmol ) as described for 7a gave Sb 
(0.55 g, 85%); [c.:]o 2 (c 0.01. CHCI3); FTIR (KBr): 2923. 2851 , 
1614,1464.40,1421,1359,1302,1254,1173.1072.813 cm- I ; IH 
NMR (400 MHz, CDCl3): /j 7.29-6.84 (ms, 12H, aromatic H), 4.79, 
4.75. 4.67 (each AB d. 2H,1 10.5, OCH2Ph), 4.26 (d, IH,11.2 7.5, 
H-l), 3.79-3.58 (overlapping signals, 2H, H-3,5), 3.79 (m, 9H, 
PhOCH3), 3.68 (m, 2H, H-6a,6b), 3.56 (s, 3H, OCH3), 3.43-3.39 
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(overlapping signals, 2H, H-2,4), 1.63 (m, 2H, aliphatic 
OCH2CllHz3 ), 1.29-1.24 (ms, 20H, aliphatic OCHZClOH20CH3), 0.88 
(t, 3H,1 7.0, aliphatic OCll H22CH3); 13C NMR (COCl3): (j 159.3, 
159.2,159.1, 130.9, 130.8, 130.5 (each s, each aromatic C), 129.8, 
129.6, 129.5, 113.8, 113.7 (each d, each aromatic CH), 104.8 (d, 
C-1). 84.4, 82.1, 77.7, 75.3 (each d), 74.9, 74.6, 74.4 (each t, each 
OCH2Ph), 71.9 (t, aliphatic CH2), 69.7 (t, C-6), 57.1 (q, OCH3), 
55.3, 55.2 (each q, each PhOCH3), 31.9, 29.7, 29.68, 29.65, 29.63, 
29.5, 29.4, 26.2, 22.7 (each t, each aliphatic CH2), 14.1 (q, 
aliphatic CH3); LRESIMS: Found, mlz 745.3; required, 745.9 
[M+Nar. Anal. Calcd for C43H6209: C, 71.44; H, 8.64. Found: C, 
71.19; H, 8.70. 
3.1,20. Methyl 6-0-dodecanyl-cx-D-glucopyranoside (9a) 
Compound Sa (1.45 g, 2.0 mmo!) was dissolved in 3:1 MeCN-
H20 (21 mL), and cerric ammonium nitrate (8.85 g, 16.16 mmol) 
was added. The solution was allowed to stir at room temperature 
for 24 h.3o It was then concentrated in vacuo, and the residue 
was purified by chromatography (petroleum ether-EtOAc) to give 
9a (0.53 g, 73%); [cc]o 78.8 (c 0.04, CHCh); FTIR (KBr): 3416, 2919, 
2851, 1467, 1372, 1128, 1043, 1019 cm-1; lH NMR (400 MHz, 
CDCh): (j 4.98 (br s, lH, OH), 4.75 (d, IH,11.Z 3.5, H-l), 4.34 (br s, 
IH, OH), 4.01 (br s, IH, OH), 3.75 (apt t, IH,h3 9.5,h4 9.5, H-3), 
3.66 (m, 2H, H-6), 3.54-3.44 (overlapping signals, 3H, H-2,4,5), 
3.37 (s, 3H, OCH3), 1.58 (m, 2H, aliphatic CH2Cll H23 ), 1.28-1.25 
(ms, 20H, each aliphatic CHZClOHzoCH3), 0.88 (t, 3H,1 6.5,1 7.0, ali-
phatic Cll H20CH3); 13C NMR (COCI3): <5 99.7 (d, C-1). 74.5, 72.3, 
72.2, 71.2 (each d) 70.6 (t, aliphatic CHz), 69.5 (t, C-6), 55.4 (q, 
OCH3), 32.1, 29.9, 29.88, 29.86, 29.83, 29.7, 29.6, 26.3, 22.9 (each 
t, each aliphatic CHz), 14.3 (q, aliphatic CH3); LRESIMS: Found, 
m/z 385.2; required, 385.5 [M+Nar. Anal. Calcd for ClgH3S06: C, 
62.95; H, 10.57. Found: C, 62.60; H, 10.67. 
3.1.21. MethyI6-0-dodecanyl-p-D-glucopyranoside (9b) 
Treatment of Sb (0.44 g, 0.6 mmol) as described for Sa gave 9b 
(0.17 g, 76%); [ex]o-l (c 0.03, CHCh); FTIR (KBr): 3405, 2922, 2850, 
1470,1391,1128,1109,1048cm-1; lH NMR(400MHz, CDCI3): b 
4.20 (d, IH,iJ.z 7.5, H-l), 3.89 (s, IH, OH), 3.74 (m, 2H, H-6a,6b), 
3.66 (m, IH, H-5), 3.54 (s, 3H, OCH3), 3.52-3.44 (overlapping sig-
nals, 2H, H-3,4), 3.35 (apt t, IH,h3 8.0, H-2), 1.58 (m, 2H, aliphatic 
OCHZCllHz3)' 1.28-1.11 (ms, 20H, aliphatic OCHZClOHzoCH3), 0.88 
(t, 3H, 1 6.5, 1 7.0, aliphatic OCllHzzCH3); 13C NMR (CDCI3): (j 
103.5 (d, C-l), 76.5, 74.4, 73.4, 72.1, (each d), 71.6 (t, aliphatic 
CHz), 70.9 (t, C-6), 57.1 (q, OCH3), 31.9, 29.7, 29.66, 29.65, 29.58, 
29.53,29.4,26.0,22.7 (each t, each aliphatic CHz), 14.1 (q, aliphatic 
CH3); LRESIMS: Found, mlz 385.2; required, 385.5 [M+Nar. Anal. 
Calcd for ClgH3S06: C, 62.95; H, 10.57. Found: C, 62.83; H, 10.36. 
3.1.22. Methyl 2,3-di-O-benzyl-4,6-di-O-benzylidene-cx-D-
glucopyranoside (lOa) 
A solution of la (1.0 g, 5.2 mmol), p-toluenesulfonic acid 
(10 mg) and benzaldehyde dimethylacetal (1.5 mL, 10.3 mmol) in 
anhyd MeCN (25 mL) was stirred for 24 h at room temperature. 
Me3N (0.5 mL) was added to neutralise the solution, and the mix-
ture was then stirred for 1 h. The product was filtered off as a white 
solid, washed with petroleum ether and dried. The benzylidene-
protected intermediate was then dissolved in anhyd OMF 
(15 mL), and the solution was cooled to O°c. NaH (0.74 g, 
18.4 mmol) was added slowly, followed by benzyl bromide 
(2.5 mL, 20 mmol). The mixture was then warmed to room temper-
ature and stirred overnight. MeOH (10 mL) was added to quench 
the reaction, and the mixture was stirred for a further 1 h.24 The 
mixture was then concentrated under diminished pressure and 
purified by chromatography (petroleum ether-EtOAc) to give lOa 
(2.0g, 95%); [1X]o 0.7 (c 0.05, CHCl3); FTIR (KBr): 3063, 3031, 
1109,1088,735, 692cm-1; lH NMR (400 MHz, COCh): (j 7.50-
7.22 (ms, 15H, each aromatic H), 5.54 (s, IH, CHPh), 4.85 (AB d, 
2H,1 4.0, OCHzPh), 4.82 (AB d, 2H,1 12.0, OCH2Ph), 4.59 (d, 1 H, 
iJ.z 3.5, H-l), 4.26 (dd, IH,1s.6> 10.0,16>.6b 4.5, H-6a), 4.05 (apt t, 
IH, h3 9.0, h4 9.0, H-3), 3.83 (m, IH, H-5), 3.70 (apt t, IH,1s.6b 
10.5, H-6b), 3.62-3.54 (overlapping signals, 2H, H-2,4), 3.39 (s, 
3H, OCH3); 13C NMR (COCI3): <5 138.7, 138.1, 137.4 (each s, each 
aromatic C), 128.89, 128.43, 128.29, 128.20, 128.10, 128.01, 
127.90,127.57,126.0 (each d, each aromatic CH), 101.2 (d, C-l), 
99.2 (d, CHPh), 82.1, 79.2, 78.6, 62.3 (each d), 75.3, 73.8 (each t), 
69.1 (t, C-6), 55.3 (q, OCH3 ); LRESIMS: Found, m/z 463.3; required, 
463.5 [M+Ht. Anal. Calcd for CZSH3006: C, 72.71; H, 6.54. Found: C, 
72.31; H, 6.56. 
3.1.23. Methyl 4,6-di-O-lauroyl-cx-D-glucopyranoside (12a) 
3.1.23.1. Methyl 2,3-di-O-benzyl-4,6-di-O-lauroyl-cx-D-glucopy-
ranoside (tta). Compound lOa (1.7 g, 3.6 mmol) was dis-
solved in MeOH (50 mL), and a catalytic amount of TsOH was 
added. The solution was stirred at room temperature overnight, 
after which Et3N (2 mL) was added to quench the reaction.31 The 
mixture was concentrated under diminished pressure, and the 
crude diol residue was dissolved in anhyd pyridine (70 mL). 4-Di-
methylaminopyridine (OMAP, catalytic amt) and lauroyl chloride 
(3.3 mL, 14.4 mmol) were added, and the reaction was stirred at 
room temperature for 3 h.26 The solution was then concentrated 
under diminished pressure, and the crude product was purified 
by chromatography (petroleum ether-EtOAc) to give tta (1.0 g, 
38%). FTIR (KBr): 2925, 2853, 1743, 1455, 1360, 1167, 1105, 
1045,734 cm-1; lH NMR (400 MHz, COCl3): b 7.34-7.26 (multiple 
signal, 10H, each aromatic H), 5.01 (dd, IH,h4 9.5,hs 10.0, H-4), 
4.78 (AB d, 2H,1 11.5, OCHzPh), 4.73 (AB d, 2H,1 12.0, OCH2Ph), 
4.59 (d, IH,11.Z 3.5, H-l), 4.15 (dd, IH,1s.6> 5.5, 16>.6b 12.5, H-6a), 
4.04 (dd, IH,JS.6b 2.0, H-6b), 3.92 (apt t, IH,h3 9.5, H-3), 3.87-
3.82 (m, IH, H-5), 3.59 (dd, IH, H-2), 2.36-2.27 (m, 4H, each ali-
phatic OCOCHZClOHz1 ), 1.67-1.56 (m, 4H, each aliphatic 
OCOCHzCHzCgHI9), 1.26-1.16 (ms, 32H, each aliphatic OCOCZH4-
CSH16CH3), 0.88 (t, 6H,1 6.5,17.0, each aliphatic OCOClOHzoCH3); 
13C NMR (COCl3): (j 173.6, 172.4 (each s, each C=O), 138.4, 137.9 
(each s, each aromatic C), 128.51, 128.32, 128.18, 128.05. 127.69, 
127.57 (each d, each aromatic CH), 98.2 (d, C-l), 79.51, 79.18, 
69.5,67.7 (each d), 75.4, 73.6 (each t, each CHzPh), 62.2 (t, C-6), 
55.4 (q, OCH3), 34.15, 34.03, 33.99, 31.9, 29.62, 29.60, 29.49, 
29.44, 29.35, 29.34, 29.28, 29.26, 29.15, 29.13, 29.07, 24.76, 
24.70,22.69 (each t, each aliphatic CHz), 14.1 (q, aliphatic CH3)' 
3.1.23.2. MethyI4,6-di-O-lauroyl-cx-D-glucopyranoside (12a). 
Compound l1a (0.84 g, 1.14 mmol) was dissolved in EtOH (2.5 mL), 
and Pd/C (0.3 g) was added. The mixture was allowed to shake un-
der a hydrogen atmosphere of 2 psi until all protecting groups had 
been removed (TLC) to yield 12a. The suspension was filtered and 
concentrated in vacuo27 to give 12a (0.47 g. 75%). [1X]o 4.33 (c 0.03. 
CHCh); FTIR (KBr): 3456, 2918. 2849, 1737, 1701. 1468. 1301. 
1240.1187, 1046cm-1; lH NMR (400 MHz. COCI3): (j 4.87 (dd. 
IH.13,4 9.5.hs 10, H-4), 4.82 (d. IH.iJ.z 4.0, H-l). 4.23 (dd, IH. 
1S.6b 2.0. 16>.6b 12.0, H-6b), 4.12 (dd. IH.1s.6> 2.0, H-6a). 3.91 (ddd, 
lH. H-5), 3.84 (apt t, IH. h3 9.5, H-3). 3.64 (m. IH. H-2), 3.44 (s. 
3H, OMe). 2.37-2.32 (m, 4H, each aliphatic OCOCHZClOH21 ). 
1.68-1.55 (m, 4H, each aliphatic OCOCHzCHzCgH19), 1.30-1.26 
(multiple signals, 32H. each aliphatic OCOCZH4CsH16CH3). 0.88 (t. 
6H.1 6.5.1 7.0. each aliphatic OCOClOHzoCH3); 13C NMR (COCI3): (j 
173.63,173.58 (each s, each C=O), 99.0 (d. C-1). 72.9, 72.7. 70.3, 
67.7 (each d), 62.2 (t. C-6). 55.5 (q. OMe), 34.2. 34.1. 34.0. 31.9. 
29.63, 29.61. 29.50. 29.47, 29.45, 29.36, 29.30, 29.27, 29.14, 
29.08,24.84.24.82,24.70,22.70 (each t, each aliphatic CHz), 14.1 
(q. aliphatic CH3); LRESIMS: Found. m/z 559.5; required, 559.8 
[M+Ht. Anal. Calcd for C31Hss08: C. 66.63; H, 10.46. Found: C, 
66.66; H. 10.79. 
A. Smith et a/./Carbohydrate Research 343 (2008) 2557-2566 2565 
3.1.24. General procedure for the preparation of pentaerythri-
tol esters 
Pentaerythritol 13 (1.0 g, 7.3 mmol), lauroyl chloride (4.8 mL, 
21 mmol) and 4-dimethylaminopyridine (DMAP, catalytic amt) 
were dissolved in anhyd pyridine (50 mL) and stirred at 50°C for 
24 h.26 The solution was then concentrated in vacuo, and the fol-
lowing mono-O-Iauroyl 14 and di-O-Iauroyl 15 products were 
isolated by chromatography (petroleum ether-EtOAc). A tetra-
O-Iauroyl derivative was also isolated (0.39 g, 6%): 
3.1.25. Mono-O-Iauroyl pentaerythritol (14) 
Yield: 0.33 g (14%); FTlR (KBr): 3462, 2914, 2848, 1737, 1712, 
1476, 1187, 1038, 1005 cm-I; IH NMR (400 MHz, CDCI3): ii 4.10 
(s, 2H, CH20C=O), 3.80-3.61 (overlapping signals, 9H, 3 x CH20H, 
3 x OH), 2.34 (t, 2H,J 6.0,J 7.0, aliphatic OCOCHlCIOHlI ), 1.61 (m, 
2H, aliphatic OCOCH2CH2CgHIg), 1.26 (ms, 16H, aliphatic 
OCOClH4CsHI6CH3), 0.88 (m, 3H, aliphatic OCOCIOHlOCH3); BC 
NMR (CDCh): ii 175.0 (s, C=O), 62.7, 62.4 (each t, each CH20), 
45.3 (s, C(CHl )4), 34.2. 31.9, 29.59, 29.57, 29.44, 29.30, 29.23, 
29.15, 24.9, 22.6 (each t, each aliphatic CHl ), 14.1 (q, aliphatic 
CH3); LRESlMS: Found mlz 341.2; required, 341.45 [M+Nar. Anal. 
Calcd for C17H340 s: C, 64.12; H, 10.76. Found: C, 64.08; H, 10.79. 
3.1.26. Di-O-Iauroyl pentaerythritol (15) 
Yiled: 1.074 g (29%); FTIR (KBr): 3351,2915,2850, 1739, 1701, 
1471, 1163, 978, 719 cm-l ; lH NMR (400 MHz, CDCI3): ii 4.12 (s, 
4H, each CHlOC=O), 3.58 (s, 4H, each CHlOH), 3.22 (br s, 2H, each 
OH) 2.34 (t, 4H,J 7.5,J 7.5, each aliphatic OCOCH2CIOHl1 ), 1.62 (t, 
4H, J 6.5, J 6.5, each aliphatic OCOCHlCH2CgHIg), 1.29-1.26 (ms, 
32H, each aliphatic OCOC2H4CsHI6CH3), 0.88 (t, 6H,) 6.5,J 6.5, each 
aliphatic OCOCIOH20CH3); BC NMR (CDCI3): ii 174.4 (s, each C=O), 
62.4 (t, each CH20), 44.7 (s, QCH2)4), 34.2, 31.9, 29.56, 29.29, 29.21, 
29.11,24.9,22.6 (each t, each aliphatic CH2), 14.1 (q, each aliphatic 
CH3); LRESlMS: Found mlz 501.5; required. 501.75 [M+Hr. Anal. 
Calcd for C2gHs606: C, 69.56; H, 11.27. Found: C, 69.64; H, 11.31. 
3.1.27. Tetra-O-Iauroyl pentaerythritol 
Yield: 0.39 g (6%); FTIR (KBr): 2917, 2849, 1735, 1336, 1299, 
1250,1154,1111, 1002cm-l ; IH NMR (400 MHz, CDeI3): ii 4.11 
(s, 8H, each CH10C=0), 2.30 (t, 8H, J 7.5, ) 8.0, each aliphatic 
OCOCH1CIOH11 ), 1.60 (t, 8H, J 6.5, ) 7.0, each aliphatic 
OCOCH1CH2CgHI9), 1.41-1.26 (ms, 64H, each aliphatic 
OCOC2H4CsHl6CH3), 0.88 (t, 12H, ) 6.5, } 7.0, each aliphatic 
OCOCIOH10CH3); BC NMR (CDCb): ii 173.2 (s, each C=O), 62.1 (t, 
each CH20), 41.8 (s, QCH2)4), 34.1, 31.9, 29.59, 29.45, 29.31, 
29.23, 29.11, 24.8, 22.7 (each t, each aliphatic CH2), 14.1 (each q, 
each aliphatic CH3); LRESlMS: Found mlz 888.7; required, 888.36 
[M+Nar. Anal. Calcd for CS3HIOOOg: C, 73.56; H, 11.65. Found: C, 
73.60; H, 11.58. 
3.2. Evaluation of antimicrobial activity 
3.2.1. Preparation of bacterial cultures 
Bacteria used in this study were S. aureus ATCC 25923 and E. coli 
ATCC 25922. Stock cultures were maintained in tryptic soy broth 
(TSB, Sharlau Chemie, Spain) supplemented with 20% glycerol at 
-70°C. Cultures were routinely grown by subculturing 100 ilL of 
stock culture into 9 mL TSB and incubating at 35°C for 18 h. Cul-
tures were then maintained on tryptic soy agar (TSA, Sharlau Che-
mie, Spain) plates at 4°C. Working cultures were prepared by 
inoculating a loop of pure culture into TSB and incubating at 
35°C for 18 h. A bacterial suspension was prepared in saline solu-
tion (NaeI 0.85%, BioMerieux, France) equivalent to a McFarland 
standard of 0.5, using the Densimat photometer (BioMerieux, SA, 
France), to obtain a concentration of 1 x lOs cfu/mL. This suspen-
sion was then serially diluted in TSB to obtain a working concen-
tration of 1 x 106 cfu/mL. 
3.2.2. Antimicrobial activity assay 
Stock solutions (100 mmol) of test compounds and standards 
were prepared in sterile aqueous-alcoholic diluent (1:1 EtOH-
distilled H20) and stored at -20°C. Stock solutions were diluted 
in TSB to obtain initial working concentrations (10 or 20 mmol). 
Working test compounds and standards were serially diluted in 
sterile TSB to a final volume of 100 ilL within the 96-well plate. 
Freshly prepared inoculum (100 ilL) of the organism under study 
was added to each appropriate well. The final concentration of 
each microorganism in each well was ~5 x 105 cfu/mL, and the 
concentration range of chemical compounds was from 1:2 to 
1 :256. Each concentration was assayed in duplicate. The following 
controls were used in the microplate assay for each organism and 
test compound: blank, uninoculated media without test compound 
to account for changes in the media during the experiment; nega-
tive control. uninoculated media containing only the test com-
pound; positive control 1, inoculated media without compound; 
positive control 2, inoculated media without compound but 
including the corresponding sugar to evaluate any effect of the 
sugar alone; and positive control 3, inoculated media without com-
pound but with the equivalent concentration of EtOH used to dis-
solve the test compound, thereby assessing any activity of the 
alcohol. The 96-well plates were incubated at 35°C for 18 h in a 
microtiterplate reader (PowerWave microplate Spectrophotome-
ter, BioTek), and effects were monitored by measuring the optical 
density (00) at 600 nm for each well every 20 min with 20 s agita-
tion before each 00 measurement. Each experiment was replicated 
three times. The MIC was defined as the lowest concentration of 
compound that showed no increase in 00 values for all the repli-
cates compared to the negative control after 18 h. Subtraction of 
the absorbance of the negative control eliminated interferences 
due to variation in the media. 
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INTRODUCTION 
• MRSA and antibiotic resistance Is a global concern. Consequently, new antistaphylococcal agents are needed. Unlike antibiotics, fatty acids and their 
derivatives have modes of action that appear to be non-specific and development of resistance to these compounds has not been reported W. 
• The antimicrobial activity of fatty acids and derivatives has been well documented (Ill. Previous work in this laboratory showed that novel carbohydrate 
fatty acid (CFA) derivatives had antimicrobial activity against food borne pathogens and spoilage microorganisms DIll • 
• It has been reportedlOO that the half life of monolaurin In cultures of S. aureus was ca. 5 min, attributed to its cleavage by cellular esterases, which raised 
the question as to whether the ester conjugate or free fatty acid derived from hydrolysis of the ester, was responsible for the antimicrobial activity. 
• In contrast to fatty acid ester conjugates, corresponding ether conjugates should then remain antimicrobial for a longer period of time[V], assuming 
the fatty acid component does not require release by esterases for efficacy. 
AIMS 
This study was designed to investigate and compare the In vitro antimicrobial activity of a range of pure, novel CFA esters and fatty acid ethers, using 
commercial fatty acids and monoglycerides as control compounds against S. aureus and MRSA strains. The resulting findings enabled insights into 
structure/activity relationships and the mechanism of action of these compounds. The role of the caribohydrate moiety in the antibacterial activity of these 
compounds is discussed. 
SYNTHESIS & METHODOLOGY 
~c,~ 
~ , 
MethyI6-0-1auroyl-O!-D-
glucopyranoside 
H2:lCl1...-....~0 
HO 0 
HO 0Me 
HO 
• Methy16-0-dodecanyl-,B-
D-glucopyranoside 
~.~~ 
Z 
Melhyl 6-0-dodecanyl-a-
D-glucopyranosidc 
H15C1Jl~0 
HO 0 
H 
HO OMe , 
Methy16-0-OCLaDoyL-a-D-
glucopyranoside 
MeLhyI6-0-lauroyl-,B-D-
glucopyranoside 
H"c"Jl~ 
HO 0 
HO 
• 0Me 
MethyI6-0-lauroyl-a.D-
mannopyranoside 
Leakage of Intracellular 
material absorbing at 260nm 
was examined following 
exposure to CFA derivatives 
at 4x MIC to assess 
membrane damage. 
StnIctures of tile novel aortlohydrne r.tty Kid derivllti_ 
~ and invesllg.t.d [~l. Minimum InhibitDry Co~ (Mle) using In Ib5ortMnce ...... IM«tl mIcrodUutlon method. 
RESULTS AND DISCUSSION 
I FA 1\£ ~tiityaidWiv.iiws 
l\tauJpim IAo\M..K 1 2 3 4 5 6 ~ 
S aureuY ~2S923 10 o.~ 5 0.31 o.~ o.~ 25 25 o.~ ., .. .. no 
S GWf!US N::IC um 10 o.~ 25 0.31 o.~ 0.111 1.25 1.25 o.~ 
S aureuY ~33591 10 o.~ 25 1.25 o.~ o.~ 25 5 o.~ t s aureuY ~33592 W o.~ 25 0.111 0.111 o.~ 5 25 0.16 
S GWf!US ~43300 10 0.111 25 0.111 0.111 o.~ 10 25 0.111 
_ l1gn •• ~anLrQI 
~r.:ft~·~~~".~~~(W For each analySis the Mle was recorded as the concentration (mM) that resulted in total Inhibition of all replicates at 370C after 24 hours. 1. a-lauric eslEr; 2. a-lauric ether; 3. (Haurie ester; 4. p-Iaurlc ether; 5. a-caprylic ester; 6, 
a -lauric ester of mannose lna'ellse in tile ...... of UY ablortling substances from 
I) S. au~ATCC25923, b) S. au_ATCC43300 (MRSA) 
• Compounds 2, 3 and 6 showed the highest growth-inhibitory effect against S. aureus and MRSA, comparable to Monolaurin. Compound 1 was 
comparable to U",ric acid. Compound 4 (II ether) was less inhibitory than the corresponding ester (compound 3) and ether analog (compound 2). 
• Antimicrobial activity for compound 5 was better than the Caprylic acid and comparable with Monocaprylin. 
• The concentration of UV absorbing substances released increased with exposure time for all compounds, with the exception of the laurate ether of 
methyl ~-D-glucopyranoside. 
CONCLUSIONS 
• It was observed that ether derivatives (compounds 2 and 4) retained 
antimicrobial activity, indicating that hydrolysis of the ester bond may not be 
necessary for antimicrobial activity. 
• Alternatively, the role of the carbohydrate moiety ((1, vs. ~) might also playa 
role, as both ether analogs had different antimicrobial efficacy. 
• Membrane damage may account for one part of the mode of action of these 
compounds as shown by the release of UV absorbing substances. 
• The exact mode of action of the different CFA compounds still requires 
further evaluation. 
• The results of the novel CFA derivatives will have clinical significance owing to 
their activities against MRSA. 
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Abstract: 
In vitro antimicrobial activity and mechanisms of action of novel carbohydrate 
fatty acid derivatives against Staphylococcus aureus and MRS A 
P. Nobmann, 1. Dunne, G. Henehan, P. Bourke 
School of Food Science and Env. Health, Dublin Institute of Technology, Dublin, 
Ireland 
Background: MRSA is a global concern. Consequently, new antimicrobial agents are 
needed. Fatty acids and derivatives have several non-specific modes of action and 
development of resistance has not been reported!. Previous work reported carbohydrate 
fatty acid (CFA) derivatives with antimicrobial activity against Listeria spp. and 
spoilage bacteria2• 
Objectives: To compare the in vitro antimicrobial activity of pure, novel CFA esters and 
fatty ethers as antimicrobials against S. aureus (MRSA). To ascertain the role of free 
fatty acid and carbohydrate moieties in antimicrobial efficacy, enabling insights into 
structure/activity relationships and mechanism of action. 
Methods: Broth microdilution method to determine minimum inhibitory concentrations 
(MIC) and effects on the lag phase. Leakage of 260 nm-absorbing materials was 
examined. 
Results: Laurate ether of methyl a-D-glucopyranoside and laurate ester of methyl {3-D-
glucopyranoside had the highest growth inhibitory effect. Considerable extension of the 
lag time was observed at sub-MIC values for some compounds. The concentration of 
UV absorbing material released increased with exposure time for all compounds, except 
for the laurate ether of methyl {3-D-glucopyranoside. 
Conclusions: S. aureus (MRSA) were significantly inhibited by the derivatives. 
Membrane damage may account for one part of the mode of action of these compounds. 
Release of fatty acid may not be essential for antimicrobial activity. Some of the 
compounds may have clinical significance owing to their activities against MRSA. 
References: 
1. Kabara&Marshall. 2005 Medium-chain fatty acids and esters. In Antimicrobials in 
foods. Davidson, Sofos & Brannen, 3rd ed. p. 327-360, CRC Press, Boca Raton, FL 
2. Nobmann, P.; Smith, A.; Dunne, J. Henehan, G.; & Bourke, P. 2009 The 
antimicrobial efficacy and structure activity relationship of novel carbohydrate fatty acid 
derivatives against Listeria spp. and food spoilage microorganisms. Int J Food 
Microbiol128 (3),440-445. 
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Synthesis and antimicrobial activity of novel carbohydrate fatty acid 
derivatives against food pathogens and spoilage microorganisms 
INTRODUCTION 
• There Is current demand within the food Industry for alternatIVe approaches for control of microbial spoilage and safety Issues. 
• The antimicrobial actIVity of fatty acids and derivatives has been well documented w. Commercially, the most common of these are glycerol moooiaurate 
(ML) and sucrose esters. 
• It has been reportedOO that the half life of monolaurin in cultures of S. aureus was ca. 5 min, attributed to Its cleavage by cellular esterases, which raised 
the question as to whether the ester conjugate or free fatty acid derived from hydrolysis of the ester, was responsible for the antimicrobial activity. 
• In contrast ID fatty acid ester conjugates, corresponding ether conjugates should then remain antimicrobial for a longer period of timer" ], 
assuming the fatty add component does not require release by esterases for efficacy. 
AIMS 
The objective of this study was to compare the in vitro antimicrobial activity of a range of pure novel carbohydrate fatty acid derivatives to ascertain 
any role of the free fatty acid and/or carbohydrate in antimicrobial activity. Fatty acid esters were compared with their corresponding fatty acid 
ethers to investigate the role of the glycoconjugate linkage. The anomeric configuration of the carbohydrate moiety was also investigated to help 
elucidate any role of the carbohydrate in the antimicrobial efficacy Free fatty acids (FA) and monoglycerides (MG) were also assessed as controls. 
SYNTHESIS & METHODOLOGY J1 
~ TIPSa. Im,D'oJF,rt 55'',0 0." 
I~I 1f:5 
.... .. ,t .. . 
General routes to mono-substituted carbohydrate esters and ethers[JvJ, Minimum Inhibitory Concentrations were measured 
using an absorbance based broth microdilution 
method to compare compound efficacy. 
RESULTS ANI) DlSCliSSION 
Microorganism 
FA MG Carbohydrate fatty acid derivatives 
LA CA ML MC 1 2 3 4 5 6 
L. illnocua NCTC 11288 
L. mOllocylogelles A TCC 7644 
L. lIIollocylogelles NCTC 11994 
L. lIIollocylogelles NCTC 7973 
S. alll'ellS A TCC 25923 
S. aureus (MRSA) ATCC 33591 
E. coli A TCC 25922 
E. coli NCTC 12900 
S. Typhimurium ATCC 14028 
E. aerogelles A TCC 13048 
P. fluorescens 
II.II~ 
~h 
2:; 
1 ~ 
I'.f> 
. ' 
> 20 
12.5 
>20 
> 20 
> 20 
5 OM 2.5 
>5 0.04 5 
>5 0.04 2.5 
5 o.o·~ 2.5 
5 0.04 2.5 
>5 0.04 2.5 
10 20 
10 12.5 5 
> 20 20 > 20 
20 20 \0 
5 20 5 
IUIH 0.04 0.08 0.63 0.04 
(I.(IR 0.04 0.08 2.5 2.5 0.04 
0 . .3 1 0.04 0.16 > 2.5 1.25 0.04 
O . O ~ 0.04 0.16 > 2.5 0.31 0.04 
(UI 0.04 0.04 2.5 2.5 0.04 
0.3 1 0.04 0.04 2 .5 0.04 
20 20 20 20 12.5 ?;:20 
12.5 10 12.5 \0 12.5 N.D 
20 >20 > 20 20 >20 N.D 
20 >20 >20 > 20 >20 N.D 
> 20 >20 > 20 > 20 5 N.D 
For each analysis the MIC was recorded as the concentration (mM) that resulted in tornt Inhibition of all replicates at 370C after 18 hours. N.D: Not detennined 
1. MethyI6~taLU'O'fl-a-D-9Iucopyranoslde (atfe~; 2. MethyI6-0-d00ecanyl-u-D-glucopyranoside (ethel); 3. MethyI6-(HauroyH3-D1:IIucopyranoslde (ester); 
4. Methy16-O-dodecanyt-fJ.-D-gllJCOpyranoslde ("thel); 5. MethyI6-O-octanoyl-a-D-glocopyranoside (an.t); 6. Methyl 6-O-lauroyl-a -D-mannopyranoside (astal) 
• Carbohydrate mono-fatty add esters and ethers based on glucose and mannose (1-6) were synthesised. 
• Antimicrobial activity of compounds 2, 3 and 6 was comparable with Y,io"o:aur;n against S. aureus and Usteria spp. Compound 1 was comparable 
ID . Compound 4 (p ether) was less Inhibitory than the corresponding ester(Compound 3). 
• Antimicrobial activity for Compound 5 was comparable with Monocaprylin and these compounds were more active than lauric derivatives against £ 
coli and P. Ruoresrens. However all showed compounds had comparatively negligible antimicrobial efficacy for Gram negative microorganisms. 
CONCLUSIONS REFERENCES 
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• These results indicate that the anomerlc configuration of the carbohydrate c} Ferer, I!t al. 2005. Enzyme and MIcrObIal Technology 36, 391-398 
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• It was Interesting ID nob! that ether derivatIVes (Compounds 2 and 4) ~II) Veri, et aI. 19114. The Journal d BIological O1emlstJy 259, 8115-8121 
retillned anHmlcroblal acUvfty IndlcllHng that hydrolysis of the ester bond may [Iv) Smith et al. 2008. calbChydrll1e ReseIIrdl. In Press 
not be necessary for anllmlaoblal activity. The role of the carbohydrate In ACKNOWLEDGMENTS 
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Abstract: 
Synthesis And Antimicrobial Activity Of Novel Carbohydrate Fatty Acid 
Derivatives On Food Pathogens And Food Spoilage Microorganisms. 
Patricia Nobmann, Aoife Smith, Julie Dunne, Gary Henehan, Paula Bourke 
Dublin Institute of Technology, Dublin, Ireland 
There is increased interest within the food industry for novel natural anti-microbial 
preservatives due to consumer demand for food products with fewer synthetic additives, 
increased safety, quality and shelf-life. Alternative strategies include the use of novel 
antimicrobials, such as fatty acid derivatives which have proven bacteriostatic and 
bactericidal properties against a diverse range of bacteria. 
A series of mono-substituted carbohydrate fatty acid (CF A) compounds focusing on 
caprylic and lauric acids have been synthesized. Chemical routes allowing the 
attachment of the fatty acid as either an ester or corresponding ether to the 
monosaccharide 6-hydroxyl were developed to synthesize carbohydrate derivatives with 
structural differences, enabling comparative studies on the structure/activity relationship 
for antimicrobial efficacy and mechanism of action. 
The range of synthesized CF A derivatives were assessed for in vitro antimicrobial 
effects against different pathogenic and spoilage bacteria and their efficacy was 
compared with commercially available compounds with proven antimicrobial activity 
such as monolaurin and monocaprylin, as well as the pure free fatty acids, lauric acid 
and caprylic acid. An absorbance based broth micro dilution assay was used to measure 
the minimum inhibitory concentration (MIC) and increase in lag phase. 
The antimicrobial efficacy of the CF A derivatives was comparable to monolaurin. CF A 
derivatives were significantly more effective against Gram positive bacteria, with MIC 
values between O.04mM and O.16mM, than Gram negative bacteria with MIC values of 
~OmM. 
Among the carbohydrate derivatives synthesized, the laurate ether of methyl a-D-
glucopyranoside and laurate ester of methyl {j-D-glucopyranoside showed the highest 
growth inhibitory effect. 
The synthesis of both ester and ether fatty acid derivatives of the same carbohydrate, in 
tandem with alpha and beta configuration of the carbohydrate moiety suggest that the 
carbohydrate is involved in the antimicrobial activity. Thus, CFA derivatives with 
different structures have great potential for developing antibacterial agents relevant to 
the food industry. 
60th Irish Universities Chemistry Research Colloquium, 
University College Cork, 11th_13th June 2008. 
Synthesis of novel carbohydrate fatty acid derivatives, 
antimicrobial efficacy and structure/ activity relationship 
School of Food Science and Environmental Health. 
Dublin Institute of Technology (DIT). Catha I Brugha St., Dublin 1, Ireland. 
INTRODUCTION 
• Altematlve approaches for microbial control and shelf life 
extension include the use of naturally derived antimicrobials such as 
fatty acid derivatives wh ich have proven bacteriostatic and 
bactericidal properties against a diverse range of bacteria. 
• In addition, recent studies have shown fatty acids, particularly 
lauric acid, combined with existing antimicrobial agents show activity 
against methicillin-resistant Staphylococcus aureus (MRSA) and 
therefore show potential in the healthcare industry. 
• TIlls project involves the design and synthesis of a series of 
carbohydrate fatty acid ester and ether derivatives. 
AIMS 
• To investigate if the antimicrobial activity of fatty acid compounds 
can be enhanced using a carbohydrate delivery system. 
• To synthesise derivatives with structural differences to enable 
comparative studies. 
• To compare carbohydrate delivery systems with non-biological 
polyhydroxylated systems. 
SYNTHESIS & METHODOLOGY 
H~O 
HO 
HO 
HO 0Ma 
TIPSCI, 
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55% 
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86% 
~0 H0~ 1 HO 
H Otl!e 
O~ Ho4; HO~MQ 2 
• General routes to mono-substituted carbohydrate esters and 
ethers. 
• Microtlter plate assay 
RESULTS AND DISCUSSION 
• A series of structurally related carbohydrate mono-fatty acid ester 
and ether derivatives based on glucose, galactose and mannose 
were synthesised (1-7). 
• Non-carbohydrate polyhydroxylated ester derivatives were also 
synthesised for comparative purposes (8-9). 
• In addition, a carbohydrate di-fatty acid ester derivative was 
synthesised (10) 
• TIle antimicrobial effICacy reported as Minimum Inhibitory 
Concentration (MIC), is shown in the table below. 
'lrc.".." 
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"110 
· 
au. 
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, 
~.~ UI_ ..... ~,,~ .,.- ..... 
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", . ." 
· ~~ CLNIIIIII .I11III ~~ NIA N/A 
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• The antimicrobial activity of Compounds 2, 3 and 6 were 
comparable with Monolaurin® against S. aureus. 
• TIle derivatives 1, 4 and 7 was less inhibitory 
.TIle antimicrobial activity of Compound 5 was comparable with 
monocaprylin against S. aureus. 
• By comparison, none of the synthesised compounds had 
antimicrobial effICaCY against E. coli. 
• TIlere was no antimicrobial activity associated with the mono 
substituted pentaerythritol 8 . 
• TIle results for dl-substltuted derivatives 9 and 10 are not available 
due to poor solubility in the test medium . 
CONCLUSIONS 
• carbohydrate fatty derivatives have been synthesised which have 
antimicrobial efficacy comparable with commercially available 
antimicrobials against S. aureus 
.TIlese results indicate that the nature of the carbohydrate plays a 
vital role in the effICaCY, and therefore further optimisation may be 
possible. 
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Abstract: 
Synthesis, antimicrobial efficacy and structure/activity relationship of novel 
carbohydrate fatty acid derivatives 
Patricia Nobmann, Aoife Smith, Paula Bourke, Julie Dunne, Gary Henehan 
Dublin Institute o/Technology. Cathal Brugha Street, Dublin 1, Ireland. 
The antimicrobial activity of fatty acids and derivatives has been well documented.! 
Commercially, the most common of these are glycerol monolaurate (Lauricidin®) and 
sucrose esters. There is current demand within the food industry for alternative 
approaches, including the use of novel antimicrobials such as fatty acid esters, for 
control of microbial spoilage and safety issues. Recent studies reported that fatty acids, 
particularly lauric acid, combined with existing antimicrobial agents have activity 
against methicillin-resistant Staphylococcus aureus (MRSA) and that carbohydrate 
esters can affect the growth of S. sobrinus, therefore these compounds have potential in 
the healthcare industry. 2 
The objectives of this study were to compare the in vitro anti-microbial activity of a 
range of pure novel carbohydrate fatty acid esters (1) with the corresponding fatty acid 
ethers (2) as well as commercial fatty acids and mono glycerides to ascertain any role of 
the free fatty acid and/or carbohydrate in the antimicrobial efficacy. The antimicrobial 
efficacy of these compounds was compared quantitatively to allow an estimation of the 
enhancement of the efficacy over the free fatty acids and commercial standards. 
Although much work in this area has focused on enzymatic synthesis of sugar 
derivatives for commercial application, this work has designed synthetic routes to allow 
the production of pure, novel, regiochemically defined monosaccharide fatty acid esters, 
and their corresponding ethers. The synthesis of carbohydrate derivatives with structural 
differences enables comparative studies to attain information on the structure/activity 
relationship with respect to antimicrobial efficacy and mechanism of action. The 
contribution of fatty acid chain length to the antimicrobial activity was also investigated. 
The antimicrobial efficacy of the compounds was measured using an absorbance based 
broth microdilution assay to determine the minimum inhibitory concentration (MIC). 
The synthesis of both ester and ether fatty acid derivatives of the same carbohydrate, in 
tandem with alpha and beta configuration of the carbohydrate moiety suggest that the 
carbohydrate is involved in the antimicrobial activity. 
RCO~O HO 0 
HO 
HO OMe 
1 
RC~O 
HO 0 
HO 
HO OMe 
2 
I a) Bergsson, G., et ai, International Journal of Antimicrobial Agents, 2002, 20, 258-262. 
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1' 1 HUIlI CIU" 
• There Is inaeased Interest In the food Indusby for 
antimicrobial preservatives that are perrelved as more "natural". 
• Alternative strategies for microbial control and shelf life 
extension Include the use of novel antlmlaoblals. 
• Example: fatty acid der1vatIves which have proven 
bacteriostatic and bacterlddal properties against a diverse range 
of bacteria. 
• This project involves the design and synthesis of novel mono-
substituted carbohydrate fatty add ester and ether derivatives. 
• Investigates whether the antimlaobial activity of fatty acid 
compounds can be enhanced using a carbohydrate delivery 
system. 
S " III~SI S. S IIU ( II IU S & \I~ IIIOIlOI 0( . ' 
• A series of protectionjdeprotectlon steps whereby the fatty 
acid Is attached to the 6- OH position. 
• The synthesis of carbohydrate derivatives With structural 
dllferenres enables comparative studies. 
• Antimicrobial efflcacy tested with the mlcrobroth dilution 
method. 
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• Six compounds, their corresponding sugars, and lauric acid and 
monolaurln as controls were tested against two Gram + (Usterla 
innocua and StaphylococaJs 8ureu1) and one Gram - (EsdIMchIa 
coil) mlaoorganlsms. 
• Esters comparable with monolaurln against Gram + 
• None of the compounds had comparable activity against Gnvn -
• Ether compounds were less Inhlbltory than the ester fonns. 
• Protected compounds had no effect on any of the microorganisms 
tested. 
Mlnlm.1 ,,, IC\_I.-
Compound L. InntH:ulI S.lIureus E. cDII 
1 O.ORmM O.ORmM >20mM 
2 
3 O.ORmM O.ORmM >20mM 
.. SmM 2.SmM N.D 
5 >IOmM >IOmM >20mM 
8 SmM >IOmM >20mM 
7 0.31 mM 0.31 mM >20mM 
8 O.08mM O.08mM >20mM 
j"u'·utlM 
The results obtained In this study showed an antImtaobIal effect 
of the carbohydrate Fatty Add derivatives synthesised against 
Gram positive bacteria. 
W. WIlI.IIIIIo!ID ...... Dr -.. RIzpIIrId<, Dr Ken GIIso ... Dr v_ ~ _ 
C81Ior. UCD .... Dr ~ Rye, _ Spec C81Ior UCD. 
IUtdhg lilt litis proJect _ provided by orr SInnd I Grn. 
Abstract: 
Synthesis of novel carbohydrate fatty acid derivatives and the relationship of 
structure with anti-microbial efficacy 
Aoife Smith, Patricia Nobmann, Julie Dunne, Paula Bourke, Gary Henehan 
Dublin Institute a/Technology, Cathal Brugha Street, Dublin 1, Ireland. 
There is increased interest within the food industry for anti-microbial preservatives that 
are perceived as more "natural" due to consumer demand for food products with fewer 
synthetic additives but increased safety, quality and shelf-life .. Alternative strategies for 
microbial control and shelf life extension include the use of novel antimicrobials, such 
as fatty acid derivatives which have proven bacteriostatic and bactericidal properties 
. d' fb' 12 agamst a lverse range 0 actena.' 
Among such fatty acid derivatives are carbohydrate fatty acid esters, which have 
previously been generated enzynIatically to yield non-regiocontrolled mixtures. The 
current work employs a protection / deprotection strategy allowing the divergent 
synthesis of pure compounds with a fatty acid attached to a carbohydrate primary 
hydroxyl. Altering the carbohydrate and the fatty acid enables comparative studies to 
attain information on the structure / activity relationship with anti-microbial efficacy and 
mechanism of action. To date, a series of glucopyranoside fatty acid esters (1) and ethers 
(2) focusing on caprylic and lauric acids have been synthesised. The antimicrobial 
efficacy of these novel compounds compared with commercially available standards 
such as monolaurin and pure fatty acids is under evaluation against common food 
pathogen organisms. The synthesis of these compounds, along with preliminary 
microbiological results, will be presented. This group of compounds has numerous 
potential applications within the food and healthcare industries. 
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~ 100 ~~------------ - --------
:a 
.5 SO 1---- - __ ::;;;.- __ . _ 
"' 
o ~--.. ~ ~ ________ _ 
16 24 32 40 
L-GJulanllue (PM3-Bl) 
.~ ~::~ 
1l'100 -
:a 
<5 50 .. 
o 
o 
~conlrol 
a eLher(9a) 
16 24 32 40 
Time (h) 
~aesICT(4a) 
~belhcr(9b) 
48 
48 
a-O-Iaclose (PMI-D9) 
~IOO 1------------
.~ ::1 
l 
o 50 ~--------~~~----------
~-.... -~~ 
16 24 32 40 48 
Glucuronamide (PMI-H7) 
II ISO 
'§ 
200
t ~100 ~ .,~ !~~!riQ o 50 '" ____ " l!: 
16 24 32 40 
3-0-bela-D-galaclopyranosyl-D-arabinose (PM2 
B12) 
16 
~~ODIJOI 
a ether (9a) 
24 32 40 
Tlmelh) 
---- iii esler(4a) 
~bether(9b) 
2,3-Butanone (PM2-HII) 
200 
48 
4S 
~ 150 +---------------------------
'§ 
~ 100 ~--------j 50 +-----~'~~~----------=_"'" 
~ 100 
'a 
16 24 32 40 48 
L-Alanine (PM3-A7) 
---- ------
.~ ::: j 
~ 50 +------- ---------------
oL. .. ~ .... ~~:::4::::::~r=~:~ 
16 24 32 40 48 
L-Isoleucine (PM3-B4) 
200 --------------------------
. Iso ~I-------------------------~ I i 100 ~I------
o 50 ----~;;;;;; .. ;;;;;; 
O ~~--~~ __ .. -~--
o 16 24 32 40 48 
Timll!th\ 
.-.-control ~aeslcr(4a) 
a ether (9a) -/of- b eLher (9b) 
L-l..eucioe (PM3-B5) 
200 ,-----~ 150 ~1---------------------------
f'~Gh~ 
16 24 32 40 
L-VaLioc (PM3-C9) 
200 . 
.12 150 
§ 
1 100 
.§ 50 
~ 
16 24 32 40 
N-Acelyl-D~lucosamine (PM3-El1) 
o 
o 16 24 32 40 
Tlmf!fll' 
~control ~aester(4a) 
a ether (9a) ~ b cther (9b) 
D.L-a-Amino-N-Butyric acid (PM3~?) 
200 
,!a 150 -\- -----
§ 
48 
48 
~ 100 1-------- ---------------
1 50 
o 16 24 32 40 48 
Phosphate (PM4-A2) 
200 .,.-- ----
~ ISO ~--------------
'g 
~IOO 
~ 50 t-~~~== .. :::-.... ~ .... ~. 
16 24 32 40 
Adenoswe-5'-mooophosphale (PM4·A 9) 
200 ----
.~ 150 I 
~100 ----­
·S 
48 
.!J 50 t- --.#----------
-...- control 
16 24 
Time (h) 
a etber(9a) 
32 40 
~acster(4al 
----- b ether (9b) 
48 
48 
L-Threon ine (PM3-B 11) 
200 --
'~ 150 J ___________ _ 
~ 100 ------] 
0
50
=-&:=== 
16 24 32 40 48 
L-Homoserine (PMJ-Cl1) 
200 ,---------------
!I 150 I '§ 
1':: ----~OnIiilIlll ....... ¥IIII-... IiII .. 
o 
o 16 24 32 40 48 
Cytidille (PM3·F4) 
200 ~------------
.12 150 ~---------------
§ 
~ LOO 
1 50 
16 24 12 40 48 
Tlme(bl 
~conlrol -e-a ester (4a) 
aether-(9a) ~beLher(9b) 
Ala.()in (PM3-H2) 
16 24 32 40 48 
Trimel3-phosphate (PM4-A4) 
200 --
~ 150 ---------
'§ 
~,OO ---- -------------] 
050 .. ----
16 24 32 40 
Adenoswe-2 I,3'-cyclic-mooopbosphate (PM4-A11) 
200 .,---
1150 I ~ 100 +1------
g 50 ~.M .... l-------
O .. ~~ __ ~ .. ~----~ 
48 
16 24 32 40 48 
-+- control 
a clhcr(9a) 
Time (h) 
~aester(4a) 
-tt- b ether (9b) 
L--Valine (PMJ-C2) 
200 
~150 +--------------
'~ 
~100 -l---------------'o~ 
50 
16 24 32 40 48 
Glucurooamide (PM3-E6) 
200 r= 
.~ 150 
1100 
'~ 
0 50 
16 24 32 40 48 
AllaolOin (PM3-G5) 
l= .~ 150 ~IOO 'a e 
0 
16 24 32 40 48 
Tlm ... (hl 
......... control - a ester (4a) 
a ether (9a) ............. b ether (9b) 
AJa-l<u (PM3-H6) 
16 24 32 40 48 
AdenQsine-2'-lllooopbosphate (PM4-A8) 
200 -----------------------------
~ 150 ---------------------------
'§ 
~ 100 .. 
.~ 
o 50 
16 24 32 40 48 
Adenosine-3·.5'~yelic-mooopbosphale (PM4-
A12) 
16 24 32 40 48 
Time (h) 
~coDtrol - 8 eslcr(4a) 
a ether (9a) ............. b ether (9b) 
D,L-alpha-Glycerol phosphate (PM4-B3) 
.~ 150 
~100 +~---­
'il 
2OO~ 
~ 50 -------------0 ...... _ ___ _ 
o '6 24 32 40 48 
Guanosine-3,-monophosphate (PM4-B9) 
200 I 
~50 ~-------------
.§ 
~oo -
-~ 
050 
o~~~~-------
.6 24 32 40 48 
Cytidioe-3'-monopbospbate (PM4-C9) 
200 ---- ---------
~50 +1-----------­
§ I 
Joo----
.~ 
050 ~--- ----~~-------
.6 24 
Timr(hl 
-+- ConlrOJ 
a eLber(9a) 
32 40 
___ a ester (4a) 
- - b eLhcr(9b) 
O-Phospho-D-Tyrosinc (PM4-EI) 
[6 24 32 40 
TelrathiOlJale (PM4-F4) 
200 , -----------------
48 
48 
~.50 +_-------------g 
~.OO +_--.~ .... ~._------
g50 ,. -
-
[6 24 32 40 48 
N-Aeetyl-L-CySLeinc (PM4-G-l) 
200 --------------------
.~150 
§lOO ---~ ...... ;_--------
-~ 
o 50 --1-- ----------------
[6 24 32 40 48 
Tlm.(h) 
-+- ComroJ - a cster(4a) 
a ether (9a) ......w- b ether (9b) 
Carbamyl phosphate (PM4-BS) 
200 r----------------------
fO 1--------------------
_~oo t----
8 050 r-----.~ 
.-
.6 24 32 40 
Guanosine-2',3'-<:yclic monophosphale (PM4-
011 ) 
200 ~-----~----------
!,50 tl--------------------! '00 I 
o 50 1-..---;;"j~-----------
o .. ~ __ ~~~ __ ~_.--~ 
o .6 24 32 40 48 
Pbospbo-L-argiolnc (PM4-D4) 
200 
.~ 150 
48 
~IOO t------ ------------ --
-0 
8 
o 50 
-+- Conltol 
a clher(9a) 
16 24 
Time (h) 
32 40 
- 3 ester (4a) 
~beLber(9b) 
Phosphocreatine (PM4-E3) 
48 
200 ,---------------_ 
!!l 150 
'§ 
~ 100 
-o~ 
50 
[6 24 32 
Ditbiophosphalc (PM4-F6) 
200 -
.~ ISO 
40 48 
~ 100 r-l~;;;;;:;;--------g 50 t----._' -----------------L 
[6 24 32 40 48 
S-Metbyl-L-CYSLeine (PM4-G2) 
200 ,------------- ---
~150 t_-----------------
.§ 
~JOO 
1 50 t_--~f_~==~--------
16 24 32 40 48 
Time(hl 
......... ;~:h~1(9a) :::b~C:r\~~) 
D-l-phospho glyceric acid lPM4-B6) 
200 
_! [50 t_------------------
~lOO 1_----
1 
050~!::::= 
16 24 32 40 48 
CytidiD.e-2'-monophosphalC (PM4-C8) 
200 
_~ 150 1-----------------
~100 ;------] 
o 50 t_---- --.-I----------
16 24 32 40 48 
O-Phospho-D~erillc (PM4-D5) 
2oo ,-----~----------------
~ 150 1------------__ ' 
-§ 
~ 100 1- ----
~ 50 t_----~ 
16 24 32 40 48 
TimeC") 
......... Conlro! - sesler(4a) 
a elber (9a) ~ b ether 
Thiosulfale (PM4-F3) 
200 ,------ ---------
~150 t_-------------------------
.~ 
rl00 
g 50 t_--~----------------------
o __ ~ .... ____________ _ 
o 16 24 32 40 48 
L-Cysleinyl~lycine (PM4-F9) 
200 
.. "~ .~ ~100 -l ......... 
o 50 
16 24 32 40 48 
D-Metbionine (PM4-G8) 
200 ,------ -----------
.~ 150 1- ------------
I 100 t----.,~ . ._... _ . ----- -
~ so 
" 
16 24 32 40 48 
TimeCb) 
~Conlrol - a ester (4a) 
a ether (9a) ~ b ether (9b) 
Thiourea (PM4-H2) 
200 .,------....;..--....;..----
"tSO 
.§ 
900 ~---------------------
.~ 
050 
16 24 32 40 48 
Posi tive control: L-Glulamme (PM6-A2) 
200 1~-----------
Ala~lu (PM6-A6) 
200 ,-----
.~ ISO +1-----------
!l I 100 -t-----
6 
o 
~COutrol 
a eLher(9a) 
16 24 32 40 
Time (h) 
......... a cslcr (4a) 
b eiher (9b) 
48 
AJa-Tbr (PM6-B2) 
200 T---~~~--~-------
·!:::1-
'2 
.5 SO _~....,,.a .  - ... ---• 
16 24 32 40 48 
Arg-Val (PM6-C6) 
200 
~ 150 
.~ 
~IOO 
~ 
0 50 r-
16 24 32 40 48 
Cys-Gly (PM6-D4) 
200 ~ ----------------
.~ISO 1-1---------
~IOO 't---" 
.~ 
OSo t-~~~:; 
16 24 32 40 48 
Timerhl 
.......... COnLroI - a esler(4a) 
a ether (9a) ~ b ether (9b) 
D,(....Lipoamide (PM4-H4) 
200 
",ISO t------- - ---- -----
'§ 
~oo r-------c~~~-------------
.~ 
050 
16 24 32 40 48 
A1a-Arg (PM6-A4) 
200 ---------------------------
"'ISO LI-------------------------
·li 
~ 100 ---------------- - --- • .-
.~ 
o SO~ 
o • , 
16 24 
16 24 
Time (h) 
.......... COntrol 
a eLber(9a) 
32 40 48 
hu. * It 
32 40 
_ a ester (4a) 
............. b ether (9b) 
48 
Arg-Gln (PM6-B8) 
200 .,---
r
SO 
I f: +~---------------------
O __ ~~ .... ~ __ ~ ____ __ 
o 16 24 32 40 48 
Asn-Glu (PM6-C7) 
200 
.~ 150 I 
~ 100 
~ 
0 50 
16 24 32 40 48 
GIn-Gly (PM6-D6) 
~I OO 
.~~::~ 
.~ ".~~ o SO 
I 
o --~ ________________ ...
16 24 
Time(hl 
.......... COntrol 
a clber(9a) 
32 40 
............ a e5ler(4a) 
--- b ether (9b) 
48 
2-Hydroxyethanc sulronic acid (PM4-HI O) 
200 
" ISO 01- --------------------
'§ 
~ 100 -I-----.. ~ 
.~ 
o SO • o __ ~ __ ~t:~: _______ 
o 16 24 32 40 48 
Ala-As. (PM6-AS) 
200 ~------------------------
"150 ~-----------------------
.~ 
~ tOO 
l 
o SO +--------"-~~ .. ~~ .. ~ .. 
... =_~.,.; ___ .... r' 
o 16 24 
Ala-Leu (PM6-A9) 
~::~ ~ 100 +~------­
'a 
650 1-'., 1 
32 40 
16 24 32 40 
TIDI.(hl 
.......... Cootrol 
a etber(9a) ----a ester (4a) 
--- b ether (9b) 
Arg-Glu (PM6-B9) 
48 
48 
200 ~1-- --------
.~ ISO I 
~ 100 +.-------- ~----------
~ 
S: CI ~!SS~ 
16 24 
Asp-Ph. (PM6-DI) 
16 24 
G1y-Cis (PM6-E4) 
200 ...-------
32 40 48 
32 40 48 
"'ISO ~------------------
'g 
..gIOO 
~ SO tL:::;;~~~ 
16 24 32 40 48 
Time (h) 
----Conlrol ~aesler(4a) 
a elber (9a) -.- b ether (9b) 
Gly-Ie. (PM6'-E7) 
200 r--------------------------
"ISO 
.~ 
~lOO 
.~ 
050t1C~~ 
16 24 40 48 
lie-Ala (PM6-G31 
200 
1'50 1-1---------
rO I 
050~-~~~~ ........ 
O ----~ .. --__ --------~ 
o 16 24 32 40 48 
Leu-AI. (PM6-H41 
200 -------------------------
O ----~------------~ o 
-'-Control 
a ctbcr(9a) 
16 24 
Tfm~(h) 
32 40 
- aesler(4a) 
~bclhcr(9b) 
Positive control: L-Glulamioe (PM7-A2) 
48 
,,150 +------------ ------------200~
roo -----
8 ~~~~~~r~~~~~~ o SO ~ 
o~~~==~----~~ 
16 24 32 40 48 
Mel-Gln (PM7·B9) 
200 .--------------------------
"150 ··1------------------------
"g 
~lOO 
l 
o SO 
16 24 32 40 48 
Met-Phe (PM7-CS) 
200 ,--------------------------
.;1 ISO +----------- - ------------
§ 
~ 100 +---------._-----------
~ 50 L-------~~~~~~~~~ 
I 
32 40 48 
........ CODIIOI - aesler(4a) 
a elher(9a) --- b elbet (9b) 
Gly-ThT(PM6-FI) 
ne-Gly (PM6-G6) 
200 -------------------------
16 24 32 40 48 
Leu-Arg (PM6-H5) 
200 -------- ------------
,,150 ~I-----------------------, 
'§ 
~100 ----------------------
~ 
o SO 
16 24 32 40 48 
Time (h) 
.......... Colllrol 
a ether (9a) 
----8 e5Ler(4a) 
- belher(9b) 
Lys-Al. (PM7-A6) 
200 -----------------
16 24 32 40 
16 24 32 40 
48 
48 
Met-pro (PM7-C6) 
200 ~--------~~--~---------
'" ISO +1------------------------
{IOO E-------------------------
o so t 1 ~===== 
16 24 32 40 
Time (h) 
........ COntrol - aeslcr(4a) 
a elber(9a) --betber(9b) 
His-Gly (PM6-F6) 
200 
"ISO ~-----------------.~ 
~IOO 1----------------
6 so 1"-' 
16 24 32 40 48 
lie-Val (PM6-H3) 
200 
,,150 ~----------------
"§ 
~100 +-------' -----------------l 
o SO 
16 24 32 40 48 
Lys-GI. (PM7-A81 
200~  .~ IlO 
~100 +--------------------------------
Lo -J:-::I!' ':~.-"----
O~~~~ .. ~----__ __ 
16 24 32 40 48 
.~ 
50 -------<..,~-----------------
16 24 32 40 48 
Met-Val (PM7-C8) 
200 .---------------------------
"ISO ~----------------.~ 
1100 +------- --
.~ ~~~ 
o sa · ~ 
O ~~ .. ~~~ ______ ... 
o 16 24 32 40 
Time (h) 
~CODlrOJ 
--a ester (4a) 
a clber(9a) ---M- b ether (9b) 
Ph.-IIe (PM7-{;11) 
200 r---------------------------
.!lISO I 
flOO +------,.." 
o SO -"-- - - - :1I~~!!!!!!!!!!!!!!!!!!!I!!!!!!!!!! 
200 i 
",ISO 
"§ 
16 24 
Pro-Phe (PM7-DIO) 
16 24 
SeT-Pro (PM1-E7) 
32 40 
32 40 
200 .,..----------------- -
ZlISO +------------------
§ 
~100 -1------- --
'a 
8 
050 -----
48 
48 
16Tim" 11-1 .32 40 48 
"'-'- Conlrol - a ester (4a) 
a clber (9a) ..........- b ether (9b) 
Thr-Glu (PM7-FI) 
200 r------------------
Zl I SO -1------
'g 
~100 
~ 
o SO 
16 24 32 40 48 
Thr-Met (PM7·F4) 
200 I 
ISO ----- ----
16 32 40 48 
Tyr-Gln (PM7-G6) 
200 --------------------------
.... 
......... COnlIo] 
a ether (9a) 
16 24 
Tlmefhl 
r 
32 40 
--- a ester (4a) 
b ether (9b) 
48 
Pro-Gin (PM7-D6) 
200 r---------------------------
.~ 150 
~ 100 --------........ 
1 50 r---,.l: ____ .---------
~ 
16 24 32 40 
Ser-Ala (PM7-El) 
"~::: I 
~lOO t--------,,--- --~ 
o 5: :::::~:~~;.=~:::::::: 
o 16 24 32 40 4& 
Thr·AI. (PM7·EII) 
200 -------- ----------------
"~ISO --------------------------
16 24 32 40 48 
Time (h) 
~Control ---' aester(4a) 
a ether (9a) - b ether (9b) 
Thr-Gly (PM7-F2) 
200 ,.-----------------~ 150 j "§ 
~ 100 ------- -::-----------_ 1 so __ J.H~~t~~~~~~,~!!!t!!.!!!.!!!!! 
o __ ~ .. ______ ------... 
16 24 J2 40 48 
4 • 
16 24 32 40 48 
Tyr-Glu (PM7-G7) 
200 ---------------------
O ~~--.... ~----~ ... 
o 16 24 
Time (h) 
-'-ConlroJ 
a ether (9a) 
32 40 
......... a ester (4a) 
- belber(9b) 
48 
48 
2oo r-___ P~ro_-~u ~(P~~~17~"D~?~) _____ _ 
.!:l 150 
§ 
~ 100 
~ 
o SO 
16 24 32 40 48 
SeT-His (PM7-E3) 
200 
1150 I "~ 100 '1--- ---
o SO · -_,t!!.~~I!!!~ 
16 24 32 40 4& 
16 24 32 40 48 
Time(hl 
~ Control ---- a ester (4a) 
a tiber (9a) ---.- b tibeT (9b) 
Thr-uu (PM7-F3) 
200 
Ekr-----·-
O __ ~ ........ __________ .. 
o 16 24 32 40 48 
T",-Gly (PM7 -F9) 
"~:: j ~100 ------------------------------
~ ,= * 050 _ _ 
~ .... ~------
16 24 32 40 4& 
G1y-Asll (PM8-A12l 
200 ,----------------
~ISO r-------~~~~---------------.~ 
~lOO 
l 
o SO 
~ConlIol 
a elhcr(9a) 
16 24 
Tim. (h) 
32 40 
......... a ester (4a) 
............ b ether (9b) 
48 
(i1y-11«.MI·8lj u,,· ..... (.ldl·SIO) s.,· ..... (.Ml-D1l 
F~ 1=1 f~ 1 t:. ... !.L. .. -o:  I ., ._ - ., 7 
= 
. £ 
• 
• " " " 
.. .. • 
" " " 
.. .. • " " " 
.. .. 
VOl· ... I.o ('MH'.1 VOI.(lIo!PMl-ElI b<u·",,·lIiom·Il-"j 
~ 
i=1 
m 
'1'10 .'. , 
r,· ". L !. F.r • !. r • • 
• • 
" " " 
.. .. • 
" " " 
.. .. 
" " " 
.. .. 
2.4.1 Alpha ester (4a) hits: PM)) 
Chlortetracycline 
Tim. 
, 
,~serlesl -S!flUs2 Str,1!'S3 sen~ , 
!-.-SnnO - 5.,..,55 ___ "'IIIU --Sime56 
Cloxacillin 
I--+--S<1ne-;, Seflc~ S""f'';} '' sc,,~ I 
_ 5 .. ,, "'>5 - Sc" e!ti ---+---5,,"1l51 --&>t,C!f.8 
Alpha ester (4a) hits: PM12 
.. 
Penicillin G 
1_!5ow"~ - Ir"'Ol Stl ' ,11'.1 tH .... 1 
_ ......e. '-"....., -1--~~"<!'4 
Penimepieycline 
.. 
1_ "_ ~ s.",", ....., :::;j 
....... ----~-----...... 
*r------------------------i 
,,-
'-1 --= --= ''-:_= --''' '-''' --"'-=""---==·-'-'""1 
------..,..~ .... -.- -- -
Alpha ester (4a) hits: PM14 
300 
250 
-j 200 
Ii :: 
.. 
Sodium cyanate 
-~~~ 
----, po 
./ 
~ 
-::. -
II 
" 
20 
TIme 
I 
I 
I 
24 
Lincomycin 
,1 000 I-------------;~--~* 
f 
. 
,., 
... , 
1"" i: 
.. 
• 
o .. 
TIm. 
I~$o_'-~'.Z Soc,,.,.} ..... , 
_ nrr.-t _ $<,-.6 --t- s.-, ... 7 -..., .... 
NafcUUn 
Tim . 
1""'-'.fII,,"' k '-" ... .....a ~ 
_ SC',c-.5 - Snr,a..:; _ Scr,cs1 - - .....,J 
Carbenicillin 
l1 i .L~ 
~ 
f Vl/' , ~ --- ~.-~ 
~ j 
• • • v • ", ;] 
11 (111n 
' .rotnO mycln 
1-+-.. _. ~~ .. ,~ .,-,' 
1- .. --~ ... · .. - ... ...oJ - - .. • .... 1 
i~Sbt I ,.. , - 9>-,.,.1 SJr 'OIJ -fO---"""-) 
_ SY,...., _ fuI0l08 _ 9>","'1-_ ..... 
......-.S.rinl - S.rlu 2 
----S.IIUS - 5111 1,,6 --+-- Slrlu7 --au .lit 
50 
o 
• 
1 
i : 
Amoxicillin 
" ..... 
.. 
I~ .... -I - ....... ~ - ---I 
_ ......... _ S er ,(:>l) ___ :MItBI --_ 
Cephalothin 
r /'. ~ 
F 
.... ~-
-
.. 
1---<l- 5t"Ul - 8..-11 .. 2 S..-iNJ :t.f .... t 
_ 8.,.,16 --SlIf iuG ~-So.i9s1 --... .... 
l --+--scr' CtlI l _Sc,,~ s.., ,, oo-3 .......... ] 
_8e' ,~ __ s~ ".,.., ---+- St:"",,7 --_ 
J 
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1 .,r 
"""" 
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Alpha ester (4a) hits: PMJ3 
Aziocillin 
,. 
\-+--"''''''1 - .... ~ IW-' ~I"'I 
--... _--------
Carbenic illin 
300,----__ ------------------------, 
250I-------iiiJ!iiiiiiiiil 1 200 1--~"'lI!II. { '50 I---~"~~~~~~ .... ____ "~ 
~ 
>oo~ __ ~~--------____ ---. ____ --~ 
20' h-----------------------I 
1 :h~~~.==__~ ,,~~~ 
.. 
,~Set,asl ___ 8."1152: S.,'Hl _ ..... '"") 
_____ Slll/j~ _ Se';lIs1S ~Se"n7 --.... W .. 
Alpha ester (4a) hits: PM16 
1-Chloro-2,4·dinitrobonzooa 
rc...-' -......~ .........., - ...... 1 _____ H""~ __ SL~,,,,,,j ____ Hc"~i1 __ _ ~ 
Alpha ester (4a) hits: PM17 
Lithium chloride 
I 
r 
I 
1----: J ~ ~ , 
ro-
.. .. 
'J.. 1- ..... t - 50" '4 ... ,,,,1 "'!NoI1 
_ Su" OOI.:! _S~rli:lfti _ _ Se" "'" _ _ _ 
Alpha ester (4a) hits: PM18 
Sodium m-arsenite 
(:::::::::; ==:::--::; ::...::;{ 
Alpha ester (4a) hits: PM19 
lodonltro tetrazolium violet 
Time 
I-.....-.. _I- .. ...J ~.1lIJ ...... l _ ----.. -'--~---.. --7--...... . 
Alpha ester (4a) hits: PM20 
Amitriptyline 
Alpha ester (4a) hits: PM15 
Puromycin 
" 
.. 
Diamida 
... J 
"" 
= 
,~ " t- ~ 
00 r 
----
.. 
. 
.. 
Phenylars lne oxide 
SoeI....o - ....... 1 
... ~ --... -
0 
Lidocane 
......- ... _ , __ ... ., ... ,~ ."..1 
~.~~"'---"'''' ---''''' 1 
Phenethicillin 
r ~ 
.-1 / . 
Tlmo 
~_!'lir,...z Sor ,,,,, J """'1 
____ l~ -~,IIIG --+-- 9!!r'.1 --~" 
Orphenadrlna 
i W!-iH'-. 
I f :_~~~ 
Tim. 
Sodium azide 
. ~~----------------------~ . ,. 
,---+-5"' 1<:'&' 5 /). ,..,52 .... ~ ........ 1 
~ _ a:. .... --to- - - -..-
Chloroxyle nol 
I-+-a.l ... · -...,., "'_1 ·- ..... ~ l ~_..wl-.. _ . - _ _ 
Alpha ester (4a) hits: PM18 
Ketoprofen 
~ .. -+ .. .., 9:rlooJ _ "-'I 1 ____ .,_- 1110 , ... _ _ .. _. - - .. _ 
Antimony (III) chloride 
!~""-I---- "-- "'-1 
- .. - ...... --.. -,- - ... ~ 
Lauryl sulfobetaine 
~ r-----------------------~ 
.. 
.. 
TI ... 
11--+-;"·' _ SW,.2 "'-'~"""1 
_____ .. ~-at ... _ _ ." , - - _ 
o ,L-P ra pra nalal 
... - For ",,---
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.. 
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~A 
,... 
Tim. 
1----"-"'" --- .,.ioIILJ ... ~ ..... '1 ~9>r,<6!5 --Sr, .... " __ 3>',,,,,1 --...... 
I 
Alpha ester (4a) bits: PM20 
I 
Al ro plno I' 
: '-1 ~--'I .j 1Wt=Q~~~~ 
If: 
~~----------------~ 
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